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Summary  
Cognitive impairments are present in both schizophrenia and bipolar disorder and 
are strong predictors of functional outcomes for patients. One barrier in cognitive 
research of these disorders is the lack of large, well-characterised cross-disorder 
samples with cognitive data. The aims of this thesis were to examine cognition 
across the bipolar / schizophrenia diagnostic spectrum and to develop a new online 
cognitive battery for use in psychiatric research.  
Cognition was examined in participants with bipolar disorder, schizoaffective 
disorder and schizophrenia through a meta-analysis of existing studies and 
analysing data from a large well-characterised sample. The main finding was that 
there is a gradient of increasing cognitive impairment from bipolar disorder 
through schizoaffective disorder – bipolar type to schizoaffective disorder – 
depressive type and schizophrenia. Participants with the subtypes of 
schizoaffective disorder differed in their cognitive performance. Lifetime history of 
psychosis was associated with cognitive performance across disorders. 
An online cognitive battery was developed to assess the domains outlined by the 
Measurement and Treatment Research to Improve Cognition in Schizophrenia 
(MATRICS) initiative. The battery was validated against the MATRICS Consensus 
Cognitive Battery and showed that the tasks provided valid measurements of the 
majority of the MATRICS domains. A large sample of participants with a range of 
psychiatric disorders was recruited online. An examination of cognition in 
participants with major depressive disorder, bipolar disorder and schizophrenia 
showed that cognitive profiles were similar across disorders but participants with 
schizophrenia have more severe impairments than participants with bipolar 
disorder. An important concluding observation was that poorer cognitive 
performance was associated with poorer functional outcome across disorders.  
The findings of this thesis add to a growing literature showing the importance of 
examining cognitive function across psychiatric disorders. To date, it is the first 
study to develop and utilise an online cognitive assessment for psychiatric research.  
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Chapter 1: Introduction  
1.1 Overview 
Schizophrenia and bipolar disorder are among the most severe forms of mental 
illness and are leading causes of disability amongst young people worldwide. 
Schizophrenia is a psychotic disorder characterised by the presence of delusions, 
hallucinations and disorganised thinking. The disorder is also characterised by the 
presence of negative symptoms such as affective flattening, asociality, anhedonia 
and avolition. Whilst the psychosis experienced can be episodic in course, negative 
symptoms and cognitive impairments persist outside these episodes, which 
significantly impact their social and occupational functioning. Bipolar disorder is a 
mood disorder marked by recurrent episodes of depression and mania. It is an 
episodic illness with a better functional outcome than schizophrenia, including 
fewer or no negative symptoms and milder cognitive impairments.  
Despite the diagnostic distinction between schizophrenia and bipolar disorder, 
there are overlaps in clinical presentation and underlying biology. Depression is 
common in patients with schizophrenia and psychosis is common in bipolar 
disorder. There is evidence that there are common genetic risk variants for both 
disorders, as well as similarities in underlying neurobiology. Therefore, researchers 
have proposed that a better approach to diagnostic classification may be to focus on 
dimensional measures of psychopathology. One dimension that has been the focus 
of research studies is cognition.  
Cognitive impairments are present in both schizophrenia and bipolar disorder. 
These impairments persist during remission and are not alleviated by current 
treatments. More severe impairments have been linked to poor functional outcomes 
and are therefore a key target in the development of new treatments. Furthermore, 
it is hoped that examination of cognitive impairments across disorders will lead to 
an understanding of the underlying neurobiology of these disorders. However, a 
barrier in cognitive research is the lack of large, well-characterised cross-disorder 
samples with cognitive data. 
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1.2 Classification of the functional psychoses 
Descriptions of mental illness can be found throughout history, although the first 
attempts to create a comprehensive classification of psychiatric disorders began in 
the mid-nineteenth century [1]. In 1852, Benedict Morel described the case of a 14-
year-old boy whose academic ability had declined, had become withdrawn, was 
suffering memory loss and talked of killing his father. Morel believed the boy had 
deteriorated because of “brain degeneration of hereditary origin” and used the term, 
“demence precoce” to describe a mental deterioration at an early age [2]. In the 
same decade, Jules Baillarger and Jean-Pierre Falret independently presented 
descriptions of patients who experienced alternating periods of extreme high 
(mania) and low mood (depression) [3, 4]. Baillarger called the illness, “folie a 
double forme”, meaning dual-form insanity [4]. Falret referred to it as, “folie 
circulaire”, meaning circular insanity and suggested that there may be a genetic 
basis observing that the illness clustered in families [3].  
In 1863, Karl Kahlbaum distinguished between two groups of mental disorders 
based on their clinical courses, “vercordia” and “versania” [3]. Vercordia included 
disorders with a remitting course, such as depression and mania. Versania consisted 
of disorders with a progressive course resulting in dementia. It is thought these 
descriptions influenced the work of Emil Kraepelin, which provided a basis for the 
development of modern classifications of psychotic and affective disorders [3]. 
Between 1883 and 1899, Kraepelin published six editions of his influential 
textbook, “Compendium der Psychiatrie”, presenting a comprehensive 
classification of mental disorders [4]. Kraepelin differentiated organic psychosis 
from functional psychosis and observed that patterns of symptoms occur together. 
The functional psychoses were separated into two distinct categories, “dementia 
praecox” and “manic-depressive psychosis”. He believed that these disorders had 
distinct courses of illness and therefore the prognosis of patients could be predicted. 
Dementia praecox was described as a cognitive deterioration occurring early in life, 
accompanied by incapacitating symptoms of suspicious thoughts, hallucinations, 
apathy and withdrawal. The prognosis for this disorder was considered to be poor. 
Manic-depressive psychosis was described as an episodic disorder characterised by 
mood symptoms and a more benign outcome than dementia praecox. The term 
encompassed all possible mood dysfunction, including depression, mania and 
3 
 
mixed states, as Kraepelin believed these were manifestations of a single disease 
process [5]. These classifications became the foundation of modern classifications, 
which view bipolar disorder and schizophrenia as distinct disorders. 
1.2.1 Bipolar disorder 
Kraepelin viewed mania, depression and mixed states as a unitary disorder [5]. 
Kleist challenged this view in the mid-twentieth century, proposing a distinction 
between bipolar psychosis and unipolar psychosis (either depression or mania) [3]. 
This contrasts modern classifications, where unipolar mania is also classified as 
bipolar disorder and unipolar depression is considered under depressive disorders. 
The term, “bipolar disorder”, was first introduced to replace the older term, “manic 
depressive disorder” in the third edition of the American diagnostic system, the 
Diagnostic and Statistical Manual of Mental Disorders (DSM) [6]. This change 
reflected the polarity of mania and depression and the circularity of the disorder, 
distinguishing it from unipolar depression. The term, “hypomania”, was also 
introduced to describe a less impairing state of high mood and patients who only 
experience hypomanic episodes are given a diagnosis of bipolar II disorder [5]. The 
World Health Organisation’s International Classification of Diseases (ICD) also 
adopted these terms, although unlike the DSM’s bipolar I disorder and bipolar II 
disorder, ICD does not distinguish mania and hypomania as subtypes of bipolar 
disorder. Table 1-1 shows the current diagnostic criteria for bipolar disorder 
according to DSM-5 and ICD-10. Bipolar disorder is characterised by recurrent 
episodes of mania or hypomania, which can be accompanied by episodes of 
depression [7, 8]. Mania is defined as a period of at least one week where an 
elevated, expansive or unusually irritable mood is present and includes symptoms 
such as inflated self-esteem, decreased need for sleep, pressure of speech, racing 
thoughts and distractibility [7, 8]. This mood change must be prominent and result 
in impairment in functioning. Hypomania is defined as high mood that lasts at least 
four days but does not result in significant impairment [7, 8]. Depression describes 
a period of at least two weeks where a persistent low mood is present and includes 
symptoms such as diminished interest in activities, changes in appetite or sleep, 
psychomotor agitation or retardation, fatigue, loss of self-esteem and suicidal 
ideation or attempts [7, 8].  
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Table 1-1 Summary of diagnostic criteria for bipolar I disorder and bipolar II disorder 
DSM-5 ICD-10 
Bipolar I Disorder Bipolar II Disorder Bipolar Disorder (Mania) Bipolar Disorder (Hypomania) 
A. Meets criteria for manic episode. 
B. Not better explained by schizoaffective 
disorder, schizophrenia or other psychotic 
disorder. 
Manic Episode 
A. Abnormally and persistently elevated, 
expansive or irritable mood and 
persistently increased activity or energy 
lasting at least one week and present most 
of the day, nearly every day (unless 
hospitalisation is necessary). 
B. Three or more of the following 
symptoms (four if mood is only irritable): 
1. Inflated self-esteem / grandiosity 
2. Decreased need for sleep 
3. More talkative / pressure of speech 
4. Flight of ideas / racing thoughts 
5. Distractibility 
6. Increase in goal-directed activity / 
psychomotor agitation 
7. Excessive involvement in activities 
that have a high potential for painful 
consequences 
C. Marked impairment in functioning or 
hospitalisation or psychotic features. 
D. Not attributable to substance use or 
another medical condition. 
A. Criteria met for at least one 
hypomanic episode and at least one 
major depressive episode. 
B. There has never been a manic episode. 
C. Not better explained by 
schizoaffective disorder, schizophrenia or 
other psychotic disorder. 
Hypomanic Episode 
A. Abnormally and persistently elevated, 
expansive or irritable mood and 
persistently increased activity or energy 
lasting at least four days and present 
most of the day, nearly every day. 
B. Three or more of the symptoms (four 
if mood is only irritable) listed under 
criterion (B) for manic episode. 
C. An unequivocal change in 
functioning. 
D. The disturbance in mood and the 
change in functioning are observable. 
E. Not severe enough to cause marked 
impairment in social or occupational 
functioning or hospitalisation or 
psychotic features. 
F. Not attributable to the physiological of 
a substance or another medical condition. 
A. Meets criteria for manic episode. 
B. At least one previous affective episode 
Manic Episode 
A. Predominantly elevated, expansive or 
irritable mood for at least one week 
(unless severe enough to require hospital 
admission). 
B. Three or more of the following signs 
(four if mood is only irritable) leading to 
severe interference with functioning: 
1. Increased activity / restlessness 
2. More talkative / pressure of speech 
3. Flight of ideas / racing thoughts  
4. Loss of normal social inhibitions 
and inappropriate behaviour  
5. Decreased need for sleep 
6. Inflated self-esteem / grandiosity 
7. Distractibility or constant changes 
in activity or plans 
8. Behaviour that is foolhardy or 
reckless and whose risks the 
individual does not recognise 
9. Marked sexual energy 
C. Delusions or hallucinations may be 
present (not criterion G1(1)). 
D. Not attributable to substance use or 
organic mental disorder. 
A. Meets criteria for hypomanic 
episode. 
B. At least one previous affective 
episode 
Hypomanic Episode 
A. Elevated or irritable mood to a 
degree that is definitely abnormal for 
the individual and sustained for at least 
four consecutive days. 
B. Three or more of the signs present 
leading to some interference with 
personal functioning in daily living: 
1. Increased activity / restlessness 
2. Increased talkativeness 
3. Distractibility / difficulty in 
concentration 
4. Decreased need for sleep 
5. Increased sexual energy 
6. Mild over-spending / reckless or 
irresponsible behaviour 
7. Increased sociability / over-
familiarity 
C. Does not meet criteria for mania, 
bipolar affective disorder, depression, 
cyclothymia or anorexia nervosa. 
D. Not attributable to substance use or 
organic mental disorder. 
DSM-5, Diagnostic and Statistical Manual of Mental Disorders – Fifth Edition, ICD-10, International Classification of Diseases – Tenth Edition
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1.2.2 Schizophrenia 
Eugen Bleuler introduced the term, “schizophrenia”, in 1911 [9]. The term was 
derived from the Greek roots, “schizien” meaning “to split” and “phren” meaning 
“mind”. Bleuler adopted a psychological approach to studying his patients, 
observing their speech and behaviour and performance on psychological tests. 
Bleuler placed less emphasis on delusions and hallucinations and believed the 
symptoms of schizophrenia were the result of an underlying psychological deficit, 
a “splitting” of psychic functions [1, 9]. This view was later opposed by Kurt 
Schneider who argued that specific psychotic symptoms differentiated 
schizophrenia from other psychotic disorders and these symptoms have become 
known as “first-rank” or “Schneiderian” symptoms [1]. These symptoms include 
voices discussing or commenting in third person, passivity, subjective experience 
of thought withdrawal, insertion or broadcast and delusional perception. These 
symptoms were incorporated into modern diagnostic classification systems, 
including the DSM and ICD. However, studies have called into question the idea 
that first rank symptoms are specific to patients with schizophrenia [10, 11]. 
Therefore, the special case of first rank symptoms was removed in the latest edition 
of the DSM (DSM-5) [12].  
The works of Kraepelin, Bleuler and Schneider influenced the criteria for 
schizophrenia described in current classification systems. Both the DSM-5 and 
ICD-10 conceptualise schizophrenia as a psychotic disorder characterised by the 
presence of hallucinations, delusions, disorganised speech and behaviour, catatonia 
and negative symptoms (see Table 1-2 for current diagnostic criteria) [7, 8]. 
Hallucinations are perceptions in the absence of outside stimuli. These are most 
commonly auditory hallucinations, but patients can also present with visual, 
olfactory, tactile or gustatory hallucinations [1]. Delusions are false beliefs, which 
are held with conviction even in the face of contradictory evidence and do not fit 
with a patient’s cultural background. Disorganised speech is also known as formal 
thought disorder and refers to the disintegration of thought processes [1]. This 
results in speech that is disjointed, lacks logical structure, derails from the topic of 
conversation or contains neologisms. Negative symptoms are the loss of affective 
functions and volition [1]. These include blunted emotional responses, poverty of 
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speech (alogia) and loss of enjoyment (anhedonia), motivation (avolition) and 
social drive [1]. 
Table 1-2 Summary of diagnostic criteria for schizophrenia 
DSM-5 ICD-10 
A. At least two symptoms present for at least 
one month. One of the two symptoms must 
be delusions, hallucinations or disorganised 
speech: 
1. Delusions 
2. Hallucinations 
3. Disorganised speech 
4. Grossly disorganised or catatonic 
behaviour 
5. Negative symptoms 
B. Marked reduction in occupational or 
social functioning, or personal care or 
hygiene. 
C. Continuous signs of disturbance must 
persist for at least six months and may 
include periods of prodromal or residual 
symptoms. 
D. Schizoaffective disorder and mood 
disorder with psychotic features have been 
ruled out because either 1) no mood episodes 
have occurred concurrently with active-
phase symptoms, or 2) if mood episodes 
have occurred during active-phase 
symptoms, they have been present for a 
minority of the total duration of the active 
and residual periods of the illness.  
E. Not attributable to the physiological 
effects of a substance or another medical 
condition.  
F. If autism spectrum disorder or a 
communication disorder of childhood onset 
has been previously diagnosed, the diagnosis 
of schizophrenia is made only if prominent 
delusions or hallucinations are present for at 
least one month. 
G1. At least one symptom listed under (1) or 
two symptoms listed under (2) present most 
of the time for at least one month: 
(1) 
A. Thought echo, insertion, withdrawal 
or broadcasting 
B. Delusions of control, influence, 
passivity, clearly referred to body or 
limb movements or specific 
thoughts, actions or sensations; 
delusional perception 
C. Hallucinatory voices giving a 
running commentary on the patient’s 
behaviour or discussing patient in 
third person, or coming from some 
part of the body 
D. Persistent delusions of other kinds 
that are culturally inappropriate and 
completely impossible 
(2)  
A. Hallucinations in any modality 
occurring every day for at least one 
month, accompanied by delusions or 
persistent over-valued ideas 
B. Neologisms, breaks or interpolations 
in the train of thought resulting in 
incoherent or irrelevant speech 
C. Catatonic behaviour 
D. Negative symptoms 
G2. Most commonly used exclusion clauses 
(1) If patient meets criteria for affective 
episode, criteria listed under G1 must be met 
before disturbance of mood developed. 
(2) Not attributable to organic brain disease 
or to alcohol or drug-related intoxication, 
dependence or withdrawal. 
DSM-5, Diagnostic and Statistical Manual of Mental Disorders – Fifth Edition, ICD-10, International 
Classification of Diseases – Tenth Edition  
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1.2.3 Diagnostic issues 
Modern classification systems maintain the distinction between schizophrenia and 
bipolar disorder defined by Kraepelin despite overlap in symptom presentations 
between the disorders. Psychosis is common in bipolar I disorder and studies have 
estimated that between a half and two-thirds of patients experience at least one 
psychotic symptom over the lifetime course of their illness [13-15]. It is estimated 
that approximately 40% of patients with schizophrenia meet criteria for depressive 
disorder at some point in their illness, although estimates range between 20-60% 
depending on clinical factors, such as whether patients are in the early stages of 
illness or chronic and acutely unwell or post-psychotic [16]. Kraepelin himself 
went on to question his dichotomy remarking that “No experienced diagnostician 
would deny that cases where it seems impossible to arrive to a clear decision, 
despite extremely careful observation, are unpleasantly frequent” [17]. In 1933, 
Jacob Kasanin described a group of patients exhibiting symptoms of both psychosis 
and mood and coined the term, acute schizoaffective psychoses [18]. Patients with 
schizoaffective disorder exhibit symptoms of both schizophrenia and mood 
disorder but do not strictly meet the criteria for either alone (see Table 1-3) [7, 8]. 
Schizoaffective disorder can be further separated into subtypes depending on the 
polarity of the mood episode (mania or depression). The diagnosis has drawn 
criticism due to studies demonstrating poor reliability [19, 20] and stability [21]. 
The relationship between schizoaffective disorder and both schizophrenia and 
bipolar disorder is uncertain with theories supporting schizoaffective disorder being 
a schizophrenia or bipolar disorder sub-type, a comorbidity of schizophrenia and 
mood disorder, an independent disorder, or the midpoint of a spectrum ranging 
from a predominantly affective disorder to predominantly psychotic disorder [22]. 
The latter hypothesis suggests that prototypical bipolar disorder and schizophrenia 
lie on the extreme ends of a diagnostic spectrum with schizoaffective disorder 
occupying an intermediate position, representing patients who have features of both 
disorders [23].  
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Table 1-3 Diagnostic criteria for schizoaffective disorder 
DSM-5 ICD-10 
A. An uninterrupted period of illness during 
which there is a major mood episode (major 
depressive or manic) concurrent with 
Criterion A of schizophrenia. 
B. Delusions or hallucinations for at least 
two weeks in the absence of mood episode. 
C. Symptoms that meet criteria for a major 
mood episode are present for the majority of 
the total duration of the active and residual 
portions of the illness. 
D. Not attributable to the effects of a 
substance or another medical condition. 
 
Bipolar type: Manic episode is part of the 
presentation. 
 
Depressive type: Major depressive episode 
is part of the presentation.  
G1. The disorder meets criteria for one of 
the affective disorders of moderate or severe 
degree. 
G2. At least one of the following present 
most of the time for at least two weeks: 
1. Thought echo, insertion, broadcast or 
withdrawal 
2. Delusions of control, influence, 
passivity, clearly referred to body or 
limb movements or specific thoughts, 
actions or sensations 
3. Hallucinatory voices giving a running 
commentary on the patient’s behaviour 
or discussing patient in third person, or 
coming from some part of the body 
4. Persistent delusions of other kinds that 
are culturally inappropriate and 
completely impossible but not merely 
grandiose or persecutory 
5. Grossly irrelevant or incoherent speech 
or frequent use of neologisms 
6. Intermittent but frequent catatonic 
behaviour 
G3. Criteria G1 and G2 must be met within 
the same episode and concurrently for at 
least part of the episode. Symptoms from 
both must be prominent in the clinical 
picture. 
G4. Not attributable to organic brain disease 
or to alcohol or drug-related intoxication, 
dependence or withdrawal. 
 
Manic type: Criteria for schizoaffective 
disorder and manic episode must be met. 
 
Depressive type: Criteria for schizoaffective 
disorder and depressive episode of at least 
moderate severity must be met. 
 
Mixed type: Criteria for schizoaffective 
disorder and mixed bipolar affective 
disorder must be met. 
 
One issue is that current diagnostic criteria continue to rely on observations of 
patterns of symptoms, as the disease mechanisms of these disorders are largely 
unknown [24]. As noted above, this means there are no clear boundaries between 
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certain diagnoses, as they have overlapping symptoms. There is also heterogeneity 
within single diagnoses such that patients with the same diagnosis can exhibit 
widely different symptoms and outcomes. This categorical approach to 
classification that relies on symptom presentation rather than biology is considered 
a barrier to the development of treatments [25]. It has been proposed that a better 
approach to diagnostic classification may be to focus on dimensional measures of 
psychopathology [24, 26, 27]. One such attempt to use a dimensional approach is 
the National Institute for Mental Health’s Research Domain Criteria (RDoC) [25, 
28]. RDoC is not a clinical diagnostic tool but a framework for conducting research, 
which it is hoped will lead to an improved understanding of the underlying 
mechanisms of psychiatric disorders. An understanding of the biological basis of 
psychiatric disorders is considered the first step in the future development of a 
valid approach to diagnostic classification [25, 28].  
The RDoC framework is based on three assumptions: i) that mental illnesses are 
disorders of brain circuitry, ii) that the research approaches adopted in clinical 
neuroscience can identify neural circuit dysfunction, and iii) that genetic and 
neuroscience research will identify “bio-signatures” [25]. The RDoC approach is 
represented in a two-dimensional matrix where each row is a dimension of 
behaviour or neurobiology and each column is a unit or measurement that is used 
to assess that dimension [29]. The dimensions are arranged into five systems: 
negative valence, positive valence, cognition, social processing and arousal or 
regulatory systems. The columns are genes, molecules, cells, circuits, physiology, 
behaviour, self-reports and paradigms. It is hoped that the RDoC will encourage 
researchers to focus less on specific disorders and more on behaviours that are 
likely to have biological underpinnings. One criticism of RDoC is the lack of 
emphasis on what is already known about the clinical symptoms and aetiology of 
psychiatric disorders [24]. Certain diagnoses are more clinically similar than others. 
Owen and colleagues have proposed a model of diagnostic classification that 
incorporates dimensional approaches, as well as representing existing relationships 
between diagnoses [24, 27, 30]. This model includes intellectual disability, autism, 
schizophrenia, schizoaffective disorder and bipolar disorder given evidence of 
overlapping genetic and environmental risk factors (see Figure 1-1). It is proposed 
that these disorders occupy a gradient of neurodevelopmental impairment indexed 
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by the contributions of genetic and environmental risk. The following sections 
outline what is currently known about the epidemiology, aetiology and course of 
schizophrenia, schizoaffective disorder and bipolar disorder.  
 
Figure 1-1 Hypothesised relationship between diagnoses (adapted from Owen (2014)) 
 
1.3 Epidemiology 
Lifetime prevalence estimates are between 0.4% to 0.7% for schizophrenia [31] 
and 0.8% to 1% for bipolar disorder – type I [32-34]. The median incidence rate of 
schizophrenia was calculated to be 15.2 per 100, 000 people per year (80% 
confidence interval: 7.7-43) [31]. Schizophrenia is more common in males than 
females with a ratio of 1.4:1 [31] but this difference is not seen in bipolar disorder 
[32]. Few studies have estimated the prevalence of schizoaffective disorder, which 
may be in part due to the lack of diagnostic stability over time [35]. The existing 
data suggests lifetime prevalence of schizoaffective disorder is between 0.2% and 
1.1% [35, 36]. 
The World Health Organisation’s Global Burden of Disease Study identified 
schizophrenia and bipolar disorder, along with depression, amongst the top ten 
leading causes of disease burden in young people (ages 15- to 44- years old) [37, 
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38]. Gore et al. [37] evaluated disability-adjusted life years (DALYs) in 10- to 24-
year olds using data from the Global Burden of Disease Study. One DALY 
corresponds to one year of life lost in a population due to disability and premature 
mortality. Schizophrenia and bipolar disorder accounted for 4.1% and 3.8% of total 
DALYs. Further, neuropsychiatric disorders overall accounted for 45% of years 
lost due to premature mortality in this age group. Findings from the Global Burden 
of Diseases, Injuries and Risk Factors Study 2010 indicated that the burden of 
disease associated with schizophrenia and bipolar disorder (as measured by 
DALYs) was greatest between the ages of 25 and 50 years [39].  
The age of onset of schizophrenia and bipolar disorder is typically around late 
adolescence and early adulthood [40-42]. In schizophrenia, there is a slight sex 
difference with a peak in cases in males between the ages of 20 to 25 years old but 
a less marked and slightly older peak in females [41, 43]. After the age of 35 years, 
the number of males developing schizophrenia drops markedly but there is a 
second peak for women around age 45 [41]. One proposed explanation for this is 
that oestrogen levels may act as a protective factor before menopause, as oestrogen 
reduces sensitivity of D2 dopamine receptors [40]. This gender difference in age of 
onset is not seen in bipolar disorder [44, 45], although the first episode of mania 
may occur earlier in males than females [46]. 
Schizophrenia and bipolar disorder are associated with elevated risk of premature 
death. Standardized mortality ratios (SMR) for all-cause mortality in schizophrenia 
populations indicate that risk of death is two to three times greater than the general 
population (matched by age and sex) [31] and the life expectancy of patients is 
reduced by up to 20 years [47]. Risk of death from all causes is lower in bipolar 
disorder than schizophrenia and a long term follow up study of participants with 
affective disorders found an overall SMR of 1.58 for bipolar disorder [48]. Patients 
with bipolar disorder have a reduced life expectancy of between 12 and 15 years 
[49, 50].   
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1.4 Aetiology 
Neither genetic nor environmental risk alone can account for risk of schizophrenia 
or bipolar disorder. The aetiology of these disorders is a complex mix of genetics 
and environment. The risk factors for schizophrenia and bipolar disorder are 
outlined in the following sections.  
1.4.1 Genetic risk 
Both schizophrenia and bipolar disorder have been shown to have substantial 
heritability. Heritability estimates are around 80% for schizophrenia [51, 52] and 
60-80% for bipolar disorder [53-55]. Family studies have estimated that risk of 
schizophrenia is around 10% in first-degree relatives of patients with schizophrenia 
[53]. The risk of bipolar disorder in the first-degree relatives of individuals with 
bipolar disorder is around 8-9% [53, 55]. The risk of being admitted to hospital for 
a psychotic or affective disorder is substantially higher when both parents have a 
history of either schizophrenia (incidence rate of admission was 39%) or bipolar 
disorder (incidence rate of 25%) [56]. Adoption and twin studies have attempted to 
disentangle the effects of genetics and environment. Adopted offspring, whose 
biological parents had schizophrenia, have been shown to have around seven-fold 
risk of developing schizophrenia [53]. Adopted offspring, whose biological parents 
had bipolar disorder, have around four-fold risk of developing bipolar disorder [53]. 
In twin studies, concordance rates of schizophrenia in monozygotic twins have 
been estimated to be 40-65% compared to 2-30% in same-sex dizygotic twins [52]. 
In bipolar disorder, concordance rates are approximately 45-65% in monozygotic 
twins and 4-10% in dizygotic twins [55]. The fact that concordance rates are less 
than 100% in monozygotic twins indicates that environmental risk factors also 
contribute to the development of schizophrenia and bipolar disorder.  
Family studies have demonstrated that schizophrenia and bipolar disorder have 
shared genetic aetiology. A study of Swedish registry data showed that relative risk 
(RR) of schizophrenia is 2.4-3.9 for first-degree relatives of patients with bipolar 
disorder, whilst relative risk of bipolar disorder is 3.7-5.2 for first-degree relatives 
of patients with schizophrenia [53]. A Danish registry study also found that relative 
risk of schizoaffective disorder was increased for those with a first degree relative 
with schizophrenia (RR=2.6), bipolar disorder (RR=3.2) or schizoaffective disorder 
13 
 
(RR=1.9) [57]. This suggests that schizoaffective disorder is genetically related to 
both disorders.  
Advances in molecular genetics technology have provided new insights into the 
aetiology of psychiatric disorders. Genetic studies of schizophrenia indicate that 
both common variants with small effects and rare mutations with large effects are 
associated with increased risk of schizophrenia. A genome-wide association study 
(GWAS) of participants with schizophrenia conducted by the Schizophrenia 
Working Group of the Psychiatric Genomics Consortium (PGC) identified 128 
independent single nucleotide polymorphisms (SNPs) at 108 loci that exceeded 
genome-wide significance [58]. The 108 loci included protein-encoding genes such 
as DRD2 that encodes dopamine receptor D2 and genes involved in glutamate 
transmission, synaptic plasticity and calcium signalling. In the largest genetic study 
of participants with schizophrenia to date, Pardiñas et al. [59] identified 50 novel 
loci associated with schizophrenia and 179 genome-wide significant SNPs at 145 
loci in total. The authors quantified that 64% of these variants were within gene 
boundaries and these were more likely to be mutation-intolerant genes, including 
genes that are important for the function of the central nervous system. Common 
genetic variation accounts for approximately one-third of genetic liability for 
schizophrenia [60]. 
In addition to common genetic variants, it is increasingly recognised that certain 
rare variants also increase risk of developing schizophrenia. Copy number variants 
(CNVs) are deletions or duplications of sections of DNA greater than 1 kilobase 
(kb) in size [61]. Several rare CNVs greater than 500kb have been associated with 
increased risk of schizophrenia. One of the largest identified genetic risk factors for 
the development of schizophrenia is 22q11.2 deletion syndrome (also known as 
DiGeorge, velo-cardial-facial or Shprintzen syndrome) [62, 63]. Patients with this 
genetic syndrome have up to 30% risk of developing schizophrenia or related 
disorders [62, 63]. Deletions within the neurexin 1 gene that intersect exons also 
substantially increase risk of schizophrenia (OR=8.97) [64]. This gene encodes a 
pre-synaptic cell adhesion protein. More recently, 12 CNVs in 11 loci were shown 
to be risk factors for schizophrenia [65, 66]. These CNVs are also associated with 
intellectual disability, autism spectrum disorders and congenital malformations [65, 
66].  
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There has been less progress in identifying genetic risk variants for bipolar disorder 
than in schizophrenia research. As is the case for schizophrenia, there is evidence 
that common variants with small effects increase risk of bipolar disorder. Work by 
the Psychiatric GWAS Consortium Bipolar Disorder Working Group and a 
subsequent replication have identified associations between risk of bipolar disorder 
and several regions, including CACNA1C, ODZ4, ANK3 and 15q14 [67, 68]. 
These studies consistently identify a role for calcium channels in genetic risk for 
bipolar disorder. In contrast to research of schizophrenia, there is little evidence for 
an increased burden of CNVs in those with bipolar disorder [69-72]. There is 
preliminary evidence that the burden of CNVs is higher in those with early onset 
bipolar disorder, although this requires replication in larger samples [70, 71]. 
The Cross-Disorder Group of the Psychiatric Genomics Consortium analysed data 
on over 30,000 cases with schizophrenia, bipolar disorder, major depressive 
disorder, autism spectrum disorder and attention deficit hyperactivity disorder to 
evaluate the genetic overlap between these disorders [73, 74]. They identified SNPs 
at four loci that exceeded genome-wide significance [74]. Polygenic risk scores for 
each disorder were calculated and these scores were examined in each of the five 
disorder groups. There was significant overlap of polygenic risk between 
schizophrenia, bipolar disorder and major depressive disorder. Polygenic risk for 
autism also overlapped with both schizophrenia and bipolar disorder, whilst risk for 
attention deficit hyperactivity disorder did not overlap with the other four disorders. 
Pathway analysis provided evidence of pleiotropic effects for calcium signalling 
genes. This suggests voltage-gated calcium signalling is an important biological 
process across disorders and may be a potential treatment target. In a further study, 
they examined genetic correlations between the five disorders [73]. The highest 
genetic correlation was between schizophrenia and bipolar disorder. Moderate 
correlations were observed between bipolar disorder and major depressive disorder, 
schizophrenia and major depressive disorder, and attention deficit hyperactivity 
disorder and major depressive disorder. There was a low but significant genetic 
correlation between schizophrenia and autism spectrum disorder. It should be noted 
that there were differences in sample sizes across the disorders and the autism 
spectrum sample was small compared to the other samples. Despite this, genetic 
correlations were detected between the disorders. Overall, their results provide 
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evidence of shared risk loci between schizophrenia and bipolar disorder, as well as 
other adult and childhood onset disorders.  
1.4.2 Environmental risk 
The studies described in the previous section identified genetic variants that 
increase the likelihood of developing schizophrenia or bipolar disorder but these 
variants do not wholly explain the occurrence of these disorders. As noted above, 
concordance rates among monozygotic twins have been reported to be 40-65% in 
studies of schizophrenia and studies of bipolar disorder. This indicates that 
environmental factors are also important in the development of schizophrenia and 
bipolar disorder. A number of environmental risk factors from pregnancy through 
to early adulthood have been identified for bipolar disorder and schizophrenia. 
However, there is variability in outcomes amongst people exposed to these risk 
factors, which may be partly explained by differences in vulnerability or resilience 
[75]. Thus, it is likely that the onset of schizophrenia or bipolar disorder arise from 
a complex interaction of genes and environment [75].  
Pregnancy and birth complications may increase risk of schizophrenia. Perinatal 
complications that have been associated with risk of schizophrenia include low 
birth weight (less than 2500 grams) [76-78], shorter gestation (less than 37 weeks) 
[76, 77], asphyxia [79], use of resuscitation or incubator [77], forceps delivery [77], 
preeclampsia [80], caesarean section [81, 82], congenital malformations [80] and 
bleeding during pregnancy [78, 83]. It is currently unclear whether these 
complications are causal or are early indicators of a genetic predisposition or 
abnormal neurodevelopment. The evidence for an association between obstetric 
complications and risk of bipolar disorder is conflicting. Several small studies 
found an association between overall presence of obstetric complications and 
bipolar disorder [84, 85] but larger studies have not found evidence that obstetric 
complications increase risk of bipolar disorder [86, 87]. However, a Swedish 
registry study found evidence that a shorter gestation increases risk of bipolar 
disorder in young adults (aged 16 years) [88]. Advanced paternal age has also been 
identified as a risk factor for schizophrenia [89-91] and bipolar disorder [92]. This 
association was not explained by socioeconomic, maternal age, family history of 
psychiatric disorder or parental death [89, 91, 92]. Biological mechanisms that 
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have been proposed to explain how advanced paternal age increases risk of 
schizophrenia include an increased rate of de novo mutations or genomic 
imprinting [75, 91]. 
There is a seasonal birth pattern for patients with bipolar disorder, schizoaffective 
disorder and schizophrenia such that more patients were born in the winter and 
spring months [93]. A number of possible explanations have been proposed for this 
pattern, including seasonal variations in obstetric complications, procreational 
habits or exposure to light, toxins, nutrients, temperature, weather or infectious 
agents [93]. Seasonal changes in the rate of infectious agents may be a plausible 
explanation, as prenatal exposure to infections increases the risk of developing a 
number of psychiatric disorders including schizophrenia and bipolar disorder. 
Specifically, prenatal exposure to influenza has been associated with a four-fold 
increase in risk of bipolar disorder [94]. Exposure to influenza in the second 
trimester of pregnancy has been shown to increase risk of psychotic bipolar 
disorder but not bipolar disorder in general [95]. Prenatal infections including 
influenza, rubella and toxoplasmosis have been shown to increase of schizophrenia 
[96-98]. Prenatal exposure to infection has also been linked to autism [99] and 
cerebral palsy [100]. This suggests that prenatal exposure to infection increases 
vulnerability to brain disorders and provides support for bipolar disorder and 
schizophrenia as neurodevelopmental disorders.  
Childhood adversity or trauma has been shown to increase risk of all DSM-IV 
categories of psychiatric disorder in the World Mental Health survey of 21 high, 
middle and low income countries [101]. These adversities include parental loss, 
parental divorce or separation, parental maladjustment, neglect, abuse, life-
threatening illness or poverty before 18 years old [101]. The strongest predictors of 
psychiatric disorder were adversities associated with maladaptive family 
functioning, including parental maladjustment (parental mental illness, substance 
use disorder, criminality or family violence), physical abuse, sexual abuse and 
neglect. Patients with bipolar disorder are more likely to report experiencing severe 
child abuse, including neglect, emotional, physical and sexual abuse [102, 103]. 
Childhood neglect, abuse and bullying are also associated with increased risk of 
psychosis [104]. However, these studies have relied on self-report measures of 
childhood adversities and it has been shown that adult participants are likely to 
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under-report adversities during their childhood [105]. The relationship between 
child adversities and psychiatric disorder is complex and likely to be influenced by 
genetic factors as well as the environment [75]. For example, greater exposure to 
an adverse environment may be due to living with a parent or sibling who either 
has the disorder or exhibits poor social functioning or subclinical features of 
psychosis or mood instability, such as schizotypal traits [75]. In addition, people 
with high genetic risk may be more likely to experience adverse events, such as 
parental neglect or abuse or peer bullying, due to poor social functioning or 
personality traits [75]. Genetic factors may also influence vulnerability or resilience 
to developing psychiatric disorders following an adverse event [75].  
First- and second-generation migrants are at increased risk of developing 
schizophrenia, particularly migrants from countries in the Caribbean and sub-
Saharan Africa [106]. The high incidence of schizophrenia among first- and 
second-generation migrants from the Caribbean to the UK has been well 
documented [107-110]. This group is also at increased risk of mania [110]. These 
findings are not explained by misdiagnosis [111, 112], cannabis use [113] or high 
exposure to obstetric complications [114]. A study of participants with a first 
episode of schizophrenia in Jamaica reported an incidence rate of 1.16 per 10,000 
[115], which is comparable to the overall incidence rate of 1.17 per 10,000 reported 
by the ÆSOP study across three cities in England (London, Nottingham and 
Bristol) [116]. This suggests that genetic factors do not fully account for the higher 
incidence reported amongst migrants in the UK. Another UK-based study reported 
that siblings of second-generation African-Caribbean patients with schizophrenia 
were at greater risk of schizophrenia than the siblings of White British-born 
probands, and first-generation African-Caribbean probands [108]. This finding 
provides further support for the role of environmental factors, as first-degree 
relatives of patients born in the Caribbean had similar risk of schizophrenia as first-
degree relatives of white patients born in the UK. Social factors that may contribute 
to the high incidence of schizophrenia amongst African-Caribbean migrants 
include a greater number of adverse experiences and perceptions of discrimination 
[117, 118]. 
There is a higher incidence of schizophrenia in urban areas compared to rural areas 
[119]. It is estimated that this risk factor can account for approximately 30% of 
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schizophrenia cases [120, 121]. It has been proposed that individuals with genetic 
liability for schizophrenia are more likely to move into urban areas, although it has 
been noted that increased risk of schizophrenia is associated with an urban 
upbringing and children or adolescents are unlikely to make decisions regarding 
where their family lives [75]. There is evidence of a gene-environment interaction 
between urban birth and genetic risk. The risk of schizophrenia is higher for 
individuals who were born in an urban area and have familial liability than 
individuals born in an urban area with no familial liability [122]. Another study 
found that people who live in rural areas during their first fifteen years of life had 
an elevated risk of schizophrenia if their sibling was born in an urban area 
compared to individuals whose siblings were also born in rural areas [123]. The 
effect of urban upbringing on risk of schizophrenia is not fully explained by 
cognitive functioning [124], air pollution [125] or obstetric complications [126]. 
Excessive use of cannabis has been associated with schizophrenia [127]. A study of 
over 50,000 Swedish conscripts found cannabis use increases the risk of 
developing schizophrenia by 30% [127]. There was a linear trend for frequency of 
use and risk of schizophrenia. This risk was evident when participants who had 
used other substances were excluded and after controlling for low IQ, urban 
upbringing, cigarette smoking, poor social integration and disturbed behaviour. 
However, this association between cannabis and schizophrenia does not imply 
causation. It is possible that patients use cannabis during the prodromal phase of 
schizophrenia to combat psychological distress of early symptoms [127]. Gage et al. 
[128] used Mendelian randomisation to examine whether there is a causal 
relationship between cannabis initiation and risk of schizophrenia. There was 
evidence of a small but significant causal effect of cannabis initiation on risk of 
schizophrenia, although it should be noted that none of the SNPs associated with 
cannabis initiation that were included in this study reached genome-wide 
significance in the original GWAS. There was stronger evidence that genetic risk 
for schizophrenia is associated with likelihood of cannabis initiation. However, 
cannabis use was recorded as a binary variable (never/ever) in the original GWAS 
and therefore the study did not consider frequency of cannabis use. Therefore, 
participants who had tried cannabis once were recorded as having a history of 
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cannabis use. This is an important consideration as more frequent cannabis use is 
associated with greater risk of schizophrenia [127].  
There is conflicting evidence that cannabis use increases risk of mood disorders. 
One study found a modest association between cannabis use and risk of unipolar 
depression and a stronger association between cannabis use and risk of bipolar 
disorder, although the mean age of participants at baseline was 39 years old, older 
than the typical age of onset of bipolar disorder [129]. A second study found that 
weekly to daily use of cannabis was associated with increased incidence of bipolar 
disorder but not major depressive disorder [130]. However, the association between 
cannabis use and risk of bipolar disorder was not maintained after adjustment for 
potential confounders, including socio-demographic factors, alcohol and other 
substance use and diagnosis of other psychiatric disorders.  
The use of cocaine [131], tranquilizers [132], stimulants [132], sedatives [132] or 
non-medical use of opioids [133, 134] has been associated with increased risk of 
bipolar disorder. However, it is unclear whether there is a direct relationship 
between substance use and bipolar disorder. Genetic and environmental factors 
may confer vulnerability for both bipolar disorder and drug use [134]. For example, 
childhood abuse has been associated with increased risk of bipolar disorder [102, 
103] and substance use problems [135]. Evidence for an association between 
substance use (other than cannabis) and schizophrenia are scarce. In the study of 
Swedish conscripts, there was no association between stimulant use and risk of 
schizophrenia after adjustment for potential confounders [127]. However, a 
population study of inpatient admissions in California found a higher risk of 
schizophrenia amongst individuals who use methamphetamine compared to those 
who use cocaine or non-stimulant drugs, such as alcohol or opioids [136]. 
1.5 Course of illness and treatment 
Early behavioural signs are apparent before the onset of schizophrenia. Prior to the 
onset of psychosis, patients often exhibit a decline in academic or occupational 
functioning and social withdrawal [137]. Schizophrenia is associated with a range 
of psychotic, negative and cognitive symptoms that can influence the course of the 
disorder. The course of schizophrenia can be broadly categorised as episodic with 
intermediate periods of partial or complete remission, complete and persistent 
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remission after one or more psychotic episodes or continuous psychotic symptoms 
with no remission. A review of longitudinal studies spanning almost a century 
found that up to 30-50% of participants with psychosis have a favourable outcome 
[138]. The International Study of Schizophrenia, co-ordinated by the World Health 
Organisation, examined 18 cohorts of participants recruited across the world with 
follow-up periods of up to 25 years [139]. At follow up, 43% of participants with 
schizophrenia and 62% of participants with other psychotic disorders had a 
favourable outcome, defined as no psychotic episodes in the last two years. 
Duration of psychosis during the first two years of illness was the strongest 
predictor of both symptom severity and level of disability at follow-up. The 
Schizophrenia Health Outcomes (SOHO) study recruited 5950 participants with 
schizophrenia across ten European countries to examine longitudinal course over a 
three-year period [140]. The SOHO study defined remission as either the absence 
of positive, negative and cognitive symptoms or the presence of only mild 
symptoms maintained for a period of six months or longer. Using these criteria, 
46% of participants were considered to have achieved and maintained remission, 
16% remitted but later relapsed and 39% had a continuous course of illness. 
Similar recovery rates were reported by the ÆSOP-10 study, a ten-year 
longitudinal study of 557 participants with a first episode of psychosis [141]. In 
this study, 77% of participants who were traced had met criteria for remission 
(absence of overt psychosis for at least six months) at least once during the follow-
up period and 46% of participants met criteria for recovery (sustained remission for 
two or more years).  
Whilst positive and disorganised symptoms have been shown to be less severe in 
older patients with schizophrenia, negative symptoms are not associated with age 
suggesting that these symptoms persist across the lifespan [142]. The presence of 
prominent and enduring negative symptoms, termed deficit syndrome [143], is 
associated with poorer outcomes in patients with schizophrenia. One 20-year 
longitudinal study showed that participants with deficit schizophrenia rarely 
recovered and had a much poorer outcome after 20 years than participants with 
non-deficit schizophrenia [142]. Only 13% of these participants met criteria for 
global recovery at any of the six follow-up assessments, compared to 63% of 
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participants with non-deficit schizophrenia and 76% of participants with non-
psychotic depression.  
The main treatment for schizophrenia is antipsychotic medication. Early 
antipsychotic medications (known as typical or first generation antipsychotics) 
showed a lack of efficacy in some patients, had negligible effects on negative 
symptoms and were associated with adverse side effects, particularly 
extrapyramidal side effects and tardive dyskinesia [144]. Second generation or 
atypical antipsychotic medications have fewer extrapyramidal side effects than 
typical antipsychotics, although there is limited evidence for greater efficacy of 
atypical antipsychotics in reducing symptoms [144-149]. Olanzapine and 
risperidone were found to be superior to other atypical antipsychotics for patients 
with non-treatment resistant schizophrenia in a meta-analysis [150]. Atypical 
antipsychotics are associated with small improvements in cognitive and negative 
symptoms [144, 151]. Up to one third of patients with schizophrenia do not 
respond after successive treatments of two or more antipsychotic medications 
(other than clozapine) [152]. Clozapine has been shown to be superior in treating 
patients with treatment-resistant schizophrenia [153, 154]. There is evidence that 
patients with a shorter duration of untreated psychosis have a better prognosis, 
including less severe positive and negative symptoms and better functioning [155]. 
This has led to the introduction of early intervention services. The National 
Institute for Health and Care Excellence (NICE) recommends that these services 
should be accessible to all people with a first presentation of psychosis and should 
offer a combination of antipsychotic medication and psychological interventions 
(family intervention and individual cognitive behavioural therapy (CBT)) [156]. 
Whilst antipsychotic medications are effective in treating patients’ psychotic 
symptoms, psychosocial interventions and community support are important for 
improving patients’ social and occupational outcomes [157]. A meta-analysis of the 
efficacy of CBT for reducing symptoms found small improvements in positive and 
negative symptoms following CBT (Hedges’ g effect sizes were -0.25 and -0.13 
respectively) [158]. However, the improvements in positive and negative 
symptoms were small and not significant (Hedges’ g effect sizes were -0.08 and -
0.04) in a sub-analysis of studies that had masked the treatment assignment from 
the researchers that administered outcome assessments. 
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The course of bipolar disorder is characterised by recurrent episodes of mania, 
hypomania, depression or mixed episodes. There is little evidence that 
nonpsychotic bipolar disorder is preceded by a decline in occupational and social 
functioning [159, 160], although some studies have found social impairments are 
present but to a milder extent than those seen in schizophrenia [161, 162]. Long-
term (20-25 years) follow-up studies of participants with bipolar disorder indicate 
that the majority of participants recover from a mood episode within one year and 
episodes of depression are more frequent than episodes of mania [163, 164]. 
Depressive and mixed episodes have longer durations than mania or hypomania 
and are associated with a more chronic course of illness [163-165]. Episodes with 
psychotic features or severe psychosocial impairment have been associated with a 
lower probability of recovery [164].  
Treatment of bipolar disorder usually involves a combination of mood stabilisers, 
antipsychotic and antidepressant medication [166]. Antipsychotics have been 
shown to be effective in treating acute mania, particularly olanzapine, risperidone 
and haloperidol [167, 168]. For long term maintenance, lithium or a combination of 
lithium and valproate remains the most effective treatment for bipolar disorder 
[168-171]. However, it is estimated that up to one third of patients do not respond 
to treatment [166, 172, 173]. As noted earlier, depressive symptoms are associated 
with a poorer prognosis in bipolar disorder but there is a lack of efficacious 
treatments for bipolar depression [166]. Anti-depressants are commonly prescribed 
but current evidence suggests that these medications are scarcely more effective 
than placebos in treating patients with bipolar disorder [174, 175]. There is some 
evidence that quetiapine or a combination of olanzapine and fluoxetine may be 
beneficial in treating bipolar depression [168, 176-178].  
Participants with schizoaffective disorder are frequently grouped with participants 
with schizophrenia in longitudinal studies, although there is evidence that these 
participants may have better outcomes. A ten-year longitudinal study reported that 
participants with schizoaffective disorder had poorer global outcomes than 
participants with bipolar disorder and major depressive disorder but better 
outcomes than those with schizophrenia [179]. This study also found that 
participants with bipolar disorder or major depressive disorder who experienced 
mood-incongruent psychosis had worse outcomes than those with mood-congruent 
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psychosis. A 15-year study reported that participants with schizophrenia had more 
hospital admissions than participants with bipolar disorder and major depressive 
disorder, while those with schizoaffective disorder had an intermediate number of 
admissions [180]. Scores on the Global Functioning Scale increased from 
schizophrenia to schizoaffective disorder to bipolar disorder and major depressive 
disorder. Based on three measures of negative symptoms, 59-75% of participants 
with schizophrenia had negative symptoms compared with 53-74% of the 
schizoaffective group and 34-47% of the bipolar disorder and major depressive 
disorder group. It should be noted that these studies did not differentiate between 
the subtypes of schizoaffective disorder (bipolar and depressive). One study 
showed that participants with the depressive subtype of schizoaffective disorder 
displayed comparable levels of emotional blunting and negative symptoms to 
participants with schizophrenia, whilst participants with the bipolar subtype of 
schizoaffective disorder had fewer negative symptoms [181].  
Despite advancements in the treatment of psychotic and manic symptoms, a 
substantial proportion of patients with schizophrenia and bipolar disorder continue 
to experience disability. Aside from negative and depressive symptoms, the 
presence of cognitive impairments limits patients’ ability to maintain paid 
employment and function in the community. The number of studies into the nature 
and degree of these cognitive impairments has grown substantially in recent 
decades, as researchers attempt to identify the biological mechanisms that could be 
potential targets in the development of new treatments. 
1.6 Cognition in schizophrenia and bipolar disorder 
Deficits in cognitive ability have long been recognised as a key feature of 
schizophrenia but are increasingly recognised in patients with bipolar disorder. 
Cognitive impairments may be an important treatment target, as more severe 
impairments are linked to greater difficulties for patients in living and working 
independently. The nature and degree of these impairments across psychotic and 
affective disorders are not fully understood and there are currently no approved 
treatments for cognitive impairments.  
Numerous studies have identified relationships between cognitive function and 
measures of functional outcomes in participants with schizophrenia and bipolar 
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disorder [182, 183]. One meta-analysis showed that both neurocognitive and social 
cognitive measures are associated with functional outcomes in participants with 
schizophrenia, accounting for 4% and 16% of the variance respectively [183]. 
Similar findings were reported in a meta-analysis of participants with bipolar 
disorder [182]. In this study, overall cognitive function was most strongly 
associated with performance-based measures of functional outcomes. It was not 
possible to determine the causality of these associations or measure the impact of 
changes in cognitive performance on functional outcomes in this meta-analysis due 
to the use of cross-sectional data. Longitudinal studies indicate that cognitive 
performance measured during or soon after the first episode of schizophrenia or 
bipolar disorder is associated with later social and occupational functioning [184, 
185]. There is also evidence that a decline in cognitive function over a period of 
one to seven years is associated with greater functional disability [185, 186]. One 
study examined the association between cognitive function and overall disability in 
a cross-disorder sample of adolescents and young adults (aged 12-35 years) [186]. 
Participants were reassessed between 12 and 36 months after their initial 
assessment. Improved verbal memory and sustained attention between baseline and 
follow-up predicted greater reductions in overall disability, as measured by World 
Health Organisation’s Disability Assessment Schedule. The authors performed a 
cluster analysis and identified three cognitive subtypes that were associated with 
functional outcomes. These clusters did not differ by diagnosis, which suggests that 
cognitive function predicts functional outcomes independently of diagnosis. This 
highlights the importance of examining cognitive function across disorders.  
Another reason to examine cognitive function across disorders is that intelligence 
has been shown to be heritable. Therefore, the genetic overlap between bipolar 
disorder and schizophrenia may include genes that affect cognitive function. 
Identifying genetic variants associated with cognitive function may aid the 
discovery of biological pathways as new treatment targets. General intelligence has 
been shown to be heritable in twin studies of healthy individuals (heritability 
estimate: 0.47, [187]). Genetic studies indicate intelligence has a polygenic nature 
(SNP-based heritability: 0.20 [188]). The largest genome-wide association study of 
intelligence to date (N=78,308) implicated 52 genes through identification of 
genome-wide significant SNPs and gene-based analyses [188]. These included 
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genes previously identified as having a role in neuronal function (synapse 
formation, axon guidance, putamen volume, regulation of myogenic and neuronal 
differentiation) Genes implicated in cognitive function overlapped with genes 
implicated in schizophrenia [188]. The same study identified negative genetic 
correlations between general cognitive function and depressive symptoms and 
neuroticism. Another study reported negative genetic correlations between 
polygenic profile scores for higher cognitive ability or educational attainment, and 
schizophrenia, autism, bipolar disorder, Alzheimer’s disease and major depressive 
disorder [189]. 
1.7 Cognition in schizophrenia 
Cognitive impairments have been recognised as a central feature of schizophrenia 
since the disorder was first conceptualised in the nineteenth century [2, 3]. Morel, 
Kahlbaum and Kraepelin each described progressive deterioration in mental 
functions in their patients and considered schizophrenia to be a type of early onset 
dementia [2, 3]. However, by the second half of the twentieth century, focus had 
shifted towards the classification of psychosis and the treatment of these symptoms 
[1]. There has been a renewed interest in studying cognition in schizophrenia, due 
to the recognition that these impairments have a profound impact on functional 
outcomes [183] and advances in cognitive and neuroimaging approaches [1, 190]. 
The last three decades have seen a substantial increase in research studies 
examining cognitive impairments in participants with schizophrenia. 
1.7.1 Nature of cognitive deficits 
Heinrichs and Zakzanis [191] conducted the first meta-analysis of the studies 
comparing participants with schizophrenia to healthy controls. They calculated 22 
effect sizes from 204 studies, including measures of verbal memory, nonverbal 
memory, motor performance, visual and auditory attention, general intelligence, 
spatial ability, executive function, language and tactile transfer. Cohen’s d effect 
sizes ranged from 0.46 to 1.41 after correction for sample size and all domains 
were significant indicating that participants with schizophrenia exhibited general 
cognitive dysfunction compared to healthy controls. The worst affected cognitive 
ability was verbal memory. However, many of the studies in the meta-analysis 
included participants who were predominantly middle-aged and had been unwell 
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for long periods of time. There were several potential confounders, including 
antipsychotic medication use, symptoms and hospital admissions. The authors 
conducted a limited number of moderator analyses to examine the impact of these 
clinical variables but few studies had reported sufficient demographic and clinical 
data. Despite these limitations, the results of Heinrichs and Zakzanis’s study have 
been consistently replicated by subsequent meta-analyses, which have 
demonstrated that participants with schizophrenia perform on average one to two 
standard deviations below healthy controls [192, 193]. A meta-analysis of studies 
examining antipsychotic-naïve participants with schizophrenia also demonstrated 
impairments in verbal memory, speed of processing, working memory, attention, 
visual memory and executive function (Cohen’s d ranged from 0.74 to 1.03) [194]. 
One aspect of cognition that received little attention in these meta-analyses was 
processing speed. This is the speed with which relatively simple cognitive tasks can 
be completed. Typical measures of processing speed involve assessing how many 
trials of a simple task a participant can complete within a given time limit. Many 
higher order cognitive abilities are speed dependent. Dickinson et al. [195] 
conducted a meta-analysis of studies that assessed processing speed and compared 
the effect sizes to those obtained for other common measures of cognitive function. 
The largest effect size was for the processing speed task, Digit Symbol Coding 
(Hedge’s g = 1.57), whilst effect sizes for the remaining tasks ranged between 0.52 
and 1.41. Relatives of patients with schizophrenia also exhibited deficits on the 
Digit Symbol Coding task, as well as smaller deficits in measures of verbal 
learning, executive function and attention. Moderator analyses indicated that 
participants with a longer duration of illness and earlier age of onset had larger 
deficits in Digit Symbol Coding than younger participants or those who had been 
unwell for less than a year. A subsequent meta-analysis found a similarly large 
effect for Digit Symbol Coding (Hedge’s g = -1.50) [196]. Meta-regression 
analyses indicated that part of the heterogeneity in effect sizes for this task could be 
explained by between-study differences in publication year, differences in IQ 
between cases and controls and chlorpromazine equivalent dose. However, their 
results still suggested a large deficit in performance on the Digit Symbol Coding 
task for the schizophrenia group. 
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Deficits in social cognition have also been identified in patients with schizophrenia. 
The term, “social cognition”, describes the mental processes involved in 
understanding and managing social situations, including interpreting the intentions 
or emotions of other people [197]. Examples of these processes include the ability 
to identify emotions in faces and theory of mind, which is the ability to attribute 
and understand the beliefs, desires and intentions of others. It has been posited that 
impairments in social cognition may play a role in the development and 
maintenance of delusions [197, 198]. Impairments in theory of mind have been 
identified in participants with schizophrenia at onset and throughout the course of 
the disorder, as well as in participants at high risk of developing psychosis [199]. 
Emotion perception has also been shown to be impaired in participants with 
schizophrenia [200]. Fett and colleagues [183] conducted a meta-analysis to 
examine the relationships between functional outcome and either neurocognitive 
performance or social cognitive performance. The social cognitive domains 
included theory of mind, emotion perception and processing and social perception 
and knowledge. Associations between the domains of social cognition and 
community functioning were stronger than those found for the neurocognitive 
domains and community functioning. This suggests that impairments in social 
cognition are another important target for interventions.  
Whilst the results of these meta-analyses provided valuable insights into the nature 
and severity of cognitive impairments in schizophrenia, the studies included used a 
large variety of cognitive tasks. Therefore, the development and approval of 
cognitive-enhancing treatments was hampered by a lack of consensus on how to 
divide the specific cognitive processes affected in schizophrenia and the need for a 
standardised test battery to assess cognitive outcomes in schizophrenia. The 
National Institute of Mental Health (NIMH) in the United States launched the 
Measurement and Treatment Research to Improve Cognition in Schizophrenia 
(MATRICS) initiative in response to the mounting evidence of cognitive 
impairments in schizophrenia. The purpose of the MATRICS initiative was to 
stimulate the development of treatments that would improve cognitive outcomes in 
patients with schizophrenia and related disorders [201]. One of the objectives of 
this initiative was to identify the domains of cognition affected and create a 
cognitive battery with good psychometric properties that could be used in research 
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of cognition, particularly clinical trials of cognition-enhancing therapies. In 2003, a 
subcommittee of the MATRICS initiative reviewed the available evidence for 
separable domains of cognition and made recommendations regarding which 
domains should be included in the cognitive battery [202]. Selection of these 
separable domains was based on factor analytic studies of cognitive performance in 
participants with schizophrenia, although relevant large studies of healthy 
participants were also considered [202]. The committee selected dimensions that 
were independent or only weakly correlated with other dimensions and had been 
replicated across several studies. They also considered whether these dimensions 
were likely to be sensitive to interventions. Six domains of cognition were 
identified from factor analytic studies: speed of processing, attention / vigilance, 
working memory, verbal learning and memory, visual learning and memory and 
reasoning and problem solving. The latter domain included measures of executive 
function but was labelled “reasoning and problem solving” to distinguish the 
domain from the executive processes of working memory. In 2003, research on 
social cognition in schizophrenia was in its infancy and so the factor analytic 
studies evaluated had not included measures of social cognition. However, it was 
concluded that social cognitive processes may represent an important treatment 
target in patients with schizophrenia and so social cognition was included as the 
seventh domain. The MATRICS committee later evaluated 90 nominated tasks and 
selected a beta battery of 20 tasks [203]. These tasks were evaluated for their 
psychometric properties, tolerability and relationship with functional outcome. The 
final MATRICS Consensus Cognitive Battery consisted of ten tasks that assessed 
the seven domains of interest. However, it should be noted that the evidence for 
separable cognitive deficits in schizophrenia is controversial and some researchers 
have argued that patients exhibit a generalised cognitive deficit. 
1.7.2 General or specific cognitive deficits 
Cognitive impairments in schizophrenia are widespread, affecting almost all 
domains from basic functions to higher order processes. This has led some 
researchers to argue that these widespread impairments may be the result of a 
generalised cognitive deficit. In healthy individuals, cognitive domains are at least 
moderately correlated and the structure of cognition is thought to be hierarchical 
with domains related to general cognitive ability, known as ‘g’ [204, 205]. This has 
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led researchers to examine whether the cognitive deficits are separable processes or 
the result of a unitary deficit. Dickinson et al. used confirmatory factor analysis to 
examine whether performance on seventeen tasks followed a hierarchical six-factor 
model [206]. The six factors were verbal comprehension, perceptual organisation, 
verbal learning and memory, visual learning and memory, information processing 
speed and executive / working memory. Each factor measures a separable ability 
but the hierarchical model specified that correlations between these six factors were 
caused by their relationship to a higher order factor, general ability (‘g’). 
Confirmatory factor analysis supported this model for both the schizophrenia and 
healthy control groups. However, cognitive domains were more highly correlated 
in participants with schizophrenia than healthy individuals and there were higher 
loadings on the common factor, ‘g’. This suggests that cognitive ability is more 
unitary in patients with schizophrenia than healthy populations. General cognitive 
ability accounts for approximately two-thirds of the difference in performance 
between participants with schizophrenia and healthy participants [207, 208]. 
However, ‘g’ does not fully account for differences in processing speed and verbal 
learning between patients and controls [207, 208]. These cognitive abilities may be 
disproportionately affected in patients with schizophrenia. An alternative 
explanation is that certain cognitive tasks, such as those tapping processing speed 
and verbal memory, may be more difficult and thus larger group differences are 
detected between patients and controls. 
An important implication of these findings is that efforts to identify discrete neural 
mechanisms associated with specific cognitive deficits may be unproductive. 
However, some researchers have questioned the concept of generalised cognitive 
deficits in schizophrenia. It has been argued that aspects of the disorder, such as 
reduced motivation or antipsychotic medication, may have a general “dulling” 
effect on cognitive performance [209]. Another possible explanation for the unitary 
nature of cognitive performance in schizophrenia is cognitive scaffolding. 
Cognitive scaffolding is the process by which other cognitive processes 
compensate for deficits in specific areas of cognition and thus cognitive 
performance become less differentiated resulting in higher correlations between 
scores on tasks designed to measure different domains of cognition [210]. Other 
researchers have noted the relative non-specificity of cognitive assessments, which 
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tend to tap multiple abilities rather discrete processes [211]. There has been work 
to develop a battery of tasks that tap specific cognitive mechanisms. An example of 
this is the Cognitive Neuroscience-Based Approaches to Measuring and Improving 
Treatment Effects on Cognition in Schizophrenia (CNTRICS) initiative [212]. One 
of the aims of this initiative was to select a battery of tasks based on evidence from 
cognitive neuroscience studies. It is hoped that these tasks will be used to enhance 
translational research [212]. 
1.7.3 Course of cognitive impairments 
Cognitive deficits are relatively stable over long periods suggesting the 
impairments are not the result of neurodegeneration [213]. Indeed, there is 
evidence that cognitive deficits are present before the onset of psychosis and during 
the first episode of psychosis supporting a neurodevelopmental origin of these 
impairments. In a 30-year follow-up study, more than 1000 children were assessed 
on their cognitive abilities at seven, nine, eleven and thirteen years old [214]. 
Children who went on to develop schizophrenia exhibited deficits in verbal 
comprehension and perceptual organisation at seven years old. These children also 
gradually fell behind their peers on measures of perceptual organisation and 
processing between the ages of seven and thirteen years old. A meta-analysis of 14 
studies that assessed IQ in childhood or prior to the onset of schizophrenia found 
that full scale IQ was lower in participants who later developed schizophrenia 
[215]. The standardised mean difference between cases and controls was -0.43, 
which equated to a premorbid IQ of 93.6 in participants with schizophrenia. A one-
point decrease in premorbid IQ was associated with an increase of 3.7% in the risk 
of developing schizophrenia. There was a weaker relationship between premorbid 
IQ and risk of schizophrenia in those with the highest IQ. The study examined the 
influence of age, gender and age at onset and found greater effect sizes for studies 
whose schizophrenia group had an earlier mean age of onset. There was 
insufficient data to examine other potential clinical or demographic confounders. In 
a study of Swedish conscripts, the association between low IQ and schizophrenia 
was maintained after accounting for history of other psychiatric illness, drug use, 
place of upbringing, paternal age, disturbed behaviour in childhood, family history 
of psychiatric illness and father’s occupation [216]. 
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Cognitive deficits have been demonstrated in participants at high familial or 
clinical risk of developing schizophrenia. In one study, neurocognitive profiles 
were compared between participants who were identified as showing clinical signs 
of an early prodromal state of psychosis, those considered in a late initial 
prodromal state, participants who were experiencing their first episode of psychosis 
and participants with a diagnosis of schizophrenia (multiple episodes of psychosis) 
[217]. Participants who were considered at risk of developing psychosis (early and 
late prodromal phase) exhibited deficits in executive function and verbal memory 
relative to controls, whilst the late prodromal phase group exhibited additional 
attentional deficits. The first episode group had greater impairments than the at-risk 
groups and the multiple episode schizophrenia group exhibited the most severe 
cognitive impairments. However, it is unclear how many of the participants in the 
at-risk groups went on to have a psychotic episode. Bora et al. [218] conducted a 
meta-analysis of studies examining cognitive impairment in youths who were 
either at high familial or clinical risk of developing psychosis. Familial high risk 
(FHR) was defined as having a parent or sibling with schizophrenia or at least two 
relatives with schizophrenia. Clinical high risk (termed ultra high risk, UHR) was 
defined as youths or young adults who have sought help and met one of the 
following criteria: i) recent onset or worsening of attenuated psychotic symptoms; 
ii) recent onset of clinically significant psychotic symptoms that were not 
sufficiently sustained to meet the criteria for a psychotic disorder; or iii) genetic 
risk of psychosis plus a deterioration in their functioning. The results indicated 
impairments on measures of current and premorbid IQ, verbal memory, visual 
memory, executive function, fluency, sustained attention, verbal and visuospatial 
working memory for both participants with FHR (Cohen’s d ranged from 0.24 to 
0.81) and UHR (Cohen’s d ranged from 0.34 to 0.71). Participants with both high 
clinical and familial risk had worse cognitive scores than the other groups. 
Amongst the UHR participants, those who went on to develop psychosis were more 
impaired than those who did not but there was substantial overlap in cognitive 
scores between the two groups. This suggests that cognition may have limited 
utility on its own as a predictor of who will develop psychosis. However, a five-
year longitudinal study of UHR participants found that combined performance on 
measures of executive function, working memory, visual memory and theory of 
mind predicted conversion to psychosis [219]. Another study reported that a 
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predictive model including scores on verbal learning and processing speed tasks at 
baseline correctly reclassified 77% of participants as converting or not converting 
to psychosis [220]. However, it should be noted that in this study the group that 
converted to psychosis exhibited significantly higher levels of prodromal psychotic 
and negative symptoms at baseline, as assessed by scores on the Positive and 
Negative Syndrome Scale (PANSS) and number of participants experiencing brief 
limited intermittent psychotic symptoms. 
Numerous studies of participants admitted for a first episode of psychosis have 
identified deficits in executive function, verbal and visual memory, processing 
speed and working memory [217, 221-223]. The severity of these impairments has 
been shown to be associated with later severity of negative symptoms and poorer 
functional outcome [222, 224]. A meta-analysis of first episode studies indicated 
medium to large deficits in verbal memory, nonverbal memory, processing speed, 
language functions, visuospatial abilities, executive function, working memory, 
social cognition, attention and motor skills (Cohen’s d ranged from -0.64 to -1.20) 
[225]. The degree of impairment found was comparable to those reported in meta-
analyses of chronic patients [191-193]. This suggests that cognitive deficits are 
present at onset of the first episode of psychosis and remain stable thereafter. An 
issue with studies of first episode psychosis is that most participants are assessed 
following administration of antipsychotic medication and potentially other 
psychiatric medications. There are clear ethical difficulties in administering 
cognitive assessments for research before patients are given treatment for their 
psychotic symptoms and therefore few studies have examined cognitive deficits in 
antipsychotic-naïve patients. As noted earlier, one meta-analysis identified similar 
cognitive impairments in antipsychotic-naïve participants compared to healthy 
controls [194].  
Meta-analyses of clinical trials of antipsychotic medication have found moderate 
improvements in cognitive function when patients are treated with atypical 
antipsychotics [226, 227]. The Clinical Antipsychotic Trials of Intervention 
Effectiveness (CATIE) study was one of the largest and most comprehensive 
independent clinical trials of antipsychotic medication ever conducted [151]. The 
study found small improvements in neurocognitive performance for participants 
treated with olanzapine, quetiapine, risperidone or perphenazine after two months. 
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Similar improvements were found at six months. By 18 months, cognitive 
improvement was greater for the perphenazine group than the olanzapine and 
risperidone groups. This finding was in contrast to studies showing that atypical 
antipsychotics are superior in improving cognitive function to typical 
antipsychotics [226, 227]. However, it should be noted that participants in the 
CATIE study were chronic patients and 75% were already taking antipsychotic 
medication at baseline. In a study of 104 participants with a first episode of 
psychosis, olanzapine and risperidone were associated with improvement in 
cognitive function at six and sixteen weeks [228]. However, the improvements 
were small and only two cognitive tests (Wechsler Memory Scale – Visual 
Reproduction subtest and Trail Making Test) showed greater improvements in 
cases compared to a healthy control group. This suggests that improvements 
reported over a small period of follow-up may be due to practice or placebo effects. 
Practice effects occur due to the participant’s familiarity with the specific task, as 
the participant may memorise the stimuli, develop strategies to complete the task or 
due to procedural learning [229]. Placebo effects are the result of the participant’s 
experience of taking part in the study and occur due to factors such increased 
motivation, decreased anxiety about participating in the study or expectation bias 
[229]. The results of a study by Keefe et al. [230] provided further evidence of 
practice or placebo effects in a clinical trial of 250 participants with schizophrenia 
or schizoaffective disorder. Participants were stabilised on a second-generation 
antipsychotic and administered either donepezil (an acetylcholinesterase inhibitor) 
or placebo. Similar moderate cognitive improvements were observed in both 
groups (donepezil and placebo). Practice or placebo effects were observed across 
cognitive domains including when tasks used alternative forms at baseline and 
follow-up [229, 230]. The impact of long-term antipsychotic medication use on 
cognitive function remains unclear.  
In addition to clinical trials examining the effects of antipsychotic medication on 
cognition, numerous studies have examined the longitudinal course of cognitive 
impairments in participants with schizophrenia. A meta-analysis of these studies 
indicated slight improvements in scores on assessments of memory, executive 
function, attention and processing speed [231]. However, the mean follow-up 
period of the included studies was just 12 months and comparisons with data from 
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healthy controls suggested the slight improvements observed were due to practice 
effects. Studies that have followed up participants for longer periods (five to ten 
years) have had small sample sizes. A study of 54 participants with first episode or 
recent onset schizophrenia found that performance on the majority of cognitive 
tasks remained stable after five years, except that performance IQ and full-scale IQ 
improved [232]. Improvements in negative symptoms were associated with 
improvements in full scale IQ. Finger-tapping speed was found to be slower after 
five years. One ten-year longitudinal study found significant cognitive decline in 
participants with schizophrenia on three of the nine tasks administered [233]. These 
tasks were the picture completion and object assembly subtests of the Wechsler 
Adult Intelligence Scale and the Memory-For-Design test. However, only 24 
participants had completed the same cognitive battery at both time points and the 
effects were small. Another small study followed up participants and administered 
neurocognitive assessments five and ten years after their first episode of psychosis 
[234, 235]. The authors did not find evidence of cognitive decline after ten years 
but participants with schizophrenia showed less improvement in tasks assessing 
verbal and nonverbal recall and cognitive inhibition compared to controls.  
In conclusion, current evidence suggests that cognitive impairments are apparent in 
patients before the onset of their first episode of psychosis. These deficits remain 
stable up to ten years after the onset of the disorder. These findings support a 
neurodevelopmental origin of these impairments rather than deficits resulting from 
neurodegenerative processes. There are currently no approved treatments for 
cognitive deficits in patients with schizophrenia and at best, current antipsychotic 
medications only marginally improve these deficits [236]. 
1.8 Cognition in bipolar disorder 
Early conceptualisations of bipolar disorder described a mood disorder with 
remitting course, not typically associated with cognitive deterioration [4]. However, 
it has recently been recognised that cognitive impairments are present in patients 
with bipolar disorder and persist outside of mood episodes [237-240]. This research 
is less mature than studies of cognitive deficits in schizophrenia with the number of 
studies growing over the last 15 years.  
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1.8.1 Nature of cognitive deficits 
Five meta-analyses of studies of euthymic participants with bipolar disorder have 
been carried out to examine the nature and extent of cognitive deficits [237-241]. 
The results of these meta-analyses indicated deficits in executive function, verbal 
learning, visual learning, attention and processing speed (Cohen’s d effect sizes 
ranged from 0.28 to 1.09 across the meta-analyses). Findings across the meta-
analyses have been largely consistent particularly regarding the most and least 
impaired cognitive domains. The largest impairments were observed in executive 
function and verbal learning across all the meta-analyses. The smallest effect sizes 
were seen for forward digit span [237-239] and sustained attention [237-239]. One 
exception was Torres et al. [240] who reported one of their largest effect sizes for 
the continuous performance test but the measure was total hits, which does not 
account for false positive responses and therefore should be viewed with caution. 
Only the most recent meta-analysis [241] had sufficient data to conduct meta-
regressions with clinical variables. Their findings indicated that a younger age of 
illness onset and higher proportion of participants taking antipsychotic and 
antidepressant medications were associated with the larger effect sizes. None of the 
meta-analyses found significant effect sizes for premorbid IQ, as estimated using 
the National Adult Reading Test (NART), Wide Range Achievement Test (WRAT) 
or Wechsler Adult Intelligence Scale (WAIS) Vocabulary subtest [237-240]. 
Performance on visual copy tests was not impaired in participants with bipolar 
disorder in two meta-analyses [237, 241].  
Measures of executive function are consistently identified as showing the greatest 
impairment in participants with bipolar disorder. However, some aspects of 
executive function are more impaired than others. Within the executive function 
domain of each meta-analysis, the largest effect sizes were reported for Trail 
Making Test – part B [237-239], Wisconsin Card Sorting Task [237, 240] and the 
Stroop test [240]. This suggests that participants with bipolar disorder are 
particularly impaired on measures of cognitive flexibility and response inhibition. 
Relatives of patients with bipolar disorder also demonstrate poorer performance on 
these three measures compared to controls [237, 241].  
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In response to increasing recognition of cognitive impairments in bipolar disorder, 
the International Society for Bipolar Disorder (ISBD) established a committee to 
identify domains of impairment in bipolar disorder, evaluate the suitability of the 
MATRICS Consensus Cognitive Battery (MCCB) for research of bipolar disorder 
and propose a preliminary cognitive battery [242]. Their findings indicated that the 
majority of the MCCB tasks would be suitable for measurement of impairments in 
bipolar disorder. However, the authors concluded that more complex measures of 
executive function should be included in a cognitive battery for bipolar disorder.  
Few studies have examined social cognitive abilities in participants with bipolar 
disorder, although there is some evidence of mild to moderate deficits. A meta-
analysis of these studies examined three social cognitive abilities: emotion 
processing, theory of mind and decision-making [243]. Participants with bipolar 
disorder exhibited moderate deficits in both simple and complex theory of mind 
tasks (Cohen’s d ranged from 0.5 to 0.58). Milder deficits were found in emotion 
processing (d = 0.35), whilst decision-making skills were relatively preserved (d = 
0.15). The number of studies included in each meta-analysis was small; the 
maximum number of studies included in a single analysis was nine. This limited 
the number of potential moderators that could be examined. None of the 
moderators examined (age, sex, years of education, duration of illness or 
medication use) influenced the size of the effects reported in the studies. 
1.8.2 Subtypes of bipolar disorder 
The majority of studies examining cognitive dysfunction in bipolar disorder has 
focused on bipolar disorder – type I. There is evidence of differences in cognitive 
function between patients with bipolar I disorder and bipolar II disorder, as well as 
differences within subgroups of bipolar I disorder. 
Participants with bipolar II disorder exhibit significant cognitive impairments based 
on the findings of one meta-analysis [244]. These impairments were smaller in 
magnitude than those seen in bipolar I disorder. Specifically, participants with 
bipolar I disorder had more extensive impairments in verbal memory, visual 
memory and semantic fluency than participants with bipolar II disorder. These 
findings were not influenced by duration of illness, age of onset, depressive or 
manic symptoms, proportion of participants with a history of psychosis or 
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antipsychotic medication use. One study also found that 16% of participants with 
bipolar II disorder and 21% of participants with bipolar I disorder had clinically 
significant impairments in their attention and executive function, defined as 
performance one and a half standard deviations below the average of the healthy 
control group [245]. However, only 7% of participants with bipolar II disorder had 
clinically significant impairments in their verbal memory compared to 25% of 
participants with bipolar I disorder. This suggests that impairments in verbal 
memory may be more specific to bipolar I disorder. 
Patients with bipolar disorder who have a history of psychosis have worse 
cognitive outcomes than patients who do not have a history of psychosis. A meta-
analysis showed that participants with bipolar disorder and psychosis performed 
significantly worse than participants without psychosis on measures of planning 
and reasoning, working memory, verbal memory and processing speed, although 
effect sizes were modest [241]. These differences were not explained by between-
group differences in duration of illness, age of onset, proportion of participants 
taking antipsychotic medication or number of inpatient admissions. Only number 
of manic episodes was associated with between-group differences in global 
cognition. It has been proposed that patients with bipolar disorder with more severe 
cognitive impairments and history of psychosis may represent a subtype of bipolar 
disorder that is genetically similar to schizophrenia [246]. 
1.8.3 Course of cognitive impairments 
In contrast to patients with schizophrenia, there is little evidence of early cognitive 
deficits in individuals who later develop bipolar disorder. Premorbid IQ was not 
associated with risk of developing bipolar disorder in two population studies of 
conscripts [159, 216], although a third study of Finnish conscripts did find an 
association [247]. Evidence from the New England Family Studies indicated that 
IQ at seven years old was significantly lower in participants who went on to 
develop schizophrenia but was only marginally lower in those who developed 
bipolar disorder [248]. The study indicated that 42% of the schizophrenia group 
and 23% of the bipolar disorder group were cognitively impaired at seven years old, 
defined as IQ in the 10th percentile, compared to 7% of the control group. However, 
it should be noted that the bipolar group consisted of participants diagnosed with 
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bipolar disorder with psychosis and schizoaffective disorder – bipolar type. These 
participants exhibit more severe cognitive impairments than those with bipolar 
disorder and no history of psychosis [241].  
There is evidence that higher than average intelligence is associated with increased 
risk of developing bipolar disorder. The study of Finnish conscripts showed that 
lower performance on a visuospatial reasoning test or higher performance on an 
arithmetic reasoning test at 20 years old was associated with greater risk of 
developing bipolar disorder [247]. Individuals with the highest scores in arithmetic 
reasoning had almost a 12-fold risk of bipolar disorder. A population study of 
educational attainment at 15 to 16 years in Sweden found that students with the 
highest grades were almost four times more likely to be admitted to hospital for 
bipolar disorder in adulthood than students with average performance [249]. The 
study also found modestly increased risk of bipolar disorder in the poorest 
performing students (hazard ratio = 1.86). These risks were maintained after 
adjustment for parental education, socioeconomic status, advanced parental age, 
parental education and season of birth. A study of four population-based cohorts 
also found high performance in cognitive tests in those who went on to develop 
bipolar disorder [250]. The bipolar disorder group outperformed population norms 
on all tasks at ages 13 and 18 years, although there was only a non-significant trend 
between better verbal ability at 18 years old and increased risk of bipolar disorder. 
Overall, these studies suggest a complex relationship between premorbid IQ and 
risk of bipolar disorder with both higher and lower than average premorbid IQ 
associated with increased risk.  
There is evidence that deficits are present in participants with high genetic risk of 
bipolar disorder. A meta-analysis of 18 studies examining cognition in youth at 
familial high risk of bipolar disorder found significant deficits in general cognition 
(Cohen’s d=0.29) and social cognition (Cohen’s d=0.23) [251]. The social 
cognition domain included measures of theory of mind and emotion recognition. 
Deficits in neurocognition were modest and limited to visual memory, verbal 
memory, sustained attention and processing speed. Executive functions and 
working memory were not significantly impaired in the high-risk participants. 
Within studies that reported data on psychiatric disorders in the high-risk group, up 
to 30% of participants had a depressive disorder and up to 36% had attention 
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deficit hyperactivity disorder (ADHD). However, the proportions of participants 
with depression or ADHD did not account for the magnitude of the effect sizes. 
There was insufficient data to examine the impact of substance use, medication or 
current clinical or subclinical depressive or manic symptoms. It is unknown how 
many of the participants went on to develop bipolar disorder, as the meta-analysis 
included cross-sectional studies. 
Few studies have examined whether participants at clinical high risk of bipolar 
disorder exhibit cognitive deficits. Two studies of participants at clinical high risk 
for psychosis have reported data on those participants who went on to develop 
bipolar disorder, although the group sizes in both studies were small [252, 253]. 
Neither study found differences in neurocognitive performance between high-risk 
participants who developed bipolar disorder and high-risk participants who did not 
develop either bipolar disorder or a psychotic disorder. The first of these studies 
found similar cognitive performance between high-risk groups that developed 
bipolar disorder or schizophrenia [252]. The second study found lower verbal IQ, 
performance IQ and full scale IQ in the bipolar disorder group than a healthy 
control group [253].  
There are difficulties in conducting first episode studies with participants with 
bipolar disorder due to the nature of the diagnosis. Patients must have had multiple 
episodes before they meet ICD-10 criteria for bipolar disorder and may have had 
episodes of depression before their first manic episode. Even if a patient’s first 
recorded episode is a manic episode, they may have had untreated depressive 
episodes in the past. In addition, if their first episode is accompanied by prominent 
psychosis then they may be initially diagnosed with a psychotic disorder rather 
than a mood disorder. Therefore, identifying potential participants for a first 
episode study is difficult. Current evidence indicates that cognitive impairments are 
present at onset of the first manic episode suggesting that these impairments occur 
early in the course of the disorder. A recent meta-analysis of 15 studies that 
compared participants with a first episode of mania and healthy controls identified 
deficits in processing speed, verbal memory, visual memory, attention, reasoning, 
working memory and verbal fluency (Cohen’s d ranged from 0.31 to 0.8) [254]. 
Deficits in processing speed, verbal fluency, verbal memory and working memory 
were less pronounced in participants with first episode mania than those seen in 
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participants with first episode psychosis. Meta-regression analyses indicated that 
gender, education, age, clinical state (euthymic or non-euthymic) and drug use had 
no significant effects on differences in global cognition.  
A meta-analysis of longitudinal studies of cognitive deficits in bipolar disorder 
indicated that patient performance on 14 cognitive measures remained stable over a 
mean follow-up period of 4.62 years [255]. However, the follow-up periods of the 
included studies were relatively short, the majority being between two and five 
years. The authors were also unable to account for the impact of medication use or 
mood states. There are few longitudinal studies of cognitive deficits in bipolar 
disorder with follow-up periods of greater than five years. One study showed that 
overall cognitive impairments remained relatively stable six years after initial 
assessment [256]. However, performance of the bipolar disorder group had 
declined after six years for specific tasks, including measures of executive function, 
working memory and verbal memory. Cognitive change between baseline and six 
years on the Trail Making Test – Part B was strongly correlated with scores on the 
Functioning Assessment Short Test, which assesses occupational, cognitive and 
social outcomes.  
Bipolar disorder has a remitting course and there is some evidence that cognitive 
impairments are more severe when patients are experiencing mood symptoms than 
during remission [257, 258]. One study of participants with bipolar disorder (type I 
or type II) did not identify differences in cognitive performance between 
participants in depressed, manic or euthymic states with the exception of more 
impaired verbal fluency in the depressed group [257]. Another study found that 
residual manic or depressive symptoms were associated with poorer executive 
function in a group of stabilised participants with bipolar I disorder [258]. However, 
these studies examined cognitive function in participants in different illness states 
(depressed, manic or euthymic) rather than examining how mood changes are 
related to cognitive function. Another study found that an increase in depressive 
symptoms over three months was associated with poorer performance on a measure 
of verbal fluency [259]. Overall, there is some evidence to suggest that cognitive 
function, in particular verbal fluency and executive function, is more impaired 
during mood episodes but it is clear that cognitive impairments persist during 
euthymic periods. 
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In conclusion, studies examining premorbid IQ and risk of bipolar disorder indicate 
both higher and lower than average IQ increases risk of developing bipolar disorder. 
It has been proposed that patients with poor premorbid IQ comprise a subtype of 
bipolar disorder that is more genetically similar to schizophrenia with higher rates 
of psychosis [246].  This is based on evidence of shared genetic risk for 
schizophrenia and bipolar disorder [73, 74] and worse cognitive outcomes in 
patients with psychotic bipolar disorder [241]. Cognitive impairments are evident 
in patients at the onset of bipolar disorder and remain stable for at least several 
years, although longitudinal studies with longer follow-up periods are needed to 
determine whether cognitive performance declines after a decade or more of illness. 
Like schizophrenia, there are no approved treatments for cognitive impairment in 
bipolar disorder and few studies have examined the efficacy of current medications 
in improving cognitive function [260]. Lithium has not been shown to enhance 
cognitive function and has been associated with mild deficits in immediate verbal 
memory and psychomotor performance [261, 262]. 
1.9 Comparing cognition in schizophrenia and bipolar disorder 
Studies comparing cognitive performance between participants with schizophrenia 
and bipolar disorder can provide important insights into the nosology of these 
disorders and have the potential to identify overlapping and distinguishable 
neurobiological pathways. A meta-analysis of participants with schizophrenia and 
participants with a diagnosis of either schizoaffective disorder or affective 
psychosis revealed poorer performance in the schizophrenia group in six domains 
of cognition [263]. These domains included immediate verbal memory, full scale 
IQ, verbal working memory, delayed verbal memory, mental speed and executive 
function. However, the differences observed were small and could be explained by 
a higher percentage of males, more severe negative symptoms and younger ages at 
onset in the schizophrenia samples. The meta-analysis revealed large variation in 
the direction and size of these effects across the studies. Larger effect sizes were 
observed in a quantitative review of 31 studies, which revealed more severe 
impairment across nine cognitive domains in participants with schizophrenia 
compared to participants with bipolar disorder (including euthymic and acute 
participants) [264]. These domains were verbal fluency, verbal working memory, 
executive control, visual memory, mental speed, immediate verbal memory, IQ, 
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delayed verbal memory and concept formation. Again, there was substantial 
heterogeneity in the effect sizes reported across the studies included. However, 
similar results were observed when the analysis was limited to participants matched 
on clinical and demographic characteristics. A recent meta-analysis found that 
participants with schizophrenia are also more impaired on measures of emotion 
recognition (d = 0.39) and theory of mind (d = 0.57) than participants with bipolar 
disorder [265]. Effect sizes were comparable for social cognition and 
neurocognition measures in this meta-analysis. 
In conclusion, cognitive impairments are characteristic of both schizophrenia and 
bipolar disorder but these impairments appear to be more severe in patients with 
schizophrenia. However, the areas of cognition affected overlap; both disorders are 
associated with deficits in verbal and visual memory, attention, executive function, 
processing speed and working memory. Therefore, it has been hypothesised that 
cognitive deficits are a dimensional phenotype that cross diagnostic boundaries. 
The severity of these deficits may be a consequence of quantitative rather than 
qualitative differences in the underlying neurobiology of the disorders. 
1.10 Cognition in schizoaffective disorder 
Few studies have examined cognitive impairment in schizoaffective disorder as a 
separate diagnosis from either schizophrenia or bipolar disorder. The meta-analysis 
by Bora et al. [263] described in the previous section reported marginally larger 
effect sizes for comparisons between schizophrenia and psychotic mood disorders 
than differences between schizophrenia and schizoaffective disorder. This suggests 
that cognitive deficits associated with schizoaffective disorder are closer in severity 
to schizophrenia than those associated with mood disorders. However, the authors 
did not directly compare cognition between schizoaffective disorder and psychotic 
mood disorders.  
As described earlier in the chapter, there are efforts to examine dimensional 
approaches to psychiatric classification. Cognitive performance can be considered 
one such dimension and the advantages of studying cognition rather than clinical 
symptoms include i) reliable and valid measurements of cognitive performance 
exist, ii) the relative stability of cognitive impairments over the course of illness 
and iii) the relationship between cognitive performance and functional outcome 
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means that impairments are an important treatment target. It has been proposed that 
schizophrenia, schizoaffective disorder and bipolar disorder lie on a gradient of 
neurodevelopmental impairment such that cognitive deficits increase in severity 
from bipolar disorder to schizoaffective disorder to schizophrenia [24, 26, 27]. 
However, there are few large cognitive studies of all three disorders. One such 
study is the Bipolar and Schizophrenia Network on Intermediate Phenotypes, 
which aims to identify potential physiological and cognitive biomarkers of these 
disorders. This study found support for a gradient of cognitive impairment 
demonstrating that performance in participants with schizoaffective disorder is 
intermediate between those with bipolar disorder and schizophrenia [266]. This 
study also showed that the severity of cognitive impairments is associated with the 
predominance of psychotic symptoms. However, there are few sufficiently large 
studies to replicate and expand on these findings.  
1.11 Online cognitive testing 
Cross-disorder samples may have greater power to examine how certain genetic 
variants or neurobiological markers contribute to the development of complex 
phenotypes, such as cognitive impairments. One barrier to examining the 
environmental and genetic factors that contribute to the development of cognitive 
impairments in psychiatric disorders is the lack of sufficiently large datasets. With 
the exception of a few large cross-diagnostic studies, researchers have relied on 
meta-analyses to generate these large numbers of participants but combining 
studies with different methodologies, particularly different cognitive tasks, is 
problematic.  
The rise in internet use over the past few decades has presented researchers with 
new opportunities to collect large datasets. Internet use is widespread in the United 
Kingdom (UK). In 2017, 80% of adults accessed the internet every day and 90% of 
households had an internet connection [267]. The rate of internet use on mobile 
phones has also doubled since 2011 [267]. Therefore, researchers are increasingly 
interested in utilising the internet to recruit very large samples of participants. Early 
preconceptions about internet studies included that samples would be less diverse 
and would be over-represented by younger people [268]. However, the number of 
older adults using the internet is increasing; the most recent data from the UK’s 
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Office for National Statistics suggests that 78% of adults aged 65 to 74 years had 
used the internet in the last three months, which has increased by 26% since 2011 
[269]. Current evidence suggests that people with mental health disorders are less 
likely to access the internet, although this is improving over time [270]. A study of 
241 participants with either psychosis or depression indicated that the majority of 
participants had at least some access to the internet in 2016. Participants with 
psychosis were less likely to have access to the internet than participants with 
depression and this group were also less confident using the internet. However, 
only 18% of participants with psychosis were considered “digitally excluded” in 
2016, defined as lacking access to any internet-enabled device or lacking 
confidence in using an internet-enabled device [270]. The proportion of digitally 
excluded participants with psychosis had decreased since 2011 (30% of 
participants were defined as digitally excluded) [270]. The most common barrier to 
using the internet was concerns about security. Other barriers included lack of 
money, knowledge or places to access the internet. However, the majority of 
participants wanted to use the internet with only 16% reporting that they did not 
want to use it. It should be noted that the study was conducted in London, which 
has higher internet use than other parts of the UK and is unlikely to be 
representative of internet use amongst patients in remote regions [267]. Another 
study examined internet use amongst 337 participants with a wide range of 
psychiatric disorders, including affective disorders, schizophrenia, anxiety 
disorders, organic mental disorders, personality disorders and substance use 
disorders [271]. Approximately 80% of the participants were classified as internet 
users, defined as use of the internet at least once. Of these participants, 33% 
reported medium internet use (defined as 3.5-12.5 hours a week) and 32% of 
participants reported high internet use (defined as over 12.5 hours of internet use 
weekly). Participants who were older were less likely to use the internet frequently. 
There was no relationship between internet use and either diagnosis or illness 
severity.  
Another concern for online studies is the quality of the data collected. This is a 
particular concern for cognitive data, especially tasks that measure response time or 
those that use complex stimuli. In an unsupervised environment, the motivation of 
the participant is unknown and they may be distracted or request outside help 
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completing the tasks [272, 273]. Other considerations include the technical skills of 
the participant, the hardware they are using to complete the tasks and the quality of 
their internet connection [272]. Despite these concerns, there are a rising number of 
research projects utilising online cognitive assessments. The Twins Early 
Development Study (TEDS) recruited a sample of several thousand twins born in 
the United Kingdom between 1994 and 1996. The study developed online tasks to 
assess reading, language, mathematics and general cognitive ability in children 
aged between ten and twelve years old [274]. The battery had good internal and 
test-retest reliability. Fifteen pairs of twins also completed these tasks in person 
with a researcher within three months of completing the tasks online. The online 
tasks were highly correlated with both offline versions of the same task (correlation 
coefficients ranged between 0.52 and 0.92) and classroom assessments of reading 
and mathematics. Another study used iPads to administer a cognitive battery to 
participants in their homes unsupervised [275]. This battery showed good test-
retest reliability and was associated with the same battery administered in the clinic 
(r2=0.51). However, a disadvantage of this approach is the use of iPads, which 
needed to be delivered to and then collected from participants thus limiting the 
number of participants that can be assessed at once. This is less practical than 
hosting the cognitive tasks on a website that participants can access from their own 
devices. 
The website “TestMyBrain.org” was developed at Harvard University to collect 
large samples of cognitive data from around the world [273]. The website includes 
a number of experiments, each consisting of cognitive tasks and questionnaires, 
and provides individual feedback on the participant’s performance to encourage 
engagement in the research. The tests are taken from published research and are 
well validated. More than one and a half million people have completed tasks on 
the website since 2008, generating one of the largest datasets of cognitive 
performance in the world. In 2012, analyses of data from this project showed few 
systematic differences between web-based and laboratory-based samples on mean 
performance, performance variance and internal reliability [273]. These tests 
included online versions of the Cambridge Face Memory Test, Reading the Mind 
in the Eyes, Abstract Art Memory, Verbal Paired Associates Memory and WAIS: 
Forward Digit Span. A small proportion of the participants reported technical 
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problems or using strategies that could be considered cheating (3-5% across the 
tasks).  
An advantage of online cognitive assessments is the relative ease with which 
researchers can collect longitudinal data to measure cognitive trajectories. The 
Melbourne Community Screening Study utilised online cognitive testing to 
repeatedly assess the cognitive functions of older adults in a community setting 
[276]. Participants aged 50 or older completed monthly unsupervised cognitive 
assessments over a 12-month period. This study used the CogState battery, which 
was designed specifically for repeated testing to measure subtle changes in 
cognition over time [277, 278]. The tasks included measures of reaction time, 
visual learning, working memory, episodic memory and executive function. The 
test-retest reliability of the battery was shown to be high with intra-class correlation 
coefficients for each task ranging between 0.72 and 0.93. The retention rate of the 
study by 12-month follow-up was 43%. The majority of the tasks were 
demonstrated to be suitable for online testing based on reports of technical issues 
and integrity checks. However, the assessments of executive function and episodic 
memory were identified as potentially unsuitable for unsupervised testing due to 
9% of participants reporting technical difficulties. A limitation of this study was 
that all of the participants were experienced in using the computerised cognitive 
battery in a supervised setting and may not be representative of a typical internet-
based sample.  
The Nutrinet-Santé study is an online prospective study that aims to examine the 
relationship between nutrition, mortality and health outcomes [279]. Part of this 
study involved the development of four online cognitive tasks, including measures 
of processing speed, executive function, working memory and visual memory. 
These measures were administered to 189 participants in both supervised and 
unsupervised settings. Correlations between the supervised and unsupervised 
version of the tasks ranged between 0.42 and 0.73. Correlations were higher among 
participants with higher educational attainment and those with better knowledge of 
the internet.  
There are a number of online cognitive batteries and testing platforms that have 
been designed for use in psychiatric research. The details of four cognitive testing 
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tools are summarised in Table 1-4: Cogstate, Penn Computerised Neurocognitive 
Battery, Cambridge Neuropsychological Test Automated Battery (CANTAB) and 
TestMyBrain. Cogstate is a commercial company that develops cognitive tests for 
clinical trials, academic research and healthcare [276, 278]. They have created a 
range of cognitive batteries for studies of specific populations, including people 
with schizophrenia, Alzheimer’s disease, depression and multiple sclerosis. These 
batteries can be hosted online but the researcher needs to design and build their 
own website. Researchers at the University of Pennsylvania’s Brain Behaviour 
Laboratory designed the Penn Computerised Neurocognitive Battery (CNB) [280, 
281]. The CNB is an extensive battery that assesses nine domains of cognition and 
can be hosted online. Task selection was driven by evidence from neuroscience and 
neuroimaging studies. However, the measure of processing speed included in the 
CNB relies on motor skills, which may be compromised in older individuals or 
those with extrapyramidal side effects. It is important to include a measure of 
processing speed in a battery that will be used to assess cognition in schizophrenia, 
as patients with schizophrenia show large deficits in this domain [195]. The CNB is 
also designed for laptop and desktop computers but not touchscreen devices and is 
expensive due to ongoing costs for support, training, data validation and access to 
normative data. The CANTAB is a gold standard cognitive assessment designed by 
a leading neuroscience company in the UK, Cambridge Cognition. The tests have 
been used in over 2000 peer-reviewed publications. At the time of writing (March 
2017), Cambridge Cognition had recently released their new web-based testing 
platform, CANTAB Connect. The system was still under development so not all 
tasks were available to be hosted online and the tasks were suitable for desktop and 
laptop computers but not touchscreen devices. The cost of CANTAB is also 
calculated per participants, which is prohibitive for studies collecting very large 
samples. The TestMyBrain cognitive testing platform was developed by 
researchers at Harvard University and is hosted by the not-for-profit organisation, 
The Many Brains Project, Inc. Researchers can create a unique cognitive battery by 
selecting tasks from an extensive list. The Many Brains Project will create and host 
the website on their server so the set-up is simple and cost effective. The tests are 
taken from peer-reviewed studies and the available tasks include some from the 
MATRICS Consensus Cognitive Battery. There is an option to provide feedback to 
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participants to encourage engagement with the study. The tasks can be 
programmed to run on a wide-range of devices to meet the needs of the researcher.  
In conclusion, the internet may be a useful resource for conducting large-scale 
studies of cognitive function among participants with psychiatric diagnoses. 
Current evidence suggests that online cognitive measures are comparable to offline 
equivalents. However, at the time of writing, no published studies had investigated 
the use of online cognitive assessments in research of mental health disorders. 
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Table 1-4 Summary of available online cognitive assessments 
 Cogstate 
Penn Computerised 
Neurocognitive Battery 
CANTAB Connect TestMyBrain 
Duration 15 to 40 minutes depending on 
which battery is selected 
Approximately one hour Can create customised 
batteries so duration varies 
Can create customised 
batteries so duration varies 
Domains of cognition 
tested 
1. Visual motor function 
2. Executive function / spatial 
problem solving 
3. Psychomotor function / 
speed of processing 
4. Visual attention / vigilance 
5. Visual learning and 
memory 
6. Verbal learning and 
memory 
7. Attention / working 
memory 
8. Social cognition 
1. Abstraction and mental 
flexibility 
2. Attention 
3. Working memory 
4. Episodic memory 
5. Language reasoning 
6. Spatial processing 
7. Sensorimotor 
processing speed 
8. Motor speed 
9. Emotion identification 
1. Attention 
2. Memory 
3. Executive function 
4. Emotion / social 
cognition 
5. Psychomotor speed 
1. Verbal memory 
2. Visual memory 
3. Reasoning 
4. Processing speed 
5. Working memory 
6. Attention 
7. Emotion recognition 
8. Decision making 
9. Crystallised intelligence 
 
CANTAB: Cambridge Neuropsychological Test Automated Battery  
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Table 1-4 Summary of available online cognitive assessments 
 Cogstate 
Penn Computerised 
Neurocognitive Battery 
CANTAB Connect TestMyBrain 
Features 1. Language and culture 
independent 
2. Brief administration time 
3. Algorithms that evaluate 
performance to identify 
“suboptimal” performance 
4. Repeatable with minimal 
practice effects  
5. Battery based on 
MATRICS domains is 
available 
1. Evidence-driven 
approach to task 
selection based on the 
findings of 
neuroscience and 
neuroimaging studies 
2. Can be customised 
based on the age and 
language of the 
participants (15 
languages available) 
1. Tests have been 
published in over 2000 
peer-reviewed papers 
2. Language and culture 
independent 
3. Tests have been shown 
to be sensitive in a 
wide-range of 
participant groups, from 
participants at high risk 
of mental disorders to 
chronic schizophrenia. 
4. 30 languages supported 
1. Batteries are completely 
customisable and the 
service includes set up 
of the study website. 
2. Tests can be run on 
desktop and laptop 
computers, as well as 
touchscreen devices  
3. Tests taken from 
published peer-
reviewed studies and 
include tasks from the 
MCCB 
4. Option to provide 
feedback to participants 
Limitations 1. Website to host the tasks 
must be built separately so 
additional costs, design and 
maintenance are required 
2. Tasks were purpose built 
by Cogstate so have not 
been utilised in as many 
published studies 
1. Measures some but not 
all domains outlined by 
the MATRICS initiative 
2. Does not run on 
touchscreen devices 
3. Ongoing costs for 
support, training, data 
validation and access to 
normative data 
1. At the time of writing, 
the system was still 
under development so 
not all tasks were 
available 
2. Cost is calculated per 
participant 
3. Available for laptops 
and desktop computers 
only 
1. Developed by 
researchers at Harvard 
University so graphics 
are basic. Therefore, it 
is not as visually 
appealing as other 
systems designed by 
commercial companies. 
CANTAB: Cambridge Neuropsychological Test Automated Battery; MATRICS: Measurement and Treatment Research to Improve Cognition in Schizophrenia; MCCB: MATRICS Consensus 
Cognitive Battery
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1.12 Aim and objectives 
The aims of this PhD are to examine cognition across the bipolar / schizophrenia 
diagnostic spectrum and to develop a new online cognitive battery for use in large-
scale studies of mental health disorders.  
The objectives of the PhD are: 
1. To conduct a systematic review and meta-analysis of studies comparing 
cognitive performance in participants with schizoaffective disorder to 
participants with bipolar disorder and schizophrenia. Many of the 
existing studies that examine cognition in schizoaffective disorder are small 
and there is conflicting evidence regarding the nature and extent of 
impairments. This will be the first meta-analysis comparing cognitive 
function between participants with schizoaffective disorder and bipolar 
disorder. Meta-analyses will be conducted for seven cognitive variables. 
Further meta-analyses will be conducted to examine cognitive performance 
in the subtypes of schizoaffective disorder: bipolar or depressive.  
2. To examine cognitive impairment across the bipolar / schizophrenia 
diagnostic spectrum using existing data from a large well-characterised 
dataset. This data will be taken from the Cognition in Mood, Psychosis and 
Schizophrenia Study (CoMPaSS), a large UK-based cohort of participants 
with psychotic and affective disorders. This study aimed to test the 
hypothesis that there is a spectrum of increasing cognitive impairment from 
bipolar disorder through schizoaffective disorder – bipolar type to 
schizoaffective disorder – depressive type and schizophrenia. Cognitive 
performance will be compared between patient groups. Follow-up analyses 
will examine the relative contributions of demographic variables, clinical 
symptoms and antipsychotic medication. Ordinal logistic regression 
modelling will be used to examine whether there is a linear trend of 
increasing cognitive impairment from bipolar disorder to schizophrenia. 
The associations between cognition and lifetime symptoms domains will be 
explored across disorders. 
3. To develop an online cognitive battery for use in mental health 
research. This battery will be developed based on the recommendations of 
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the NIMH-MATRICS initiative. The battery will be piloted in a sample of 
participants with major depressive disorder, bipolar disorder and 
schizophrenia. Performance on the new battery will be compared to the 
MATRICS Consensus Cognitive Battery to determine validity.  
4. To roll out the online cognitive battery to participants who have 
previously taken part in large genetic studies within the Medical 
Research Council Centre for Neuropsychiatric Genetics and Genomics. 
Participants from CoMPaSS and the National Centre for Mental Health 
(NCMH) will be invited to complete the online cognitive study. Participants 
had a variety of mental health problems, including but not limited to 
psychotic disorders, mood disorders, anxiety disorders, autism spectrum 
disorders and posttraumatic stress disorder. The aim of this chapter will be 
to determine whether online cognitive testing is a suitable method for 
mental health research. The response rates, demographic and clinical 
characteristics of the sample and completion rates will be examined. The 
structure of the cognitive battery and the relationships between each task 
and general cognitive ability will also be examined.  
5. To examine clinical predictors of cognitive function and the 
relationship between cognition and functional outcome in a cross-
disorder sample. This study will utilise the data collected using the online 
battery to examine cognitive function in participants with major depressive 
disorder, bipolar disorder and schizophrenia. This study will examine 
whether a set of clinical variables are associated with cognitive function 
both within and across disorders. A further aim of the study will be to test 
the hypothesis that cognitive function is associated with functional outcome 
both within and across disorders.  
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Chapter 2: Cognitive Functioning in Schizoaffective 
Disorder: A Quantitative Review 
2.1 Introduction 
Schizophrenia and bipolar disorder have traditionally been considered to be 
discrete categories in diagnostic classification. In contrast, studies examining 
clinical features, genetic risk and neuroimaging data suggest there are overlaps 
between these disorders. The intermediate diagnosis, “schizoaffective disorder” 
was introduced due to the observation that some patients exhibit symptoms of 
schizophrenia and mood disturbance [20]. Schizoaffective disorder can be divided 
into subtypes based on whether the mood disturbance consists of depressive 
episodes only (depressive type) or manic episodes (known as bipolar type in DSM-
5 and manic or mixed type in ICD-10) [7, 8]. However, the relationship between 
schizoaffective disorder and schizophrenia or bipolar disorder remains unclear (see 
Chapter 1 for a more extensive overview of the diagnostic concepts). Investigating 
the nature and degree of the cognitive impairments associated with schizoaffective 
disorder may further elucidate the relationship between these disorders. 
It is well established that cognition is impaired in a large number of patients with 
schizophrenia [191]. These impairments are evident across a broad range of 
domains including visual and verbal memory, attention and executive function and 
are important predictors of outcome in patients [202]. Cognitive performance in 
affective disorders such as schizoaffective disorder and bipolar disorder is less 
clear. There are fewer studies that examine cognitive performance in 
schizoaffective disorder and bipolar disorder though there is evidence of cognitive 
impairments, albeit milder than in schizophrenia [263, 264, 282, 283]. The two 
meta-analyses conducted to date have detected heterogeneity of effect sizes 
between studies examining this question [263, 264].  
More recent reviews have attempted to reduce this heterogeneity by comparing 
specific diagnoses and subgroups [284-287]. These reviews have concluded that 
participants with schizophrenia who have limited mood symptoms or prominent 
negative symptoms exhibit the most severe cognitive deficits [284-286]. 
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Participants with bipolar disorder and no history of psychosis have the least severe 
cognitive deficits [284-286]. The cognitive performance of participants with either 
bipolar disorder and psychosis or schizoaffective disorder appears to be 
intermediate between bipolar disorder without psychosis and schizophrenia [284, 
286]. Bora et al. [284] concluded that participants who were experiencing 
psychotic symptoms during assessment exhibited similar cognitive impairments 
irrespective of diagnosis. However, Madre et al. [287] suggest that the degree of 
cognitive impairments in schizoaffective disorder is closer to that of schizophrenia 
than bipolar disorder and schizoaffective disorder may represent a subtype of 
schizophrenia. Whilst there is some agreement across these reviews, to date there 
have been no attempts to aggregate the existing data into a meta-analysis. In 
addition, no reviews have examined the subtypes of schizoaffective disorder. This 
is an important consideration, as there is evidence to suggest that the depressive 
subtype of schizoaffective disorder may be associated with cognitive impairment 
closer to that of schizophrenia, whilst those with the bipolar subtype are less 
impaired [266]. This suggests that the proportion of each subtype included in 
schizoaffective disorder samples could bias study results. 
2.2 Chapter aims and hypotheses 
The aim of this chapter was to review studies that compared cognitive performance 
in participants with schizoaffective disorder to those with schizophrenia or bipolar 
disorder. To date, no meta-analyses have been conducted comparing 
schizoaffective disorder and bipolar disorder. Studies that compared the subtypes 
of schizoaffective disorder to schizophrenia and bipolar disorder were also 
reviewed. The main hypothesis was that cognitive impairments in schizoaffective 
disorder would be intermediate between those observed in bipolar disorder and 
schizophrenia. A further hypothesis was that the depressive subtype of 
schizoaffective disorder would be associated with more severe cognitive 
impairments similar to schizophrenia, whilst impairments in the bipolar subtype 
would be less severe than those of schizophrenia but more impaired than those of 
bipolar disorder. 
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2.3 Method 
2.3.1 Study selection 
This review was conducted following guidelines from the Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses (PRISMA) [288]. Searches were 
conducted using the following databases: PubMed, PsycINFO, Web of Science and 
EMBASE. The period covered was between January 1980 and January 2018. The 
keywords, “schizophrenia”, “schizoaffective” and “bipolar” were combined with 
“cogniti*”, “neurocogniti*” and “neuropsycholog*”. The latter terms were also 
replaced with key words and phrases to describe cognitive domains (memory, 
attention and executive function). In addition to database searches, the 
bibliographies of previous reviews, meta-analyses and studies that met inclusion 
criteria were checked for additional studies. Another member of the research team 
conducted an independent search using the same strategy. The articles meeting 
inclusion criteria were selected based on the consensus of both reviewers. There 
was a high level of agreement between the reviewers. Discrepancies between the 
two independent reviews of the papers were resolved through discussion with a 
third researcher until consensus was reached.  
The inclusion criteria included all full text publications that: 
1. Directly compared participants with schizoaffective disorder to those with 
schizophrenia, bipolar disorder or both disorders but did not combine 
different diagnoses into a single group (e.g. affective psychosis).  
2. Included adults (aged 16 years or over) diagnosed using versions of DSM, 
ICD or Research Diagnostic Criteria (RDC).  
3. Included published assessments of cognition for the following domains: 
executive function, speed of processing, working memory, immediate 
verbal memory, immediate visual memory or verbal fluency. 
4. Reported independent data. When studies with overlapping samples were 
identified and both met inclusion criteria, the study with the largest sample 
was selected.  
Studies were excluded if they: 
1. Compared children or adolescent participants. 
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2. Compared participants in their first episode of psychiatric illness.  
3. Were not available in the English language.  
Recorded variables were: 
1. Name of the first author and year of publication 
2. Number of participants in each diagnostic group and proportion of subtypes 
for schizoaffective disorder 
3. Sample characteristics (inpatients or outpatients, diagnostic criteria used) 
and status of patients (acute, stabilised, in remission) where defined 
4. Cognitive test or battery results. Authors were contacted for missing data. 
5. Demographic and clinical variables for groups, including age, sex, 
education, duration of illness, age of onset and medication dose.  
2.3.2 Cognitive variables 
The a priori primary study outcome was general cognitive performance measure, 
which allowed comparisons across studies. Composite cognition effect sizes and 
95% confidence intervals were calculated using the mean and standard error of the 
effect sizes of the individual tests or domains. This included all tests reported in 
each paper in order to maximise the number of studies included. Composite scores 
were only calculated for studies with three or more tests available, as has been done 
in previous studies [289].  
In addition to general cognitive function, domains were selected based on the 
Measurement in Assessment and Treatment Research to Improve Cognition in 
Schizophrenia (MATRICS) initiative [202], which is consistent with the approach 
taken by our research team in our previous work [290]. The tasks or domain scores 
included are listed in Table 2-1. Social cognition was not included as social 
cognition can be separated into multiple domains, which is beyond the scope of the 
current review. Attention was not included due to an insufficient number of studies. 
The executive function domain was expanded beyond the reasoning and problem-
solving domain described by the MATRICS to include other higher-level cognitive 
processes such as inhibitory control and cognitive flexibility. Verbal fluency was 
included as a separate domain given that the majority of studies included a specific 
measure of verbal fluency. Tasks were assigned to domains based on the 
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MATRICS and previous reviews [263, 286], as well as discussions within the study 
team. If a study included more than one task for a single domain, the effect sizes 
were averaged to create a single domain score. For tasks with multiple outcome 
measures, the most common outcome measure used across the studies was included. 
Table 2-1 Tasks included in each domain 
Verbal 
Learning 
Visuospatial 
Learning 
Executive 
Function 
Speed of 
Processing 
Verbal 
Fluency 
Working 
Memory 
BACS: List 
Learning 
CVLT 
HVLT-R 
RAVLT 
VLMT 
WMS-III: 
Logical 
Memory 
BVRT 
CANTAB: 
Paired 
Associates 
Learning  
WMS-R: 
Figural 
Memory 
WMS-III: 
Visual 
Memory  
CANTAB: 
Stockings of 
Cambridge 
BACS: 
Tower of 
London 
BADS: 
Composite 
Score 
CCST 
(perseverative 
sorts) 
DKEFS: 
Colour-Word 
Interference 
SCWT 
TMT B (time 
taken) 
WAIS-R: 
Block Design 
WAIS-III: 
Matrix 
Reasoning 
WCST 
(perseverative 
errors) 
BACS: 
Symbol 
Coding 
d2 Test 
CNTRICS: 
Dot Probe 
Expectancy 
SDMT 
TMT A 
(time taken) 
WAIS-III: 
Symbol 
Search  
WAIS-R: 
Digit 
Symbol 
Substitution 
 
BACS: 
Verbal 
Fluency 
Category 
Fluency: 
Animal 
Naming 
COWAT 
DKEFS: 
Verbal 
Fluency 
Letter 
Fluency 
BACS: 
Digit 
sequencing 
WAIS-R: 
Digit Span 
WAIS-III: 
Digit Span 
WAIS-R: 
Block Span 
WAIS-III: 
Block Span 
WAIS-III: 
Letter-
Number 
Sequencing 
WM-MA 
2-back 
WMS-R: 
Digit Span 
WMS-R: 
Visual 
Span 
WMS-III: 
Letter-
Number 
Sequencing 
Abbreviations: BACS, Brief Assessment of Cognition in Schizophrenia; BADS, Behavioural Assessment of 
the Dysexecutive Syndrome; BVRT, Benton Visual Retention Test; CANTAB, Cambridge Neuropsychological 
Test Automated Battery; CCST, California Card Sorting Test; CNTRICS, Cognitive Neuroscience Test 
Reliability and Clinical Applications for Schizophrenia; COWAT, Controlled Oral Word Association Test; 
CVLT, California Verbal Learning Test; D-KEFS, Delis-Kaplan Executive Function System; HVLT-R, 
Hopkins Verbal Learning Test – Revised; RAVLT, Rey Auditory Verbal Learning Test; SCWT, Stroop 
Colour-Word Test; SDMT, Symbol Digits Modalities Test; TMT, Trail Making Test; VLMT, Verbal Learning 
& Retention Test; WAIS-III, Wechsler Adult Intelligence Scale - Third Edition; WAIS-R, Wechsler Adult 
Intelligence Scale – Revised Edition; WCST, Wisconsin Card Sorting Test; WM-MA, Working Memory – 
Mental Arithmetic Test; WMS-III, Wechsler Memory Scale – Third Edition; WMS-R, Wechsler Memory 
Scale – Revised Edition.  
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2.3.3 Statistical analyses 
Meta-analyses were conducted to compare general cognitive performance and 
domain-specific cognition between the following diagnoses: 
1. Schizoaffective disorder and schizophrenia (N=20) 
2. Schizoaffective disorder and bipolar disorder (N=8) 
3. Schizoaffective disorder – depressive type and schizophrenia (N=3) 
4. Schizoaffective disorder – depressive type and bipolar disorder (N=2) 
5. Schizoaffective disorder – bipolar type and schizophrenia (N=2) 
6. Schizoaffective disorder – bipolar type and bipolar disorder (N=3) 
Hedges’ g effect sizes were calculated for each pair of comparisons using the 
formulas described by Rosnow and Rosenthal [291] and Rosnow, Rosenthal and 
Rubin [292] (for formulas see Appendix A). Hedge’s correction for bias was used 
due to uneven group sizes to calculate the pooled standard deviation [293]. All 
effect sizes were calculated such that a positive effect size would indicate that the 
schizoaffective disorder group had performed better than the comparison group. 
Where papers had reported the subtypes of disorders separately (for example, 
paranoid and undifferentiated types of schizophrenia), the means and standard 
deviations were pooled to create a single diagnostic group. 
Meta-analyses were conducted using the package, “meta” in R v3.3.1. A random 
effects model was used (DerSimonian-Laird estimate [294]). Effect sizes were 
weighted using the inverse variance method. Homogeneity of the effect sizes was 
tested using the Q-test. Funnel plots and Egger’s test were used to assess reporting 
bias. Homogeneity statistics Qbet were calculated to compare the pooled effect sizes 
between the subtypes of schizoaffective disorder (i.e. the results of the 
schizoaffective bipolar/schizophrenia meta-analysis were compared with the 
schizoaffective depressive/schizophrenia meta-analysis and this was repeated for 
bipolar disorder).  
Two sets of sensitivity analyses were performed. Firstly, the meta-analysis 
comparing bipolar disorder and schizoaffective disorder was repeated excluding 
papers that included bipolar disorder - type II in their sample. Secondly, the 
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analyses were repeated excluding two studies that had samples with a mean age 
between 58 and 65 years.  
Meta-regression analyses were conducted to investigate the influence of five 
variables on the composite cognition findings. These variables were age, sex, age 
of onset, duration of illness and education. These variables have been shown to be 
associated with cognitive function and have been examined in previous meta-
analyses of cognitive function in schizophrenia and bipolar disorder [263, 264]. 
There were an insufficient number of studies to investigate the influence of 
antipsychotic dose. Only three studies comparing schizophrenia and schizoaffective 
disorder reported medication dose, whilst none of the bipolar disorder studies had 
included this data. Meta-regression analyses were performed with a random effects 
model using the restricted-information maximum likelihood method.  
2.4 Results 
2.4.1 Retrieved studies 
One hundred and seventy-seven records were identified from the initial searches 
and the abstracts screened for inclusion. Initially, 130 studies were excluded as 
either duplicates or not meeting inclusion criteria. A further 17 articles were 
excluded after examination of the full texts, mainly because these studies had 
combined diagnostic groups and thus we were unable to calculate separate effect 
sizes. This resulted in 30 studies being included in the systematic review and 29 in 
the meta-analysis (summary statistics or effect sizes were not available for one 
study). In total, there were 1462 participants with schizoaffective disorder, 2845 
participants with schizophrenia and 1054 participants with bipolar disorder. Figure 
2-1 shows the PRISMA flowchart illustrating the process of filtering potential 
studies. The final studies included are shown in Table 2-2. Not all the studies 
included in this chapter provided information on the subtypes of schizophrenia, 
schizoaffective disorder or bipolar disorder included in their sample. Information 
on subtypes was included if this information was provided in the paper.   
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The results are presented in three main sections:  
1. Comparisons between schizoaffective disorder and schizophrenia (22 
studies) 
2. Comparisons between schizoaffective disorder and bipolar disorder (8 
studies) 
3. Comparisons of all three disorders. This final section summarises the results 
of 11 studies (out of the 30 studies above) that compared all three disorders. 
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Figure 2-1 PRISMA flowchart illustrating the methodological process of filtering potential studies 
The records excluded at the screening phase (n=127) included 22 reviews and meta-analyses, 88 studies that 
compared schizophrenia and bipolar disorder but not schizoaffective disorder and 17 studies that did not fit the 
aims of this reviews. Full text articles were excluded due to combining diagnoses (n=10), children or 
adolescent participants (n=2), studies with unsuitable cognitive assessments (n=3) or studies reported 
proportion of participants impaired or not impaired (n=2).
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Table 2-2 Summary of studies included in systematic review 
Study Sample Sample Characteristics Cognitive Assessment 
Hedge’s g 
SA vs. SZ SA vs. BD 
Amann et al. [295] 26 SA (bipolar) 
45 SZ 
51 BD 
65 HC 
Acutely unwell inpatients 
DSM-IV 
Schizoaffective group also 
met RDC 
WMS-III Verbal Memory 
WMS-III Working Memory 
WMS-III Visual Memory 
BADS Total 
0.37 
0.02 
0.26 
-0.12 
0.16 
0.05 
-0.07 
0.12 
Beatty et al. [296] 11 SA  
10 SZ (3 paranoid, 7 
undifferentiated) 
Outpatients 
DSM-III-R 
CCST free sorting (perseverative sorts) 0.26  
Birindelli et al. [297] 40 SA  
64 SZ 
Outpatients 
DSM-IV-TR 
In remission 
CVLT (trials 1-5) 
TMT A 
TMT B 
WCST (perseverative errors) 
0.56 
0.08 
0.21 
0.43 
 
Bornstein et al. [298] 18 SA 
55 SZ (28 paranoid, 27 
non-paranoid) 
52 HC 
Primarily outpatients 
DSM-III-R 
WAIS-R Verbal IQ 
WAIS-R Performance IQ 
HRB Category Test (no of errors) 
WCST (perseverative errors) 
VCAT 
Verbal Fluency 
Verbal WMS-R 
Spatial WMS-R 
HRB TPT Time 
HRB TPT Memory 
HRB TPT Location 
HRB Speech Perception 
HRB Seashore Rhythm 
HRB TMT A 
HRB TMT B 
0.29 
0.11 
0.11 
0.66 
0.90 
-0.26 
0.42 
-0.01 
0.24 
-0.55 
0.47 
0.22 
0.17 
0.13 
0.47 
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Table 2-2 (cont.) Summary of studies included in systematic review 
Study Sample Sample Characteristics Cognitive Assessment 
Hedge’s g 
SA vs. SZ SA vs. BD 
Bornstein et al. [298] 
(cont.) 
18 SA 
55 SZ (28 paranoid, 27 
non-paranoid) 
52 HC 
Primarily outpatients 
DSM-III-R 
HRB Finger Tap (right) 
HRB Finger Tap (left) 
HRB Grooved Peg (right) 
HRB Grooved Peg (left) 
HRB Finger Agnosia (right) 
HRB Finger Agnosia (left) 
HRB Graphesthesia (right) 
HRB Graphesthesia (left) 
0.19 
0.34 
0.40 
0.05 
0.54 
0.35 
0.42 
0.29 
 
DeRosse et al. [299] 129 SA 
595 SZ (224 with mood, 
371 without mood) 
269 BD (Type-I with 
psychosis) 
Inpatients and outpatients 
DSM-IV 
WAIS-R Digit Span 
CVLT 
COWAT 
Verbal Fluency: Animal Naming 
TMT A 
TMT B 
0.004 
0.33 
-0.02 
0.08 
0.10 
0.04 
-0.27 
-0.23 
-0.06 
-0.28 
-0.08 
-0.38 
Evans et al. [300] 24 SA (depressive and 
bipolar subtypes) 
115 SZ 
 
Outpatients, including 
veterans 
DSM-III-R 
Verbal Ability 
Aphasia Screening Test 
WAIS-R Vocabulary 
Boston Naming Test 
WAIS-R Similarities 
Thurstone Written Fluency 
COWAT (FAS) 
-0.02 
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Table 2-2 (cont.) Summary of studies included in systematic review 
Study Sample Sample Characteristics Cognitive Assessment 
Hedge’s g 
SA vs. SZ SA vs. BD 
Evans et al. [300] 
(cont.) 
24 SA (depressive 
and bipolar subtypes) 
115 SZ 
 
Outpatients, including 
veterans 
DSM-III-R 
Psychomotor Speed 
TMT A 
WAIS-R Object Assembly 
WAIS-R Digit Symbol 
WAIS-R Block Design 
TPT 
Digit Vigilance Test (time) 
-0.16 
 
 
   Abstraction / Cognitive Flexibility 
Booklet Category Test 
TMT B 
WCST 
-0.34 
 
 
   Attention 
WAIS-R Digit Span 
Digit Vigilance Test (errors) 
-0.18 
 
 
   Learning and Incidental Memory 
CVLT (trials 1-5) 
Figure Memory Test 
(learning) 
Story Memory Test (learning) 
-0.38  
   Retention 
CVLT (long delay recall) 
Figure Memory Test (delayed) 
Story Memory Test (delayed) 
-0.32 
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Table 2-2 (cont.) Summary of studies included in systematic review 
Study Sample Sample Characteristics Cognitive Assessment 
Hedge’s g 
SA vs. SZ SA vs. BD 
Evans et al. [300] (cont.) 24 SA (depressive and 
bipolar subtypes) 
115 SZ 
 
Outpatients, including 
veterans 
DSM-III-R 
Motor 
Finger Tapping Test 
Grooved Pegboard Test 
Hand dynamometer 
-0.07  
Fiszdon et al. [301] 73 SA 
199 SZ 
Outpatients 
DSM-IV 
WCST (% conceptual level) 
WAIS-III Digit Symbol 
WAIS-III Digit Span 
WMS-R Logical Memory I 
HVLT-R 
WMS-R Figural Memory  
0.05 
0.21 
0.16 
0.34 
0.14 
0.31 
 
Gilvarry et al. [302] 296 SA 
223 SZ 
Outpatients 
RDC 
TMT A 
TMT B 
0.02 
-0.17 
 
Glahn et al. [303] 15 SA (depressive) 
15 SZ 
26 BD (11 with history of 
psychosis, 15 without 
psychosis) 
32 HC  
Outpatients 
DSM-IV 
Mixture of symptomatic 
and remitted patients 
WAIS-III Forward Digit Span 
WAIS-III Backward Digit Span 
0.20 
-0.08 
-0.27 
-0.38 
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Table 2-2 (cont.) Summary of studies included in systematic review 
Study Sample Sample Characteristics Cognitive Assessment 
Hedge’s g 
SA vs. SZ SA vs. BD 
Goldstein et al. [304] 20 SA  
63 SZ (29 
undifferentiated, 20 
paranoid, 14 residual) 
Male veterans 
Stabilised inpatients 
DSM-III-R 
HRB Category Test 
HRB TPT 
TMT B 
WCST (errors) 
WAIS-R Information  
WAIS-R Digit Span 
WAIS-R Vocabulary 
WAIS-R Arithmetic 
WAIS-R Comprehension 
WAIS-R Similarities 
WAIS-R Picture Completion 
WAIS-R Picture Arrangement 
WAIS-R Block Design 
WAIS-R Object Assembly 
WAIS-R Digit Symbol 
0.72 
0.31 
0.56 
0.14 
0.27 
-0.11 
0.85 
0.77 
1.05 
0.17 
0.55 
0.21 
0.42 
0.23 
0.35 
 
Gooding & Tallent 
[305] 
23 SA (19 bipolar, 4 
depressive) 
34 SZ (15 paranoid, 12 
residual, 6 
undifferentiated, 1 
disorganised) 
30 HC 
Outpatients 
RDC 
WCST (perseverative errors) -0.18  
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Table 2-2 (cont.) Summary of studies included in systematic review 
Study Sample Sample Characteristics Cognitive Assessment 
Hedge’s g 
SA vs. SZ SA vs. BD 
Heinrichs et al. [306] 48 SA 
103 SZ 
72 HC 
Outpatients 
DSM-IV 
WAIS-III Vocabulary  
WAIS-III Matrix Reasoning  
WAIS-III Letter-Number 
WAIS-III Symbol Search  
CVLT (trials 1-5) 
COWAT 
WRAT-3 Reading 
0.70 
0.50 
0.53 
0.63 
0.65 
0.46 
0.44 
 
Hill et al. [266] 165 SA (55 depressive, 
110 bipolar) 
293 SZ 
227 BD (all with history 
of psychosis) 
295 HC 
Outpatients 
DSM-IV 
BACS Verbal Memory 
BACS Tower of London 
BACS Symbol Coding 
BACS Verbal Fluency 
BACS Digit Sequencing 
0.05 
0.38 
0.33 
0.14 
0.10 
-0.37 
-0.24 
-0.17 
-0.32 
-0.37 
Leposavic et al. [307] 30 SA 
31 SZ (paranoid) 
30 HC 
Stabilised inpatients 
ICD-10 
VITI Information 
VITI Digit Span 
VITI Vocabulary 
VITI Arithmetic 
VITI Comprehension 
VITI Similarities 
VITI Picture Completion 
VITI Picture Arrangement 
VITI Block Design 
-0.23 
-0.31 
-0.17 
-0.65 
-0.38 
-0.08 
-0.19 
-0.07 
-0.90 
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Table 2-2 (cont.) Summary of studies included in systematic review 
Study Sample Sample Characteristics Cognitive Assessment 
Hedge’s g 
SA vs. SZ SA vs. BD 
Leposavic et al. [307] 
(cont.) 
30 SA 
31 SZ (paranoid) 
30 HC 
Stabilised inpatients 
ICD-10 
VITI Object Assembly 
VITI Digit Symbol 
MMSE 
TMT A 
TMT B  
HVOT 
RCF (delayed recall) 
RAVLT (total words) 
WCST (perseverative errors) 
-0.85 
-0.44 
-2.42 
0.16 
-0.22 
0.42 
-0.34 
0.22 
-0.77 
 
Lewandowski et al. 
[308] 
29 SA (all bipolar type) 
25 SZ 
31 BD (all with history of 
psychosis) 
20 HC 
Stabilised inpatients and 
outpatients 
DSM-IV-TR 
TMT B 0.69 -0.07 
Maj [309] 16 SA (all depressive 
type) 
20 SZ 
20 HC 
Inpatients and outpatients 
RDC 
LNNB Motor 
LNNB Rhythm 
LNNB Tactile 
LNNB Visual 
LNNB Receptive Speech 
LNNB Expressive Speech 
LNNB Writing 
LNNB Reading 
LNNB Arithmetic 
LNNB Memory 
LNNB Intellectual Processes 
LNNB Pathognomic 
0.31 
0.23 
0.13 
0.31 
0.32 
0.43 
0.35 
0.41 
0.14 
0.24 
0.18 
0.36 
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Table 2-2 (cont.) Summary of studies included in systematic review 
Study Sample Sample Characteristics Cognitive Assessment 
Hedge’s g 
SA vs. SZ SA vs. BD 
Maj [309] (cont.) 16 SA (all depressive 
type) 
20 SZ 
20 HC 
Inpatients and outpatients 
RDC 
LNNB Left Hemisphere 
LNNB Right Hemisphere 
0.27 
0.23 
 
Miller et al. [310] 26 SA (9 bipolar, 17 
depressive) 
26 SZ (8 paranoid, 3 
undifferentiated, 4 
residual, 1 disorganised) 
Male veterans 
Inpatients 
RDC 
LNNB Motor 
LNNB Rhythm 
LNNB Tactile 
LNNB Visual 
LNNB Receptive Speech 
LNNB Expressive Speech 
LNNB Writing 
LNNB Reading 
LNNB Arithmetic 
LNNB Memory 
LNNB Intellectual Processes 
LNNB Pathognomic 
LNNB Left Hemisphere 
LNNB Right Hemisphere 
BVRT 
RAVLT (trials 1-5) 
WAIS-R Verbal IQ 
WAIS-R Performance IQ 
-0.35 
0.02 
0.05 
-0.15 
0.01 
-0.44 
-0.31 
-0.18 
-0.51 
-0.36 
-0.08 
0.05 
0.03 
-0.08 
-0.53 
-0.09 
-0.24 
-0.21 
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Table 2-2 (cont.) Summary of studies included in systematic review 
Study Sample Sample Characteristics Cognitive Assessment 
Hedge’s g 
SA vs. SZ SA vs. BD 
Mueser et al. [311] 52 SA 
51 SZ 
36 BD 
Outpatients aged 50 or 
older 
DSM-IV 
Administered the DKEFS battery and 
derived factor scores (domains) using 
principal components analysis: 
 
Memory 
Verbal Fluency 
Psychomotor Speed 
Executive Functioning 
 
 
 
 
0.01 
0.01 
0.01 
0.02 
 
 
 
 
-0.04 
-0.03 
-0.05 
-0.04 
Owoso et al. [312] 63 SA 
188 SZ 
268 HC 
Outpatients 
DSM-IV-TR 
CNTRICS: Dot Probe Expectancy -0.07  
Pinna et al. [313] 66 SA 
46 SZ 
Outpatients 
DSM-IV-TR 
MMSE 
BACS Verbal Memory 
BACS Working Memory 
BACS Letter Fluency 
BACS Semantic Fluency 
BACS Symbol Coding 
BACS Tower of London 
0.05 
0.21 
0.02 
0.28 
0.18 
-0.07 
0.03 
 
Reichenberg et al. 
[314]* 
78 BD (all with history of 
psychosis) 
15 SA 
94 SZ 
Longitudinal study – tasks 
administered at 24 month 
follow-up from first 
admission 
DSM-IV 
WAIS-R Vocabulary 
WAIS-R Information 
WMS-R Verbal Paired Associates 
WMS-R Visual Reproduction 
SCWT 
TMT A 
TMT B 
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Table 2-2 (cont.) Summary of studies included in systematic review 
Study Sample Sample Characteristics Cognitive Assessment 
Hedge’s g 
SA vs. SZ SA vs. BD 
Reichenberg et al. [314] 
(cont.)* 
78 BD (all with history of 
psychosis) 
15 SA 
94 SZ 
Longitudinal study – tasks 
administered at 24 month 
follow-up from first 
admission 
DSM-IV 
WAIS-R Picture Completion 
SDMT 
WAIS-R Digit Symbol Coding 
Letter Fluency Test 
Sentence Repetition Test 
  
Savage et al. [315] 20 SA  
41 SZ (20 paranoid, 21 
undifferentiated) 
Outpatients 
DSM-IV 
SDMT 
Anomalous Sentences Repetition Test 
TMT A 
TMT B 
COWAT 
0.45 
0.15 
0.67 
0.24 
0.51 
 
Simonsen et al. [316] 27 SA 
102 SZ 
136 BD (75 with history 
of psychosis & 61 without 
/ 80 Type-I & 56 Type-II) 
280 HC 
Inpatients and outpatients 
DSM-IV 
WMS-III Logical Memory 
CVLT 
WAIS-III Digit Symbol 
WAIS-III Backward Digit Span 
WM-MA 2-back 
D-KEFS Phonetic Fluency 
D-KEFS Semantic Fluency 
D-KEFS Set Shifting 
D-KEFS Colour-Word Interference  
0.26 
0.12 
0.07 
0.10 
-0.04 
0.10 
-0.13 
-0.08 
-0.08 
-0.27 
-0.62 
-0.58 
-0.27 
-0.40 
-0.15 
-0.53 
-0.51 
-0.60 
Stip et al. [317] 13 SA  
44 SZ 
 
Outpatients 
DSM-IV 
CANTAB Motor Screening  
CANTAB Reaction Time 
CANTAB Stockings of Cambridge 
CANTAB Paired Associates Learning 
0.67 
-0.02 
-0.20 
0.40 
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Table 2-2 (cont.) Summary of studies included in systematic review 
Study Sample Sample Characteristics Cognitive Assessment 
Hedge’s g 
SA vs. SZ SA vs. BD 
Studentkowski et al. 
[318] 
28 SA  
32 BD 
DSM-IV 
Outpatients 
d2 Test (concentration) 
TMT A 
TMT B 
WAIS Forward Digit Span 
WAIS Backward Digit Span 
WAIS Forward Block Span 
WAIS Backward Block Span 
VLMT 
 -0.14 
-0.63 
-0.48 
-0.59 
-0.25 
0.72 
-0.64 
-0.73 
Szoke et al. [319] 25 SA 
48 SZ 
92 BD (52 with history of 
psychosis & 40 without) 
48 HC 
Inpatients (recruited prior 
to discharge) 
DSM-IV 
WCST 0.27 -0.65 
Torniainen et al. [320] 62 SA (52 bipolar, 10 
depressive) 
218 SZ 
123 HC 
Outpatients 
DSM-IV 
WAIS-R: Vocabulary 
WAIS-R: Digit Symbol 
TMT A 
TMT B 
WMS-R: Forward Digit Span 
WMS-R: Backward Digit Span  
WMS-R: Forward Visual Span 
WMS-R Backward Visual Span  
CVLT 
0.44 
0.42 
0.34 
0.03 
0 
0.19 
0.22 
0.32 
0.60 
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Table 2-2 (cont.) Summary of studies included in systematic review 
Study Sample Sample Characteristics Cognitive Assessment 
Hedge’s g 
SA vs. SZ SA vs. BD 
Torrent et al. [321] 34 SA (bipolar) 
41 BD (16 Type – I, 25 
Type – II, no psychosis) 
35 HC 
Outpatients 
DSM-IV 
WCST 
SCWT 
WAIS Forward Digit Span 
WAIS Backward Digit Span 
TMT A 
TMT B 
COWAT (FAS) 
Category Fluency: Animal Naming 
CVLT 
 -0.11 
0.11 
-0.13 
0.06 
-0.31 
-0.54 
-0.38 
-0.48 
-0.84 
Van Rheenen et al. 
[322] 
33 SA 
49 SZ 
35 BD (all Type-I; 26 
with psychosis, 9 without) 
Outpatients  
DSM-IV-TR 
Processing Speed  
Digit Symbol Coding 
TMT A 
DKEFS Colour-Word 
Interference (word reading and 
colour naming) 
0.24 -0.20 
   Immediate Memory 
BVMT-R (trial 1) 
HVLT-R (trial 1) 
0.92 0.51 
   Learning 
BVMT-R (trials 1-3) 
HVLT-R (trials 1-3) 
0.24 -0.07 
  Semantic Memory 
Category Fluency: Animal 
Naming 
0.59 -0.67 
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Table 2-2 (cont.) Summary of studies included in systematic review 
Study Sample Sample Characteristics Cognitive Assessment 
Hedge’s g 
SA vs. SZ SA vs. BD 
Van Rheenen et al. 
[322] (cont.) 
33 SA 
49 SZ 
35 BD (all Type-I; 26 
with psychosis, 9 without) 
Outpatients  
DSM-IV-TR 
Attention / Vigilance 
CPT-IP 
0.19 0.05 
 Working Memory 
Letter-Number Span 
WMS: Spatial Span 
(backwards) 
0.01 -0.03 
   Executive Function 
NAB Mazes 
DKEFS Colour-Word 
Interference (interference / 
switching blocks) 
0.18 0.26 
Varma et al. [323] 35 SA 
48 SZ 
48 HC 
Outpatients 
DSM-IV 
WCST (perseverative errors) 
SCWT 
VMPT 
0.10 
-0.03 
-0.28 
 
*Study not included in meta-analysis, as summary data and effect sizes were not reported. Abbreviations:  BD, Bipolar Disorder; SA, Schizoaffective Disorder; SZ, Schizophrenia; BACS, Brief 
Assessment of Cognition in Schizophrenia; BADS, Behavioural Assessment of the Dysexecutive Syndrome; BVRT, Benton Visual Retention Test; CANTAB, Cambridge Neuropsychological 
Test Automated Battery; CCST, California Card Sorting Test; CNTRICS, Cognitive Neuroscience Test Reliability and Clinical Applications for Schizophrenia; COWAT, Controlled Oral Word 
Association Test; CPT-IP, Continuous Performance Test – Identical Pairs; CVLT, California Verbal Learning Test; D-KEFS, Delis-Kaplan Executive Function System; HRB, Halstead-Reitan 
Neuropsychological Battery; HVLT-R, Hopkins Verbal Learning Test – Revised; HVOT, Hooper Visual Organisation Test, LNNB, Luria-Nebraska Neuropsychological Battery; RAVLT, Rey 
Auditory Verbal Learning Test; RCF, Rey Complex Figure Test; SCWT, Stroop Colour-Word Test; SDMT, Symbol Digits Modalities Test; TMT, Trail Making Test; TPT, Tactual Performance 
Test; VCAT, Verbal Concept Attainment Test; VITI, Wechsler’s Individual Test of Intelligence, Serbian translation of WAIS; VLMT, Verbal Learning & Retention Test; WAIS-III, Wechsler 
Adult Intelligence Scale - Third Edition; WAIS-R, Wechsler Adult Intelligence Scale – Revised Edition; WCST, Wisconsin Card Sorting Test; WM-MA, Working Memory – Mental Arithmetic 
Test; WMS-III, Wechsler Memory Scale – Third Edition; WMS-R, Wechsler Memory Scale – Revised Edition; WRAT, Wide Range Achievement Test.  
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2.4.2 Schizophrenia and schizoaffective disorder 
Meta-analysis 
Composite cognition effect sizes were calculated for 20 studies comparing 
schizoaffective disorder (n=928) and schizophrenia (n=2246). Participants with 
schizoaffective disorder performed better than participants with schizophrenia 
based on composite cognition scores (g=0.16, p=0.0004, see Figure 2-2). Effect 
size distributions were homogeneous (2=0 .007; Q=22.81, p=0.25) and there was 
no evidence of publication bias (Egger: bias = -0.33). When the two studies with 
older samples were excluded, the effect size was slightly larger (g=0.20, see 
Appendix B). 
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Figure 2-2 Forest plot of individual and pooled random effect estimates of mean differences between schizophrenia and schizoaffective disorder  
Positive effect sizes indicate better performance in the schizoaffective disorder group. 
77 
 
Cognitive domains 
In analyses examining individual cognitive domains, the schizoaffective group 
outperformed the schizophrenia group in verbal learning (g=0.27) and speed of 
processing (g=0.18), although there was evidence of heterogeneity (verbal 
learning: Q=33.91, p=0.01; speed of processing: Q=22.11, p=0.05, see Table 2-3).  
 
Table 2-3 Pooled effect sizes for comparisons between schizoaffective disorder and schizophrenia 
Domain 
Studies 
(N) 
SZ 
(N) 
SA 
(N) 
g 95% CI Z P 
Q-
test P 
Bias 
Verbal 
learning 
13 1825 745 0.27 
0.12 - 
0.41 
3.65 0.0003 0.01 0.17 
Visuospatial 
learning 
5 369 156 0.14 
-0.14 - 
0.42 
1.00 0.32 0.15 -1.93 
Executive 
function 
19 2135 1132 0.12 
-0.01 - 
0.26 
1.77 0.08 0.001 0.63 
Speed of 
processing 
14 2268 1106 0.18 
0.08 - 
0.29 
3.33 0.001 0.05 0.82 
Verbal 
fluency 
6 1243 486 0.16 
-0.003 - 
0.33 
1.93 0.05 0.08 0.74 
Working 
memory 
11 1710 661 0.10 
-0.01 - 
0.20 
1.84 0.07 0.37 -0.27 
SA, schizoaffective disorder; SZ, schizophrenia. Positive effect sizes indicate better performance in the 
schizoaffective disorder group. 
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Schizoaffective disorder subtypes 
The meta-analyses were repeated for the separate subtypes of schizoaffective 
disorder: schizoaffective bipolar type and schizoaffective depressive type (see 
Figure 2-3 for results). Only a small number of studies had reported separate 
statistics for the subtypes of schizoaffective disorder or only included one subtype 
in their sample. There was no significant difference between participants with 
schizophrenia and participants with schizoaffective disorder – depressive type 
(g=0.16, p=0.22). Participants with schizoaffective disorder – bipolar type 
outperformed participants with schizophrenia (g=0.22, p=0.03). The results of the 
Q-test and Egger’s test indicated that there was little evidence of heterogeneity or 
publication bias but these tests have low power when there is only a small number 
of studies included. The Qbet test was not significant for differences in the effect 
sizes between schizophrenia/schizoaffective depressive and 
schizophrenia/schizoaffective bipolar comparisons (p=0.67). 
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Figure 2-3 Forest plot of individual and pooled random effect estimates of mean differences between subtypes of schizoaffective disorder and schizophrenia  
Schizoaffective disorder – depressive type (participant N=86) vs. schizophrenia (participant N=328) comparison: Egger’s test bias = 0.57. Egger’s bias cannot be calculated for the 
schizoaffective disorder – bipolar type (participant N=136) vs. schizophrenia (participant N=272) comparison. Positive effect sizes indicate better performance in the schizoaffective disorder 
group. 
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Meta-regression analyses 
Meta-regression analyses were conducted to investigate the influence of five 
variables on the composite cognition findings. These variables were age, sex, age 
of onset, duration of illness and education. Meta-regression analyses were not 
significant for any of the variables examined (see Table 2-4).  
 
Table 2-4 Results of meta-regression analyses 
 N B 95% CIs p 
Age 20 -0.06 -0.52 – 0.41 0.81 
Age of Onset 8 0.69 -0.11 – 1.49 0.09 
Duration of Illness 11 0.21 -0.23 – 0.65 0.36 
Years in Education 13 0.12 -0.08 – 0.31 0.24 
Sex 15 -0.002 -0.15 – 0.14 0.98 
 
Summary 
Twenty-two studies directly compared cognitive function between participants with 
schizophrenia and schizoaffective disorder. There is evidence to suggest that those 
with schizophrenia are more impaired on measures of verbal memory [297, 298, 
306, 320], executive function [297, 298, 306], working memory [306, 320], verbal 
fluency [306], processing speed [298, 306, 315, 320] and visuospatial memory 
[317]. Hill et al. [266] reported greater overall impairment in the schizophrenia 
group compared to the schizoaffective disorder group.  
Negative symptoms were strongly associated with cognitive performance in one 
study [320] and lower cognitive abilities were demonstrated in those with non-
paranoid subtypes of schizophrenia such as undifferentiated type compared to 
paranoid schizophrenia and schizoaffective disorder [298, 304, 315]. This suggests 
that severity of cognitive impairments may be differentiated on the basis of the 
presence of negative symptoms rather than diagnosis. When Heinrichs et al. [306] 
entered cognitive scores into a regression model, performance correctly classified 
91% of participants as being diagnosed with schizophrenia but 65% of participants 
with schizoaffective disorder were misclassified as having schizophrenia 
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suggesting there is a large overlap in cognitive function. This is supported by a 
number of studies that did not report differences between schizophrenia and 
schizoaffective disorder [296, 300-302, 305, 310, 312, 313, 323]. In addition, one 
study reported better performance of participants with paranoid schizophrenia 
compared to schizoaffective disorder [307]. 
Five studies reported information regarding the subtypes of schizoaffective 
disorder included in their sample [266, 305, 309, 310, 320]. Two studies included 
higher proportions of participants with the bipolar subtype than participants with 
the depressive subtype (Gooding and Tallent [305]: 83% bipolar; Torniainen et al. 
[320]: 84% bipolar). Gooding and Tallent [305] did not find differences between 
schizophrenia and schizoaffective disorder on the WCST. Torniainen et al. [320] 
reported greater impairment in the schizophrenia group, which was associated with 
more symptomatology and higher doses of antipsychotic medication. Miller et al. 
[310] reported no differences between participants with schizophrenia and 
schizoaffective disorder on the Luria-Nebraska Neuropsychological Battery in their 
sample of 17 participants with the depressive subtype and 9 with the bipolar 
subtype. Only one study reported comparisons between schizophrenia and a 
subtype of schizoaffective disorder [309]. Maj et al. [309] included participants 
with the depressive subtype only and reported no differences between 
schizophrenia and schizoaffective disorder on the Luria-Nebraska 
Neuropsychological Battery. Finally, three studies compared performance between 
the subtypes of schizoaffective disorder and did not find significant differences 
[266, 310, 312].  
Overall, studies have reported conflicting findings regarding whether differences in 
cognitive function exist between schizoaffective disorder and schizophrenia. 
However, the balance of evidence suggests that cognitive performance does not 
differentiate those with schizophrenia and those with schizoaffective disorder, 
particularly after accounting for clinical features. There was a lack of evidence 
suggesting differences between the subtypes of schizoaffective disorder but few 
studies had examined this and sample sizes were small. To date, only one study has 
compared participants with a specific subtype of schizoaffective disorder to 
participants with schizophrenia. 
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2.4.3 Bipolar disorder and schizoaffective disorder 
Meta-analysis 
Composite cognition effect sizes were calculated for 8 studies comparing 
schizoaffective disorder (n=494) and bipolar disorder (n=827). Participants with 
schizoaffective disorder performed worse than participants with bipolar disorder 
(g=-0.27, p<0.0001, see Figure 2-4). Effect size distributions were homogeneous 
(2<0.0001; Q=6.81, p=0.45) and there was no evidence of publication bias 
(Egger: bias = 1.11). These results did not change when the analysis was repeated 
including participants with bipolar disorder – type I only (g=-0.27, see Appendix 
B). When the two studies with older samples were excluded, the effect size was 
slightly larger (g=-0.28, see Appendix B). 
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Figure 2-4 Forest plot of individual and pooled random effect estimates of mean differences between schizoaffective disorder and bipolar disorder  
Positive effect sizes indicate better performance in the schizoaffective disorder group. 
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Cognitive domains 
In analyses examining individual cognitive domains, performance in the 
schizoaffective group was worse than bipolar disorder in verbal learning (g=-0.41), 
executive function (g=-0.32), speed of processing (g=-0.27), verbal fluency (g=-
0.31) and working memory (g=-0.28, see Table 2-5). Data comparing visuospatial 
learning between bipolar disorder and schizoaffective disorder were not available. 
There was evidence of heterogeneity in the effect sizes for verbal learning 
(Q=13.41, p=0.02). 
 
Table 2-5 Pooled effect sizes for comparisons between schizoaffective disorder and bipolar disorder 
Domain 
Studies 
(N) 
BD 
(N) 
SA 
(N) 
g 95% CI Z P 
Q-test 
P 
Bias 
Verbal 
learning 
6 750 408 -0.41 
-0.64 to 
-0.18 
-3.48 0.005 0.02 -1.47 
Executive 
function 
8 877 463 -0.32 
-0.46 to 
-0.17 
-4.21 <0.0001 0.22 0.02 
Speed of 
processing 
5 705 383 -0.27 
-0.47 to 
-0.06 
-2.55 0.01 0.10 -2.54 
Verbal 
fluency 
5 708 388 -0.31 
-0.44 to 
-0.18 
-4.63 <0.0001 0.39 -1.91 
Working 
memory 
6 756 409 -0.28 
-0.40 to 
-0.15 
-4.30 <0.0001 0.42 0.75 
BD, bipolar disorder; SA, schizoaffective disorder. Positive effect sizes indicate better performance in the 
schizoaffective disorder group. 
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Schizoaffective disorder subtypes 
The meta-analyses were repeated for the separate subtypes of schizoaffective 
disorder: schizoaffective bipolar type and schizoaffective depressive type (see 
Figure 2-5 for results). Only a small number of studies had reported separate 
statistics for the subtypes of schizoaffective disorder or only included one subtype 
in their sample. The schizoaffective bipolar group had lower overall cognitive 
scores than bipolar disorder (g=-0.22, p=0.02). The schizoaffective depressive 
group were more impaired than those with bipolar disorder (g=-0.37, p=0.007). The 
results of the Q-test and Egger’s test indicated that there was little evidence of 
heterogeneity or publication bias but these tests have low power when there is only 
a small number of studies included. The Qbet test was not significant for differences 
in the effect sizes between bipolar disorder/schizoaffective depressive and bipolar 
disorder/schizoaffective bipolar comparisons (p=0.36). 
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Figure 2-5 Forest plot of individual and pooled random effect estimates of mean differences between subtypes of schizoaffective disorder and bipolar disorder  
Schizoaffective disorder – bipolar type (participant N=170) vs. bipolar disorder (participant N=385) comparison: Egger’s test bias = 1.24. Egger’s bias cannot be calculated for the 
schizoaffective disorder – depressive type (participant N=70) vs. bipolar disorder (participant N=238) comparison. Positive effect sizes indicate better performance in the schizoaffective 
disorder group. 
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Meta-regression analyses 
There was insufficient data to examine the influence of age of onset and years in 
education for studies comparing bipolar disorder and schizoaffective disorder. 
Meta-regression analyses were not significant for any of the variables examined 
(see Table 2-6).  
 
Table 2-6 Results of meta-regression analyses 
 N B 95% CIs p 
Age 8 0.38 -0.50 – 1.26 0.40 
Duration of Illness 6 0.01 -0.55 – 0.56 0.99 
Sex 8 0.02 -0.20 – 0.25 0.83 
 
Summary 
Six studies directly compared cognitive functioning between participants with 
schizoaffective disorder and bipolar disorder. The other two studies included in the 
meta-analysis reported suitable data but did not directly compare the groups. There 
were no differences between participants with schizoaffective disorder and bipolar 
disorder in a study of acutely unwell inpatients [295]. In a study of inpatients and 
outpatients, participants with schizoaffective disorder and bipolar disorder with a 
history of psychosis had similar cognitive performance [324]. However, both 
groups were more impaired on measures of verbal memory and verbal fluency than 
participants with bipolar disorder who did not have a history of psychosis [318, 
324].  
The remaining four studies included samples of euthymic outpatients [266, 311, 
321]. One of these studies only included participants without a history of psychosis 
in the bipolar disorder group and participants with the bipolar subtype in the 
schizoaffective disorder group [321]. The study included participants with bipolar 
disorder – type I and type II [321]. Hill et al. [266] included participants with both 
subtypes of schizoaffective disorder but did not compare these subtypes separately 
to participants with psychotic bipolar disorder. Lifetime history of psychosis, 
bipolar disorder type and schizoaffective subtype was not stated in the remaining 
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two studies [311, 318]. In these studies, participants with schizoaffective disorder 
were more impaired on measures of psychomotor speed [318], verbal memory [318, 
321], executive function [321] and global cognitive function [266, 311]. 
2.4.4 All three diagnostic groups 
Of the studies included in this review, there were 11 studies comparing all three 
disorders. Studies that have limited their bipolar disorder group to those with a 
lifetime history of psychosis have primarily reported no significant differences in 
global cognitive function between the three disorders [295, 308, 314, 316]. 
Simonsen et al. [316] found severity of cognitive impairments in the bipolar with 
psychosis group was similar to those with a diagnosis of schizophrenia or 
schizoaffective disorder across measures of verbal learning and memory, working 
memory and executive function, whereas the performance of the bipolar without 
psychosis group was more comparable to the healthy control group. Two studies 
included only the bipolar subtype of schizoaffective disorder and reported no 
differences between this subtype and schizophrenia or psychotic bipolar disorder, 
although in both studies the participants were highly symptomatic at the time of 
testing [295, 308].  
In the largest study to date, the cognitive profiles across the three disorders were 
similar but the severity of impairments increased from psychotic bipolar disorder to 
schizoaffective disorder to schizophrenia [266]. The authors were able to separate 
the subtypes of schizoaffective disorder and demonstrated lower cognitive 
performance in the depressive group than the bipolar group, although the 
differences were not significant. Two studies included participants with and 
without a history of psychosis in their bipolar group. These studies also found 
evidence of increasing impairment from bipolar disorder to schizoaffective disorder 
to schizophrenia on measures of executive function [319] and working memory 
[303]. This pattern was not consistent with the studies reporting differential 
patterns of performance using tasks designed to measure the same domain [303, 
319]). 
Whilst the studies described above have compared average cognitive performance 
between diagnoses, other studies have taken different approaches. DeRosse et al. 
[299] used a regression model to estimate cognitive decline based on performance 
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on measures of premorbid IQ and current cognitive function. Their results 
suggested that cognitive decline in schizoaffective disorder is greater than bipolar 
disorder. Reichenberg et al. [314] categorised participants as cognitively impaired 
according to three separate criteria and demonstrated higher rates of cognitive 
impairment in the schizophrenia and schizoaffective disorder groups compared to 
psychotic bipolar disorder, although average performance did not differ between 
groups. Van Rheenen et al. [322] used discriminant function analysis to determine 
if performance on cognitive tasks could separate disorders. A high proportion of 
those with schizoaffective disorder were misclassified as having schizophrenia or 
bipolar disorder, which does not provide validity for schizoaffective disorder as an 
independent diagnostic entity. Finally, Mueser et al. [311] showed that overall 
cognitive performance in males with schizoaffective disorder and females with 
schizophrenia was more impaired than males with bipolar disorder. 
2.5 Discussion 
The aim of this work described in this chapter was to compare cognitive outcomes 
of schizoaffective disorder with schizophrenia and bipolar disorder. This is the first 
meta-analysis to compare cognitive performance of participants with 
schizoaffective disorder and bipolar disorder. It is also the first review that has 
attempted to examine whether the subtypes of schizoaffective disorder differ in 
cognitive outcomes compared to schizophrenia and bipolar disorder.  
There were three main findings: 
1. Participants with schizoaffective disorder performed worse than those with 
bipolar disorder on global cognition and all domains. 
2. Participants with schizoaffective disorder performed better than those with 
schizophrenia on global cognition, verbal learning, and speed of processing.  
3. Cognitive impairments in participants with the depressive subtype of 
schizoaffective disorder are closer in severity to those seen in participants 
with schizophrenia, whereas participants with the bipolar subtype are more 
impaired than participants with bipolar disorder and less impaired than 
those with schizophrenia. This result was largely driven by Hill et al.’s 
study of 980 participants. 
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2.5.1 Comparisons between schizoaffective disorder and bipolar disorder 
The schizoaffective disorder group exhibited worse performance across all 
cognitive domains compared to the bipolar disorder group. This supports the 
conclusions of a review by Madre et al. [287] who suggested that cognitive 
impairments are more severe in schizoaffective disorder than in bipolar disorder. 
Other reviews have concluded that bipolar disorder and psychosis is associated 
with similar cognitive impairments to those seen in schizoaffective disorder [284], 
whilst participants with bipolar disorder and no history of psychosis have less 
severe deficits [284-286]. Consistent with this, the current review found four 
studies that had identified milder or no cognitive impairments in bipolar disorder 
without psychosis compared to the other diagnoses [303, 316, 319, 321]. This 
suggests that a lifetime history of psychosis is associated with greater cognitive 
impairments. Lifetime history of psychosis has been associated with poorer 
cognitive outcomes in bipolar disorder in a meta-analysis by Bora et al. [241]. 
However, the exact relationship between history of psychosis and cognition 
remains unclear. Bora et al. found a more severe illness course for those with a 
history of psychosis, including a higher number of admissions, younger age of 
illness onset and higher percentage of antipsychotic use but these factors did not 
explain the association between lifetime psychosis and cognitive function. Previous 
studies have rated lifetime history of psychosis as a binary measure (present or 
absent) so it is currently unknown whether a linear relationship exists between 
lifetime severity, duration or frequency of psychosis and severity of cognitive 
impairments.  
Participants with bipolar disorder – type II were not analysed separately in this 
chapter. Bipolar disorder – type I has been shown to be associated with more 
widespread cognitive impairments than type II [244]. There were a sufficient 
number of studies that had reported data on bipolar disorder – type I only to 
conduct a sensitivity analysis. The results of this sensitivity analysis were 
comparable to the meta-analysis including both subtypes. However, it was not 
possible to compare bipolar disorder – type II and schizoaffective disorder, as only 
one study reported separate data for participants with type II.  
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2.5.2 Comparisons between schizoaffective disorder and schizophrenia 
Participants with schizoaffective disorder were less cognitively impaired than 
participants with schizophrenia. This is consistent with the findings of an earlier 
meta-analysis [263]. The effect size reported in the current study (g=0.16) fell 
within the range of effect sizes reported by the earlier meta-analysis (d=0.08-0.32). 
The difference between schizoaffective disorder and schizophrenia was smaller 
than the effect size of the schizoaffective disorder and bipolar disorder analysis 
(g=0.27). This is consistent with the conclusions drawn in the review by Madre et 
al. [287], which suggested that the degree of cognitive impairments in 
schizoaffective disorder is closer to that of schizophrenia than bipolar disorder. 
The schizoaffective disorder and schizophrenia groups differed on processing 
speed (g=0.18) and verbal learning (g=0.27). Comparable effect sizes were 
reported in the meta-analysis by Bora et al. [263], which found the schizophrenia 
group were more impaired than the schizoaffective disorder group on verbal 
memory (d=0.23), Wisconsin Card Sorting Test (d=0.21) and processing speed 
(d=0.24). This is an interesting finding as previous studies have shown that most of 
the impairments in specific cognitive domains seen in patients with schizophrenia 
can be accounted for by a general intelligence factor (g). However, g does not fully 
account for deficits in processing speed and verbal learning [207, 208]. This 
suggests that these abilities may be disproportionately affected in patients with 
schizophrenia. 
2.5.3 Cognition across the three disorders 
The results of the meta-analysis indicated that cognitive performance in 
schizoaffective disorder was better than schizophrenia but worse than bipolar 
disorder. This suggests that cognitive impairments increase in severity from bipolar 
disorder to schizoaffective disorder to schizophrenia. However, the effect sizes 
were small particularly between schizoaffective disorder and schizophrenia. The 
magnitudes of the effect sizes across the studies were not influenced by age, sex, 
age of onset, duration of illness or years in education. 
It has been hypothesised that schizoaffective disorder may represent the midpoint 
in a bipolar-schizophrenia diagnostic spectrum [325]. This spectrum ranges from 
bipolar disorder without psychosis at one end and schizophrenia without affective 
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symptoms at the other with patients with features of both disorders falling at some 
point in the middle [24, 325, 326]. Researchers from the B-SNIP study have 
created a dimension to assess lifetime psychosis and mood symptoms (the Schizo-
Bipolar Scale) and examined the distribution of scores in their sample of 
participants diagnosed with schizophrenia, schizoaffective disorder and bipolar 
disorder [327]. Their findings provided support for the bipolar-schizophrenia 
spectrum by demonstrating that participants with schizoaffective disorder scored 
across the middle range of the scale and overlapped with both schizophrenia and 
bipolar disorder. The distribution of scores was not consistent with a clear-cut 
divide between schizophrenia and bipolar disorder. Higher scores on this scale 
(indicating more prominent psychosis and less prominent mood) have been shown 
to be associated with greater overall cognitive impairment [266]. Further support 
comes from evidence that the functional outcome of schizoaffective disorder is 
poorer than bipolar disorder but better than schizophrenia [179, 328]. The finding 
that the degree of cognitive impairment increases from bipolar disorder to 
schizoaffective to schizophrenia is consistent with this view. 
2.5.4 Subtypes of schizoaffective disorder 
Few studies reported the proportion of subtypes of schizoaffective disorder in their 
sample. Therefore, it is difficult to draw any firm conclusions about differences in 
cognitive performance between the subtypes and the results should be interpreted 
with caution. In the subgroup analysis, no difference in cognitive performance was 
detected between participants with the depressive subtype and schizophrenia, 
although performance was marginally better in the schizoaffective disorder - 
depressive type group. In contrast, participants with the bipolar type performed 
significantly better than participants with schizophrenia. Both subtypes were more 
impaired than bipolar disorder. These results suggest that the depressive subtype of 
schizoaffective disorder may have more severe cognitive impairments than those 
seen in the bipolar subtype and more closely resemble that of schizophrenia. 
However, the magnitude of the effect sizes did not differ between the subtypes of 
schizoaffective disorder.  
These findings are likely driven by the results reported by Hill et al. whose sample 
(N=980) was much larger than any other study included in these subtype analyses. 
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The proportion of weight assigned to Hill et al.’s study was 79.4% in the 
schizophrenia comparison and 72.4% in the bipolar disorder comparison. Thus, the 
findings of this study had a significant impact on the results of the meta-analyses. 
Hill et al.  reported greater impairment in the depressive subtype than the bipolar 
subtype but the differences between the subtypes were not significant [266]. 
Interestingly, this pattern of results is consistent with findings using the Schizo-
Bipolar Scale. Participants with the depressive subtype had a distribution of scores 
on the Schizo-Bipolar Scale that were closer to those with schizophrenia, whilst the 
bipolar subtype scores were closer to bipolar disorder [327]. Overall, these results 
suggest that the depressive subtype of schizoaffective disorder may more closely 
resemble schizophrenia than the bipolar subtype. There is a need for more studies 
with sufficiently large sample sizes to compare the subtypes of schizoaffective 
disorder with schizophrenia and bipolar disorder.  
2.5.5 Concluding statements and recommendations for future research 
This meta-analysis was the first to compare schizoaffective disorder and bipolar 
disorder and examine the subtypes of schizoaffective disorder. These results 
indicate that the severity of cognitive impairments in schizoaffective disorder is 
intermediate between schizophrenia and bipolar disorder. There was initial 
evidence that participants with the subtypes of schizoaffective disorders may 
exhibit differing levels of impairment. However, effect sizes were small and the 
results of individual studies were not consistent. 
Several limitations of this review should be noted. Only one large study reported 
separate data for the subtypes of schizoaffective disorder and was therefore 
assigned a large proportion of the weight in the subtype analyses (68-83%). 
Therefore, the results of the meta-analyses examining subtypes were driven by this 
single study. It would have been preferable to include multiple studies that included 
both subtypes but such studies have not been published. To maximise the data 
available, studies reporting data on a single subtype were included in the relevant 
meta-analysis. However, there may be differences between studies that examined 
the depressive subtype and studies that examined the bipolar subtype that cannot be 
accounted for in separate analyses and may influence the results. The studies 
included in this review employed different measures of cognition, which may 
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explain the heterogeneity in the distribution of effect sizes for some domains. 
However, there was little evidence of heterogeneity in the analyses of composite 
cognition scores. There were also differences in the inclusion of stabilised and 
symptomatic participants across studies and few included a definition of remission. 
It has been argued that cognitive impairment may be affected by illness state at the 
time of assessment.  Meta-regression analyses were conducted to examine whether 
the results were influenced by between-study differences in age, sex, age of onset, 
duration of illness and education. However, few studies had reported data on these 
variables, particularly in studies comparing schizoaffective disorder and bipolar 
disorder, so the results of these analyses should be interpreted with caution. 
This meta-analysis included studies from a wide range of countries and thus their 
methodologies differed on diagnostic criteria and cognitive assessments (both type 
and language). The use of different diagnostic criteria is particularly relevant in this 
meta-analysis, as criteria for schizoaffective disorder varies considerably between 
the Diagnostic and Statistical Manual (DSM), International Classification of 
Diseases (ICD) and Research Diagnostic Criteria (RDC). The majority of the 
studies (N=25) used DSM criteria so the diagnosis of schizoaffective disorder 
relied on mood symptoms being present for a substantial proportion of the total 
illness duration, with a period of at least two weeks of psychosis in the absence of 
mood. In contrast, ICD (utilised by one study) places an emphasis on first rank 
symptoms of schizophrenia for the diagnosis of schizoaffective disorder. Vollmer-
Larsen et al. [329] demonstrated that using ICD-10 and DSM-IV to diagnose 
schizoaffective disorder results in a different set of patients. Four studies defined 
schizoaffective disorder according to the RDC. Schizoaffective disorder in RDC 
includes a broad range of patients including those with brief psychotic symptoms 
and chronic mood symptoms, and the converse [330]. Thus, participants diagnosed 
with RDC schizoaffective disorder are a broad, heterogeneous group. The results of 
this meta-analysis are most generalizable to patients diagnosed according to the 
DSM and the results of studies using ICD or RDC may differ from those presented 
here. 
Several recommendations for future research can be made based on the findings of 
this chapter. Studies should report the clinical characteristics of their sample, 
including clinical status of participants (with defined remission criteria), measures 
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of mood and psychosis and classes and doses of psychiatric medication. These 
results also highlight the importance of considering heterogeneity within disorders. 
Combining the subtypes of schizoaffective disorder may produce conflicting results 
and hamper efforts to understand the relationship between this disorder and 
schizophrenia or bipolar disorder. There is a need for studies that are sufficiently 
large enough to separate the subtypes of schizoaffective disorder. As a minimum, 
studies should report the proportion of each subtype included in their sample. In 
addition to this, studies should report the proportion of their bipolar disorder group 
that have a lifetime history of psychosis. The current findings supported the 
findings of previous reviews, which have highlighted a poorer cognitive outcome 
for participants with bipolar disorder with psychosis compared to those without 
psychosis. Future work should attempt to explore this association further. This 
could include examining whether these associations are mediated by exposure to 
antipsychotic medication, prolonged hospitalisations or illness course and 
determining if severity of cognitive impairment is associated with severity, 
frequency or type of psychotic symptoms or episodes. This will enable a better 
understanding of cognitive impairments across these disorders, which have 
implications for treatment, diagnostic classification and informs investigations of 
the underlying aetiology. 
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Chapter 3: Examining Cognition Across the Bipolar / 
Schizophrenia Diagnostic Spectrum 
3.1 Introduction 
Cognitive impairments are a well-established feature of schizophrenia whilst there 
is ongoing debate about the nature and degree of impairment in schizoaffective 
disorder and bipolar disorder. It has been proposed that these disorders lie on a 
gradient of neurodevelopmental impairment with the severity of cognitive 
dysfunction increasing from bipolar disorder to schizophrenia [24, 26, 27]. 
Cognitive studies that provide support for a diagnostic spectrum have demonstrated 
increasing severity of impairment from bipolar disorder to schizoaffective disorder 
to schizophrenia, although these differences were not always significant [266, 303, 
314, 319] (for a comprehensive review of these studies, see Chapter 2). In one of 
the largest studies to date, Hill et al. [266] showed an association between ratings 
on the Schizo-Bipolar scale [327] and composite cognition scores with more severe 
impairments amongst those with prominent psychosis and fewer affective 
symptoms. However, findings from cognitive studies of these three disorders have 
been inconsistent with some studies indicating that performance in schizoaffective 
disorder is similar to schizophrenia [300] and others indicating no differences 
between diagnostic groups [295, 308, 316].  
There are a number of potential explanations for the conflicting findings between 
studies including differences in the use of covariates and the phase of illness of the 
study participants. Studies of symptomatic participants with schizophrenia, 
schizoaffective disorder and bipolar disorder have reported similar levels of 
impairment [295, 308]. It has been argued that cognitive impairments are state 
dependent in bipolar disorder and therefore improve during periods of remission. 
However, more recent research has demonstrated that cognitive impairments are 
present in euthymic bipolar disorder [238]. Lifetime history of psychosis in bipolar 
disorder has been identified as another important factor that may influence 
cognitive function. Studies do not consistently report the proportion of participants 
with bipolar disorder who have a lifetime history of psychosis despite evidence that 
the presence or absence of lifetime psychosis differentiates participants with 
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cognitive impairments from those without impairments [316]. Finally, studies often 
consider schizoaffective disorder as a single group despite evidence that cognitive 
impairment in the depressive subtype is closer in severity to schizophrenia than the 
bipolar subtype [266] (see meta-analytic findings of Chapter 2). This suggests 
amalgamation of both subtypes of schizoaffective disorder as a single group may 
obscure findings. At the time of writing, there have been no published studies that 
have compared the subtypes of schizoaffective disorder individually to 
schizophrenia and bipolar disorder in a single cohort.  
3.2 Chapter aims and hypotheses 
This chapter examines cognitive function in a large well-characterised sample of 
participants with bipolar disorder, schizoaffective disorder and schizophrenia. The 
sample was sufficiently large to separate schizoaffective disorder into its subtypes, 
bipolar and depressive. The main chapter hypothesis was that there is a spectrum of 
increasing cognitive impairment from bipolar disorder through schizoaffective 
disorder - bipolar type to schizoaffective disorder - depressive type and 
schizophrenia. It was also hypothesised that lifetime frequency and severity of 
psychotic symptoms (across and within diagnostic boundaries) would be associated 
with cognitive impairment. These hypotheses were tested in three ways. Firstly, 
cognitive performance was compared between the diagnostic groups. Secondly, 
ordinal logistic regression was used to examine whether there was a linear trend of 
increasing cognitive impairment from bipolar disorder through schizoaffective 
disorder - bipolar type to schizoaffective disorder - depressive type and 
schizophrenia. Thirdly, the associations between cognition and symptom domains 
were explored in a cross-disorder analysis.  
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3.3 Method 
3.3.1 Sample 
The data obtained for this study was taken from the Cognition in Mood, Psychosis 
and Schizophrenia Study (CoMPaSS) sample, an ongoing UK-based study that 
investigates genetic and environmental factors that contribute to susceptibility to 
psychosis and cognitive deficits. All participants gave written informed consent 
and were reimbursed for their participation. The study had UK multi-site NHS 
ethics approval. 
Cases 
Cases were recruited from the community via outpatient clinics, clozapine and 
depot clinics, and through the use of posters, leaflets, website and voluntary 
organisations. Participants were also referred to the study from other studies within 
the department including the National Centre for Mental Health (NCMH) and the 
Bipolar Disorder Research Network (BDRN). Most participants were outpatients at 
the time of assessment and inpatients were only recruited if they were deemed 
clinically well enough to give informed consent according to their clinical team. 
Inclusion criteria for the study included all persons aged 16 or over, who have been 
in contact with mental health services with a current diagnosis of schizophrenia, 
schizoaffective disorder, bipolar disorder or related psychotic illness. Exclusion 
criteria included all persons under 16 years old, unable to speak English, unable to 
give informed consent or suffering from a neurological or cognitive condition (i.e. 
dementia or amnesia), which in the opinion of the investigators was likely to 
impact on their ability to participate in the study. Those with signs or symptoms of 
current substance misuse or dependence were discussed beforehand to determine 
suitability and were asked to abstain for 24 hours before their participation if they 
were able to do so. Concerns regarding substance use, including risk to the 
researcher or risk of withdrawal symptoms for the patient, were discussed with 
their clinical team prior to participation in the study.  
Participants were interviewed using the Schedules for Clinical Assessment in 
Neuropsychiatry (SCAN) [331]. This interview was reviewed along with available 
clinical records by trained raters to determine a consensus lifetime DSM-IV-TR 
diagnosis (inter-rater reliability Kappa statistics: schizophrenia=.83, schizoaffective 
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disorder – depressive type=.63, schizoaffective disorder – bipolar type=.72, bipolar 
disorder=.85) [332]. The final sample included 824 participants with a diagnosis of 
schizophrenia (N=558), schizoaffective disorder – depressive type (N=112), 
schizoaffective disorder – bipolar type (N=76) or bipolar disorder (N=78). The 
bipolar disorder group included all participants who met criteria for a diagnosis of 
bipolar disorder – type I (N=68) or type II (N=10), of which 59 had a lifetime 
history of psychosis according to scores on the Bipolar Affective Disorder 
Dimension Scale (BADDS) [333]. Further details of the BADDS ratings are 
provided in Section 3.3.2 but history of psychosis was defined as at least one 
psychotic symptom present during their course of illness (a score of at least 10 on 
the BADDS psychosis dimension. 
Controls 
One hundred and three control participants were recruited from the same 
communities through job centres, leisure centres and the use of adverts and leaflets. 
Participants completed a brief clinical interview (Mini-International 
Neuropsychiatric Interview (MINI) [334]) as a screen for mental disorders. 
Controls were excluded if they met criteria for schizophrenia or bipolar disorder or 
there was a family history of these conditions. None of the controls met criteria for 
any psychiatric disorder or reported taking psychiatric medication. 
3.3.2 Measures 
Cognitive assessment 
Cognitive ability was assessed using the Measurement and Treatment Research to 
Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery 
(MCCB)[203]. This battery was designed specifically for use in schizophrenia 
research but has been shown to be a valid and reliable cognitive measure in bipolar 
disorder [335-337]. The MCCB assesses seven domains of cognition using ten 
tasks (for a summary see Table 3-1). The battery takes approximately one hour to 
complete. 
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Table 3-1 Description of the MCCB 
Domain Task Task Description 
Speed of Processing 
Brief Assessment of Cognition in 
Schizophrenia: Symbol Coding 
P uses the key to assign the 
correct numbers to a series 
of symbols 
 Category Fluency: Animal Naming 
P names as many animals as 
they can in 60 seconds 
 Trail Making Test: Part A 
P connects the numbered 
circles in ascending order 
Working Memory 
Wechsler Memory Scale III: 
Spatial Span 
P must tap the blocks in the 
sequence they have just 
seen 
 Letter-Number Span 
P rearranges a string of 
numbers and letters into 
ascending numbers 
followed by letters 
alphabetically 
Attention / Vigilance 
Continuous Performance Test: 
Identical Pairs 
P responds every time an 
identical pair of numbers 
flash on the screen 
consecutively 
Verbal Learning 
Hopkins Verbal Learning Test – 
Revised 
P immediately recalls a list 
of 12 words  
Visual Learning 
Brief Visuospatial Memory Test – 
Revised 
P immediately recalls the 
shape and location of 6 
figures 
Reasoning and 
Problem Solving 
Neuropsychological Assessment 
Battery: Mazes 
P draws a line through the 
maze from the start point to 
the finish point 
Social Cognition 
Mayer-Salovey-Caruso Emotional 
Intelligence Test: Managing 
Emotions 
P presented with a social 
scenario and must judge a 
response on a scale of very 
ineffective to very effective. 
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Scoring and imputation 
For each task, z scores were derived using the mean and standard deviation of the 
control sample (sample characteristics: 50% males, mean age = 41.7 years). As the 
Trail Making Test (TMT) scores were not normally distributed, the raw scores 
were log transformed before being converted. In addition to this, TMT scores had 
their sign reversed so that lower scores represented poorer performance and thus 
their direction was the same as the other tasks. Missing values were imputed using 
the formula described in the MCCB manual [338]. Imputed scores were only 
included in analyses of domains with more than one test and the composite scores. 
Domain and composite scores were calculated following the MCCB manual 
procedures. Composite scores were only calculated if a participant had completed 5 
or more domains. Full details of the imputation methods including formulas can be 
found in Appendix C. 
Premorbid IQ 
Scores on the National Adult Reading Test (NART) were used to estimate 
premorbid IQ [339]. The NART is a widely used measure of premorbid IQ. The 
test consists of 50 irregularly spelled words that the participant must read aloud. 
These words cannot be guessed on the basis of their spelling and therefore 
performance is dependent on familiarity with the words. Reading ability is thought 
to be relatively preserved after the onset of psychiatric illness and is considered a 
valid method of estimating premorbid intelligence. 
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Clinical measures 
Clinical measures were rated based on the SCAN interview [331] and available 
clinical records. In addition to the measures described below, participants were 
rated on current global functioning using the Global Assessment Scale (GAS)[340]. 
Intraclass correlation coefficients for the clinical variables ranged from 0.71 to 0.95.  
Symptom dimensions  
The following scales were used to record symptom severity and frequency: 1) 
Bipolar Affective Disorder Dimension Scale (BADDS) [333]; 2) Scale for the 
Assessment of Positive Symptoms (SAPS) [341] and 3) Scale for the Assessment 
of Negative Symptoms [342]. Trained raters determined scores on these scales 
following review of the SCAN interview and case notes. The BADDS comprises of 
four dimensions each rated on a scale of 0 to 100: mania, depression, psychosis and 
incongruence. Rating of the BADDS is based on the participant’s lifetime history 
of each dimension. The Mania, Depression and Psychosis dimensions are designed 
to reflect the severity and frequency of clinical and subclinical episodes. Higher 
scores on these scales indicate more severe and frequent episodes. If psychosis is 
present during mania or depression, the minimum score that can be assigned for 
mania or depression dimension is 80. The psychosis dimension is rated based on 
the presence of psychotic symptoms as a proportion of the participant’s overall 
duration of mental illness.  The incongruence dimension is designed to measure the 
relationship between psychotic and affective symptoms and is based on current 
diagnostic criteria. This scale indicates the extent to which psychotic symptoms 
occur during or outside episodes of mood and is only rated if the participant has 
experienced at least one symptom of psychosis. Higher scores indicate more 
frequent psychosis outside of mood episodes.  
Psychotic symptoms were also rated using the Scale for the Assessment of Positive 
Symptoms (SAPS) and negative symptoms were rated using the Scale for the 
Assessment of Negative Symptoms (SANS). The SAPS consists of symptoms and 
behaviours grouped into four domains, “Hallucinations”, “Delusions”, “Bizarre 
Behaviour” and “Formal Thought Disorder”, which are rated from 0 to 5 based on 
severity. The SANS is also rated from 0 to 5 based on severity and symptoms are 
grouped into five domains, “Affective Flattening”, “Alogia”, “Avolition – Apathy”, 
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“Anhedonia – Asociality” and “Attention”. The final domain of the SANS, 
“Attention”, was not rated in this study. Total scores for the SAPS and SANS were 
calculated by summing the global scores of each domain. SAPS and SANS were 
rated based on the participant’s presentation and report of the last two weeks 
(current SAPS and SANS) and across the lifetime using information from the 
SCAN interview and case notes (lifetime SAPS and SANS).  
Antipsychotic medication 
Doses of antipsychotic medication at time of assessment were calculated as 
olanzapine equivalents [343]. Lifetime antipsychotic exposure was rated as the 
total number of months a participant had taken antipsychotic medication, excluding 
self-reported periods of non-compliance or breaks in prescribed medication. 
3.3.3 Statistical analysis 
Comparing cognition between diagnostic groups 
Statistical analyses to compare the groups were performed using R version 3.1.2. 
For each cognitive domain and across diagnostic groups, performance was 
compared using analysis of covariance (ANCOVA) with age and sex as covariates 
and followed up with Tukey’s HSD for pairwise comparisons. Pairwise 
comparisons were conducted between the following groups: 
1. Healthy controls and bipolar disorder 
2. Healthy controls and schizoaffective disorder – bipolar type 
3. Healthy controls and schizoaffective disorder – depressive type 
4. Healthy controls and schizophrenia 
5. Bipolar disorder and schizoaffective disorder – bipolar type 
6. Bipolar disorder and schizoaffective disorder – depressive type 
7. Bipolar disorder and schizophrenia 
8. Schizoaffective disorder – bipolar type and schizoaffective disorder – 
depressive type 
9. Schizoaffective disorder – bipolar type and schizophrenia 
10. Schizoaffective disorder – depressive type and schizophrenia 
Bonferroni correction was used to adjust for multiple comparisons resulting in an 
alpha of 0.00625 (0.05/8, 7 domains and composite score). The alpha was not 
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corrected further for the number of pairwise comparisons, as Tukey’s HSD is 
already a conservative test that corrects for family-wise error rate. Effect sizes were 
calculated by dividing mean group difference by the pooled standard deviation 
[344] (see Appendix A for formulas). Repeated measures analysis of variance was 
used to compare profiles of cognitive performance between groups. The within-
subject factor was cognitive domain. This is consistent with the approach used in 
previous studies to compare cognitive profiles [266, 314]. 
The assumptions of ANCOVA include normal distribution of the data and 
homogeneity of variances across groups. Whilst the results of Shapiro-Wilk tests 
were significant for all domains (except speed of processing) indicating deviation 
from normality, visual inspection of Q-Q plots revealed overall normal 
distributions. Homogeneity of variance was assessed with Levene’s test and by 
calculating the variance ratios (highest variance divided by lowest variance). The 
variances were homogeneous across the groups with no variance ratios exceeding a 
value of 2. 
Secondary analyses 
Sensitivity analyses were conducted excluding participants diagnosed with bipolar 
disorder – type II, as there is evidence that these individuals have better cognitive 
functioning than participants with bipolar disorder – type I [245, 345]. A sensitivity 
analysis was also conducted by conducting an ANCOVA that only included 
participants who were taking antipsychotic medication at the time of assessment, 
given evidence that participants with bipolar disorder who are taking antipsychotic 
medication have worse cognitive function [258, 346]. 
The effects of potential confounding variables were investigated by conducting five 
sets of ANCOVAs for the covariates of interest. Age and sex were included as 
covariates in all analyses. These analyses included cases only. The covariates 
included in each analysis are listed below: 
1. Olanzapine equivalent dose 
2. Duration of antipsychotic exposure 
3. Current SAPS total score 
4. Current SANS total score 
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5. Olanzapine equivalent dose, duration of antipsychotic exposure, current 
SAPS total score, current SANS total score and lifetime depression 
(BADDS depression dimension) 
The final set of analyses examined whether differences in premorbid IQ could 
account for differences observed between the groups. NART scores, age and sex 
were entered as covariates in this model. This set of analyses included both cases 
and controls. 
Variance inflation factors (VIF) were calculated to check the assumption of no 
collinearity between predictors. Age and duration of antipsychotic exposure were 
correlated, although variance inflation was low. Analyses were repeated using age-
adjusted cognition scores (residuals taken from linear regressions of age against 
each cognitive domain). The results of the analyses using age-adjusted cognition 
scores were consistent with the original analyses and so the original analyses are 
presented here. 
Examining cognition as a dimension across diagnostic groups 
To test the hypothesis that cognition can be considered a dimensional phenotype 
showing increasing impairment from bipolar disorder to schizoaffective disorder - 
bipolar type to schizophrenia and schizoaffective disorder - depressive type, an 
ordinal regression analysis was conducted using SPSS version 22 with diagnosis as 
the outcome, composite cognition score as the predictor and age and sex as 
covariates. Schizophrenia and schizoaffective disorder - depressive type were 
combined given pre-existing data showing that their degree of impairment is 
comparable [266]. Diagnosis was coded on an ordinal scale combining 
schizoaffective disorder – depressive type and schizophrenia: 0 – schizoaffective 
disorder - depressive type and schizophrenia, 1 – schizoaffective disorder - bipolar 
type and 2 – bipolar disorder. The analysis was repeated including olanzapine 
equivalent dose, antipsychotic exposure in months and current negative symptoms 
as covariates in the model.  
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Two sets of follow-up analyses were conducted with diagnosis coded in the 
following ways: 
1. Each diagnosis assigned to separate groups and coded as: 0 – schizophrenia, 
1 – schizoaffective disorder - depressive type, 2 – schizoaffective disorder - 
bipolar type and 3 – bipolar disorder. These groups reflect those included in 
the analysis comparing cognition between diagnoses.  
2. The subtypes of schizoaffective disorder combined into a single group: 0 – 
schizophrenia, 1 – schizoaffective disorder and 2 – bipolar disorder. This 
was done to mirror the groups included in previous studies, which have 
combined the subtypes of schizoaffective disorder. 
The purpose of these follow-up analyses was to provide comparisons against the 
first model, using groupings that reflect current diagnostic categories and those 
used in previous studies of cognitive function across these disorders. 
Ordinal regression outputs a single coefficient for the effect of the explanatory 
variable across all levels of the dependent variable since there is an assumption that 
the coefficients must be equal across all levels (known as the assumption of 
proportional odds). This assumption was tested using the test of parallel lines in 
SPSS and the results of this test for each ordinal regression are presented in the 
results.  
Cross disorder symptom dimensions and cognitive performance 
Linear regression analyses were conducted using R version 3.1.2 to determine if 
symptom dimensions were associated with cognitive performance. Each symptom 
dimensions (scores on each of the BADDS dimensions, SAPS and SANS) were 
entered into separate linear regressions as predictors with composite cognition 
score as the outcome and age and sex as covariates. This was initially conducted 
across the whole sample. However, scores on the BADDS dimensions are 
influenced by diagnosis. For example, participants with bipolar disorder or 
schizoaffective disorder – bipolar type would have high scores on the mania 
dimension, whilst participants with schizophrenia or schizoaffective disorder – 
depressive type would have scores of zero. This could result in an association 
between mania scores and cognitive performance. Therefore, the analyses were 
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repeated within two subgroups: 1) bipolar disorder and schizoaffective disorder - 
bipolar type as one group and 2) schizoaffective disorder - depressive type and 
schizophrenia as one group. Bonferroni correction was used to adjust for multiple 
comparisons resulting in an alpha of 0.00833 (0.05/6, 6 symptom dimensions). All 
linear regressions were then repeated including age, sex, current negative 
symptoms (total SANS scores), olanzapine equivalent dose and antipsychotic 
exposure in months as covariates. 
Inspections of Q-Q plots confirmed that the residuals for all analyses were 
normally distributed. Residuals and standardized residuals were plotted against 
fitted values to ensure homoscedasticity of the errors. Standardized residuals were 
plotted against leverage to identify potential outliers. One outlier was identified 
when the additional covariates (negative symptoms, antipsychotic dose and 
exposure) were added so this individual was excluded from these analyses. 
Variance inflation factors were calculated to identify collinearity between the 
predictors. Lifetime and current SANS scores were highly correlated (r=0.86) so 
current SANS scores were removed as a covariate in the regressions examining the 
association between lifetime SANS scores and cognition. 
3.4 Results 
3.4.1 Sample size and completeness of data 
Complete cognitive data was available for verbal learning, reasoning and problem 
solving, speed of processing and working memory resulting in a total of 927 
participants (824 cases and 103 controls) for these analyses. Of the remaining 
domains, 4 participants failed to complete the BVMT-R, 20 did not complete the 
MSCEIT ME and 55 did not complete the CPT-IP. For participants with missing 
data, composite scores were imputed for participants who had completed at least 
five tasks. Therefore, it was possible to impute a composite score for all but one 
participant resulting in 926 participants with composite scores. There was no 
missing data for the control group. The number of available data points for each 
diagnostic group can be found in Appendix D. 
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3.4.2 Demographic variables 
Demographic and clinical variables are displayed for each diagnostic group in 
Table 3-2. There were no differences in age between the groups. Groups differed 
on proportion of males (χ2=61.39, 1.48 x 10-12) with more males observed in the 
schizophrenia group; therefore sex was used as a covariate in all analyses. There 
were differences in estimated premorbid IQ (F=22.64, p<2.2 x 10-16) and years in 
education (F=14.19, p=5.12 x 10-9), which were lower for those with schizophrenia 
and schizoaffective disorder - depressive type compared to those with bipolar 
disorder and schizoaffective disorder - bipolar type. Groups differed on current 
positive and negative symptoms (SAPS: F=65.96, p=3.13 x 10-14; SANS: F=64.16, 
p=7.58 x 10-14) with lower scores in those with bipolar disorder compared to all 
other groups. Measures of current global functioning (Global Assessment Scale) 
differed between groups (F=4.99, p=0.002) with higher scores observed in the 
bipolar disorder group. 
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Table 3-2 Clinical and demographic variables 
DSM-IV Diagnosis 
Healthy 
Controls 
Bipolar 
Disorder 
Schizoaffective 
Disorder – 
Bipolar Type 
Schizoaffective 
Disorder – 
Depressive Type 
Schizophrenia 
Test 
Statistic 
P Value 
N 103 78 76 112 558   
Age 41.7 (16.1) 45.8 (10.6) 43.8 (10.6) 44.1 (10.1) 43.3 (11.9) 1.40 0.23 
Sex (% males) 50 40 46 40 69 61.39 1.48 x 10-12 
NART score 32.4 (7.1) 31.2 (10.6) 29.6 (10.2) 25.4 (9.6) 23.7 (11.3) 22.41 1.2 x 10-17 
Years in Education 14.7 (3.2) 14.6 (3.3) 13.7 (3.0) 12.3 (2.3) 12.7 (2.7) 14.19 5.12 x 10-9 
Taking Antipsychotic (%)  63 75 78 86 25.51 1.2 x 10-5 
Olanzapine Equivalent 
Dose* 
 8 (12) 15 (10) 15 (13.5) 13.7 (13.7) 26.79 6.51 x 10-6 
Antipsychotic exposure in 
months* 
 60 (102) 153 (181.5) 168 (164.5) 170 (168) 39.97 1.08 x 10-8 
Current SAPS*  0 (0) 2 (5) 2 (5) 3 (6) 65.96 3.13 x 10-14 
Current SANS*  0.5 (3) 4 (5) 6 (7) 5.5 (7) 64.16 7.58 x 10-14 
GAS Past Week  70.8 (14.2) 60.1 (16.8) 58.6 (15.8) 60.2 (15.1) 4.99 0.002 
Figures represent means and standard deviations, except for proportions and scores with non-normal distributions. *Medians and interquartile ranges are presented due to non-normal 
distribution. Test statistic is F value (ANOVA or Kruskal-Wallis Analysis of Variance) for continuous variables and Χ2 for proportions. Current SAPS and SANS scores represent the sum of the 
global scores. SAPS: Scale for the Assessment of Positive Symptoms; SANS: Scale for the Assessment of Negative Symptoms; GAS: Global Assessment Scale; NS: Not Significant.
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3.4.3 Comparison of cognition between diagnostic groups 
There was a significant main effect of diagnosis for all domains of cognition 
(composite cognition: F(4, 921) = 94.12, p<0.00625, see Table 3-3 for domain 
results). Figure 3-1 displays the marginal mean z scores (adjusted for age and sex) 
for each diagnostic group and the control group. Cognitive impairments increased 
in severity from bipolar disorder to schizoaffective disorder – bipolar type to 
schizophrenia and schizoaffective disorder – depressive type. 
Effect sizes are displayed for each pairwise comparison in Figure 3-2. All 
diagnostic groups were impaired across cognitive domains compared to controls 
except for social cognition in those with bipolar disorder. The bipolar disorder 
group was the least impaired of the diagnostic groups, performing 0.5 to 1.25 
standard deviations below the mean of the control group across domains 
(composite cognition: g=1.12, p<0.001). The schizoaffective disorder - bipolar type 
group was more impaired than the bipolar disorder group although this does not 
withstand correction for multiple testing (composite cognition: g=0.44, p=0.02). 
The schizophrenia and schizoaffective disorder - depressive type groups were the 
most cognitively impaired and did not differ on any cognitive variable (composite 
cognition: g=0.07, p=0.90) corroborating the a priori decision to amalgamate these 
groups for these analyses. These participants were more impaired than those with 
schizoaffective disorder - bipolar type (schizophrenia: g=0.52, p<0.001; 
schizoaffective disorder - depressive type: g=0.45, p=0.01) and those with bipolar 
disorder (schizophrenia: g=0.90, p<0.001; schizoaffective disorder - depressive 
type: g=0.83,p<0.001). 
In contrast to other domains, levels of impairment in social cognition between 
schizoaffective disorder - bipolar type, schizoaffective disorder - depressive type 
and schizophrenia did not differ (Hedge’s g ranged between 0.05 and 0.28). All 
three of these groups were more impaired than bipolar disorder on social cognition 
(Hedge’s g ranged between 0.50 and 0.81). Given this pattern of results, composite 
scores were derived excluding social cognition and the analysis repeated. When 
social cognition was excluded, the difference in composite cognition between 
schizoaffective disorder - bipolar type and bipolar disorder was reduced (g=0.37, 
p=0.06) and the remaining pairwise comparisons did not change.  
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Table 3-3 Cognitive performance in each diagnostic group 
Domain Task HC BD SAB SAD SZ Fdf  p    Partial η2 
Verbal Learning HVLT-R 
28.81 
(3.89) 
24.32 
(5.76) 
22.34 
(5.36) 
19.85 
(6.27) 
19.25 
(6.11) 
F4, 922=63.75 p<2.20 x 10-16 0.22 
Reasoning & 
Problem Solving 
NAB: Mazes 
19.50 
(5.56) 
14.42 
(6.87) 
12.49 
(7.12) 
9.73 
(7.02) 
11.19 
(7.22) 
F4, 922=43.85 p<2.20 x 10-16 0.16 
Visual Learning BVMT-R 
25.92 
(6.62) 
20.69 
(7.50) 
18.34 
(7.56) 
15.75 
(8.53) 
14.65 
(8.29) 
F4, 918=52.93 p<2.20 x 10-16 0.19 
Social Cognition MSCEIT: ME 
95.14 
(8.75) 
93.23 
(10.04) 
87.40 
(9.62) 
87.96 
(11.15) 
85.06 
(10.21) 
F4, 902=25.07 p<2.20 x 10-16 0.10 
Attention / 
Vigilance 
CPT: IP 
2.76 
(0.66) 
2.23 
(0.81) 
2.15 
(0.78) 
1.88 
(0.78) 
1.81 
(0.80) 
F4, 867=35.44 p<2.20 x 10-16 0.14 
Speed of 
Processing 
TMT A 
28.30 
(9.17) 
37.32 
(13.78) 
43.36 
(19.15) 
49.04 
(21.62) 
51.03 
(26.24) 
F4, 922=82.52 p<2.20 x 10-16 0.26 BACS: Symbol Coding 
58.02 
(11.26) 
46.50 
(11.87) 
43.28 
(12.63) 
37.28 
(12.26) 
36.47 
(12.84) 
Category Fluency: 
Animal Naming 
27.70 
(7.68) 
22.59 
(6.59) 
21.88 
(6.01) 
19.33 
(6.05) 
19.47 
(5.96) 
Means (SDs) of raw scores are reported. All case-control comparisons were significant (p<.001), except for bipolar disorder on social cognition (not significant). Partial η2 indicates the 
proportion of variance in cognitive scores that is associated with diagnosis. HC, healthy controls; BD, bipolar disorder; SAB, schizoaffective disorder – bipolar type; SAD, schizoaffective 
disorder – depressive type; SZ, schizophrenia; ANCOVA, analysis of covariance; HVLT-R, Hopkins Verbal Learning Test – Revised; NAB, Neuropsychological Assessment Battery; BVMT-R, 
Brief Visuospatial Memory Test – Revised; MSCEIT: ME, Mayer-Salovey-Caruso Emotional Intelligence Test: Managing Emotions; CPT: IP, Continuous Performance Test: Identical Pairs; 
TMT, Trail Making Test; BACS, Brief Assessment of Cognition in Schizophrenia; WMS III: SS, Wechsler Memory Scale III: Spatial Span; LNS, Letter Number Span  
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Table 3-3 (cont.) Cognitive performance in each diagnostic group 
Domain Task HC BD SAB SAD SZ Fdf p Partial η2 
Working Memory 
WMS III: SS 
17.31 
(3.10) 
14.04 
(3.12) 
13.50 
(3.08) 
12.56 
(3.45) 
12.86 
(3.70) 
F4, 922=51.42 p<2.20 x 10-16 0.18 
LNS 
15.80 
(3.14) 
13.31 
(3.68) 
12.34 
(3.61) 
10.76 
(4.49) 
10.58 
(4.35) 
Composite Cognition Score F4, 921=94.12 p<2.20 x 10-16 0.29 
Composite Cognition Score without Social Domain F4, 921=90.16 p<2.20 x 10-16 0.28 
Means (SDs) of raw scores are reported. All case-control comparisons were significant (p<.001), except for bipolar disorder on social cognition (not significant). Partial η2 indicates the 
proportion of variance in cognitive scores that is associated with diagnosis. HC, healthy controls; BD, bipolar disorder; SAB, schizoaffective disorder – bipolar type; SAD, schizoaffective 
disorder – depressive type; SZ, schizophrenia; ANCOVA, analysis of covariance; HVLT-R, Hopkins Verbal Learning Test – Revised; NAB, Neuropsychological Assessment Battery; BVMT-R, 
Brief Visuospatial Memory Test – Revised; MSCEIT: ME, Mayer-Salovey-Caruso Emotional Intelligence Test: Managing Emotions; CPT: IP, Continuous Performance Test: Identical Pairs; 
TMT, Trail Making Test; BACS, Brief Assessment of Cognition in Schizophrenia; WMS III: SS, Wechsler Memory Scale III: Spatial Span; LNS, Letter Number Span  
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Figure 3-1 Cognitive profiles for participants with bipolar disorder, schizoaffective disorder - bipolar type, schizoaffective disorder - depressive type and schizophrenia  
Error bars indicate ±1 standard error 
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Figure 3-2 Pairwise comparisons  
Each 3x3 section displays the Hedge’s g effect sizes for the difference between two diagnostic groups for each 
domain of cognition. Positive effect sizes indicate that the group on the horizontal bottom row performed better 
than the group on the left-hand vertical column. Lighter shade p<0.05, darker shade p<0.00625.  
 
SAB 
0.36 0.28 0.32 
Verbal 
Learning 
Reasoning 
& Problem 
Solving 
Visual 
Learning 
0.60  0.10 0.32 
Social 
Cognition 
Attention / 
Vigilance 
Speed of  
Processing 
0.25 0.44  
Working 
Memory 
Composite 
Cognition 
Score 
  
SAD  
0.74 0.68 0.61 0.43 0.39 0.32 
0.50 0.44 0.78 -.05 0.35 0.47 
0.61 0.83   0.39 0.45   
SZ  
0.84 0.45 0.74 0.52 0.18 0.45 0.10 -.20 0.14 
0.81 0.53 0.80 0.24 0.43 0.51 0.28 0.09 0.05 
0.54 0.90   0.33 0.52   -.03 0.07   
BD SAB SAD 
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When the control group were included, diagnostic group explained a significant 
proportion of the variance in cognition scores with partial η2 ranging from 0.10 to 
0.29. Given that the differences between cases and controls were highly significant, 
the analyses were repeated excluding controls to determine the proportion of 
variance explained by differences in diagnosis. These results are displayed in Table 
3-4. Estimated variance explained by diagnosis ranged from 0.04 to 0.09 after 
excluding healthy controls. 
 
Table 3-4 ANCOVA results excluding healthy control group 
Domain 
ANCOVA Results 
Fdf p Partial η2 
Verbal Learning F3, 820=17.84  3.2 x 10-11 0.06 
Reasoning & Problem Solving F3, 820=12.03 1.0 x 10-7 0.04 
Visual Learning F3, 816=18.62 1.1 x 10-11 0.06 
Social Cognition F3, 800=12.89 3.2 x 10-8 0.05 
Attention / Vigilance F3, 765=10.07 1.7 x 10-6 0.04 
Speed of Processing F3, 820=22.85 3.3 x 10-14 0.08 
Working Memory F3, 820=12.35 6.6 x 10-8 0.04 
Composite Score F3, 819=27.04 <2.2 x 10-16 0.09 
Partial η2 indicates the proportion of variance in cognitive scores that is associated with diagnosis. 
Comparing cognitive profiles 
In order to test whether between group differences were qualitative or merely 
quantitative, cognitive profiles were compared between diagnostic groups using 
repeated measures analysis of variance, with cognitive domain included as the 
within-subject factor. Mauchly’s test indicated that the assumption of sphericity 
had been violated (χ2(20)=360.23, p=3.5 x 10-64) therefore degrees of freedom were 
corrected using Huynh-Feldt  estimates of sphericity. The diagnosis-by-domain 
interaction was not significant (F=1.62, df=15.50, 3051.33, p=0.06). The analysis 
was repeated excluding social cognition (given the quantitative differences in this 
domain) and the diagnosis-by-domain interaction was not significant (F=1.604, 
df=1.60, 2680.70 p=0.07) indicating that patterns of cognitive ability did not differ 
by diagnostic group but rather differed quantitatively. 
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Sensitivity analyses 
Bipolar disorder type I and type II 
Given that there is some evidence to suggest patients with bipolar disorder – type II 
are less cognitively impaired than those with bipolar disorder – type I [245, 345], 
the analysis was repeated including only participants with bipolar disorder – type I 
(N=68). This did not change the results or post hoc comparisons (see Table 3-5).  
 
Table 3-5 Comparisons of cognitive performance when only bipolar disorder - type I was included 
Domain 
Effect of Diagnosis Pairwise 
Comparisons 
Fdf p Partial η2 
Verbal Learning F4, 912=64.25 <2.2 x 10-16 0.22 
SAD < BD2 
SZ < BD2 
SAD < SAB1 
SZ < SAB2 
Reasoning & 
Problem Solving 
F4, 912 =43.74 <2.2 x 10-16 0.16 
SAD < BD2 
SZ < BD2 
SAD < SAB1 
Visual Learning F4, 912=51.13 <2.2 x 10-16 0.18 
SAD < BD2 
SZ < BD2 
SZ < SAB2 
Social Cognition F4, 892=24.65 <2.2 x 10-16 0.10 
SAB < BD2 
SAD < BD2 
SZ < BD2 
Attention / Vigilance F4, 857=35.22 <2.2 x 10-16 0.14 
SAD < BD1 
SZ < BD2 
SZ < SAB2 
Speed of Processing F4, 912=81.39 <2.2 x 10-16 0.26 
SAD < BD2 
SZ < BD2 
SAD < SAB2 
SZ < SAB2 
Working Memory F4, 912=49.91 <2.2 x 10-16 0.18 
SAD < BD2 
SZ < BD2 
SZ < SAB2 
Composite Score F4, 911=92.74 <2.2 x 10-16 0.29 
SAB < BD1 
SAD < BD2 
SZ < BD2 
SAD < SAB1 
SZ < SAB2 
All case-control comparisons were significant (p<.001), except for bipolar disorder on social cognition (no 
significant difference). Partial η2 indicates the proportion of variance in cognitive scores that is associated with 
diagnosis. BD, bipolar disorder; SA, schizoaffective disorder; SZ, schizophrenia; 1p<.05, 2p<.00625 
(Bonferroni-corrected)  
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Although the groups were small, cognitive performance was compared between 
participants with bipolar disorder – type I and bipolar disorder – type II. There 
were no significant differences between these groups (composite cognition: g=0.07, 
p=0.83, see Table 3-6). 
 
Table 3-6 Comparison of cognitive performance in bipolar disorder type I and type II 
Domain 
Marginal Means 
Hedge’s g p Bipolar I 
(N=68) 
Bipolar II 
(N=10) 
Verbal learning -1.14 -1.86 -0.479 0.146 
Reasoning & Problem 
Solving 
-0.81 -1.25 -0.335 0.313 
Visual Learning -0.88 -0.45 0.36 0.274 
Social Cognition -0.21 -0.36 -0.121 0.706 
Attention -0.76 -0.81 -0.039 0.908 
Speed of Processing -1.12 -1.06 0.054 0.859 
Working Memory -1.06 -0.66 0.356 0.292 
Composite -1.22 -1.31 -0.073 0.834 
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Participants taking antipsychotic medication only 
Given evidence that participants with bipolar disorder who are taking antipsychotic 
medication have worse cognitive function [258, 346], the analyses were repeated 
only including participants who were taking antipsychotic medication at the time of 
the assessment (bipolar disorder: N=48; schizoaffective disorder – bipolar type: 
N=56; schizoaffective disorder – depressive type: N=80; schizophrenia: N=448). 
These results are displayed in Table 3-7. The effect of diagnosis persisted but none 
of the pairwise comparisons for attention were significant at the Bonferroni-
corrected alpha value of 0.00625. 
 
Table 3-7 Comparison of cognitive performance for cases currently taking antipsychotic medication only 
Domain Fdf p Partial η2 
Pairwise 
Comparisons 
Verbal Learning F3, 628=7.98  3.2 x 10-5 0.04 
SAD < BD2 
SZ < BD2 
SZ < SAB1 
Reasoning & Problem 
Solving 
F3, 628=7.13 0.0001 0.03 
SAD < BD2 
SZ < BD2 
SAD < SAB1 
Visual Learning F3, 624=9.76 2.7 x 10-6 0.05 
SAD < BD2 
SZ < BD2 
SZ < SAB1 
Social Cognition F3, 614=7.88 3.7 x 10-5 0.04 
SAB < BD1 
SAD < BD1 
SZ < BD2 
Attention / Vigilance F3, 587=4.31 0.005 0.02 SZ < BD1 
Speed of Processing F3, 628=14.27 5.3 x 10-9 0.06 
SAD < BD2 
SZ < BD2 
SAD < SAB1 
SZ < SAB2 
Working Memory F3, 628=9.09 6.8 x 10-6 0.04 
SAD < BD2 
SZ < BD2 
SZ < SAB1 
Composite Score F3, 627=15.25 1.4 x 10-9 0.07 
SAD < BD2 
SZ < BD2 
SZ < SAB2 
Partial η2 indicates the proportion of variance in cognitive scores that is associated with diagnosis. BD, bipolar 
disorder; SAB, schizoaffective disorder – bipolar type; SAD, schizoaffective disorder – depressive type; SZ, 
schizophrenia; ANCOVA, analysis of covariance. 1p<0.05; 2p<0.00625 (Bonferroni-corrected) 
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Effects of clinical and demographic variables 
Medication effects 
The effects of both lifetime duration of antipsychotic medication and olanzapine 
equivalent dose were investigated. Duration of antipsychotic exposure was 
associated with all cognitive domains. The estimated proportion of variance in 
cognitive scores explained by duration of antipsychotic exposure ranged from 0.01 
to 0.04 (see Table 3-8). The main effect of diagnostic group on cognitive scores 
remained significant after controlling for duration of antipsychotic exposure, 
although the proportion of variance explained by diagnosis was reduced (partial η2 
ranged from 0.02 to 0.06). Post hoc comparisons revealed a reduction in the 
magnitude of the differences between groups (see Table 3-8).  
Olanzapine equivalent dose was associated with all cognitive domains, except 
social cognition, with the estimated proportion of variance explained ranging 
between 0.01 and 0.04 (see Table 3-9). The main effect of diagnostic group on 
cognitive scores remained significant after controlling for olanzapine equivalent 
dose, although the proportion of variance explained by diagnosis was reduced 
(partial η2 ranged from 0.03 to 0.08). Post hoc comparisons revealed a reduction in 
the magnitude of the differences between groups (see Table 3-9).  
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Table 3-8 The effects of diagnostic group and duration of antipsychotic exposure on cognitive performance 
Domain 
Effect of Diagnosis Effect of Duration of Antipsychotic Exposure Pairwise 
Comparisons Fdf p Partial η2 Fdf p Partial η2 
Verbal Learning F3, 766=8.84 9.2 x 10-6 0.03 F1, 766=28.50 1.2 x 10-7 0.04 
SAD < BD2 
SZ < BD2 
SAD < SAB1 
SZ < SAB1 
Reasoning & 
Problem Solving 
F3, 766 =5.90 6.0 x 10-4 0.02 F1, 766=17.10 3.9 x 10-5 0.02 
SAD < BD2 
SZ < BD1 
SAD < SAB1 
Visual Learning F3, 762=12.29 7.4 x 10-8 0.05 F1, 762=23.96 1.2 x 10-6 0.03 
SAD < BD2 
SZ < BD2 
SZ < SAB2 
Social Cognition F3, 750=8.48 1.5 x 10-5 0.03 F1, 750=8.57 0.004 0.01 
SAB < BD1 
SAD < BD1 
SZ < BD2 
Attention / 
Vigilance 
F3, 715=6.00 4.8 x 10-4 0.03 F1, 715=11.86 6.1 x 10-4 0.02 
SZ < BD2 
SZ < SAB1 
Speed of Processing F3, 766=14.57 3.1 x 10-9 0.05 F1, 766=12.71 3.9 x 10-4 0.02 
SAD < BD2 
SZ < BD2 
SAD < SAB2 
SZ < SAB2 
Working Memory F3, 766=8.62 1.3 x 10-5 0.03 F1, 766=14.90 1.2 x 10-4 0.02 
SAD < BD2 
SZ < BD2 
SZ < SAB1 
Composite Score F3, 765=16.18 3.4 x 10-10 0.06 F1, 765=33.69 9.5 x 10-9 0.04 
SAD < BD2 
SZ < BD2 
SZ < SAB2 
SAD < SAB1 
Partial η2 indicates the proportion of variance in cognitive scores that is associated with diagnosis. BD, bipolar disorder; SAB, schizoaffective disorder – bipolar type; SAD, schizoaffective 
disorder – depressive type; SZ, schizophrenia; ANCOVA, analysis of covariance; 1p<0.05, 2p<0.00625 (Bonferroni-corrected) 
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Table 3-9 The effects of diagnosis and olanzapine equivalent dose on cognitive performance 
Domain 
Effect of Diagnosis Effect of Olanzapine Equivalent Dose Pairwise 
Comparisons 
Fdf p Partial η2 Fdf p Partial η2 
Verbal Learning F3, 774=13.03  2.6 x 10-8 0.05 F1, 774=26.61 3.2 x 10-7 0.03 
SAD < BD2 
SZ < BD2 
SAD < SAB1 
SZ < SAB2 
Reasoning & 
Problem Solving 
F3, 774 =9.23 5.3 x 10-6 0.03 F1, 774=10.13 0.002 0.01 
SAD < BD2 
SZ < BD2 
SAD < SAB1 
Visual Learning F3, 770=15.90 4.9 x 10-10 0.06 F1, 770=24.19 1.1 x 10-6 0.03 
SAD < BD2 
SZ < BD2 
SZ < SAB2 
Social Cognition F3, 757=9.72 2.7 x 10-6 0.04 F1, 757=4.22 0.04 0.01 
SAB < BD1 
SAD < BD1 
SZ < BD2 
Attention / 
Vigilance 
F3, 722=7.31 7.8 x 10-5 0.03 F1, 722=25.69 5.1 x 10-7 0.03 
SZ < BD2 
SZ < SAB2 
Speed of 
Processing 
F3, 774=18.43 1.5 x 10-11 0.07 F1, 774=12.83 3.6 x 10-4 0.02 
SAD < BD2 
SZ < BD2 
SAD < SAB1 
SZ < SAB2 
Working Memory F3, 774=10.33 1.1 x 10-6 0.04 F1, 774=14.38 1.6 x 10-4 0.02 
SAD < BD2 
SZ < BD2 
SZ < SAB1 
Composite Score F3, 773=21.42 2.5 x 10-13 0.08 F1, 773=31.85 2.3 x 10-8 0.04 
SAD < BD2 
SZ < BD2 
SZ < SAB2 
SAD < SAB1 
Partial η2 indicates the proportion of variance in cognitive scores that is associated with diagnosis. BD, bipolar disorder; SAB, schizoaffective disorder – bipolar type; SAD, schizoaffective 
disorder – depressive type; SZ, schizophrenia; ANCOVA, analysis of covariance; 1p<0.05, 2p<0.00625 (Bonferroni-corrected) 
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Current positive and negative symptoms 
Current positive symptoms were only associated with social cognition 
(F(1,790)=5.31, p=0.02, see Table 3-10 for full results), although explained a small 
proportion of the variance in performance on this domain (partial η2=0.01). The 
effect of diagnosis on social cognition remained significant after adjusting for 
positive symptoms, although differences between schizoaffective disorder (both 
subtypes) and bipolar disorder were attenuated. Negative symptoms were 
significantly associated with all cognitive domains but the effect of diagnosis 
remained significant after adjusting for these symptoms (see Table 3-11). The 
estimated proportion of variance in cognitive scores explained by current negative 
symptoms ranged from 0.02 to 0.07. Differences between groups were attenuated 
for social cognition, attention, speed of processing and working memory after 
adjusting for negative symptoms. 
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Table 3-10 The effects of diagnosis and total SAPS scores on cognitive performance 
Domain 
Effect of Diagnosis Effect of Current Positive Symptoms Pairwise 
Comparisons 
Fdf p Partial η2 Fdf p Partial η2 
Verbal Learning F3, 807=17.58  4.6 x 10-11 0.06 F1, 807=1.29 0.26 0.002 
SAD < BD2 
SZ < BD2 
SAD < SAB1 
SZ < SAB2 
Reasoning & Problem 
Solving 
F3, 807 =12.06 9.9 x 10-8 0.04 F1, 807=1.51 0.22 0.002 
SAD < BD2 
SZ < BD2 
SAD < SAB1 
Visual Learning F3, 804=18.61 1.1 x 10-11 0.07 F1, 804=0.19 0.67 2.6 x10-4 
SAD < BD2 
SZ < BD2 
SZ < SAB2 
Social Cognition F3, 790=9.90 2.1 x 10-6 0.04 F1, 790=5.31 0.02 0.01 
SAB < BD1 
SAD < BD1 
SZ < BD2 
Attention / Vigilance F3, 755=7.79 4.0 x 10-5 0.03 F1, 755=2.05 0.15 0.003 
SZ < BD2 
SZ < SAB2 
SAD < BD1 
Speed of Processing F3, 807=19.55 3.1 x 10-12 0.07 F1, 807=2.17 0.14 0.003 
SAD < BD2 
SZ < BD2 
SAD < SAB2 
SZ < SAB2 
Working Memory F3, 807=11.10 3.8 x 10-7 0.04 F1, 807=1.20 0.28 0.001 
SAD < BD2 
SZ < BD2 
SZ < SAB1 
Composite Score F3, 807=24.52 3.4 x 10-15 0.08 F1, 807=0.46 0.50 4.8 x 10-4 
SAB < BD1 
SAD < BD2 
SZ < BD2 
SZ < SAB2 
SAD < SAB1 
Total SAPS were calculated by summing the global scores (hallucinations, delusions, bizarre behaviour and positive formal thought disorder). Partial η2 indicates the proportion of variance in 
cognitive scores that is associated with diagnosis. BD, bipolar disorder; SAB, schizoaffective disorder – bipolar type; SAD, schizoaffective disorder – depressive type; SZ, schizophrenia; 
1p<0.05, 2p<0.00625 (Bonferroni-corrected) 
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Table 3-11 The effects of diagnosis and total SANS scores on cognitive performance 
Domain 
Effect of Diagnosis Effect of Current Negative Symptoms Pairwise 
Comparisons 
Fdf p Partial η2 Fdf p Partial η2 
Verbal Learning F3, 805=10.88  5.2 x 10-7 0.04 F1, 805=35.82 3.3 x 10-9 0.04 
SAD < BD2 
SZ < BD2 
SAD < SAB1 
SZ < SAB2 
Reasoning & 
Problem Solving 
F3, 805=6.09 4.2 x 10-4 0.02 F1, 805=29.74 6.6 x 10-8 0.04 
SAD < BD2 
SZ < BD2 
Visual Learning F3, 802=13.86 8.1 x 10-9 0.05 F1, 802=14.89 1.2 x 104 0.02 
SAD < BD2 
SZ < BD2 
SZ < SAB2 
Social Cognition F3, 789=8.77 1.0 x 10-5 0.03 F1, 789=32.80 1.5 x 10-8 0.04 
SAB < BD1 
SAD < BD1 
SZ < BD2 
Attention / Vigilance F3, 755=5.49 9.8 x 10-4 0.02 F1, 755=28.20 1.5 x 10-7 0.04 
SZ < BD1 
SZ < SAB1 
Speed of Processing F3, 805=13.51 1.3 x 10-8 0.05 F1, 805=60.42 2.4 x 10-14 0.07 
SAD < BD2 
SZ < BD2 
SAD < SAB1 
SZ < SAB2 
Working Memory F3, 805=7.16 9.5 x 10-5 0.03 F1, 805=33.60 9.7 x 10-9 0.04 
SAD < BD2 
SZ < BD2 
SZ < SAB1 
Composite Score F3, 805=16.71 1.6 x 10-10 0.06 F1, 805=64.75 3.1 x 10-15 0.07 
SAD < BD2 
SZ < BD2 
SZ < SAB2 
SAD < SAB1 
Total SANS were calculated by summing the global scores (affective flattening, alogia, avolition / apathy and anhedonia / asociality). Partial η2 indicates the proportion of variance in cognitive 
scores that is associated with each variable. BD, bipolar disorder; SAB, schizoaffective disorder – bipolar type; SAD, schizoaffective disorder – depressive type; SZ, schizophrenia; 1p<0.05, 
2p<0.00625 (Bonferroni-corrected) 
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Modelling the contributions of clinical variables 
Diagnosis, olanzapine equivalent dose, duration of antipsychotic exposure, total 
current SANS scores, total current SAPS scores, and lifetime depression (as 
measured by the BADDS depression dimension) were added as predictors into a 
single model. The main effect of diagnostic group on composite cognition 
remained significant (F(3,694)=8.33, p=1.9 x 10-5, see Table 3-12). After correction 
for multiple testing, there were significant differences in composite cognition 
between schizoaffective disorder - depressive type and bipolar disorder (g=0.65, 
p<0.001) and schizophrenia and bipolar disorder (g=0.58, p<0.001). The effect of 
diagnosis was not significant for the domains of reasoning and problem solving, 
social cognition or attention / vigilance at the Bonferroni-corrected alpha of 
0.00625.  
 
Table 3-12 Main effect of diagnostic group after accounting for all covariates 
Domain 
Effect of Diagnosis Pairwise 
Comparisons Fdf p Partial η2 
Verbal Learning F3, 694=4.65  0.003 0.02 
SZ < BD1 
SAD < BD1 
Reasoning & 
Problem Solving 
F3, 694=3.67 0.01 0.02 SAD < BD1 
Visual Learning F3, 691=8.02 2.9 x 10-5 0.03 
SAD < BD2 
SZ < BD2 
SZ < SAB1 
Social Cognition F3, 683=3.26 0.02 0.01 SZ < BD1 
Attention / 
Vigilance 
F3, 651=2.24 0.08 0.01 NS 
Speed of 
Processing 
F3, 694=7.58 5.4 x 10-5 0.03 
SAD < BD2 
SZ < BD2 
SAD < SAB1 
SZ < SAB2 
Working Memory F3, 694=4.27 0.005 0.02 
SAD < BD1 
SZ < BD1 
Composite Score F3, 694=8.33 1.9 x 10-5 0.04 
SAD < BD2 
SZ < BD2 
SZ < SAB1 
SAD < SAB1 
Partial η2 indicates the proportion of variance in cognitive scores that is associated with diagnosis. BD, bipolar 
disorder; SAB, schizoaffective disorder – bipolar type; SAD, schizoaffective disorder – depressive type; SZ, 
schizophrenia; ANCOVA, analysis of covariance; 1p<.05, 2p<.00625 (Bonferroni-corrected) 
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The effects of each predictor on composite cognition scores are shown in Table 
3-13. Of the clinical variables, current negative symptoms explained the largest 
proportion of variance in cognitive scores (F(1,694)=47.07, p=1.5 x 10-11, partial 
η2=0.06). This was followed by diagnosis (partial η2=0.04). Olanzapine equivalent 
dose and antipsychotic exposure in months explained the same proportion of 
variance (partial η2=0.03). Neither current positive symptoms nor lifetime 
depression scores were associated with cognitive performance.  
 
Table 3-13 Effect of each variable on composite cognition 
 Fdf p Partial η2 
Diagnosis F3, 694=8.33 1.9 x 10-5 0.04 
Sex F1, 694 = 0.17 0.68 2.5 x 10-4 
Age F1, 694 = 43.55 8.3 x 10-11 0.06 
Olanzapine 
Equivalents 
F1, 694 = 18.74 1.7 x 10-5 0.03 
Antipsychotic 
Exposure in Months 
F1, 694 = 19.29 1.3 x 10-5 0.03 
Current SAPS Total F1, 694 = 0.33 0.57 4.8 x 10-4 
Current SANS Total F1, 694 = 47.07 1.5 x 10-11 0.06 
BADDS Depression F1, 694 = 1.05 0.31 0.002 
Partial η2 indicates the proportion of variance in cognitive scores that is associated with diagnosis. BADDS, 
Bipolar Affective Disorder Dimension Scale; SANS, Scale for the Assessment of Negative Symptoms; SAPS, 
Scale for the Assessment of Positive Symptoms. 
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Premorbid IQ 
Diagnostic group had significant effects on all domains of cognition when NART 
scores were entered as a covariate (see Table 3-14). However, post hoc 
comparisons between the groups in attention and working memory did not survive 
correction for multiple testing, except for all case-control comparisons. The 
differences between schizoaffective disorder – bipolar type and bipolar disorder 
were larger after accounting for premorbid IQ (composite cognition: g=0.60, 
p=0.003). The proportion of variance in cognitive performance explained by NART 
scores ranged between 0.06 and 0.32.  
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Table 3-14 The effects of diagnostic group and NART score on cognitive performance 
Domain 
Effect of Diagnosis Effect of NART Score 
Pairwise 
Comparisons 
Fdf p Partial η2 Fdf p Partial η2 
Verbal Learning F4, 876 = 40.18 <2.2 x 10-16 0.16 F1, 876 = 197.45 <2.2 x 10-16 0.18 
SAD < BD2 
SZ < BD2 
Reasoning & 
Problem Solving 
F4, 876 = 27.79 <2.2 x 10-16 0.11 F1, 876 = 88.99 <2.2 x 10-16 0.09 
SAD < BD2 
SZ < BD2 
Visual Learning F4, 872 = 28.82 <2.2 x 10-16 0.12 F1, 872 = 192.47 <2.2 x 10-16 0.18 
SAD < BD2 
SZ < BD2 
Social Cognition F4, 859 = 13.45 1.2 x 10-10 0.06 F1, 859 = 50.64 2.4 x 10-12 0.06 
SAB < BD2 
SZ < BD2 
Attention / Vigilance F4, 831 = 18.72 9.6 x 10-15 0.08 F1, 831 = 160.11 <2.2 x 10-16 0.16 SZ < BD1 
Speed of Processing F4, 876 = 56.75 <2.2 x 10-16 0.21 F1, 876 = 168.77 <2.2 x 10-16 0.16 
SAD < BD2 
SZ < BD2 
Working Memory F4, 876 = 29.95 <2.2 x 10-16 0.12 F1, 876 = 413.14 <2.2 x 10-16 0.32 
SAD < BD1 
SZ < BD1 
Composite Score F4, 875 = 67.40 <2.2 x 10-16 0.24 F1, 875 = 389.01 <2.2 x 10-16 0.31 
SAB < BD2 
SAD < BD2 
SZ < BD2 
All cases were significantly impaired compared to controls, except for comparisons between the BD group and controls on social cognition and visual learning. Partial η2 indicates the proportion 
of variance in cognitive scores that is associated with diagnosis. BD, bipolar disorder; SAB, schizoaffective disorder – bipolar type; SAD, schizoaffective disorder – depressive type; SZ, 
schizophrenia; ANCOVA, analysis of covariance. 1p<0.05; 2p<0.00625 (Bonferroni-corrected) 
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3.4.4 Examining cognition as a dimension across diagnostic groups 
Schizoaffective disorder – depressive type and schizophrenia as one group 
Ordinal regression analyses were conducted to test the hypothesis that cognition 
can be considered a dimensional phenotype showing increasing impairment from 
bipolar disorder to schizoaffective disorder – depressive type / schizophrenia. 
Participants were assigned scores from 0 to 2 based on their diagnosis (0 = 
schizoaffective disorder - depressive type / schizophrenia, 1 = schizoaffective 
disorder - bipolar type and 2 = bipolar disorder). Diagnosis was entered as the 
outcome variable with composite cognition scores as the predictor and age and sex 
as covariates.  
Ordinal regression analysis indicated that higher cognitive scores were associated 
with higher scores on the diagnostic scale supporting a spectrum of increasing 
impairment from bipolar disorder to schizoaffective disorder - bipolar type to 
schizophrenia/schizoaffective disorder - depressive type. An alternative way of 
interpreting this result is that among the clinical cases participants with a one 
standard deviation higher score in composite cognition were almost twice as likely 
to be diagnosed with schizoaffective disorder - bipolar type or bipolar disorder 
compared to schizophrenia (OR = 1.98, p = 2.4 x 10-16, see Table 3-15). The 
assumption of proportional odds was confirmed using the test of parallel lines (𝜒2 = 
4.97, df = 3, p = 0.174) and by comparing the coefficients for binary regressions for 
each cut-off point in the scale (see Appendix E). The results were similar when 
social cognition was excluded from the composite score. The results of the ordinal 
regression did not change after adjustment for olanzapine equivalent dose, 
antipsychotic exposure in months and current negative symptoms (OR = 1.63, p = 
4.9 x 10-7), although this result should be interpreted with caution given the 
proportional odds assumption was violated in this model (χ2=26.98, p=1.5 x 10-4).  
The analysis was followed up with binary regressions between the diagnostic 
groups (model 1: BD and SAB; model 2: SAB and SAD/SZ) to compare the 
gradients from one diagnosis to the next on the scale. The resulting coefficients 
were equivalent for models 1 and 2. This confirmed that there is a gradient of 
increasing impairment from bipolar disorder to schizoaffective disorder - bipolar 
type to schizophrenia / schizoaffective disorder - depressive type.  
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Table 3-15 Ordinal regression results and post hoc comparisons 
 
Logistic 
Coefficient 
Standard 
Error 
Odds 
Ratio 
95% 
Confidence 
Intervals 
p value 
Composite score1 0.69 0.08 1.98 1.68 to 2.33 2.4 x 10-16 
Composite score 
without social 
cognition 
0.67 0.08 1.96 1.67 to 2.27 8.2 x 10-16 
With clinical 
covariates2 
0.49 0.10 1.63 1.35 to 1.97 4.9 x 10-7 
Post hoc tests      
BD vs. SAB 0.50 0.16 1.65 1.20 to 2.26 0.002 
SAB vs. SAD / 
SZ 
0.45 0.11 1.56 1.27 to 1.92 2.6 x 10-5 
BD vs. SAD / SZ 0.88 0.12 2.41 1.91 to 3.05 2.5 x 10-13 
BD, Bipolar Disorder; SAB, Schizoaffective Disorder – Bipolar Type; SAD, Schizoaffective Disorder – 
Depressive Type; SZ, Schizophrenia. 1Model fit: chi-square = 103.57 (p = 2.7 x 10-22). Goodness of fit: i) 
Pearson chi-square = 1636.42 (p=0.527); ii) Deviance chi-square = 903.30 (p=1.00). 2Proportional odds 
assumption violated (χ2=26.98, p=1.5 x 10-4). 
 
All groups 
In the second ordinal model, participants were assigned scores from 0 to 3 based on 
their diagnosis (0 = schizophrenia, 1 = schizoaffective disorder – depressive type, 2 
= schizoaffective disorder – bipolar type and 3 = bipolar disorder). These groups 
reflect those included in the analysis comparing cognition between diagnoses. 
Ordinal regression analysis indicated that higher cognitive scores were associated 
with higher scores on the diagnostic scale (see Table 3-16). Participants with a one 
standard deviation higher score in composite cognition were 59% more likely to be 
grouped in a higher category on the scale compared to a lower category (OR = 1.59, 
p = 2.7 x 10-13). However, the test of parallel lines was significant indicating that 
the proportional odds assumption had been violated in this model (𝜒2 = 27.61, df = 
6, p = 1.1 x 10-4). This indicates that the logistic estimates are not equal across all 
levels of the dependent variable therefore the combined estimate for the model is 
not accurate. This was confirmed by comparing the coefficients for binary 
regressions for each cut-off point in the scale (see Appendix E). The results were 
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similar when social cognition was excluded from the composite score and after 
adjustment for olanzapine equivalent dose, antipsychotic exposure in months and 
current negative symptoms (OR = 1.35, p = 4.5 x 10-5). The analysis was followed 
up with binary regressions between the diagnostic groups to compare the gradients 
from one diagnosis to the next on the scale. These results indicated that participants 
with a one standard deviation higher score in composite cognition were only 8% 
more likely to be diagnosed with schizoaffective disorder - depressive type type 
compared to schizophrenia suggesting that these diagnoses could be considered as 
a single category. 
 
Table 3-16 Ordinal regression results and post hoc comparisons 
 
Logistic 
Coefficient 
Standard 
Error 
Odds 
Ratio 
95% 
Confidence 
Intervals 
p value 
Composite score1 0.46 0.06 1.59 1.40 to 1.80 2.7 x 10-13 
Composite score 
without social 
cognition 
0.44 0.06 1.56 1.37 to 1.75 2.4 x 10-12 
With clinical 
covariates 
0.30 0.07 1.35 1.17 to 1.56 4.5 x 10-5 
Post hoc tests 
BD vs. SAB 0.50 0.16 1.65 1.20 to 2.26 0.002 
BD vs. SAD 0.80 0.15 2.22 1.67 to 2.96 5.5 x 10-8 
BD vs. SZ 0.91 0.13 2.48 1.94 to 3.18 6.0 x 10-13 
SAB vs. SAD 0.42 0.13 1.52 1.17 to 1.97 0.002 
SAB vs. SZ 0.47 0.11 1.60 1.29 to 1.99 1.9 x 10-5 
SAD vs. SZ 0.08 0.09 1.08 0.92 to 1.28 0.362 
BD, Bipolar Disorder; SAB, Schizoaffective Disorder – Bipolar Type; SAD, Schizoaffective Disorder – 
Depressive Type; SZ, Schizophrenia. 1Model fit: chi-square = 113.70 (p = 1.8 x 10-24). Goodness of fit: i) 
Pearson chi-square = 2434.90 (p=0.653); ii) Deviance chi-square = 1497.63 (p=1.00). 
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Schizoaffective disorder as one group 
The final ordinal model included schizoaffective disorder as a single category (0 = 
schizophrenia, 1 = schizoaffective disorder and 2 = bipolar disorder). This was 
done to mirror the groups included in previous studies, which have combined the 
subtypes of schizoaffective disorder. Ordinal regression analysis indicated that 
higher cognitive scores were associated with higher scores on the diagnostic scale 
(see Table 3-17). Participants with a one standard deviation higher score in 
composite cognition were 57% more likely to be diagnosed with schizoaffective 
disorder or bipolar disorder compared to schizophrenia (OR = 1.57, p = 2.1 x 10-12). 
As previously, the test of parallel lines was significant (𝜒2 = 20.03, df = 3, p = 1.7 x 
10-4) indicating the logistic estimates were not equal across all levels of the 
dependent variable. This was confirmed by comparing the coefficients for binary 
regressions for each cut-off point in the scale (see Appendix E). The results were 
similar when social cognition was excluded from the composite score. The results 
of the ordinal regression did not change after adjustment for olanzapine equivalent 
dose, antipsychotic exposure in months and current negative symptoms (OR = 1.33, 
p = 1.5 x 10-4). The analysis was followed up with binary regressions between the 
diagnostic groups to compare the gradients from one diagnosis to the next on the 
scale. These results indicated that participants with a one standard deviation higher 
score in composite cognition were twice as likely to be diagnosed with bipolar 
disorder compared to schizoaffective disorder but only 25% more likely to be 
diagnosed with schizoaffective disorder compared to schizophrenia. This suggests a 
steeper gradient between bipolar disorder and schizoaffective disorder than there is 
between schizoaffective disorder and schizophrenia.  
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Table 3-17 Ordinal regression results and post hoc comparisons 
 
Logistic 
Coefficient 
Standard 
Error 
Odds 
Ratio 
95% 
Confidence 
Intervals 
p value 
Composite 
score1 
0.45 0.06 1.57 1.38 to 1.78 2.1 x 10-12 
Composite score 
without social 
cognition 
0.42 0.06 1.54 1.35 to 1.72 2.4 x 10-11 
With clinical 
covariates 
0.28 0.07 1.33 1.15 to 1.54 1.5 x 10-4 
Post hoc tests 
BD vs. SA 0.68 0.13 1.98 1.53 to 2.55 1.9 x 10-7 
SA vs. SZ 0.22 0.07 1.25 1.09 to 1.44 0.002 
BD vs. SZ 0.91 0.13 2.48 1.94 to 3.18 6.0 x 10-13 
BD, Bipolar Disorder; SA, Schizoaffective Disorder; SZ, Schizophrenia. 1Model fit: chi-square = 111.16 (p = 
6.2 x 10-24). Goodness of fit: i) Pearson chi-square = 1596.08 (p=0.782); ii) Deviance chi-square = 1246.48 
(p=1.00).  
 
3.4.5 Cross disorder symptom dimensions and cognitive performance 
Median symptom dimension scores for each diagnostic group are presented in 
Table 3-18. Figure 3-3 displays cognition scores plotted against each symptom 
dimension. Higher scores on the lifetime BADDS mania dimension predicted better 
cognitive performance (B=0.010, SE=0.001, p=3.6 x 10-14), whilst there was a 
trend association between BADDS depression scores and cognition 
(B=0.003, SE=0.001, p=0.056). Higher scores on the lifetime BADDS psychosis 
and incongruence dimensions predicted poorer cognitive performance (psychosis: 
B=-0.016, SE=0.002, p<2.2 x 10-16; incongruence: B=-0.017, SE=0.002, p<2.2 x 
10-16). Higher scores on the lifetime SAPS and SANS scales also predicted poorer 
cognitive performance (SAPS: B=-0.051, SE=0.015, p=8.5 x 10-4; SANS: B=-
0.088, SE=0.011, p=2.4 x 10-15).   
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Table 3-18 Median and interquartile ranges for symptom dimensions 
 
Bipolar 
Disorder 
Schizoaffective 
Disorder – 
Bipolar Type 
Schizoaffective 
Disorder – 
Depressed Type 
Schizophrenia 
BADDS 
Mania 
82 (21.5) 82 (5) 0 (1) 0 (0) 
BADDS 
Depression 
69.5 (22.25) 81 (7.5) 85 (11) 60 (72) 
BADDS 
Psychosis 
22.5 (40) 75 (40) 80 (40) 100 (10) 
BADDS 
Incongruence 
18 (30) 70 (20) 70 (20) 97 (10.5) 
SAPS 5 (5) 10 (4) 9 (3) 10 (4) 
SANS 4 (4.75) 6 (5.5) 7 (5) 7 (6) 
BADDS, Bipolar Affective Disorder Dimension Scale; SAPS, Scale for the Assessment of Positive Symptoms; 
SANS, Scale for the Assessment of Negative Symptoms. 
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Figure 3-3 Symptom dimension scores and composite cognition scores  
From top left to bottom right: BADDS depression, BADDS mania, BADDS psychosis, BADDS incongruence, 
total SAPS scores and total SANS scores. Line represents the regression line and the shaded region indicates 
95% confidence intervals. 
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In the subgroup analyses (bipolar disorder and schizoaffective disorder - bipolar 
type only, schizophrenia and schizoaffective disorder - depressive type only), 
neither BADDS mania nor depression scores predicted performance but higher 
BADDS psychosis scores were associated with lower cognitive scores (bipolar / 
schizoaffective disorder - bipolar type: B=-0.014, SE=0.003, p=7.9 x 10-7; 
schizophrenia / schizoaffective disorder - depressive type: B=-0.010, SE=0.003, 
p=0.0008). Higher scores on the BADDS incongruence dimension were also 
associated with lower cognitive scores (bipolar / schizoaffective disorder - bipolar 
type: B=-0.012, SE=0.003, p=0.0002; schizophrenia / schizoaffective disorder - 
depressive type: B=-0.012, SE=0.004, p=0.0008). Higher lifetime SAPS total 
scores were associated with lower cognitive scores in the schizophrenia / 
schizoaffective disorder - depressive type (B=-0.049, SE=0.017, p=0.004) but not 
in the bipolar / schizoaffective disorder - bipolar type subgroup (B=-0.023, 
SE=0.031, p=0.459). Finally, lifetime SANS total scores were associated with 
lower cognitive scores in the schizophrenia and schizoaffective disorder - 
depressive type subgroup (B=-0.088, SE=0.012, p=3.5 x 10-13) but not in the 
bipolar disorder and schizoaffective disorder - bipolar type subgroup (B=-0.052, 
SE=0.027, p=0.053).  
All analyses were repeated adjusting for age, sex, antipsychotic exposure in months, 
olanzapine equivalent dose and current negative symptoms (see Table 3-19). The 
associations between BADDS psychosis and cognition, as well as BADDS 
incongruence and cognition, remained significant. However, these associations did 
not survive correction for multiple testing in the subgroup analyses. Lifetime SAPS 
scores were not associated with cognitive scores after inclusion of the covariates 
(B=-0.023, SE=0.02. p=0.14). Higher lifetime SANS scores was associated with 
lower cognitive performance (B=-0.081, SE=0.01, p=2.7 x 10-12), except in the 
bipolar / schizoaffective disorder - bipolar type subgroup analysis.  
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Table 3-19 The associations between symptom dimensions and cognition after adjusting for age, sex, antipsychotic exposure in months, olanzapine equivalent dose and current 
negative symptoms* 
 All Groups BD and SAB SAD and SZ 
 B SE p B SE p B SE p 
BADDS Depression 0.002 0.001 0.07 -0.004 0.004 0.33 0.002 0.001 0.11 
BADDS Mania 0.007 0.001 5.8 x 10-7 0.002 0.01 0.78 0.005 0.003 0.09 
BADDS Psychosis -0.011 0.002 9.2 x 10-8 -0.010 0.003 0.003 -0.006 0.003 0.04 
BADDS Incongruence -0.012 0.002 4.3 x 10-8 -0.007 0.003 0.03 -0.009 0.004 0.01 
SAPS -0.023 0.02 0.14 -0.001 0.03 0.97 -0.022 0.018 0.21 
SANS* -0.081 0.01 2.7 x 10-12 -0.024 0.03 0.41 -0.082 0.012 6.2 x 10-11 
*Current negative symptoms were not included as a covariate in the analysis of lifetime SANS scores and cognition due to collinearity. BADDS, Bipolar Affective Disorder Dimension Scale; 
SAPS, Scale for the Assessment of Positive Symptoms; SANS, Scale for the Assessment of Negative Symptoms; BD, Bipolar Disorder; SAB, Schizoaffective Disorder – Bipolar Type; SAD, 
Schizoaffective Disorder – Depressive Type; SZ, Schizophrenia. 
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3.5 Discussion 
The main aim of this chapter was to test the hypothesis that there is a spectrum of 
increasing cognitive impairment from bipolar disorder to schizoaffective disorder - 
bipolar type to schizophrenia and schizoaffective disorder - depressive type. A 
second aim was to examine the relationship between lifetime measures of symptom 
domains and cognitive function. There were three key results of this study: 
1. In accordance with the study hypothesis, cognitive profiles were similar 
across disorders but impairments increased in severity from bipolar disorder 
to schizoaffective disorder - bipolar type to schizophrenia and 
schizoaffective disorder - depressive type. There were no differences 
between schizophrenia and schizoaffective disorder - depressive type in 
severity of cognitive impairments. Ordinal regression modelling provided 
further support for a gradient of increasing cognitive impairment across 
disorders demonstrating a linear trend between cognitive scores and an 
ordered diagnostic scale.  
2. Antipsychotic medication use, negative symptoms and premorbid IQ 
account for some of the variation between diagnoses but the overall effect 
of diagnosis persists after accounting for these variables.  
3. Greater frequency and severity of psychosis and negative symptoms are 
associated with lower cognitive performance, whilst mania and depression 
are not. 
Each of these findings is discussed in detail in the following sections. 
3.5.1 Cognitive performance in the bipolar / schizophrenia spectrum 
Cognitive profiles were similar across disorders but impairments increased in 
severity from bipolar disorder to schizophrenia and schizoaffective disorder - 
depressive type. Performance in the schizoaffective disorder - bipolar type group 
was intermediate between bipolar disorder and schizophrenia, although the 
differences between schizoaffective disorder – bipolar type and bipolar disorder 
were not significant. The ordinal regression model provided further support for a 
gradient of increasing impairment demonstrating an association between cognitive 
scores and an ordered diagnostic scale. The optimal ordinal model combined 
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schizoaffective disorder - depressive type and schizophrenia into a single category. 
These results are consistent with the results of previous studies showing that 
multiple domains of cognition are affected and these impairments increase in 
severity from bipolar disorder to schizophrenia [266, 303, 314, 319]. These results 
expand on existing literature by demonstrating that schizoaffective disorder - 
depressive type lies on the severe end of the cognitive spectrum with schizophrenia.  
Performance across the cognitive domains was equivalent in the schizophrenia and 
schizoaffective disorder - depressive type groups. These results question the 
validity of distinguishing between schizophrenia and the depressive subtype of 
schizoaffective disorder. In addition, the two disorders did not differ on estimated 
premorbid IQ, years in education, antipsychotic medication use, current positive 
and negative symptoms and scores on the Global Assessment Scale. 
Schizoaffective disorder – depressive type is distinguished from schizophrenia in 
DSM-IV on the basis that depressive episodes are present for a substantial 
proportion of the total illness duration (now defined as the majority of the illness 
duration in DSM-5). However, patients with schizophrenia are at increased risk of 
developing depression. It is estimated that approximately 40% of patients with 
schizophrenia meet criteria for depressive disorder at some point in their illness, 
although estimates range between 20-60% [16]. Taken together, this evidence 
suggests that schizoaffective disorder - depressive type and schizophrenia could be 
considered as a single diagnosis representing the severe end of a spectrum of 
cognitive impairment. This was supported by the findings of the ordinal regression 
analyses.  
The schizoaffective disorder - bipolar type group was less cognitively impaired 
than the schizoaffective disorder - depressive type and schizophrenia groups, 
occupying an intermediate position between these disorders and bipolar disorder. 
This finding may at least partly explain why studies of cognition in schizoaffective 
disorder report conflicting findings. The subtypes of schizoaffective disorder were 
combined into a single category in a supplementary analysis (see Appendix F). 
Significant differences were found between schizoaffective disorder and 
schizophrenia in visual learning despite the similarities in performance between the 
depressive subtype and schizophrenia. These results suggest that amalgamation of 
the subtypes may obscure findings.  
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Differences in overall cognition between schizoaffective disorder - bipolar type and 
bipolar disorder were not significant after correction for multiple testing. However, 
the effect size between these groups (g=0.44) was larger than that observed 
between schizophrenia and schizoaffective disorder - depressive type (g=0.07). 
This may explain why a linear trend from bipolar disorder to schizoaffective 
disorder - bipolar type to schizophrenia and schizoaffective disorder - depressive 
type was still observed in the ordinal regression analysis. We used a conservative 
Bonferroni-corrected alpha value of 0.00625 to control the type-I error rate but at 
the cost of loss of power, which could explain the lack of significant difference. 
However, it should be noted that there were smaller differences between 
schizoaffective disorder - bipolar type and bipolar disorder on individual domains, 
which were not significant even at alpha=0.05. 
Diagnostic groups were differentiated based on severity of cognitive impairments 
but the overall pattern of impairment was similar between the groups (Fig. 3-1). 
This suggests cognitive impairment can be considered a dimensional phenotype 
that cuts across diagnostic boundaries. Similarities between the cognitive profiles 
of these disorders are consistent with a shared underlying neurobiology that differs 
quantitatively rather than qualitatively across the diagnostic groups [24, 26, 27]. 
Indeed, there is some evidence that regions of grey matter reductions overlap 
across these disorders, although results for bipolar disorder have been less 
consistent [347-350]. In addition, there is evidence of an overlap in genetic 
susceptibility across these disorders [30, 53, 73, 74]. Overall, these results question 
the validity of a Kraepelinian boundary between schizophrenia and bipolar disorder 
and provide support for a dimensional model of psychotic and affective disorders. 
Whilst neurocognitive impairments were evident across all diagnoses, impairments 
in social cognition were not present in bipolar disorder but were observed in 
schizophrenia and both subtypes of schizoaffective disorder. This is consistent with 
previous studies that have measured cognitive impairment using the MCCB in 
bipolar disorder [335-337]. The largest difference between participants with 
schizoaffective disorder - bipolar type and bipolar disorder was observed in social 
cognition suggesting there may be some distinction in the cognitive processes 
underlying these disorders despite similar neurocognitive profiles. Social cognition 
was also the only domain associated with current positive symptoms. Previous 
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studies have demonstrated associations between domains of social cognition, 
particularly theory of mind deficits, and psychotic symptoms in schizophrenia 
[351-353]. These results suggest that certain social cognitive tasks may 
differentiate bipolar disorder from other disorders within the bipolar / 
schizophrenia spectrum. Whilst deficits in performance on the MSCEIT ME may 
not be present in bipolar disorder, there is evidence of impairments in facial 
emotion recognition and theory of mind in bipolar disorder [199, 243]. However, a 
meta-analysis identified more severe deficits in these domains in schizophrenia 
than bipolar disorder [265]. The association between social cognitive impairment 
and psychosis provides support to cognitive models of psychosis that posit a role 
for social interpretations in the development of psychotic thinking [354].  
3.5.2 Demographic and clinical variables 
Diagnostic groups differed on proportion of males, premorbid IQ, years in 
education, current dose of antipsychotic medication, lifetime duration of 
antipsychotic use, current symptoms and global functioning. Therefore, sex was 
included as a covariate in all analyses that compared the diagnoses and a series of 
secondary analyses were performed to determine whether differences in 
antipsychotic medication use, current symptoms or premorbid IQ could account for 
the differences found between diagnostic groups. The main effect of diagnosis 
remained significant in these secondary analyses. However, when these variables 
were included as covariates the differences between diagnostic groups were 
attenuated.  
Higher doses of antipsychotic medication have been shown to be associated with 
poorer cognition [355] and this was observed in the sample. The current study 
expands on these findings by demonstrating that duration of antipsychotic exposure 
is also associated with cognitive performance. Both dose of and duration of 
exposure to antipsychotic medication partially accounted for the differences 
between diagnostic groups. It should be noted that duration of antipsychotic use in 
months is a simplistic measure of exposure and it does not consider the types or 
doses of antipsychotic medication taken by the participant. Antipsychotic exposure 
could also be measured as cumulative dose over time but this data was not 
available. Current positive symptoms were not associated with any of the cognitive 
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domains, except social cognition, suggesting that the effects of antipsychotic 
medication are not related to severity of current symptoms of psychosis. However, 
the findings from the linear regression analyses suggest that lifetime frequency and 
severity of psychotic symptoms are associated with cognitive deficits. Further work 
is needed to disentangle the effects of medication and severity of psychosis. The 
effect of diagnosis persisted after inclusion of antipsychotic medication despite the 
differences between groups being attenuated. This suggests that differences in 
antipsychotic medication use do not explain cognitive impairments. This is 
supported by studies showing that cognitive deficits are present prior to the onset of 
schizophrenia [159, 356]. The influence of other psychotropic medications, such as 
lithium, was not considered in these analyses. However, lithium use has been 
shown to have little impact on cognitive function and is unlikely to explain these 
results [261]. 
Whilst current positive symptoms were only associated with social cognition, 
current negative symptoms were associated with all domains of cognition. Current 
negative symptoms also explained a higher proportion of the variance in cognitive 
scores than diagnosis. Differences in social cognition, attention, speed of 
processing and working memory between groups were attenuated after accounting 
for current SANS scores. This is consistent with a meta-analysis that found 
differences in cognition between schizophrenia and affective psychosis were partly 
driven by differences in the severity of negative symptoms [263]. This result is not 
surprising given that negative symptoms include poverty of thinking and loss of 
motivation and interest, all of which are likely to influence performance on difficult 
cognitive tasks. These results were consistent with the linear regression analyses 
that demonstrated a relationship between lifetime history of negative symptoms and 
cognitive performance, which is discussed further in the section below.  
Estimated premorbid IQ scores followed a similar pattern to the cognitive domains 
with the poorest scores evident in the schizophrenia and schizoaffective disorder – 
depressive type groups. When NART scores were included as a covariate, there 
were no significant differences between schizoaffective disorder - bipolar type and 
either schizophrenia or schizoaffective disorder - depressive type. This suggests 
that the cognitive decline associated with these disorders is similar but differences 
emerge because participants with schizophrenia and schizoaffective disorder - 
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depressive type have lower premorbid IQ. However, differences between 
schizoaffective disorder - bipolar type and bipolar disorder were larger after 
accounting for premorbid IQ. This suggests that schizoaffective disorder - bipolar 
type is associated with greater cognitive decline than bipolar disorder. However, 
this was not empirically tested in the present study. DeRosse et al. [299] used a 
regression model to estimate cognitive trajectories and identified greater cognitive 
decline in schizoaffective disorder compared to schizophrenia and bipolar disorder. 
However, both the current study and DeRosse et al. [299] used cross-sectional data 
and a retrospective estimate of premorbid IQ. Although the NART is one of the 
most widely used measures of premorbid IQ in the UK, it has been shown to differ 
from measures of IQ taken in childhood overestimating premorbid IQ by 15 points 
on average [357]. However, these analyses were concerned with the relative 
differences between participants in their NART score and therefore lack of 
accuracy in predicting exact IQ should not be an issue. A longitudinal study would 
provide more accurate estimations of cognitive decline across disorders.  
3.5.3 Lifetime symptom dimensions and cognitive impairment 
In the cross-diagnostic analysis, higher scores on the BADDS mania dimension 
were associated with better cognitive performance. However, this result was not 
replicated in the subgroup analyses and may be driven by the effect of diagnosis, as 
participants with schizoaffective disorder - bipolar type and bipolar disorder scored 
higher on the BADDS mania dimension and cognitive tasks. The BADDS 
depression dimension was also associated with better cognitive performance across 
the whole samples but the regression coefficient was small (B=0.003) and this 
association was not found in analyses of the subgroups. Again, this result is more 
likely to reflect diagnostic group differences than scores on the depression scale, as 
the largest group (schizophrenia) had lower scores on the depression scale. 
Higher scores on the psychosis dimensions (BADDS psychosis and lifetime SAPS 
scores) were associated with poorer cognitive performance. Lifetime history of 
psychosis has been shown to be associated with poorer cognition in previous 
studies [284, 303, 316]. These studies have considered lifetime psychosis as a 
binary measure (present or absent) rather than a dimensional measure. Our results 
expand on these findings by demonstrating that lifetime frequency and severity of 
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psychosis predicts severity of cognitive impairments. However, only the BADDS 
psychosis dimension was associated with cognition after accounting for negative 
symptoms and antipsychotic medication. This discrepancy between the BADDS 
psychosis and SAPS results is likely to be caused by insufficient power in the 
SAPS analysis to detect an association due to missing data; 92 observations (11% 
of cases) were missing for the SAPS variable compared to 9 missing observations 
(1%) on the BADDS psychosis variable. 
Higher scores on the lifetime SANS were associated with poorer cognitive 
performance. The association between the SANS scale and cognitive scores was 
consistent with previous meta-analyses of studies of schizophrenia [358, 359]. The 
relationship between negative symptoms and cognition remains unclear but there 
are similarities between these types of symptoms. Both negative symptoms and 
cognitive impairments present premorbid, current treatments are not effective for 
either set of symptoms and both are strong predictors of functional outcome. There 
is some evidence that negative symptoms partially mediate the relationship 
between cognition and functional outcome [359]. However, it has been argued that 
the associations between negative symptoms and cognition are weak and may 
indicate distinct neurobiological pathways [360, 361]. 
The final association was between the BADDS incongruence dimension and 
cognition. The incongruence dimension indicates the extent to which psychotic 
symptoms occur during or outside of mood episodes. It is based on diagnostic 
criteria for affective and psychotic disorders, as described in DSM-IV and ICD-10. 
Higher scores on this dimension indicate more frequent psychosis outside of mood 
and were associated with more severe cognitive impairment. Scores on this scale 
increase from bipolar disorder to schizoaffective disorder to schizophrenia, as the 
scale reflects diagnostic criteria for these disorders. Therefore the association in the 
cross-disorder analysis is not surprising and likely reflects the cognitive differences 
between diagnostic groups.  
The BADDS was treated as a continuous measure in these analyses, although a 
previous study considered the BADDS as an ordinal measure [362]. The BADDS 
consists of “anchor points” whereby the participant’s worst episode defines the 
lowest rating they can be allocated and then points are added based on their 
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remaining episodes of illness. Therefore, the scale is not completely linear. 
Allardyce et al. [362] grouped participants on an ordinal scale based on their 
BADDS score. Whilst this makes interpretation of the scale easier, the 
disadvantage of this is that information is lost and it assumes that all participants 
within a certain range of the BADDS are the same. The BADDS was analysed as a 
continuous measure in this study to ensure that the complete range of scores could 
be included. The distribution of the residuals was normal and thus it did not violate 
the assumptions of linear regression. This does not impact the overall results, which 
would not have changed regardless of whether the BADDS were treated as 
continuous or ordinal variables. 
3.5.4 Generalizability of the results 
CoMPaSS is a UK-based study that recruits participants from outpatient clinics, 
clozapine clinics, depot clinics, early intervention psychosis services, and voluntary 
organisations. Despite the wide-ranging recruitment methods employed, there are 
number of potential sources of recruitment bias in the sample. The protocol for the 
study takes two to three hours to complete including a face-to-face interview, 
cognitive assessment and a blood sample. This may be a barrier to participation for 
some patients, particularly those who are most severely impaired or are functioning 
well and work full time. The predominant method of recruitment was through 
secondary services so the sample is over-represented by participants with a more 
chronic course of illness and under-represented by individuals who have been 
unwell in the past and subsequently recovered and were discharged from 
psychiatric services. A large proportion of the participants with schizophrenia were 
recruited through clozapine clinics so the schizophrenia group is predominantly 
those with treatment-resistant schizophrenia. The sample is comprised of stabilised 
participants rather than acutely unwell participants. Therefore, the results 
generalise to stable patients treated in the community but a different pattern of 
results may be observed in acutely unwell participants, such as inpatients. Finally, 
these findings are based on participants diagnosed according to DSM-IV criteria. 
This is important given differences in the criteria for schizoaffective disorder 
between diagnostic manuals. Diagnosis of schizoaffective disorder in DSM-IV 
relies on mood symptoms being present for a substantial proportion of the total 
illness duration, with a period of at least two weeks of psychosis in the absence of 
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mood. In contrast, ICD and RDC place more emphasis on the first rank symptoms 
of schizophrenia. Vollmer-Larsen et al. [329] demonstrated that using ICD-10 and 
DSM-IV to diagnose schizoaffective disorder results in a different set of patients. 
Therefore, the results presented here may not generalise to patients diagnosed 
according to ICD or RDC. 
3.5.5 Concluding statements and future work 
Several limitations of this study should be noted. There was a larger sample of 
participants with schizophrenia than bipolar disorder because the main aim of the 
CoMPaSS study was revised at a later stage of recruitment to focus solely on 
schizophrenia-spectrum disorders. However, all patient groups were recruited as 
part of a single study and all aspects of recruitment, response rates, phenotyping 
and determining diagnosis were equivalent across groups. In addition to this, all of 
the groups had a large number of participants and these analyses were able to detect 
differences between the groups. The inter-rater reliability for schizoaffective 
disorder – depressive type was low (Kappa=0.63), although this Kappa value is 
higher than those reported in a review of the diagnostic reliability of 
schizoaffective disorder [20]. As noted in section 3.5.1, depression is a common 
co-morbidity in patients with schizophrenia. Criterion C for schizoaffective 
disorder in DSM-IV states that the mood disturbance must be present for a 
“substantial proportion” of the illness but this proportion is poorly specified. Thus, 
schizoaffective disorder – depressive type is distinguished from schizophrenia and 
co-morbid depression based on a subjective judgement about the duration of 
depressive symptoms. The lack of evidence for clinical differences between these 
two disorders (except duration of depression) and poor reliability of the diagnosis 
of schizoaffective disorder further questions the validity of distinguishing between 
them. The bipolar disorder group consisted of a mixture of patients with and 
without a lifetime history of psychosis. Given the small number of participants 
without psychosis, it was not possible to separate the group into those with and 
without history of psychosis to examine differences between these groups and 
schizophrenia or schizoaffective disorder. However, analyses were conducted to 
determine whether there is a linear relationship between lifetime psychosis and 
cognitive function. Current depressive or manic symptoms were not considered as 
covariates in these analyses. Studies have shown that depressive and manic 
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symptoms are associated with poorer cognitive performance (particularly on 
measures of verbal fluency and executive function) in participants with bipolar 
disorder [257-259]. One study also demonstrated a negative correlation between 
depressive symptoms and cognitive performance in participants with schizophrenia 
[363]. However, cognitive impairments have been shown to persist during periods 
of remission in patients with bipolar disorder [238]. The MCCB was designed for 
use with participants with schizophrenia. Previous studies of bipolar disorder have 
failed to find deficits in executive functioning using the NAB Mazes task [242, 335, 
337]. The authors of these studies note that more complex measures of executive 
function, such as the Wisconsin Card Sorting Task, may be more sensitive to 
detecting deficits in bipolar disorder. Although the bipolar group was impaired on 
the NAB Mazes relative to controls, this task may not have been sufficiently 
complex to differentiate bipolar disorder and schizoaffective disorder – bipolar type. 
Furthermore, the bipolar group was not impaired on the social cognition task 
(MSCEIT) but previous studies have identified deficits in theory of mind and 
emotion recognition suggesting that patients with bipolar disorder do have 
impairments in specific domains of social cognition [199, 243]. 
This study has several strengths. It is one of the largest samples to date and was 
sufficiently large enough to separate the subtypes of schizoaffective disorder. The 
sample is well characterised with consensus lifetime diagnoses based on semi-
structured interview and medical records. The findings were robust to the inclusion 
of current symptoms and antipsychotic medication as covariates. A lifetime 
measure of antipsychotic medication (duration of exposure in months) was 
included in addition to controlling for current dose of antipsychotic medication. 
In conclusion, it has been demonstrated that there is a gradient of increasing 
cognitive impairment from bipolar disorder to schizoaffective disorder - bipolar 
type to schizophrenia and schizoaffective disorder - depressive type. Differences in 
cognitive profiles between the diagnoses were quantitative rather than qualitative. 
Participants with the depressive subtype of schizoaffective disorder displayed 
comparable cognitive performance to participants with schizophrenia. This argues 
against separating schizophrenia and schizoaffective disorder - depressive type for 
such analyses. This study was the first to use a regression model to demonstrate a 
gradient of cognitive impairment. This study also showed that a dimensional 
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measure of lifetime psychosis is linearly associated with cognition. These results 
offer important insights for psychiatric nosology providing support for a 
dimensional model of psychotic and affective disorders rather than diagnostic 
categories. These findings also have implications for the development of therapies 
that restore cognitive function and the provision of social support for patients in the 
community. All patient groups exhibited cognitive impairments relative to the 
controls. Therapies developed to improve cognition should be targeted towards 
patients with schizoaffective disorder and bipolar disorder, as well as schizophrenia. 
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Chapter 4: Development of an Online Cognitive Battery 
for Use in Research of Psychiatric Disorders 
4.1 Introduction 
Emerging evidence in the fields of cognitive neuroscience, genetics and psychiatry 
has highlighted the need for large samples to be recruited [274]. There is increasing 
interest in examining genetic and environmental factors that contribute to the 
development of cognitive impairments in patients with psychiatric disorders both 
within and across diagnostic boundaries. However, few studies have collected 
sufficiently large cross-diagnostic datasets and collection of this data is logistically 
challenging and expensive. 
Web-based data collection is an effective way to acquire large amounts of cognitive 
data using minimal resources. Advantages to web-based methods include: 1) 
relatively inexpensive costs per participant [272, 274]; 2) automatic data entry that 
limits errors [272]; 3) ability to recruit from locations that would normally be out 
of reach [268]; 4) promotion of research to the public [268]. Studies comparing 
web-based and traditional cognitive tasks have reported high correlations, few 
systematic differences between the assessments and good internal reliability of 
online tasks [273, 274, 276]. However, questions remain over whether 
unsupervised online tasks are a suitable alternative to traditional pen and paper 
tasks, particularly amongst individuals with psychiatric disorders who may have 
moderate to severe cognitive impairments. One issue is participation bias, as online 
studies may exclude individuals who are less computer literate or who do not have 
internet access.  
An important consideration when developing a cognitive battery is which domains 
of cognition to include. There has been no consensus on which domains of 
cognition should be examined in psychiatric disorders with the exception of 
schizophrenia. The National Institute of Mental Health’s (NIMH) Measurement 
and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) 
initiative was formed to stimulate the development of new treatments for cognitive 
impairments in psychotic disorders. One of the objectives of the MATRICS was to 
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create a cognitive battery with good psychometric properties that could be used in 
research of cognition in schizophrenia [201]. Consultations with more than 130 
scientists and an evaluation of factor analytic studies led to the selection of seven 
cognitive domains and a set of criteria for evaluating tasks for inclusion in the 
battery [202]. The seven cognitive domains were: speed of processing, working 
memory, verbal memory, visual memory, attention/vigilance, reasoning and 
problem solving, and social cognition. An expert committee then evaluated 90 
nominated tasks and shortlisted 36 tasks for inclusion [203]. The psychometric 
properties, tolerability and relationship with functional outcome of each task were 
evaluated to select a final MATRICS Consensus Cognitive Battery (MCCB). 
Although the MCCB was developed to assess cognitive function in schizophrenia, 
the battery has also been used in studies of bipolar disorder [335, 336] and major 
depressive disorder [364]. Whilst the MCCB is considered a gold standard 
cognitive assessment, there are some disadvantages to administering the battery. 
The MCCB predominantly consists of pen and paper tasks and has to be 
administered by a specially trained researcher. The battery also takes up to one and 
a half hours to complete. The administration and duration of the battery means that 
collecting data on very large numbers of participants is labour intensive.  
This chapter describes the development and validation of an online cognitive 
battery for use in research of psychiatric disorders. The conception and design of 
the online cognitive battery were completed in the first two years of the PhD, as 
well as the process of gaining ethical approval. The aim was to develop a cognitive 
battery that assessed the domains outlined by the MATRICS initiative. I developed 
the online cognitive battery in collaboration with The Many Brains Project, Inc. 
The Many Brains Project is a not-for-profit organisation that develops online 
cognitive testing tools for use in research studies. The tests are taken from 
published research. The Many Brains Project hosts a website, “testmybrain.org”, 
which collects cognitive data from around the world. The website includes 
cognitive tasks and questionnaires and provides individual feedback on the 
participant’s performance to encourage engagement in the research. They have 
collected data on hundreds of thousands of participants including those with 
cognitive impairments. Analysis of the data from the “testmybrain.org” website 
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showed few systematic differences between web-based and laboratory-based 
samples on mean performance, performance variance and internal reliability [273].  
This chapter is separated into two parts. The first part details the development of 
the study website. I selected the tasks in consultation with researchers within the 
MRC Centre for Neuropsychiatric Genetics and Genomics at Cardiff University 
and The Many Brains Project. The second part of this chapter describes a pilot and 
validation study. I piloted the new cognitive battery with a group of participants 
with a range of psychiatric disorders and validated it against the MATRICS 
Consensus Cognitive Battery (MCCB).  
4.2 Part 1. Development of the study website 
4.2.1 Selection of the cognitive tasks 
I selected the tasks to assess, as closely as possible, the domains outlined by the 
National Institute of Mental Health’s (NIMH) Measurement and Treatment 
Research to Improve Cognition in Schizophrenia (MATRICS) initiative (see 
Section 1.7.1 for more details about the MATRICS domains). I chose The Many 
Brains Project as a collaborator (http://www.manybrains.net/), as the set-up of the 
website was simple, the tasks are taken from published studies and included 
computerised versions of some of the tasks included in the MATRICS Consensus 
Cognitive Battery (MCCB). The Many Brains Project provided trial versions of all 
of the tasks they have developed. Each task included a brief description of the task 
and the abilities that the task was designed to assess. I evaluated twenty tasks on 
administration times, similarities to the equivalent MCCB task and factors that 
would influence participants’ engagement in the task, such as difficulty, enjoyment 
and ease of use. Based on these evaluations, I selected a preliminary battery in 
consultation with my supervisory team. We then consulted with The Many Brains 
Project before making the final selection. The tasks included in the battery and the 
equivalent MCCB tasks are shown in Table 4-1. Not all of the tasks are equivalent 
due to the lack of an available equivalent measure. In addition to tasks assessing 
the MATRICS domains, a measure of crystallised intelligence was included 
(Vocabulary). Vocabulary is thought to be preserved after onset of a psychiatric 
disorder and is used as an estimate of premorbid IQ [357, 365]. The National Adult 
Reading Test (NART, [339]) was included in the face-to-face assessment as a 
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comparison. The NART is a widely used measure of premorbid IQ [357, 366] and 
is included in the CoMPaSS study (see Chapter 3). There is increasing interest in 
measuring risk-taking propensity in participants with psychiatric disorders, 
particularly bipolar disorder, and so an additional domain (strategic risk taking) 
was included. A full description of each task and the reasons for their selection are 
given in the following sections. 
 
Table 4-1 Online and MCCB tasks  
Domain Online Task MCCB Task 
Speed of Processing Digit Symbol Coding BACS: Digit Symbol 
Coding  
Verbal Learning Verbal Paired Associates  Hopkins Verbal Learning 
Test - Revised 
Working Memory Backward Digit Span Letter-Number Sequencing 
Visual Learning Hartshorne Visual Working 
Memory 
Brief Visuospatial Memory 
Test – Revised 
Social Cognition Morphed Emotion 
Identification 
MSCEIT: Managing 
Emotions 
Reasoning and Problem 
Solving 
Matrix Reasoning Test NAB: Mazes 
Attention Multiple Object Tracking Continuous Performance 
Test – Identical Pairs 
 Online Task Offline Task 
Premorbid IQ Vocabulary National Adult Reading Test 
BACS: Brief Assessment of Cognition in Schizophrenia; MCCB: MATRICS Consensus Cognitive Batter; 
MSCEIT: Mayer-Salovey-Caruso Emotional Intelligence Test; NAB: Neuropsychological Assessment Battery 
 
The order of the tests was initially selected to reflect the order of the tasks included 
in the MCCB. However, following consultation with The Many Brains Project, the 
Matrix Reasoning Test was moved closer to the end of the battery, as this task is 
one of the most challenging and the longest and may be most likely to discourage 
participants from completing the remaining tasks. As the Verbal Paired Associates 
(VPA) task is a delayed verbal memory task, it has two phases and so the order was 
also altered to accommodate another task between the learning and test phases of 
this task. The Morphed Emotion Identification was selected as the task to go 
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between the learning and test phases of the VPA, as there is no verbal component 
to this task and so it was less likely to interfere with performance on the VPA 
verbal task.  
The tests were designed to run on desktop and laptop computers, touchscreen tablet 
computers and smart phones. It was important that tasks could be run on smart 
phones, as there is evidence that the increase in internet use amongst patients with 
psychiatric disorders between 2011 and 2016 was driven by the increase in daily 
use of internet-enabled mobile phones rather than an increase in computer use 
[270]. The Many Brains Project developed the cognitive tasks and hosted the 
cognitive tasks on their secure TestMyBrain server, which could be accessed using 
a study-specific website link. The assessments load in the participant’s internet 
browser and the data is stored locally during each task. At the end of each task the 
data is encrypted and uploaded to a secure server. The websites were designed to 
comply with current UK data security best practice in consultation with Cardiff 
University’s IT Systems Security Team and Research Governance Officers 
following ethical approval (SMREC reference number: 15/64). All aspects of the 
project are compliant with the principles of the United Kingdom’s Data Protection 
Act 2018 and the General Data Protection Regulation (GDPR). 
All tasks were trialled on a small sample of healthy volunteers (N=9) prior to the 
commencement of the validation study. This was to determine approximate 
administration times. Details of each task are described below and the tasks are 
shown in order of administration in Table 4-2. An example of the test website can 
be found in Appendix H and a test link is provided here: 
https://www.testmybrain.org/launch/cfgen/id-new.html?id=ThesisLink.  
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Digit Symbol Coding (cognitive domain: speed of processing) 
Digit Symbol Coding [367] is considered one of the most robust measures of 
cognitive impairment in schizophrenia and has been shown to better discriminate 
participants with schizophrenia from healthy controls compared with many widely 
studied cognitive tests [195]. It is included as a measure of processing speed in the 
MCCB. Scores on this task are associated with measures of functional outcome 
[368, 369]. Impairments in this task are also consistently found in participants with 
bipolar disorder [237, 238, 240]. During the task, a key of nine symbols and 
corresponding numbers is shown at the top of the screen (see Figure 4-1). 
Participants must select the number that corresponds to each target symbol (“1”, “2” 
or “3”). The outcome measure was the number of correct responses in 90 seconds. 
 
 
Figure 4-1 Example trial of Digit Symbol Coding 
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Morphed Emotion Identification (social cognition) 
The MATRICS committee selected the Mayer-Salovey-Caruso Emotional 
Intelligence Test – Managing Emotions subtest (MSCEIT-ME) to be included in 
the MCCB as a measure of social cognition. Our experience in administering this 
task to over 1000 people is that participants frequently require guidance and 
explanations of the MSCEIT-ME task scenarios, which would not be possible in 
our online design of the tasks. Previous studies have not found impairments on the 
MSCEIT-ME in participants with bipolar disorder [335, 337], including the study 
described in Chapter 3. However, participants with bipolar disorder and 
schizophrenia have been shown to display impairments in their ability to recognise 
emotional facial expressions [243, 370]. Given that impairments are present across 
disorders, the Morphed Emotion Identification task was selected. This task uses the 
face datasets developed by Perrett and colleagues at the University of St. Andrews, 
United Kingdom [371, 372]. Participants are presented with a face and must decide 
whether the face looks angry, fearful, happy or disgusted (see Figure 4-2). Faces 
are morphed between a neutral face and each emotion at varying intensities. The 
outcome measure was the number of correct responses out of 60 faces. Each face is 
presented on the screen for one second and the participant has ten seconds to 
respond once the face has disappeared. 
 
Figure 4-2 Example trial of Morphed Emotion Identification 
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Verbal Paired Associates (verbal learning) 
There were specific challenges with selecting a suitable measure of verbal learning 
that would be practical in an unsupervised, online setting. If the words on the task 
were presented verbally then participants would be required to have a speaker on 
their computer or mobile device. This may have resulted in a greater number of 
participants requesting support given that some of the participants were likely to 
have substantial cognitive impairments. There were also issues with how the 
responses would be inputted. Participants would need access to a microphone if 
they were asked to recall the words aloud. Alternatively, the participants could 
have typed their responses but this could negatively impact the scores of 
participants who struggle with spelling or typing. In both cases, the responses 
would need to be scored by a researcher rather than automatically. This would be 
impractical for large samples of participants.  
Measures of paired associate learning have been shown to load onto the same 
factor as list learning tasks in factor analytic studies [202]. Therefore, the Verbal 
Paired Associates task was included as an alternative to traditional verbal learning 
tasks [273, 373]. This task assesses word learning and episodic memory. A set of 
25 unrelated word pairs are presented on the screen in the learning phase (see 
Figure 4-3). During the test phase, participants are presented with the first word 
from each previously presented word pair and must select the second word from 
four options. The outcome measure was the number of correct responses out of 25 
word pairs. 
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Figure 4-3 Example of the learning phase of Verbal Paired Associates 
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Backward Digit Span (working memory) 
Initially, an online version of the Letter-Number Sequencing task from the MCCB 
was selected as the measure of working memory. However, there were technical 
problems in developing a mobile version of the task and so the task was replaced 
with the Backward Digit Span. Scores on Backward Digit Span have been shown 
to load onto the same factor as Letter-Number Sequencing in factor analytic studies 
[202]. The Backward Digit Span task is a frequently used measure of working 
memory [367]. Participants are presented with a sequence of numbers and must 
recall them in the reverse order (see Figure 4-4). The lengths of the sequences 
increase every two trials until the participant is no longer able to correctly recall the 
sequence backwards. The outcome measure was the maximum length of number 
sequence the participant was able to recall backwards. 
 
 
Figure 4-4 Screenshot of Backward Digit Span 
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Hartshorne Visual Working Memory (visual learning) 
Like measures of verbal learning, there were challenges in selecting a measure of 
visual learning that would be suitable to administer online. It was not possible to 
include a free recall task such as the Brief Visuospatial Memory Test – Revised 
from the MCCB, as this would require participants to reproduce figures and could 
not be scored automatically. Therefore, a measure of recognition was included as 
an alternative. 
The Hartshorne Visual Working Memory task was selected as a measure of visual 
learning [374]. In this task, four shapes are presented at four positions around a 
central cross (see Figure 4-5). These objects are then replaced with one object in 
the location of one of the previous objects. The participant must decide whether 
that object is the same or different than the object that was previously in that 
location. The outcome measure was the number of correct responses out of 42 trials. 
 
 
Figure 4-5 Example trial of Hartshorne Visual Working Memory Task 
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Matrix Reasoning Test (reasoning and problem solving) 
The Matrix Reasoning Test is a nonverbal abstract problem-solving task [367]. 
Seven out of the 13 factor analytic studies evaluated by the MATRICS initiative 
identified a reasoning and problem solving or executive function dimension and the 
Matrix Reasoning Test was one of the tasks that loaded highly on this factor [202]. 
In this task, a set of images is shown on the screen that follows a logical rule (see 
Figure 4-6). The participant must determine the rule and select the image that best 
completes the set. The outcome measure was the number of correct responses out 
of 35 trials. 
 
 
Figure 4-6 Example trial of the Matrix Reasoning Test 
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Balloon Analogue Risk Task (strategic risk taking) 
The Balloon Analogue Risk Task (BART) [375] has been highlighted as a 
promising cognitive measure for use in bipolar disorder [242], although to date it 
has been used in a limited number of studies of psychiatric disorders. Performance 
on the BART has been associated with self-reported risk behaviours and 
impulsivity [375]. Over 30 trials, the participant is presented with a series of 
balloons that have different popping thresholds. For each trial, the participant must 
blow up the balloon by clicking on a button and decide when to stop and cash in 
their points (see Figure 4-7). The larger the balloon at the end of the trial, the more 
points a participant is rewarded but no points are given if the balloon pops. The 
primary outcome measure of the BART is the number of points awarded although 
the number of times the balloon pops is also recorded. The outcome measure was 
the number of points collected by inflating 30 balloons. Higher scores indicate 
more effective strategic risk-taking. 
 
 
Figure 4-7 Example trial of Balloon Analogue Risk Task 
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Multiple Object Tracking (attention) 
The Multiple Object Tracking paradigm was developed as a measure of visual 
cognition [376]. In this task, participants must follow multiple targets as they move 
across the screen amongst other identical objects (see Figure 4-8). This task has 
several advantages over other sustained attention tasks such as the Continuous 
Performance Test. The task involves attending to multiple moving objects rather 
than a single object and this is thought to be more characteristic of real-world 
attention. The task requires active attention to target objects rather than passive 
vigilance. This may be beneficial for keeping participants engaged in the task in an 
unsupervised setting. The outcome measure was the number of correct responses 
over 30 trials. Within a trial, each correctly identified target is one point. 
 
 
Figure 4-8 Example trial of Multiple Object Tracking 
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Vocabulary (premorbid IQ) 
Vocabulary is thought to be preserved after onset of a psychiatric disorder and has 
been used in research as an estimate of premorbid IQ [357, 365]. In the Vocabulary 
test [377, 378], participants are shown a target word and asked to select which of 
four words is closest in meaning to the target word (see Figure 4-9). There are 
twenty words in total and the total score was used as the outcome measure for this 
task. 
 
 
Figure 4-9 Example trial of the Vocabulary task 
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Table 4-2 Tasks included in the online cognitive battery 
Domain Task 
Administration 
Time* 
Outcome Scoring 
Speed of 
Processing 
Digit Symbol 
Coding 
2 minutes 30 seconds 
Number of correct responses 
in 90 seconds. 
Social 
Cognition 
Morphed Emotion 
Identification 
3 minutes 
Number of correct responses 
out of 60 faces. 
Verbal 
Learning 
Verbal Paired 
Associates  
6 minutes 
Number of correct responses 
out of 25 word pairs. 
Working 
Memory 
Backward Digit 
Span 
3 minutes 
Maximum length of number 
sequence the participant was 
able to recall backwards.  
Visual 
Learning 
Hartshorne Visual 
Working Memory 
3 minutes 30 seconds 
Number of correct responses 
out of 42 trials. 
Reasoning 
and 
Problem 
Solving 
Matrix Reasoning 
Test 
15 minutes 
Number of correct responses 
out of 35 patterns. 
Strategic 
Risk 
Taking 
Balloon Analogue 
Risk Task 
4 minutes 
Number of points collected by 
inflating 30 balloons. Higher 
scores indicate more effective 
strategic risk-taking. 
Attention 
Multiple Object 
Tracking 
7 minutes 30 seconds 
Number of correct responses 
over 30 trials. Within a trial, 
each correctly identified 
target is 1 point.  
Premorbid 
IQ 
Vocabulary 3 minutes 
Number of correct responses 
out of 20 words. 
*Administration times are based on the assessments of healthy volunteers recruited in a small pilot study (N=9)
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4.2.2 Development of a brief online clinical questionnaire 
In addition to the cognitive assessment, a brief online clinical questionnaire was 
designed to assess concurrent factors that may impact cognitive performance. The 
brief questionnaire was hosted online using the Bristol Online Survey (BOS, 
https://www.onlinesurveys.ac.uk). The assessment included questions about current 
diagnosis, medication, medical history, substance use and current mood. Current 
symptoms of depression and anxiety were assessed using Hospital Anxiety and 
Depression Scale (HADS)[379]. The reliability of administering the HADS online 
has been established, although scores may be inflated when the questionnaire is 
completed online compared to pen and paper administration [380-382]. Current 
symptoms of mania and hypomania were assessed using the Altman Self-Rating 
Mania Scale (AMS)[383]. The AMS has been administered on smartphones and 
via the internet in studies of self-monitoring [384] and interventions [385, 386] for 
bipolar disorder. Current psychotic and negative symptoms were not assessed due 
to the lack of reliable, valid self-report questionnaires.  
4.2.3 Website design 
Each stage of participation in the online study is shown in Figure 4-10. The study 
was designed as a closed system, such that only participants who had been invited 
to take part could access the website. Each participant was assigned a linked 
anonymous unique identification number (ID) and a unique website link was 
generated using BOS. When participants clicked on this link, their ID was 
completed automatically in the relevant field. This reduced the possibility of 
participants’ incorrectly entering their ID.  
The study was separated across two websites, BOS and TestMyBrain. Participants 
were sent a link to the BOS website, which contained an information page, consent 
form and the clinical questionnaire (the pages of the website can be found in 
Appendix G). Participants indicated their consent by ticking a box at the bottom of 
the information page. The final page on BOS contained a unique website link to the 
TestMyBrain cognitive assessments. The study was designed such that the 
participant’s ID would be linked from the BOS website to the TestMyBrain 
website without input from the participant. The TestMyBrain website contained 
links to each task in the order shown in Table 4-2 (the main page of the website is 
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shown in Appendix H). Once each task had been completed, the link would be 
crossed out to prevent participants completing the same task twice and their score 
was saved on the server. Participants who did not complete all of the tasks in the 
battery were sent a follow-up email by a member of the study team that included 
their link to the TestMyBrain website to enable them to complete the remaining 
tasks. It was not possible to include a button on the TestMyBrain website that 
would send participants the link automatically, as this would have compromised 
their anonymity. The websites were designed to comply with current UK data 
security best practice in consultation with Cardiff University’s IT Systems Security 
Team and Research Governance Officers following ethical approval (SMREC 
reference number: 15/64).  
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Figure 4-10 Stages of the online study BOS: Bristol Online Survey 
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4.3 Part 2. Pilot and validation of the online cognitive assessment 
4.3.1 Method 
Methodological considerations and power calculation 
In the validation study, convergent validity was examined by conducting 
correlations between MCCB and online tasks that assess equivalent cognitive 
domains. There is no consensus on the minimum acceptable correlation between 
tasks for validation because the correlation partly depends on the extent to which 
the new task and gold standard task are purported to measure the same concept 
[387]. In addition, the correlation between a new task and the gold standard task 
cannot exceed the square root of the product of the test-retest reliabilities of both 
tasks so the limit of the correlation between the tasks is not ±1[272]. However, 
previous validation studies using the MCCB have reported correlations of 0.22-
0.84 between tasks assessing equivalent domains [277, 278]. Some of the online 
tasks were more similar to the equivalent MCCB tasks than others. Therefore a 
minimum acceptable threshold of r>0.2 was set, as large correlations would not be 
expected between tasks that did not use similar methodology to measure the 
domains (for example, social cognition was assessed using a facial recognition task 
in the online battery and emotion management task in the MCCB). An exception to 
this rule was applied for the speed of processing domain. I selected the same task 
online as was included in the MCCB (Digit Symbol Coding) to measure speed of 
processing. A higher correlation was expected between these tasks given that the 
methodology used is almost identical so the minimum acceptable threshold for 
correlation was set at r>0.4. 
A priori power calculations determined that a sample size of 65 would give 80% 
power to detect a correlation coefficient of 0.4 with a Bonferroni-corrected alpha 
value of 0.00625 (0.05/8 correlations). A sample of 65 would give 13% power to 
detect a correlation coefficient of 0.2 with a Bonferroni-corrected alpha value of 
0.00625 and 37% power at an alpha value of 0.05. A sample size of 311 
participants would have been required to achieve 80% power to detect a correlation 
coefficient of 0.2 at an alpha value of 0.00625. This would not have been feasible 
within the time period and thus the recruitment target was set at 65 participants. 
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This number included healthy controls and participants with major depressive 
disorder, bipolar disorder and schizophrenia. 
Sample 
Participants (N=67) were recruited from two previous studies conducted within the 
MRC Centre for Neuropsychiatric Genetics and Genomics: National Centre for 
Mental Health (NCMH) and Cognition in Mood, Psychosis and Schizophrenia 
Study (CoMPaSS). The aim of both studies is to investigate the genetic and 
environmental factors that contribute to susceptibility to mental health disorders 
and as such there are genotype and phenotype data available for all participants. 
Recruitment for these studies is ongoing and includes recruitment through 
outpatient clinics as well as non-systematic methods, such as leaflets, radio 
advertisements and through their websites. Both studies include confirmation of 
consent from participants to be approached for other research within the centre. 
Participants with one of three diagnoses, major depressive disorder, bipolar 
disorder or schizophrenia, were recruited for this PhD study. These three diagnostic 
groups were selected given extensive research establishing the characteristics of 
cognitive performance of those with each of these disorders using offline, 
traditional cognitive testing. In addition, there were large numbers of participants 
with these disorders in the samples that would be invited to take part in the main 
study (Chapter 5).  
National Centre for Mental Health 
Participants with bipolar disorder (N=17) and major depressive disorder (N=15) 
were recruited from the National Centre for Mental Health (NCMH). Participants 
were recruited both prospectively at the time of interview by NCMH and 
retrospectively through invitation letters or emails to past NCMH participants who 
had provided consent to be re-contacted for future research. The NCMH sample 
includes over 10000 individuals with a range of diagnoses including bipolar 
disorder, schizophrenia, autism, post-traumatic stress disorder and depression. One 
of the main aims of NCMH is to recruit a cohort of individuals who consent to be 
approached for other studies to develop psychiatric research in Wales. Participants 
are administered a brief interview and provide a blood sample. Participants are 
asked the question, “Has a doctor or health professional ever told you that you have 
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any of the following diagnoses?” Participants are given a list of diagnoses and 
asked to indicate all diagnoses that apply. They are then asked to indicate which of 
the diagnoses they have ticked would they consider to be their primary, secondary 
and tertiary diagnoses. Finally, they are asked the question, “If we were to speak to 
your clinical team or general practitioner, would they agree with that?” This is 
consistent with the approach taken by other large studies with self-report measures 
of diagnosis, such as the UK Biobank [388]. Their diagnosis is then confirmed with 
their clinical team where possible. Participants who responded that their primary 
diagnosis was major depressive disorder or bipolar disorder were included in this 
study. 
For this study, a conservative definition of depression was chosen that required a 
reported diagnosis and previous treatment with at least one antidepressant 
medication. The 17 participants who self-reported a diagnosis of bipolar disorder 
included 11 participants with type I, five participants with type II and one 
participant with schizoaffective disorder – bipolar type. Of these 17 participants, 10 
participants had also been interviewed with the Mini-International 
Neuropsychiatric Interview (MINI, [334]) as part of another study and their 
diagnosis of bipolar disorder was confirmed for all ten participants. A further 
participant had completed the Schedule for Clinical Assessment in Neuropsychiatry 
(SCAN, [331]) as part of an in depth NCMH assessment and their diagnosis was 
confirmed.  
Cognition in Mood, Psychosis and Schizophrenia Study (CoMPaSS) 
Participants with a DSM-IV diagnosis of schizophrenia (N=16) were recruited 
retrospectively from the Cognition in Mood, Psychosis and Schizophrenia Study 
(CoMPaSS). The recruitment methods and protocol of CoMPaSS have been 
previously described in Chapter 3. The study includes over 1200 individuals with 
schizophrenia and related psychotic disorders. The aim of this study is to examine 
the associations between genetic and environmental factors and cognitive 
impairment in psychosis. Participants are interviewed using the SCAN [331]. This 
interview is then reviewed along with available clinical records by trained raters to 
determine a consensus lifetime DSM-IV diagnosis. 
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Inclusion criteria for the validation study were aged 16 or above, able to understand 
written and spoken English and no uncorrected deficits in sight or hearing. 
Exclusion criteria included any individuals who at the time of screening were 
current inpatients, under the care of a crisis resolution and home treatment team, 
had been admitted to hospital in the last three months or had changed their 
psychiatric medication in the last three months. Potential participants were 
discussed with a member of their clinical team to determine suitability for the study 
and assess risk prior to participation. There were no specific exclusion criteria for 
neurological conditions but information was collected on medical conditions that 
are related to cognitive impairments. 
Controls (N=19) were recruited from the same communities as cases through the 
NCMH and advertisements in job centres, leisure centres and local shops. 
Participants who reported a current or previous psychiatric diagnosis or had ever 
been prescribed psychiatric medication were excluded. Of the 19 participants, 13 
completed the MINI [334] as part of another study and the remaining participants 
completed the NCMH assessment. None of the controls met criteria for any 
psychiatric disorder or reported taking psychiatric medication. 
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Study design 
Participants were asked to complete two cognitive batteries on consecutive days: 
1. MATRICS Consensus Cognitive Battery (MCCB) and the National Adult 
Reading Test. Full details of the MCCB are available in Chapter 3 and a 
summary of the tasks is shown in Table 4-3. 
2. The online cognitive battery 
Table 4-3 Summary of MCCB Tasks 
Domain Task Task Description 
Speed of 
Processing 
Brief Assessment of Cognition in 
Schizophrenia: Symbol Coding 
P uses the key to assign the 
correct numbers to a series of 
symbols 
 Category Fluency: Animal Naming 
P names as many animals as 
they can in 60 seconds 
 Trail Making Test: Part A 
P connects the numbered 
circles in ascending order 
Working Memory 
Wechsler Memory Scale III: Spatial 
Span 
P must tap the blocks in the 
sequence they have just seen 
 Letter-Number Span 
P rearranges a string of 
numbers and letters into 
ascending numbers followed 
by letters alphabetically 
Attention / 
Vigilance 
Continuous Performance Test: 
Identical Pairs 
P responds every time an 
identical pair of numbers flash 
on the screen consecutively 
Verbal Learning 
Hopkins Verbal Learning Test – 
Revised 
P immediately recalls a list of 
12 words  
Visual Learning 
Brief Visuospatial Memory Test – 
Revised 
P immediately recalls the 
shape and location of 6 
figures 
Reasoning and 
Problem Solving 
Neuropsychological Assessment 
Battery: Mazes 
P draws a line through the 
maze from the start point to 
the finish point 
Social Cognition 
Mayer-Salovey-Caruso Emotional 
Intelligence Test: Managing 
Emotions 
P presented with a social 
scenario and must judge a 
response on a scale of very 
ineffective to very effective. 
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The batteries were completed on separate days to combat potential fatigue effects. 
The total study time was three hours (one and a half hours each day). A trained 
researcher administered the MCCB in a supervised setting on the first day then 
participants completed the online cognitive battery and clinical questionnaire 
unsupervised on the second day. Most participants completed the online stage at 
home. However, individuals without personal internet access were given the 
opportunity to complete the online stage in a clinical testing room within the 
Division of Psychological Medicine and Clinical Neurosciences at Cardiff 
University. Two participants completed the online stage at the university and one 
participant completed the online stage at their local psychiatric clinic. Although 
this environment does differ from a home setting, every effort was made to ensure 
that participants completed the tasks without input from the researcher. The order 
of completion was not counterbalanced for practical reasons; firstly, participants 
from NCMH could be recruited prospectively by completing the MCCB with a 
researcher immediately after completing the NCMH assessment therefore the order 
of completion could not be randomly assigned, secondly, it would have been 
difficult to ensure that participants assigned to complete the online part first did so 
before their appointment, as they were not supervised. However, the order of 
completion was counterbalanced for participants in the healthy control group 
(N=19). Informed consent was obtained at both stages, in writing prior to 
administration of the MCCB and online prior to completing the online cognitive 
battery.  
The stages of the study were: 
1. Participants met with a researcher, gave informed consent and completed 
the MCCB. Participants also completed the mood questionnaires, HADS 
and AMS.  
2. The researcher entered the participant’s ID number onto the BOS study 
page and a personalised website link was generated and emailed to the 
participant. 
3. The participant clicked on the link in the email and was taken to a study 
welcome page on BOS (see Appendix G). They read an information page, 
indicated their consent to participate by clicking on a tick-box and 
completed the questions (including HADS and AMS). At the end of the 
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questionnaire, they were asked to click on another link to the online 
cognitive battery. 
4. Participants completed the online cognitive tasks on a study-specific 
website created by The Many Brains Project.  
5. Participants were asked to return a feedback questionnaire on completion of 
the study (see Appendix I). They rated the overall online battery on 
enjoyment, duration and difficulty and rated the clarity of the instructions 
and information given. They named the tasks they liked the most and least. 
They also provided information on any technical difficulties they 
experienced.  
Statistical analysis 
All statistical analyses were conducted in R version 3.3.0. Completion rates for 
each task of the new battery were examined to assess the tolerability in an 
unsupervised setting. Data from the feedback questionnaires were studied to further 
assess tolerability. The demographic and clinical characteristics of the sample were 
examined. The distribution of scores for each task was examined to identify 
obvious floor or ceiling effects and determine if the data was normally distributed. 
Basic summary statistics were calculated for each task in each group, including 
mean, standard deviation, skew and kurtosis. Z scores on each MCCB task were 
calculated for each participant using the means and standard deviations of the 
control group recruited as part of CoMPaSS (N=103, see Chapter 3 for full details). 
Validation analyses 
Convergent validity was examined by conducting correlations between the MCCB 
and online tasks that assess equivalent cognitive domains (see Table 4-1 for 
comparisons). There is no equivalent to the Balloon Analogue Risk Task in the 
MCCB so this task was not included in these correlation analyses. Correlations 
were conducted across the whole sample and for cases only. Based on previous 
validation studies using the MCCB [277, 278], the minimum acceptable thresholds 
for the correlations was set at r>0.4 for speed of processing and r>0.2 for all other 
domains (see “Methodological considerations and power calculation” section for 
details). Pearson’s correlations were used when task performance was normally 
distributed, whilst Spearman’s correlations were used for tasks that were not 
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normally distributed. Bonferroni correction was used to adjust for multiple 
comparisons resulting in an alpha of 0.00625 (0.05/8, 8 domains). These 
correlations were followed up with correlations between each online task and all 
other individual tasks of the MCCB.  
Exploratory analyses were conducted to determine whether each online task was 
correlated with a measure of general cognitive performance (‘g’). To derive ‘g’ a 
principal components analysis was conducted including all tasks from the MCCB. 
The first principal component score for each participant was taken as a measure of 
‘g’. In the whole sample (all cases and controls), ‘g’ explained 48% of the total 
variance. Within the combined cases only group, ‘g’ explained 52% of the total 
variance. Pearson’s and Spearman’s correlations were used to test whether there 
was a significant association between each online task and ‘g’ measured offline at a 
Bonferroni corrected alpha of 0.00556 (0.05/9 online tasks). 
4.3.2 Results 
Demographic and clinical characteristics of the sample 
The demographic and clinical characteristics of each group are shown in Table 4-4. 
The sample had a wide age range (22 to 78 years old, mean=47 years, SD=14.8) 
and had a higher percentage of females (58%) than males. Most participants with a 
psychiatric diagnosis were taking psychiatric medication at the time of the online 
assessment (80%) and all had taken psychiatric medication in the past. Rates of 
current depression and anxiety were calculated based on the cut-off points specified 
in the HADS questionnaire (score >10) [379]. Based on this threshold, 6% of the 
sample had current depression and 28% had current anxiety.  Over two-thirds of 
the sample had at least A-level qualifications (72%).  
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Table 4-4 Demographic and clinical characteristics of sample 
 
Healthy 
Controls 
Major 
Depressive 
Disorder 
Bipolar 
Disorder 
Schizophrenia 
N 19 15 16 15 
Age 49.8 (15) 52.4 (10.5) 
51.1 
(13.8) 
49.8 (12.4) 
Proportion Female (% 
Female) 
12 / 19 
(63%) 
10 / 15 
(67%) 
11 / 16 
(69%) 
5 / 15 (33%) 
Estimated IQ1 105.4 (17.8) 
100.2 
(14.7) 
96.2 
(19.6) 
86.9 (19.2) 
Highest Qualification     
None 0 1 0 1 
11+ 0 0 0 1 
CSE or equivalent 0 2 0 2 
GCSE or equivalent 0 2 5 3 
A-level or equivalent 5 5 5 6 
Degree 8 3 5 1 
Postgraduate degree 5 2 1 1 
Lifetime Occupation     
Senior official 0 0 1 1 
Professional 8 7 5 1 
Technical 3 1 3 2 
Administration 2 4 2 1 
Service work 3 2 1 5 
Trade work 0 0 0 3 
Factory or plant work 0 1 0 0 
Elementary occupation 1 0 2 0 
Armed forces 0 0 0 1 
Never worked 0 0 1 0 
Full-time student 1 0 0 0 
Voluntary work 0 0 0 1 
Proportion Taking 
Psychiatric Medication 
(% taking) 
0/19 (0%) 
8 /15 
(53%) 
14 /16 
(88%) 
15/15 (100%) 
HADS Depression Score2 2 (4) 3 (6) 4 (8) 6 (5) 
Proportion Current 
Depression (%) 
1/19 (5%) 0/15 (0%) 
1/16 
(6%) 
2/14 (14%) 
HADS Anxiety Score2 3 (6) 8 (7) 8 (5) 12 (12) 
Proportion Current 
Anxiety (%) 
1/19 (5%) 4/15 (27%)  
5/16 
(31%) 
8/14 (57%) 
AMS Score2 5 (5) 2 (5) 2.5 (3) 4 (4) 
Numbers indicate mean and standard deviation for continuous data and proportions for categorical data. Mood 
scores shown are based on HADS and AMS responses on the day participants completed the MCCB. 1IQ score 
estimated based on NART scores [339]. 2Median and interquartile range shown.
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Completion rates 
Sixty-seven participants were initially recruited into the study but two participants 
were excluded resulting in a total sample size of 65. The first of these participants 
failed to complete the online study and did not respond to further attempts to 
contact and was thus excluded from further analyses. The second participant did 
not wish to continue with the online study due to a relapse in their illness so was 
excluded from these analyses. 
Although participants were encouraged to complete the online battery and MCCB 
on consecutive days, they completed the online battery unsupervised and therefore 
it was difficult to ensure that they did so (see Figure 4-11). Participants who did not 
complete the online battery within 24 hours of the face-to-face interview were 
followed up with a telephone call and again at 1 and 2 weeks. Twenty-two (out of 
65) participants completed the tasks as requested over two consecutive days. Four 
participants completed the online tasks on the same day as the MCCB tasks. Of the 
remaining participants, the majority completed the second battery within 2-7 days 
(N=26), seven participants completed the second battery 8-14 days later, two 
participants completed the second 15-30 days later and four completed over 30 
days later. The longest duration between batteries was 74 days. 
These figures are based on the day participants began completing the online tasks. 
However, five participants completed the online battery over two days. Three of 
these participants had a diagnosis of schizophrenia and two had a diagnosis of 
bipolar disorder. One of the participants did not complete all the tasks, completing 
five out of the nine tasks. Two participants reported technical difficulties that were 
subsequently resolved and so they completed the remaining tasks on a different day. 
Notably, all five participants had lower composite cognition z scores than the mean 
for their diagnostic group. 
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Figure 4-11 Time taken between completing the online and MCCB batteries 
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Online task completion 
In total, 58 out of 65 participants (89%) completed all the online tasks. Complete 
data was available for Digit Symbol Coding, Backward Digit Span and Morphed 
Emotion Identification. The number of scores for each task is shown Table 4-5.  
 
Table 4-5 Completion rates for online battery 
Online Task 
Healthy 
Controls 
Major 
Depressive 
Disorder 
Bipolar 
Disorder 
Schizophrenia Total 
N 19 15 16 15 65 
Digit Symbol Coding 19 15 16 15 65 
Verbal Paired 
Associates 
19 15 15 14 63 
Backward Digit Span 19 15 16 15 65 
Hartshorne Visual 
Working Memory 
Test 
19 15 16 13 63 
Morphed Emotion 
Identification 
19 15 16 15 65 
Matrix Reasoning 
Test 
19 15 15 15 64 
Balloon Analogue 
Risk Task 
19 15 15 14 63 
Multiple Object 
Tracking 
19 15 14 15 63 
Vocabulary 17 15 15 15 62 
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MCCB task completion 
The majority of participants completed all the MCCB tasks (60 out of 65 
participants (92%)). One participant with schizophrenia did not complete the 
Letter-Number Sequencing or Continuous Performance Test – Identical Pairs but 
was able to complete all the online tasks. Two participants with major depressive 
disorder were unable to tolerate the Continuous Performance Test – Identical Pairs 
of the MCCB. One participant with bipolar disorder was unable to complete the 
Hopkins Verbal Learning Test – Revised, Letter-Number Sequencing, Brief 
Visuospatial Memory Test – Revised and Animal Naming. This participant 
completed all the online tasks. Another participant with bipolar disorder was 
unable to tolerate the Continuous Performance Test – Identical Pairs of the MCCB. 
Complete data was available for the control group for both the online and MCCB 
tasks. However, two participants were excluded from analyses of NART scores 
because English was their second language and the NART is not recommended in 
these cases, as the scores are likely to be underestimates of IQ [339]. 
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Comparison of completion rates between batteries 
Table 4-6 shows the completion rates for the online and MCCB batteries in this 
sample, as well as completion rates for the tasks in the CoMPaSS sample in 
Chapter 3. Completion rates did not differ between the batteries (χ2(14)=2.11, p=1). 
 
Table 4-6 Available data for online battery, MCCB battery and MCCB data from CoMPaSS sample 
Domain Online Battery MCCB 
MCCB (CoMPaSS 
Sample, Chapter 3) 
Speed of Processing1 65 (100%) 65 (100%) 923 (99%) 
Verbal Learning 63 (97%) 64 (98%) 927 (100%) 
Social Cognition 65 (100%) 64 (98%) 907 (98%) 
Working Memory2 65 (100%) 63 (97%) 921 (99%) 
Visual Learning 63 (97%) 64 (98%) 923 (99%) 
Reasoning & 
Problem Solving  
64 (98%) 65 (100%) 927 (100%) 
Attention 63 (97%) 61 (94%) 872 (94%) 
 Vocabulary NART NART Chapter 3 
Vocabulary 62 (95%) 62 (95%) 780 (84%) 
1Only Digit Symbol Coding included from the MCCB; 2Only Letter-Number Sequencing included from the 
MCCB. 
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Feedback questionnaire results / tolerability 
Feedback was received from 41 participants, including 15 healthy controls, 7 
participants with depression, 6 with bipolar disorder and 11 with schizophrenia 
(two questionnaires were returned without ID numbers and so their diagnoses were 
unknown). All participants agreed that the instructions given at the start of the 
study were clear and rated the clinical questionnaire on BOS positively. 
Overall the cognitive tasks were rated as enjoyable and of reasonable duration and 
difficulty (see Figure 4-12). Two participants rated the duration of the battery as 
“poor”. One commented that they found the duration “very tiring”. Both 
participants had a diagnosis of schizophrenia. Two participants rated the difficulty 
as “poor”. One participant commented that the tasks were “too quick” and “much 
harder than I thought”. This participant had a diagnosis of depression. A quarter of 
participants who returned their feedback questionnaire reported Multiple Object 
Tracking as the best task (N=12) and Verbal Paired Associates as the worst task 
(N=11). Of the 40 that responded to the question, 34 participants (85%) reported 
that they would be “more likely” to take part in future online studies after taking 
part in this study, whilst 5 participants responded, “don’t know” and 1 participant 
responded that they were “less likely”. 
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Figure 4-12 Feedback received from participants 
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Technical difficulties 
Six participants (9%) reported technical difficulties. Four of these technical issues 
were resolved and it was not possible to identify the cause of the remaining two 
problems. Five participants were able to complete all the tasks so this did not 
impact on the availability of data for these participants. One participant did not 
complete the Hartshorne Visual Working Memory task, as the task kept freezing on 
their computer. It was unclear what caused this issue but as the tasks are 
downloaded onto the local computer, it is possible that this may have been a 
problem with the participant’s computer. This participant completed the remaining 
tasks. As noted above, two participants who reported technical issues had to 
complete the tasks over two days. 
Two participants reported problems related to their own computer or internet. One 
participant reported that the website kept redirecting to “testmybrain.org”. This was 
identified as a problem with the participant’s browser settings and the participant 
resolved this with instructions from the researcher. One participant reported that 
their signal was lost halfway through but was able to complete the study when they 
reloaded their browser. 
The remaining four participants reported problems with the tasks. As noted above, 
one participant reported that the Hartshorne Visual Working Memory task kept 
freezing. Three participants reported a task repeating. On further inspection, two of 
these participants had completed a task twice. In both cases, the tasks had been 
completed hours apart suggesting that the participant had accidentally clicked on 
the same link twice. To combat this, we implemented a feature that crossed out a 
task upon completion. The first score recorded was taken for each participant. The 
third participant reported that the Vocabulary task repeated twice within a three-
minute period. It was unclear what caused this. 
For the latter four participants, the impact of technical difficulties on task 
performance was evaluated by calculating their ranks on tasks completed before 
and after the problem occurred (see Table 4-7). Participants were ranked within 
their diagnostic group. For two of the participants, the technical problem occurred 
on either the first or last task so it was not possible to compare performance before 
and after the problem occurred. One of the participants (A) exhibited their worst 
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performance on all of the tasks they completed after the technical issue. The 
remaining participant (C) exhibited their worst performance on three of the four 
tasks completed after the technical issue. 
 
Table 4-7 Ranks for participants who experienced technical difficulties 
 DGS MEIT VPA BDS HVMT MRT BART MOT Vocab 
A 5 4 4 2.5 4.5 9 6.5 14 9.5 
B 15 12 1 13.5 15 13.5 14 14 4 
C 7 1 6 1  11 13 5 7 
D 6 10.5 5.5 11 9 1.5 7 3 8.5 
Tasks completed after the technical issue occurred are shown in bold. DGS, Digit Symbol Coding; MEIT, 
Morphed Emotion Identification Task; VPA, Verbal Paired Associates Task; BDS, Backward Digit Span; 
HVMT, Hartshorne Visual Memory Task; MRT, Matrix Reasoning Test; BART, Balloon Analogue Risk Task; 
MOT, Multiple Object Tracking; Vocab, Vocabulary 
 
Descriptive statistics 
MCCB tasks 
Z scores on each MCCB task were calculated for each participant to quantify the 
levels of impairment exhibited by participants relative to a control group (see Table 
4-8). Z scores were derived using the means and standard deviations of the 103 
control participants recruited as part of CoMPaSS. These scores were not adjusted 
for age or gender. The healthy control group performed on average half a standard 
deviation below the controls from the CoMPaSS study (mean Z score = -0.51). The 
major depressive disorder group performed over half a standard deviations below 
the CoMPaSS controls (mean Z score = -0.62). Performance in the bipolar disorder 
group was between a half and one standard deviation below the CoMPaSS controls 
(mean Z score = -0.85). The schizophrenia group performed between one and two 
standard deviations below the CoMPaSS controls (mean Z score = -1.76). 
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Table 4-8 Mean z scores for each group 
MCCB Domain 
Task 
Healthy 
Controls 
Major 
Depressive 
Disorder 
Bipolar 
Disorder 
Schizophrenia 
 Mean (SD) Mean (SD) Mean (SD) Mean (SD) 
Speed of Processing -0.40 (0.83) -0.92 (0.76) -1.00 (1.01) -1.77 (1.26) 
Trail Making Test – Part A -0.43 (0.83) -0.92 (0.83) -1.07 (1.43) -1.90 (1.27) 
BACS Digit Symbol 
Coding 
-0.33 (1.06) -0.85 (1.02) -1.13 (1.09) -1.44 (1.19) 
Fluency: Animal Naming -0.20 (0.74) -0.43 (0.59) -0.39 (0.55) -0.89 (0.79) 
Verbal Learning     
Hopkins Verbal Learning 
Test - Revised 
-0.45 (1.23) -0.89 (1.21) -1.05 (1.69) -2.11 (1.90) 
Working Memory -0.44 (0.78) -0.62 (0.88) -0.66 (0.97) -1.20 (1.21) 
WMS-III Spatial Span -0.51 (0.77) -0.81 (0.90) -0.85 (1.19) -1.07 (1.30) 
Letter-Number Span -0.30 (1.03) -0.32 (1.10) -0.47 (0.91) -1.21 (1.07) 
Reasoning & Problem 
Solving 
    
NAB Mazes -0.35 (1.15) -0.50 (1.46) -0.62 (1.37) -1.32 (1.16) 
Visual Learning     
Brief Visuospatial Memory 
Test - Revised 
-0.71 (1.15) -0.66 (1.45) -0.81 (1.23) -1.27 (1.33) 
Social Cognition     
MSCEIT: Managing 
Emotions 
0.45 (0.78) 0.35 (0.96) -0.27 (0.53) -1.07 (0.82) 
Attention     
Continuous Performance 
Test – Identical Pairs 
-0.63 (0.85) -0.31 (1.02) -0.84 (1.12) -0.69 (0.82) 
Composite Cognition -0.51 (0.81) -0.62 (1.19) -0.85 (0.96) -1.76 (1.17) 
Means and standard deviations are shown. BACS: Brief Assessment of Cognition in Schizophrenia; WMS-III: 
Wechsler Memory Scale – Third Edition; NAB: Neuropsychological Assessment Battery; MSCEIT: Mayer-
Salovey-Caruso Emotional Intelligence Test.  
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Online tasks 
Table 4-9 shows means and standard deviations for each task grouped by diagnosis, 
along with maximum possible scores, skew and kurtosis. The proportion of 
participants who achieved the lowest and highest possible score were calculated for 
each task to determine whether floor or ceiling effects were present. Except for 
Vocabulary where five participants achieved the maximum score, none of the 
participants achieved the maximum or minimum scores on any of the tasks. This 
suggests that there were no ceiling or floor effects present. The distributions of 
scores for each task are shown in Figure 4-13. The distribution of scores on the 
Verbal Paired Associates task was highly positively skewed (skew=1.31), whilst 
the distribution of the Backward Digit Span was moderately positively skewed 
(skew=0.42). Scores on three tasks were negatively skewed: Balloon Analogue 
Risk Task (skew=-1.65), Matrix Reasoning Test (skew=-0.97) and Vocabulary 
(skew=-0.57).  
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Table 4-9 Group performance on the online tasks 
Online Task 
Max. 
Score  
Healthy Controls 
Major Depressive 
Disorder 
Bipolar Disorder Schizophrenia Skew Kurtosis 
Digit Symbol Coding N/A 38.00 (7.79) 34.60 (6.03) 33.81 (8.73) 30.07 (8.80) -0.17 -0.23 
Morphed Emotion 
Identification 
60 36.32 (8.91) 34.20 (5.97) 33.88 (6.60) 27.53 (5.17) 0.04 -0.54 
Verbal Paired Associates 25 8.42 (3.72) 7.27 (5.44) 9.27 (5.04) 7.57 (4.77) 1.31 1.60 
Backward Digit Span N/A 4.58 (1.50) 5.47 (1.85) 3.50 (1.03) 3.87 (1.77) 0.42 -0.74 
Hartshorne Visual 
Working Memory Test 
42 32.58 (4.13) 31.33 (3.48) 30.38 (3.86) 29.85 (4.10) -1.21 -0.10 
Matrix Reasoning Test 35 24.11 (6.71) 25.00 (7.81) 21.13 (8.19) 18.8 (7.45) -0.97 -0.03 
Balloon Analogue Risk 
Task 
N/A 836.84 (206.67) 938.67 (101.57) 828.33 (217.17) 800.71 (221.86) -1.65 3.16 
Multiple Object Tracking 120 83.16 (12.95) 79.73 (15.15) 76.07 (17.54) 72.13 (13.30) 0.01 -0.90 
Vocabulary 20 14.78 (3.62) 16.80 (2.40) 14.13 (3.64) 11.47 (4.14) -0.57 -0.52 
189 
 
 
Figure 4-13 Histograms showing the distribution of scores for each online task 
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Convergent validity: Comparison of the MCCB and online battery 
The results of correlations between tasks measuring equivalent domains are shown 
in Table 4-10. In the entire group, scores from seven out of the eight online tasks 
were correlated with scores from the MCCB equivalents (r ranged from 0.26 to 
0.73). Correlations between tasks assessing speed of processing (r=0.73, 95% CIs: 
0.59-0.83), verbal learning (r=0.41, 95% CIs: 0.18-0.57), reasoning and problem 
solving (r=0.53, 95% CIs: 0.33-0.70) and premorbid IQ (r=0.64, 95% CIs: 0.44-
0.78) were significant at the Bonferroni-corrected alpha level of 0.00625. In the 
cases only group, scores from six out of the eight online tasks were correlated with 
scores from the MCCB equivalents (r ranged from 0.33 to 0.69). Correlations 
between tasks assessing speed of processing (r=0.69, 95% CIs: 0.50-0.82), 
reasoning and problem solving (r=0.55, 95% CIs: 0.29-0.75) and premorbid IQ 
(r=0.60, 95% CIs: 0.38-0.76) were significant at the Bonferroni-corrected alpha 
level of 0.00625. 
 
Table 4-10 Results of correlation analyses between online and offline tasks that assess equivalent 
domains 
Domain 
Cases and Controls Cases Only 
r 95% CIs p r 95% CIs p 
Speed of 
Processing 
0.73 0.59-0.83 4.4 x 10-12 0.69 0.50-0.82 1.1 x 10-7 
Verbal Learning* 0.41 0.18-0.57 0.001 0.40 0.11-0.64 0.008 
Working Memory 0.34 0.10-0.54 0.007 0.36 0.07-0.59 0.02 
Visual Learning 0.12 -0.13-0.36 0.35 0.15 -0.15-0.43 0.33 
Social Cognition 0.26 0.01-0.47 0.04 0.33 0.04-0.56 0.03 
Reasoning and 
Problem Solving* 
0.53 0.33-0.70 7.1 x 10-6 0.55 0.29-0.75 9.7 x 10-5 
Attention 0.34 0.09-0.55 0.008 0.31 -0.01-0.56 0.06 
Premorbid IQ* 0.64 0.44-0.78 2.1 x 10-8 0.60 0.38-0.76 4.4 x 10-6 
*Spearman’s rank correlation rho shown instead due to non-normal distribution for these tests. 
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The cases completed the MCCB prior to the online battery for practical reasons; 
firstly, participants from NCMH could be recruited prospectively by completing 
the MCCB with a researcher immediately after completing the NCMH assessment 
therefore the order of completion could not be randomly assigned, secondly, it 
would have been difficult to ensure that participants assigned to complete the 
online part first did so before their appointment, as they were not supervised. 
However, the controls were counterbalanced. Although the groups were small, the 
controls were grouped according to whether they completed the MCCB (N=10) or 
online battery first (N=9) and scores on tasks were compared between the two 
groups, adjusting for age and gender. If one group scored consistently higher on 
one battery than the other then this may indicate the presence of greater practice 
effects when completing the batteries in a specific order. This would indicate a 
methodological issue with administering the MCCB first to all the cases. There 
were no differences in performance between the groups, except that the group who 
completed the MCCB had better scores on the MSCEIT (see Appendix J). 
Correlations between all tasks  
Figure 4-14 displays correlations between the online and MCCB tasks. Scores for 
the online Digit Symbol Coding, Verbal Paired Associates, Matrix Reasoning Test 
and Vocabulary were most highly correlated with their equivalent MCCB tasks. 
The remaining tasks were more highly correlated with tasks other than their 
equivalent MCCB task. The Morphed Emotion Identification Task was most highly 
correlated with the Mazes task (r=0.56, 95% CIs: 0.36-0.71). The Backward Digit 
Span was most highly correlated with the Continuous Performance Test (r=0.41, 
95% CIs: 0.18-0.60). The Multiple Object Tracking Test was most highly 
correlated with the Digit Symbol Coding (r=0.54, 95% CIs: 0.34-0.69). Whilst the 
Hartshorne Visual Working Memory task was not correlated with the Brief 
Visuospatial Memory Test – Revised, scores from this task were correlated with 
Digit Symbol Coding (r=0.28, 95% CIs: 0.04-0.50). The Balloon Analogue Risk 
Task did not have an equivalent task in the MCCB and scores from this task 
showed low correlations with the MCCB tasks; the highest correlation observed 
was with the Hopkins Verbal Learning Test - Revised (r=0.25, 95% CIs: 0.00-0.47). 
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Figure 4-14 Pearson correlations between all online and MCCB tasks  
Red squares indicate tasks assessing the same domain. Only tasks from the MCCB with an equivalent online 
task are shown (Trail Making Test – A, Animal Naming and Wechsler Memory Scale III: Spatial Span have 
been excluded). BVMT-R, Brief Visuospatial Memory Test – Revised; CPT IP, Continuous Performance Test: 
Identical Pairs; HVLT-R, Hopkins Verbal Learning Test – Revised; MSCEIT ME, Mayer-Salovey-Caruso 
Emotional Intelligence Test: Managing Emotions; NAB, Neuropsychological Assessment Battery; NART; 
National Adult Reading Test.  
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Comparison of the online tasks and g 
Each online task was correlated with a measure of general intelligence (g) derived 
from the MCCB tasks (see Table 4-11). In the entire group, scores from eight out 
of the nine online tasks were correlated with g (r ranged from 0.30 to 0.74). 
Correlations between g and Digit Symbol Coding (r=0.74, 95% CIs: 0.60-0.84), 
Verbal Paired Associates (r=0.44, 95% CIs: 0.19-0.62), Morphed Emotion 
Identification (r=0.58, 95% CIs: 0.39-0.73), Backward Digit Span (r=0.42, 95% 
CIs: 0.18-0.61), Matrix Reasoning Test (r=0.59, 95% CIs: 0.38-0.73), Multiple 
Object Tracking (r=0.53, 95% CIs: 0.31-0.69) and Vocabulary (r=0.36, 95% CIs: 
0.08-0.61) were significant at the Bonferroni-corrected alpha level of 0.00556. In 
the cases only group, scores from seven out of the nine online tasks were correlated 
with g (r ranged from 0.36 to 0.73). Correlations between g and Digit Symbol 
Coding (r=0.73, 95% CIs: 0.54-0.85), Morphed Emotion Identification (r=0.54, 
95% CIs: 0.27-0.72), Backward Digit Span (r=0.43, 95% CIs: 0.14-0.65), Matrix 
Reasoning Test (r=0.61, 95% CIs: 0.35-0.78) and Multiple Object Tracking (r=0.50, 
95% CIs: 0.22-0.71) were significant at the Bonferroni-corrected alpha level of 
0.00556. 
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Table 4-11 Correlations between online tasks and g 
Online Task 
Cases and Controls Cases Only 
r 95% CIs p r 95% CIs p 
Digit Symbol 
Coding 
0.74 0.60 – 0.84 1.1 x 10-11 0.73 0.54 – 0.85 7.0 x 10-8 
Verbal Paired 
Associates* 
0.44 0.19 – 0.62 0.001 0.35 0.01-0.62 0.03 
Morphed Emotion 
Identification 
0.58 0.39 – 0.73 1.0 x 10-6 0.54 0.27 – 0.72 0.0003 
Backward Digit 
Span 
0.42 0.18 – 0.61 0.001 0.43 0.14 – 0.65 0.005 
Hartshorne Visual 
Working Memory 
0.30 0.04 – 0.52 0.023 0.25 -0.07 – 0.53 0.12 
Matrix Reasoning 
Test* 
0.59 0.38-0.73 9.7 x 10-7 0.61 0.35-0.78 3.4 x 10-5 
Balloon Analogue 
Risk Task* 
0.11 -0.17-0.35 0.43 0.15 -0.17-0.46 0.37 
Multiple Object 
Tracking 
0.53 0.31 – 0.69 2.2 x 10-5 0.50 0.22 – 0.71 0.001 
Vocabulary* 0.36 0.08-0.61 0.006 0.38 0.06-0.65 0.02 
*Spearman’s rank correlation rho shown instead due to non-normal distribution for these tests. 
 
4.4 Discussion 
This chapter describes the development of an online cognitive battery for use in 
research of psychiatric disorders. The battery was designed to test the domains 
specified by the NIMH’s MATRICS initiative. Participants with either one of three 
psychiatric diagnoses or no history of mental health problems were recruited as 
part of a pilot and validation study. Feedback received from participants was 
largely positive with only three participants rating any aspect of the battery as 
“poor”. The results of the validation study indicated that the online battery is a 
suitable tool for mental health research, providing valid measurements of the 
majority of MATRICS domains.  
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The tasks were well tolerated with 58 out of 65 participants completing all the 
online tasks. This was comparable to the MCCB, which was completed by 60 of 
the 65 participants. Five participants completed the online battery over at least two 
separate visits to the website. These participants had a diagnosis of either 
schizophrenia or bipolar disorder. Notably, all five participants had lower MCCB 
composite cognition z scores than the mean for their diagnostic group. This 
suggests that participants with greater cognitive impairment may poorly tolerate the 
online battery over a single session. A solution to this problem would be to include 
a feature that allows participants to quit the study, save their website link and 
continue later. The issue with completing the task over two or more days is that 
questionnaires containing measures of current mood or current substance use could 
only be analysed with cognitive data collected on the same day. Another solution 
would be to reduce the number of tasks included in the battery. 
4.4.1 Validation of the online battery 
Convergent validity was assessed by conducting correlations between tasks that 
measure equivalent domains. Seven out of eight online tasks were correlated with 
the MCCB equivalent (r=0.26-0.73). The validation study sought to determine 
whether the online tasks provide suitable measures of the MATRICS domains. 
However, there are two considerations. Firstly, this study compared unsupervised 
online tasks to primarily pen and paper tasks administered by a researcher. 
Secondly, the online tasks were different to those included in the MCCB. Both of 
these differences are likely to affect the magnitude of the correlations between the 
tasks. Examining the correlation for speed of processing provides some insight into 
the extent to which the correlations are affected by online/offline testing or 
differences in the methodology of the tasks since the speed of processing domain 
was measured using offline and online versions of the same task, Digit Symbol 
Coding. These tasks were the most highly correlated in the whole sample (r=0.73, 
95% CIs: 0.59-0.83) and amongst the cases only (r=0.69, 95% CIs: 0.50-0.82). 
When considering the validity of a new cognitive task, the correlation between a 
new task and the gold standard task cannot exceed the square root of the product of 
the test-retest reliabilities of both tasks [272]. The test-retest reliability of the Digit 
Symbol Coding subtest of the BACS has been estimated to be between 0.83 and 
0.90 [389]. Taking this into account, the online and offline versions of Digit 
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Symbol Coding were highly correlated. This suggests that differences in online and 
offline administration do not have a large impact on the magnitude of the 
correlations. Therefore, differences in the methodology of the online tasks and the 
MCCB tasks may explain the smaller correlations observed for some domains. A 
further consideration is the delay between administering the first and second 
battery, which may have affected the results. This difference was minimised by 
requiring participants to complete the online battery 24 hours after the MCCB, 
although it was difficult to ensure they did so and concomitant factors, such as 
mood scores, could change even across short time periods. However, the majority 
of participants exhibited minimal changes in mood scores across the two 
assessments. For example, 69% of participants exhibited a change of two points or 
less between the first and second administration of the HADS depression subscales, 
whilst 72% of the sample exhibited a change of two points or less in the HADS 
anxiety subscale. The association between mood scores and performance on the 
online battery is examined further in Chapter 6.  
The remaining online tasks were selected to measure the same domains of the 
MCCB but did not use similar methodology. Three online tasks were most highly 
correlated with MCCB tasks assessing the same domain: Verbal Paired Associates 
(VPA), Matrix Reasoning and Vocabulary. The VPA task was selected as an 
alternative measure of verbal learning due to the practical difficulties of creating 
internet-based list learning, free recall tasks (such as the Hopkins Verbal Learning 
Test – Revised (HVLT-R) from the MCCB). The VPA task assesses delayed 
recognition of word pairs. Measures of paired associate learning have been shown 
to load onto the same factor as list learning tasks in factor analytic studies [202]. 
Despite the differences in methodology between the tasks, the correlation between 
scores on the VPA and HVLT-R was moderate (r=0.41, 95% CIs: 0.18-0.57) and 
the VPA was more highly correlated with HVLT-R than any other MCCB task. 
The MATRICS initiative selected the NAB: Mazes subtest as their measure of 
reasoning and problem solving. This task was not available using the TestMyBrain 
platform so Matrix Reasoning was selected as an alternative. Both the NAB: Mazes 
subtest and Matrix Reasoning are measures of non-verbal problem solving but their 
methodology differs. The NAB: Mazes subtest requires the participant to find the 
correct route through a maze and each trial includes an increasingly complex maze. 
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Performance on Matrix Reasoning depends on the participant identifying the 
correct pattern and selecting the image that completes this pattern. Performances on 
these two tasks were moderately correlated (r=0.53, 95% CIs: 0.33-0.70) 
suggesting that Matrix Reasoning is a suitable alternative to the NAB: Mazes. 
Finally, performance on the Vocabulary test was correlated with the NART (r=0.64, 
95% CIs: 0.44-0.78). The NART is a widely used measure of premorbid IQ [357, 
366]. Vocabulary was included as a measure of crystallised intelligence. However, 
a longitudinal study is required to examine whether performance on the Vocabulary 
task is stable before and after illness onset. 
Three online tasks had correlations that met the minimum acceptable threshold of 
r>0.2: Backward Digit Span, Morphed Emotion Identification and Multiple Object 
Tracking. These tasks had higher correlations with MCCB tasks other than their 
equivalent. This suggests that there was significant overlap in the processes being 
assessed by the online tasks and these tasks may lack specificity in measuring the 
MATRICS domains. This is consistent with research showing that cognitive 
domains are at least moderately correlated and different cognitive abilities are 
related to a higher order factor (g) [204, 205]. The majority of the online tasks were 
correlated with a measure of g derived from scores on the MCCB. Studies have 
examined whether the cognitive domains measured by the MCCB are separable. 
Factor analytic studies of the MCCB are conflicting, with studies indicating that 
this battery can be reduced into fewer domains [390, 391] but another showing that 
the seven domain model is the best fit for the data [392]. A factor analysis of the 
online battery with a larger dataset would assess whether the online battery 
assesses separable domains. 
The Hartshorne Visual Working Memory task was not correlated with the BVMT-
R (r=0.12, 95% CIs: -0.13-0.36). This task had low correlations with g (r=0.30, 
95% CIs: 0.04-0.52), Digit Symbol Coding (r=0.28, 95% CIs: 0.04-0.50) and NAB 
Mazes (r=0.27, 95% CIs: 0.03-0.49). This suggests the task may be an adequate 
measure of general cognitive function but should not be considered a measure of 
visual learning. It should be noted that 8% of the sample reported that Hartshorne 
Visual Working Memory was their least favourite task. Therefore, the low 
correlations may reflect participants disengaging with this task.  
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The Balloon Analogue Risk Task (BART) was not correlated with g (R=0.18, 95% 
CIs: -0.09-0.42) or any of the MCCB tasks. This was not surprising given the 
BART is a behavioural measure rather than a neurocognitive task and the MCCB is 
primarily made up of neurocognitive measures. Nevertheless, the BART is a useful 
measure of risk taking behaviour that does not rely on self-report. Lejuez et al. 
[375] examined correlations between the adjusted number of balloon pumps 
(average number of pumps excluding exploded balloon trials) and measures of risk 
taking. Performance on the BART was correlated with questionnaires assessing 
sensation seeking, impulsivity and behaviour constraint (control, harm avoidance 
and traditionalism). The BART was also correlated with actual risk taking 
behaviours over the past twelve months, including smoking, excessive alcohol use, 
number of classes of drugs taken, gambling, unsafe sexual practices, stealing and 
infrequent seatbelt use. Therefore, inclusion of this task in the battery will allow us 
to assess strategic risk taking across a range of psychiatric disorders and determine 
whether this is associated with functional outcome. 
In conclusion, the majority of the online tasks were correlated with their MCCB 
equivalents but this may reflect the tendency for all cognitive tasks to be at least 
moderately correlated. Digit Symbol Coding, Matrix Reasoning, Vocabulary and 
Verbal Paired Associates were most highly correlated with their equivalent tasks 
suggesting that these tasks were the most valid measures of processing speed, 
reasoning and problem solving, premorbid IQ and verbal learning respectively.  
4.4.2 Methodological considerations of validating cognitive assessments 
The psychometric properties of a cognitive assessment should be evaluated under 
the same conditions as future studies. Whilst the online tasks were well tolerated in 
the current study, the participants may have been motivated by factors such as the 
interaction with a researcher. The motivations of participants in a completely 
unsupervised study are relatively unknown and therefore it is not possible to 
predict how many of these participants are likely to complete all the tasks based on 
the current study. Participants also needed to be available during the weekdays to 
complete the MCCB with a researcher, although appointments were flexible and 
included evenings to limit recruitment bias. This would not be a constraint in an 
unsupervised online study. Most participants completed the online battery at home 
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but a small number attended the clinical testing facility in MRC CNGG, as they did 
not have internet at home. These participants were left to complete the tasks 
uninterrupted. This option will also be made available to participants without 
internet during the main study. 
The psychometric properties of a cognitive assessment should also be evaluated in 
a sample that is representative of the population that it is intended to be used to 
assess. Participants with depression, bipolar disorder and schizophrenia were 
recruited for this study, as these diagnoses are associated with varying levels of 
cognitive impairment (from mild to severe). However, the schizophrenia and 
bipolar disorder groups (mean z scores: -1.76 and -0.85 respectively) were not as 
cognitively impaired as the schizophrenia and bipolar groups in CoMPaSS (mean z 
scores: -2.40 and -1.21 respectively, see Chapter 3). The explanations for this are 
unclear but participants with more severe impairments may be less likely to 1) have 
internet access; 2) have sufficient computer skills or 3) want to take part in an 
unsupervised study. There were also some differences in the recruitment methods 
between the validation study and CoMPaSS, which may explain the differing levels 
of impairment. Recruitment for the validation study was predominantly through 
letters, whilst the recruitment methods of CoMPaSS are varied and include face-to-
face recruitment from mental health clinics. The latter method may be more 
effective in recruiting patients with more severe impairments, which is an 
important consideration for an online cognitive study.  
There was some evidence of recruitment bias in this study. Examination of the 
demographic and clinical characteristics of the sample indicated that participants 
had a wide age range (22 to 78 years old) and consisted of slightly more females 
than males (58%). Most of the sample had at least A-level qualifications and 32% 
of the participants were professionals. The protocol for the validation study was 
demanding, requiring a time commitment of three hours over two days and this is 
likely to affect recruitment in this study. Participants were also reimbursed for their 
time. Therefore, the characteristics of this sample may differ from those who 
complete the online study alone, which is an unpaid study with a time commitment 
of one hour. The participants were not compared to participants from the parent 
studies, as most participants from these studies were not invited to take part in the 
validation study. Comparisons between participants from the online study and 
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those who did not take part were conducted in a larger sample and can be found in 
the next chapter (Chapter 5). 
4.4.3 Concluding statements and future work 
The online cognitive battery has several strengths. Selection of the tasks was 
evidence-based and driven by the work of the NIMH-MATRICS initiative. All 
tasks were taken from published research and have been used extensively in online 
research through the work of The Many Brains Project and their website 
“testmybrain.org”. The tasks work on a range of devices including touchscreen 
devices such as tablet computers and smartphones. The strengths of the validation 
study include the recruitment of individuals with a range of psychotic and affective 
disorders. Participants completed the online battery unsupervised at home, as 
would be expected in an online study.  
Several limitations of the validation study should be noted. The test-retest 
reliability of the online battery was not assessed in this study. In assessing validity, 
the correlation between a new task and the gold standard task cannot exceed the 
square root of the product of the test-retest reliabilities of both tasks [272]. 
Therefore, the upper limits of the correlations between tasks were unknown. 
However, whilst knowing the upper limits of the correlations would be helpful for 
interpretation of the results, these would not change the magnitude or significance 
of the correlations that were found between the tasks. Participants were asked to 
return feedback questionnaires after they had completed the online battery. Two-
thirds of participants returned these questionnaires. Therefore, the experiences of 
the remaining third of participants are unknown. The order of completion of the 
batteries was not counterbalanced for practical reasons. However, the order of 
completion was counterbalanced in the healthy control group and there was no 
evidence that completing the MCCB first had a negative impact on the results. This 
study did not address whether the online tasks are associated functional outcome, 
although this is addressed in Chapter 6.  
In conclusion, a new online cognitive battery was designed to assess the domains 
of cognition outlined by the NIMH-MATRICS initiative. Sixty-five participants 
with no history of mental disorder, major depressive disorder, bipolar disorder or 
schizophrenia were administered the MCCB and new online battery as part of a 
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pilot and validation study. Findings from the validation study indicated that the 
online cognitive battery is a suitable tool for mental health research, providing 
valid measurements of the majority of NIMH-MATRICS domains. The battery was 
well tolerated by the participants and feedback was largely positive. This online 
battery will be used to gather cognitive data from participants of large psychiatric 
genetics studies within the MRC Centre for Neuropsychiatric Genetics and 
Genomics. Data from this study will be combined with data from the parent studies 
to investigate the genetic and environmental factors that contribute to the 
development of cognitive impairments across psychiatric disorders. 
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Chapter 5: Internet-based Cognitive Testing in Research 
of Psychiatric Disorders 
5.1 Introduction 
Online cognitive testing is being increasingly utilised in studies of healthy 
populations to collect large datasets or for longitudinal studies with repeated testing 
[273, 274, 276, 279]. At the time of writing, there have been no published studies 
using online cognitive testing in populations with psychiatric disorders. In Chapter 
4, the validity and tolerability of a new online cognitive battery for use in mental 
health research were examined. The next stage in development of the online 
cognitive battery is to determine whether this is an effective method for collecting 
cognitive data at large scale.  
5.1.1 Internet-based research in mental health 
A key consideration of internet-based research is the representativeness of the 
recruited sample, particularly given the possibility of recruitment bias. The most 
obvious problem is that participants need access to the internet and a computer to 
take part. A study of internet usage amongst individuals with psychiatric disorders 
identified barriers to accessing the internet include concerns about security, lack of 
financial resource to purchase internet enabled devices, impaired access to social 
environments with internet facilities and lack of confidence in using the internet 
[270]. Individuals with psychosis have been shown to be less likely to have internet 
access [270, 271]. One study identified a negative correlation between age and 
frequency of internet use in a cross-disorder sample of participants [271]. 
Most online studies of psychiatric populations have been clinical trials for internet-
based therapies. The first trials for internet-based therapies began in the late 1990’s 
and the most common form of internet-based therapy that has been studied is 
cognitive behavioural therapy (CBT) [393, 394]. Studies have examined the 
efficacy of online therapies and psychoeducation programmes in treating a wide-
range of diagnoses, including depressive disorders [395, 396], anxiety disorders 
[397-402], post-traumatic stress disorder [403], obsessive-compulsive disorder 
[404, 405], bipolar disorder [385, 406-408] and psychotic disorders [409]. 
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Participants are recruited into these studies through a range of methods including 
advertisements (both online and traditional media), epidemiological studies or 
referrals from health professionals [394]. Few studies have examined the 
characteristics of internet-based samples in mental health research but there is 
evidence that these participants have higher levels of education than the general 
population [394]. To my knowledge, there have been no studies examining the 
response rates and characteristics of participants with psychiatric disorders who 
have completed an online cognitive assessment. 
5.1.2 Online cognitive testing 
Several studies have utilised online cognitive assessments to recruit participants for 
research [273, 274, 276, 279](for a comprehensive overview of these studies see 
Chapter 1). Overall these studies have demonstrated that cognitive data collected 
using the internet is comparable to data gathered using face-to-face cognitive 
testing methods (pen and paper or supervised computerised tasks). These studies 
have included self-selected samples (participants who have found the study online 
themselves) [273] or invited participants from existing studies [274, 276, 279]. 
However, few studies have provided information on participation rates or formally 
compared the characteristics of the internet-based sample to the original cohort 
from which participants were recruited. This is an important consideration as 
internet-based samples may not be as representative as samples recruited for face-
to-face studies. One study that reported response rates and completion rates for 
their online cognitive battery was the Twins Early Development Study (TEDS) 
[274]. This study recruited a sample of more than 4000 twins born in the United 
Kingdom between 1994 and 1996. The study developed online tasks to assess 
reading, language, mathematics, and general cognitive ability in children. 
Participants were assessed using the online battery at two follow-up periods at ten 
and twelve years old. At both follow-up periods, 71% of the TEDS sample agreed 
to participate in the study (80% of the sample had internet access). At 10 years old, 
the cognitive battery consisted of eight tasks and 65% of participants completed the 
entire battery. At 12 years old, the cognitive battery consisted of 15 tests separated 
into two parts. Completion rates for this follow-up period were lower with 62% 
completing all the tasks included in part A, 48% completing all the tasks in part B 
and 37% completing both parts of the cognitive battery (15 tasks). Another study 
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examined participant attrition using three online variants of a Stop Signal Task 
[410]. Participants were asked to complete a minimum of four sessions of cognitive 
testing over four days. Of the 482 participants who signed up to take part in the 
study, 419 (87%) participants completed at least one test and 265 (55%) 
participants completed the required four testing sessions.  
To date, there have been no published studies that have examined completion rates 
for an online cognitive battery in an internet-based sample of participants with 
psychiatric disorders. Studies using face-to-face cognitive batteries, such as the 
MATRICS Consensus Cognitive Battery (MCCB) or the Brief Assessment of 
Cognition in Schizophrenia (BACS), in psychiatric populations have reported high 
completion rates [389, 411]. A large multi-site study of participants with 
schizophrenia reported that 98.5% of their sample had complete data on the 
MATRICS Consensus Cognitive Battery (MCCB) [411]. In Chapter 3, 89% of 
participants in the study had full data on the MCCB. Similar completion rates were 
reported by a study evaluating the reliability of the BACS to assess participants 
with schizophrenia (100% of the sample completed at least five out of six tasks 
[389]). However, completion rates may be lower for an online unsupervised study.  
5.1.3 Factor analysis of cognitive batteries 
Scores on pairs of cognitive tasks are moderately correlated and studies have 
shown that a single factor ‘g’ can account for a high percentage of the variance in 
cognitive batteries, such as the MCCB and BACS [206, 412]. Whilst the MCCB 
was designed to assess seven specific domains affected in schizophrenia, factor 
analytic studies of the MCCB have supported 7 factors [392] and 3 factor models 
[390, 391]. Hochberger et al. [412] examined the factor structure of the BACS 
battery in a large sample of participants with bipolar disorder, schizoaffective 
disorder and schizophrenia. A single factor solution was the best model for the 
BACS data across all diagnostic groups and accounted for 47-53% of the variance. 
The implication of this is that much of the pattern of cognitive deficits observed 
across disorders can be explained by a global deficit. The results of the validation 
study in Chapter 4 indicated that each online task assessed multiple domains of 
cognition rather than specific abilities. However, the factor structure of the battery 
was not assessed due to an insufficient sample size. The recommended sample size 
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for factor analysis is at least 300 participants with a minimum of ten respondents 
per variable [413, 414]. Therefore, a further aim of this chapter was to conduct an 
exploratory analysis to evaluate the structure of the online cognitive battery. 
5.2 Chapter aims 
This chapter describes the main recruitment phase of the online study. Participants 
from two studies within the MRC Centre for Neuropsychiatric Genetics and 
Genomics were invited to complete the study: National Centre for Mental Health 
(NCMH) and Cognition in Mood, Psychosis and Schizophrenia Study (CoMPaSS). 
Individuals with a range of mental health disorders were invited to participate. The 
first aim of this study was to determine whether online cognitive testing is a 
suitable method for mental health research. Three sets of analyses were conducted 
to evaluate the online sample: 
Analysis 1. Response rates were calculated across the two studies and within 
specific diagnostic groups. 
Analysis 2. The clinical and demographic characteristics of the sample were 
examined to evaluate whether there is recruitment bias in this 
online sample. These characteristics were compared with those of 
individuals who were invited to take part in the study but did not 
participate in order to determine whether the study sample was 
representative of the original cohort. 
Analysis 3. Completion rates were calculated for each task. The demographic 
and clinical characteristics of participants who completed all of 
the study were compared with those who did not complete the 
full battery. 
The results of the validation study suggested that each online task assessed multiple 
domains of cognition rather than specific abilities. However, there were an 
insufficient number of participants to conduct a factor analysis. Therefore, a further 
aim of this chapter was to evaluate the structure of the cognitive battery (Analysis 
4). The purpose of this exploratory analysis was to determine whether the new 
battery could be reduced into separable cognitive domains. The relationships 
between each task and a measure of general cognitive function (g) were examined.  
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5.3 Method 
5.3.1 Sample 
Participants were recruited from the databases of two studies: Cognition in Mood, 
Psychosis and Schizophrenia Study (CoMPaSS) and the National Centre for 
Mental Health (NCMH). These studies have been described in detail elsewhere 
(see Chapters 3 and 4) but brief details of recruitment and diagnoses are provided 
below. Both studies include confirmation of consent from participants to be 
approached for other research within the centre.  
Recruitment to the online study is ongoing but this chapter includes data from 
participants who were recruited before October 2017. The total number of 
invitations sent between June and September 2017 was 3590. Inclusion criteria 
were aged 16 or above, able to understand written and spoken English and no 
uncorrected deficits in sight or hearing. There were no specific exclusion criteria 
given the practical difficulties involved in pre-screening participants for an online 
study but the online questionnaire included questions about current substance use, 
history of neurological conditions and whether participants had been admitted to 
hospital or had a change in their medication in the last three months. 
CoMPaSS recruitment 
CoMPaSS is a study of over 1200 individuals with schizophrenia and related 
psychotic disorders recruited primarily from outpatient clinics. Participants were 
interviewed using the Schedule for Clinical Assessment in Neuropsychiatry [331]. 
This interview is then reviewed along with available clinical records by trained 
raters to determine a consensus lifetime diagnosis.  
At the time of writing, letters had been sent to 127 participants from CoMPaSS (see 
Appendix K for full letter). The letters included a website address for the study and 
a unique ID number and password for each participant. Participants who were 
interested in the study could type the website address into their internet browser 
and use their ID number and password to log in and access the information 
webpage, consent form and the study. Participants were also given the option to 
contact the study team by telephone, email or by returning a reply slip.  
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The reply slip had three options: 
1. Would like to take part in the study and has provided an email address. 
2. Does not have access to the internet but would like to hear about other ways 
to take part in the study. 
3. Does not want to receive further contact about this study.  
Participants who selected option 1 were contacted via email and given further 
information and instructions on how to access the website. Participants who 
selected option 2 (would like to participate but no internet) were contacted to 
discuss other ways that they could participate in the study. These participants were 
given the option to attend the clinical assessment suite at Cardiff University and 
provided with information about other potential locations, such as local libraries or 
charity centres. 
NCMH recruitment 
The NCMH sample includes over 10,000 individuals with a range of diagnoses 
including bipolar disorder (N=1083), schizophrenia (N=557), autism spectrum 
disorders (N=465), post-traumatic stress disorder (N=1050) and major depressive 
disorders (N=5050). One of the main aims of NCMH is to recruit a cohort of 
individuals prepared to be approached for other studies in order to develop 
psychiatric research in Wales. Participants are asked the question, “Has a doctor or 
health professional ever told you that you have any of the following diagnoses?” 
Participants are given a list of diagnoses and asked to indicate all diagnoses that 
apply. They are then asked to indicate which of the diagnoses they have ticked 
would they consider to be their primary, secondary and tertiary diagnoses. Finally, 
they are asked the question, “If we were to speak to your clinical team or general 
practitioner, would they agree with that?” Their diagnosis is then confirmed with 
their clinical team where possible.   
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The total number of invitations sent between June and September 2017 was 3463. 
Participants from NCMH were recruited in three stages:  
1) An advertisement was put in the NCMH bi-annual newsletter calling for 
participants to contact the study team if they were interested in 
participating.  
2) Invitations were sent in batches of between 200 and 400 to consecutive 
NCMH participants who had provided an email address and consented to be 
re-contacted (N=2772). These participants were sent an invitation email that 
contained their unique study link (see Appendix K for emails to cases and 
controls). Participants who were interested in the study could click on this 
link to access the information page, consent form and the study.  
3) The remaining participants who had not provided an email address when 
they participated in the NCMH study were sent invitation letters (see 
Appendix K for full letter). These invitations were sent in batches of 200 to 
consecutive NCMH participants. Recruitment of these participants is 
ongoing but at the time of writing, letters had been sent to 691 participants. 
Letters were sent in groups according to the participant’s reported 
diagnosis.  
The first round of letters were sent to participants with schizophrenia and bipolar 
disorder, as these diagnoses were the focus of the final study described in Chapter 6. 
As has been previously described in the CoMPaSS recruitment section, participants 
were sent letters that contained a link to the study website and their unique 
username and password. They were given the option to go online and complete the 
study in their own time or contact the study team by telephone, email or by 
returning a reply slip. The reply slip had the same three options as those sent to the 
CoMPaSS sample: 1) would like to take part and has provided an email address, 2) 
does not have access to the internet but would like to hear about other ways to take 
part in the study, or 3) does not want to receive further contact about this study. 
Participants who selected option 1 were contacted via email and given further 
information and instructions on how to access the website. Participants who 
selected option 2 (would like to participate but no internet) were contacted to 
discuss other ways that they could participate in the study. These participants were 
given the option to attend the clinical assessment suite at Cardiff University and 
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provided with information about other potential locations, such as local libraries or 
charity centres. 
Diagnostic categories 
The NCMH cohort includes over 90 categories of mental health diagnoses. 
Therefore, participants were grouped into diagnostic categories for the purposes of 
reporting response rates. These groups were driven by current diagnostic criteria 
(DSM-V and ICD-10) but also depended on the number of participants in the 
cohort with that particular diagnosis. For example, NCMH has a special interest in 
recruiting participants with bipolar disorders, schizophrenia spectrum disorders and 
post-traumatic stress disorder, due to the research interests of the Division of 
Psychological Medicine and Clinical Neurosciences. Therefore, mood disorders 
were separated into unipolar and bipolar depression. Psychotic disorders were 
separated into schizophrenia-spectrum disorders (schizophrenia and schizoaffective 
disorder) and other psychotic disorders (delusional disorder, psychosis not 
otherwise specified). Participants with post-traumatic stress disorder were 
separated from participants with other anxiety disorders. A breakdown of the 
diagnostic categories and disorders can be found in Table 5-1.  
An “other disorder” category was included for participants who could not be 
grouped into any of the other diagnostic categories or had been recorded as “other” 
for the diagnosis variable. This category included:  
1) Diagnoses for which there were an insufficient number of participants to 
include a specific diagnostic category (total number of invited participants 
was less than 20), such as adult participants who had been diagnosed with 
behavioural or developmental disorders in childhood or adolescence, 
participants diagnosed with Alzheimer’s or other types of dementia, other 
neurological disorders with psychiatric symptoms, intellectual disability, 
alcohol misuse or dependence, mood disorder during pregnancy, tic 
disorder, or a psychotic episode with a specified organic cause.  
2) Participants who had been rated as having an “other psychiatric disorder”, 
“other mood disorder” or “other psychological illness” in the NCMH 
sample. These categories included participants who reported: 
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a. Subclinical symptoms of psychosis or mood disorder but had not 
been given a diagnosis by a health professional. 
b. A history of self-harm without a diagnosis. 
c. Bereavement or work stress requiring a period of leave from their 
occupation or referral to occupational health or counselling services. 
Table 5-1 Diagnostic categories 
Diagnostic Categories Diagnoses Included 
Unipolar mood disorders 
Single episode or recurrent major depressive 
disorder and depressive disorder not otherwise 
specified (NOS) 
Bipolar spectrum disorders 
Bipolar disorder type I, type II, manic or 
hypomanic episode, cyclothymia and bipolar 
NOS 
Schizophrenia spectrum disorders Schizophrenia and schizoaffective disorder 
Post traumatic stress disorder  
Anxiety disorders 
Panic disorder, agoraphobia, specific phobias, 
social phobias, generalised anxiety disorder, 
anxiety NOS 
Autism spectrum disorders Autism, Asperger’s syndrome 
Attention deficit hyperactivity disorder  
Personality disorders 
Borderline personality disorder and other 
personality disorders* 
Other psychotic disorders 
Delusional disorder, psychosis NOS, substance 
induced psychotic disorder 
Eating disorders 
Anorexia, bulimia, binge eating disorder and 
eating disorder NOS 
Obsessive compulsive disorder  
Other psychiatric disorders 
Behavioural or developmental disorders with 
onset in childhood or adolescence, Alzheimer’s 
or other types of dementia, Parkinson’s disease, 
intellectual disability, organic psychosis, 
alcohol misuse or dependence, mood disorder in 
pregnancy, tic disorder, other psychiatric 
disorder, other mood disorder, or other 
psychological illness. 
*Participants with personality disorders other than borderline personality disorder are included in a single 
category (“other personality disorder”) in NCMH and the type of personality disorder is not specified. 
211 
 
5.3.2 Measures 
Cognitive assessment 
All tasks from the validation study were included in the main study given that the 
battery as a whole was well tolerated by participants (see Chapter 4). This would 
also allow me to combine data from the validation and main studies in future 
analyses. However, it should be noted that Hartshorne Visual Working Memory 
was not correlated with the measure of visual learning from the MATRICS 
Consensus Cognitive Battery. Full details of the online cognitive battery can be 
found in Chapter 4. The battery comprises of 9 tasks that each assess a separate 
domain of cognition. The domains are speed of processing, verbal learning, 
working memory, visual learning, reasoning and problem solving, attention, social 
cognition, strategic risk taking and premorbid IQ. The tasks are shown in order of 
administration in Table 5-2. Participants clicked on a study-specific website link to 
access the tasks. Each task loads in the participant’s internet browser and the data is 
stored locally until the task ends then the data is encrypted and uploaded to a secure 
server. The battery takes 45-50 minutes to complete.
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Table 5-2 Descriptions of the tasks included in the online battery 
Domain Task Description Outcome Scoring 
Speed of 
Processing 
Digit Symbol 
Coding 
P uses the key to assign the 
correct numbers to a series 
of symbols. 
Number of correct 
responses in 90 seconds. 
Social 
Cognition 
Morphed Emotion 
Identification 
P decides whether a face 
looks angry, fearful, happy 
or disgusted. 
Number of correct 
responses out of 60 faces. 
Verbal 
Learning 
Verbal Paired 
Associates  
P must memorise word 
pairs and select the word 
that was shown with each 
target word. 
Number of correct 
responses out of 25 word 
pairs. 
Working 
Memory 
Backward Digit 
Span 
P recalls a sequence of 
numbers in reverse order.  
Maximum length of 
number sequence the 
participant was able to 
recall backwards.  
Visual 
Learning 
Hartshorne Visual 
Working Memory 
P decides whether an object 
is the same or different 
from the previous object in 
that location. 
Number of correct 
responses out of 42 trials. 
Reasoning 
and 
Problem 
Solving 
Matrix Reasoning 
Test 
P selects the image that best 
completes a pattern. 
Number of correct 
responses out of 35 
patterns. 
Strategic 
Risk 
Taking 
Balloon Analogue 
Risk Task 
P collects as many points as 
possible by blowing up 
balloons but no points are 
given if the balloon pops. 
Number of points 
collected by inflating 30 
balloons. Higher scores 
indicate more effective 
strategic risk-taking. 
Attention 
Multiple Object 
Tracking 
P follows multiple targets 
as they move amongst 
identical objects.  
Number of correct 
responses over 30 trials. 
Within a trial, each 
correctly identified target 
is 1 point.  
Premorbid 
IQ 
Vocabulary 
P selects which word is 
closest in meaning to the 
target word. 
Number of correct 
responses out of 20 words. 
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Scoring and imputation 
The outcome measure for each task can be found in Table 5-2. For each task, z 
scores were derived using the mean and standard deviation of the healthy controls. 
This included the controls recruited during the pilot and validation study (total N = 
67). Missing data was imputed using the method described in the manual of the 
MATRICS Consensus Cognitive Battery (MCCB) [338]. Full details of the 
imputation methods including formulas can be found in Appendix C. Imputed data 
was used solely to derive general cognitive performance scores (g). Imputed scores 
were not included in analyses of individual tasks given that the imputation 
algorithms rely on information from other tasks for that participant and so are not 
suitable for domain or task specific analyses. Data was imputed for participants that 
had completed at least 5 tasks of the battery, which is consistent with the approach 
used for MCCB data in Chapter 3, meaning that those with data for less than five 
tests were not included in the analysis calculating ‘g’. 
Demographic and clinical variables 
Participants completed an online questionnaire prior to completing the cognitive 
battery (see Appendix G for full questionnaire). This questionnaire included 
questions about current diagnosis, medication, medical history, substance use and 
current mood. Current symptoms of depression and anxiety were assessed using the 
Hospital Anxiety and Depression Scale (HADS) [379]. Current symptoms of mania 
and hypomania were assessed using the Altman Mania Scale (AMS) [383]. Current 
psychotic and negative symptoms were not assessed due to the lack of reliable, 
valid self-report questionnaires. Following the pilot and validation study, two 
further questionnaires were added to assess level of disability, education and 
occupation. These two questionnaires are described in detail in the following 
sections. Data collected as part of the original parent studies were combined with 
the online data from the current study to evaluate further clinical variables, 
including lifetime diagnosis, age of onset and history of hospital admissions. 
WHODAS 2.0 
The 12-item self-report version of the World Health Organisation Disability 
Assessment Schedule Version 2 (WHODAS 2.0) was included as a measure of 
functional outcome [415]. The WHODAS 2.0 asks participants to rate how much 
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difficulty they have had in the last 30 days completing everyday tasks. It covers six 
domains of functioning: cognition (understanding and communicating), mobility, 
self-care, social interactions, life activities (domestic responsibilities, leisure and 
work) and participation in the community. Items were rated on a difficulty scale 
from none, mild, moderate, severe to extreme / cannot do and each item is allocated 
a score of 0-4 based on these respective ratings. The maximum score on the 12-
item questionnaire is 48 and higher scores indicate more severe disability. 
Participants were asked to record the number of days the difficulties were present 
in the last 30 days. They were also asked how many days they were either “totally 
unable” to carry out their activities or had to “cut back or reduce” their activities 
because of their illness. The primary outcome measure was total score on the 12 
items (maximum score of 48).  
Education and occupation 
Highest educational attainment was separated into seven categories based on 
educational qualifications in the United Kingdom: 1) 11+ examinations; 2) CSE or 
equivalent; 3) GCSE or equivalent; 4) A-level or equivalent; 5) degree and 6) post-
graduate degree. Occupations were categorised based on the Office for National 
Statistics’ classifications [416] into the following groups: 1) managers and senior 
officials; 2) professional occupations; 3) associate professional and technical 
occupations; 4) administrative and secretarial occupations; 5) skilled trade 
occupations; 6) personal, sales and customer service occupations; 7) process, plant 
and machinery operatives and 8) elementary occupations. Participants who were 
currently employed were asked to indicate if they were working full-time or part-
time. Participants who were not working were classified as: 1) unemployed; 2) not 
working due to sickness and 3) voluntary work.  
Data from parent studies 
Data on lifetime diagnosis, age of onset and history of hospital admissions were 
obtained from the parent studies, CoMPaSS and NCMH. The methods for 
determining lifetime diagnoses have been described in the “Sample” section of this 
chapter. In CoMPaSS, age of onset was defined as the age at which the 
participant’s symptoms caused impairment in their life. Impairment was defined as: 
1) disruption in work or social life more or less completely, 2) fights or other 
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violence, 3) job loss or unable to work, 4) police involvement, 5) family separation, 
6) hospital admission or 7) receiving specific treatment. This was rated according 
to participants’ responses to the SCAN interview and review of clinical records. In 
NCMH, participants were asked to report the age at which they first developed 
mental health problems and the age at which these problems caused impairment in 
their life. Age of first impairment was taken as the main measure of age of onset. 
Finally, participants were categorised according to whether they had ever been 
admitted to a psychiatric unit (yes/no) based on data from CoMPaSS (number of 
admissions) and NCMH (ever admitted to hospital). 
5.3.3 Statistical analysis 
All statistical analyses were performed using R version 3.3.0. 
Analysis 1: Response rates 
Response rates were calculated as the number of participants who completed the 
study (or at least parts of the study) as a percentage of the total number of 
participants who were invited. This was further broken down by recruitment 
strategy to allow specific response rates to be calculated for each parent study and 
split into email and letter invitations. Response rates were also broken down by 
diagnostic groups to determine whether participants with certain diagnoses were 
more likely to take part in the study. 
Analysis 2: Demographic and clinical characteristics 
Summary statistics or proportions were generated to examine the demographic and 
clinical characteristics of the internet sample. The variables examined were age, 
gender, education level, current occupation and currently taking psychiatric 
medication. In the NCMH cohort, the demographic and clinical characteristics of 
the participants (N=317) were compared to invited individuals who did not 
participate in the study (N=3145).  
Proportions (gender, occupation, ever admitted to hospital, diagnosis and 
recruitment method into NCMH) were analysed using chi-square tests. Chi-square 
was used to examine the proportion of participants who: 1) had a degree and 2) did 
not have any qualifications. For contingency tables larger than 2x2, standardised 
residuals were calculated for each cell to determine the strength of the differences 
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between observed and expected values. Standardised residuals have an 
approximate normal distribution (mean of 0 and standard deviation of 1) and so can 
be used to identify cells that contribute to a significant chi-square statistic [417, 
418]. Standardised residuals are calculated using the formula: 
𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑𝑖𝑠𝑒𝑑 𝑅𝑒𝑠𝑖𝑑𝑢𝑎𝑙 =  
(𝑂𝑏𝑠𝑒𝑟𝑣𝑒𝑑 𝑐𝑒𝑙𝑙 𝑐𝑜𝑢𝑛𝑡 − 𝐸𝑥𝑝𝑒𝑐𝑡𝑒𝑑 𝑣𝑎𝑙𝑢𝑒)
√𝐸𝑥𝑝𝑒𝑐𝑡𝑒𝑑 𝑣𝑎𝑙𝑢𝑒
 
 
Given that standardised residuals have an approximate normal distribution, they 
can be interpreted in the same way as z-scores, such that a standardised residual of 
±2 indicates that the cell’s observed frequency is significantly less than or greater 
than expected at p<0.05. A more conservative cut-off was selected for the 
standardised residuals of ±3 to adjust for multiple comparisons. Thus, cells with a 
standardised residual of greater than 3 or less than -3 were considered significant.  
For continuous variables, normal distribution was determined through visual 
inspection of histograms and an F test was used to compare the variances between 
the two groups. Age was normally distributed and the variance was homogeneous 
between groups so a t-test was conducted to compare the groups. Non-normally 
distributed and ordinal variables (age of onset and education) were analysed using 
the Wilcoxon rank sum test.  
Logistic regression was conducted to determine the association between 
demographic and clinical variables and participation in the study. The outcome 
measure was participation in the study, a binary variable coded as “yes” or “no”. 
The predictor variables were diagnosis, recruitment method into NCMH, age of 
onset, highest educational attainment and lifetime occupation. Variance inflation 
factors were calculated to identify collinearity between the predictors.  
Analysis 3: Completion rates 
Completion rates were calculated for each individual task. Completion rates were 
also calculated for each diagnostic group. Participants were grouped into three 
categories based on the number of tasks they had completed: full data (9 tasks, 
N=224), partial data (1-8 tasks, N=82) or no data (0 tasks, N=36). These three 
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groups were compared on the following variables: age, gender, HADS depression 
score, HADS anxiety score, highest educational attainment, diagnosis and 
WHODAS disability scores. 
Proportions (gender and diagnosis) were analysed using chi square tests. 
Standardised residuals were calculated for each cell to determine the strength of the 
differences between observed and expected values [417, 418]. Standardised 
residuals have an approximate normal distribution (mean of 0 and standard 
deviation of 1) and so can be used to identify cells that contribute to a significant 
chi-square statistic. A critical value of ±3 was selected to adjust for multiple 
comparisons (see above for full details and formula). For the diagnosis variable, 20 
out of 39 cells had expected counts under 5 thus violating an assumption of chi-
square tests. Therefore, Fisher’s exact test was performed in R to produce a 
simulated p-value [419, 420]. As this method does not produce a chi-square 
statistic, data was resampled using the Monte-Carlo method and an approximate 
chi-square statistic and corresponding p-value were calculated [421]. 
For continuous variables, normal distribution was determined through visual 
inspection of histograms and Levene’s test was used to compare the variances 
between the groups. Age was normally distributed and the variance was 
homogeneous between groups so analysis of variance was conducted to compare 
the groups. Non-normally distributed and ordinal variables (HADS depression 
scores, HADS anxiety scores, highest educational attainment and WHODAS 
disability scores) were compared between the three groups using Kruskal-Wallis 
tests.  
Analysis 4: Factor analysis 
The structure of the online cognitive battery was examined by conducting 
correlations between all the tasks. These analyses were followed up with 
exploratory factor analysis. The number of factors was identified using scree plots 
and parallel analysis. Principal axis factoring with oblique rotation (direct oblimin) 
was conducted to identify the factors. These analyses were conducted using all 
available data collected online to ensure a sufficient sample size and included data 
collected as part of the validation study (see Chapter 4, total N=382). The analyses 
were first conducted on all participants with complete data (N=292). Missing data 
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were then imputed using the methods described in the “Scoring and imputation” 
section above, and the analyses were repeated (N=321). 
The correlations between each online task and measures of ‘g’ taken from scores 
on the online battery were examined. Measures of ‘g’ were derived for participants 
who had completed at least 5 tasks (N=321). Principal components analysis (PCA) 
was conducted including all the online tasks except for the task of interest. For 
example, in the correlation between ‘g’ and Digit Symbol Coding, ‘g’ was derived 
by conducting a PCA including all the tasks except Digit Symbol Coding. The first 
principal component score for each participant was taken as a measure of ‘g’. PCA 
was conducted on complete data and then repeated including the participants with 
imputed scores. Classical multidimensional scaling (MDS) was conducted on a 
Euclidean distance matrix to derive a third measure of ‘g’. MDS is an analogous 
approach to PCA but an advantage to this approach is that it can accommodate 
missing data [422, 423]. The ‘g’ derived using MDS was highly correlated with the 
‘g’ derived using complete data (r=0.997) and the ‘g’ derived including imputed 
data (r=0.987). Correlations were conducted between each task and the three 
measures of ‘g’. Pearson’s correlations were used when task performance was 
normally distributed, whilst Spearman’s correlations were used for tasks that were 
not normally distributed.  
5.4 Results 
5.4.1 Analysis 1: Response rates 
The response rates for each recruitment strategy are shown in Table 5-3. The initial 
advertisement in the NCMH newsletter resulted in 18 participants completing the 
study. Between June and September 2017, invitations (emails or letters) were then 
sent to 3463 individuals who had taken part in NCMH. Participation rates were 
higher for email invitations than letter invitations (10% and 5% respectively). 
Letters were sent to 127 individuals from CoMPaSS. The response rate was lower 
from these participants than NCMH participants (4%) although of note the 
CoMPaSS sample were recruited up to 10 years ago in comparison to 5 years for 
NCMH. Forty-one individuals responded to express an interest in the study but did 
not have access to the internet. The majority of these individuals lived in areas 
outside of Cardiff (N=32) so were unable to travel to participate in a clinical testing 
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room within the Division of Psychological Medicine and Clinical Neurosciences at 
Cardiff University and did not take part in the study. The remaining nine 
participants were located within the city of Cardiff. Of these nine individuals, one 
participated in the study by accessing the internet using facilities at a local 
community centre and the remaining eight individuals did not take part because 
they did not wish to travel (N=2), wanted to be re-contacted at a later date (N=1), 
could not be contacted due to an incorrect telephone number (N=1) or did not 
respond to attempts to contact them (N=4).  
In total, 324 participants consented to the study from invitations. Therefore, the 
total number of participants was 342 once the 18 participants who responded to the 
newsletter advertisement are included. The sample included 297 participants with a 
mental health diagnosis and 45 healthy controls. 
 
Table 5-3 Response rates broken down by recruitment strategy 
Recruitment 
Method 
Number of 
invitations 
sent 
Number 
of 
refusals 
Number of 
interested 
participants 
without 
internet1 
Number of 
participants 
consented 
Response 
rate 
NCMH 
Emails 
2772 3 N/A 288 10% 
NCMH 
Letters 
691 43 40 31 5% 
CoMPaSS 
Letters 
127 5 1 5 4% 
Total 3590 51 41 324 9% 
1Of these individuals, one participant was consented into the study 
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The response rates were broken down by diagnostic categories for participants 
recruited from the NCMH sample, as these participants have a variety of 
psychiatric diagnoses (see Table 5-4). Diagnoses were ascertained from 
participants’ responses to the question, “Has a doctor or health professional ever 
told you that you have any of the following diagnoses?” Participants were given a 
list of diagnoses and asked to indicate all diagnoses that apply. They were then 
asked to indicate which of the diagnoses they have ticked would they consider to 
be their primary, secondary and tertiary diagnoses and whether their doctor would 
agree with this. Only primary diagnoses are included in this analysis. Of the 3463 
participants who were sent invitations, 3457 either reported that they had been 
given a diagnosis by a health professional or were healthy controls. The diagnoses 
of the remaining six participants were listed as “unknown”. The highest response 
rates were observed for participants with obsessive-compulsive disorder, although 
only a small number of participants with this disorder were invited. Other groups 
with high response rates included the healthy controls and participants with anxiety 
disorders, personality disorders and eating disorders. Participants with 
schizophrenia, other psychotic disorders and post traumatic stress disorder had the 
lowest response rates.
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Table 5-4 Response rates for participants sent invitation emails or letters from NCMH 
Diagnosis 
Number of 
invitations 
sent 
Number of 
participants 
consented 
Response rate 
Healthy controls 250 44 17.6% 
Unipolar mood disorders1 1031 94 9.1% 
Bipolar spectrum disorders2 861 85 9.9% 
Schizophrenia spectrum 
disorders3 
355 15 4.2% 
Post traumatic stress disorder 321 18 5.6% 
Anxiety disorders4 179 20 11.2% 
Autism spectrum disorders5 96 10 10.4% 
Attention deficit hyperactivity 
disorder 
77 7 9.1% 
Personality disorders6 67 9 13.4% 
Other psychotic disorders7 52 1 1.9% 
Eating disorders8 40 5 12.5% 
Obsessive compulsive disorder 22 5 22.7% 
Other psychiatric disorders9 106 6 5.7% 
Total 3457 319 9.2% 
1Single episode or recurrent major depressive disorder and depressive disorder not otherwise specified (NOS); 
2Bipolar disorder type I, type II, manic or hypomanic episode, cyclothymia and bipolar NOS; 3Schizophrenia 
and schizoaffective disorder; 4Panic disorder, agoraphobia, specific phobias, social phobias, generalised 
anxiety disorder, anxiety NOS; 5Autism, Asperger’s syndrome; 6Borderline personality disorder and other 
personality disorders; 7Delusional disorder, psychosis NOS, substance induced psychotic disorder; 8Anorexia, 
bulimia, binge eating disorder and eating disorder NOS; 9This category included invited participants rated as 
having a behavioural or developmental disorders with onset in childhood or adolescence (N=18), Alzheimer’s 
or other types of dementia (N=17), Parkinson’s disease (N=1), intellectual disability (N=4), organic psychosis 
(N=2), other psychiatric disorder (N=39), other mood disorder (N=6), other psychological illness (N=7), 
alcohol misuse or dependence (N=6), mood disorder in pregnancy (N=1), post natal depression (N=3) or tic 
disorder (N=2). 
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The NCMH has been recruiting participants since 2012 so response rates were 
further broken down by year of participation (see Figure 5-1). Response rates were 
higher for participants who had taken part in NCMH in the last two years (2016: 
10.7%; 2017: 11.4%). 
 
 
Figure 5-1 Response rate by year of participation in NCMH 
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5.4.2 Analysis 2: Demographic and clinical characteristics 
The demographic and clinical characteristics of the cases and controls are shown in 
Table 5-5. The age range of the internet sample was 18 to 83 years old 
(mean=46.95, standard deviation=14.77). Most participants were female (64%). 
The percentage of participants that were educated to at least degree level was 41%. 
Almost half of the participants (43%) were in paid employment at the time of 
assessment. Current occupations were varied with the largest proportion of 
employed participants working in professional roles (18%). Of those in 
employment (N=162), 65% worked full time. The remaining participants were 
mainly retired (17%) or not working due to sickness or disablement (18%). 
Table 5-5 Characteristics of the internet sample 
Demographic and Clinical Characteristics Cases Controls 
N 297 45 
Age 46.4 (14.1) 50.6 (18.4) 
Number of females (% Female) 191 (64.3) 29 (64.4) 
Number of participants currently taking psychiatric 
medication (%) 
232 (78.1) N/A 
Highest qualification   
None 11 0 
11+ 1 0 
CSE or equivalent 13 0 
GCSE or equivalent 43 1 
A-level or equivalent 89 9 
Degree 72 17 
Postgraduate degree 36 14 
Other 13 2 
Current occupation   
Senior official 5 1 
Professional 42 18 
Technical 18 2 
Administration 18 4 
Service work 19 1 
Trade work 5 2 
Factory or plant work 1 0 
Elementary occupation 2 0 
Not working due to sickness 56 1 
Full-time student 23 3 
Homemaker 15 0 
Unemployed 17 1 
Voluntary work 15 0 
Retired 43 10 
N/A: not applicable 
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Given the majority of those who participated originated from the NCMH cohort, 
NCMH participants were chosen to examine whether those that participated 
differed from non-responders. These analyses were conducted amongst cases only 
and then repeated in the sample of healthy controls.  
Cases 
The demographic and clinical characteristics of the NCMH participants (N=275) 
were compared to invited individuals from the NCMH cohort who did not 
participate in the study (N=2936, see Table 5-6). Participants who consented to the 
study did not differ from non-participants in age (t(3205)=-0.24, p=0.81) or gender 
(χ2(1)=1.59, p=0.21). There were differences in the proportion of diagnoses 
between the two groups (χ2(11)=28.9, p=0.002). Examination of the standardised 
residuals indicated the participant group had fewer participants with schizophrenia 
spectrum disorders (standardised residual = -3.1) than would be expected. The 
groups differed on lifetime occupation (χ2(8)=29.9, p=2.2 x 10-4). In the participant 
group, there were more participants who had worked in a professional occupation 
than would be expected (standardised residual = 4.3). There was a significant 
difference in highest educational attainment between the participant and non-
participant groups (Wilcoxon (3351)= 4413331, Z=-3.8, p=1.5 x 10-4). A higher 
proportion of the participant group had a degree (42%) compared to the non-
participant group (34%, χ2(1)=6.72, p=0.01). A lower proportion of the participant 
group did not have any qualifications (4%) compared to the non-participant group 
(10%, χ2(1)=7.77, p=0.005). Methods of recruitment into the original NCMH study 
were compared and indicated differences between the two groups (χ2(9)=35.21, 
p=5.5 x 10-5). A higher proportion of the participant group had been recruited 
through the media (standardised residual = 3.62) and referrals from other research 
studies (standardised residual = 3.05) and fewer participants had been recruited 
from secondary and specialist psychiatric services (standardised residual = -3.98) 
than the non-participant group. There were no differences in the proportion of 
participants who had ever been admitted to hospital between the groups (36%, 
χ2(1)=1.24, p=0.27). Participants had a younger age of onset than non-participants, 
which was marginally significant (Wilcoxon (3010)=363081, Z=-2.21, p=0.03).  
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Diagnosis, method of NCMH recruitment, highest educational attainment, lifetime 
occupation and age of onset were entered as predictors in a logistic regression with 
participation as the outcome measure. In this model, diagnosis, age of onset, 
educational levels and occupations were not associated with participation. 
Participants who had been recruited into NCMH through secondary or specialist 
psychiatric services were less likely to participate than participants recruited 
through media advertisements (OR=0.62, 95% CIs: 0.43-0.88, p=0.008).  
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Table 5-6 Demographic and clinical characteristics of participants and non-participants from NCMH 
Demographic and Clinical Characteristics Participants Non-participants 
N 275 2936 
Age 46.9 (14.3) 46.6 (14.2) 
Number of females (%) 178 (64.7) 1789 (60.9) 
Highest qualification   
None 12 282 
11+ 1 29 
CSE or equivalent 3 97 
GCSE or equivalent 46 582 
A-level or equivalent 94 901 
Degree 79 652 
Postgraduate degree 30 251 
Lifetime occupation   
Senior official 15 182 
Professional 87 602 
Technical 53 476 
Administration 34 408 
Service work 57 789 
Trade work 10 144 
Factory or plant work 2 72 
Elementary occupation 5 56 
Never worked due to sickness1 0 28 
Never worked1 1 25 
Voluntary work1 0  28 
Diagnoses   
Unipolar mood disorders2 94 937 
Bipolar spectrum disorders3 85 776 
Schizophrenia spectrum disorders4 15 340 
Post traumatic stress disorder 18 303 
Anxiety disorders5 20 159 
Autism spectrum disorders6 10 86 
Attention deficit hyperactivity disorder 7 70 
Personality disorders7 9 58 
Other psychotic disorders8 1 51 
Eating disorders9 5 35 
Obsessive compulsive disorder 5 17 
Other psychiatric disorders10 6 100 
Number of participants with ≥1 admission (%) 90 (32.7) 1055 (35.9) 
Age of Onset11 16 (14) 18 (15) 
Numbers indicate mean and standard deviation for continuous data, counts are shown for highest qualification 
(ordinal data) proportion data. 1These groups were combined into a “Never worked” group for analyses; 2Single 
episode or recurrent major depressive disorder and depressive disorder NOS; 3Bipolar disorder type I, type II, 
manic or hypomanic episode, cyclothymia and bipolar NOS; 4Schizophrenia and schizoaffective disorder; 
5Panic disorder, agoraphobia, specific phobias, social phobias, generalised anxiety disorder, anxiety NOS; 
6Autism, Asperger’s syndrome; 7Borderline personality disorder and other personality disorders; 8Delusional 
disorder, psychosis NOS, substance induced psychotic disorder; 9Anorexia, bulimia, binge eating disorder and 
eating disorder NOS; 10Full details of this category can be found in the “Diagnostic categories” on page 209; 
11Median and interquartile range shown due to non-normal distribution 
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Controls 
The demographic and clinical characteristics of the healthy control participants 
from NCMH (N=44) were compared to invited healthy controls from the NCMH 
cohort who did not participate in the study (N=206, see Table 5-7). Participants 
who consented to the study did not differ from non-participants in gender 
(χ2(1)=1.3 x 10-30, p=1) or lifetime occupation (χ2(8)=6.93, p=0.53). The groups 
differed in age (t(248)=-2.64, p=0.009), as the mean age of the participant group 
was older than the non-participant group. There was a significant difference in 
highest educational attainment between the participant and non-participant groups 
(W(3351)=20305, Z=-2.49 p=0.01). A higher proportion of the participant group 
had a degree (71%) compared to the non-participant group (50%, χ2(1)=5, p=0.03).  
 
Table 5-7 Demographic and clinical characteristics of participants and non-participants from NCMH 
(healthy controls) 
Demographic and Clinical Characteristics Participants Non-participants 
N 44 206 
Age 50.9 (18.3) 43.5 (16.4) 
Number of females (%) 29 (65.9) 138 (67) 
Highest qualification   
None 0 3 
11+ 0 1 
CSE or equivalent 1 3 
GCSE or equivalent 1 18 
A-level or equivalent 10 68 
Degree 20 68 
Postgraduate degree 8 22 
Lifetime occupation   
Senior official 7 17 
Professional 14 55 
Technical 7 33 
Administration 7 23 
Service work 5 46 
Trade work 0 2 
Factory or plant work 0 1 
Elementary occupation 0 3 
Never worked due to sickness1 0 0 
Never worked1 0 1 
Voluntary work1 0 1 
Numbers indicate mean and standard deviation for continuous data, counts are shown for highest qualification 
(ordinal data) and proportion data. 1These groups were combined into a “Never worked” group for analyses. 
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5.4.3 Analysis 3: Completion rates 
In total, 342 participants were consented into the study and completed the first 
stage (questionnaire). Of these participants, 306 completed at least 1 cognitive task. 
Of the 306 participants who completed any cognitive tasks, 35 participants 
completed the tasks over at least two separate days. Completion rates for each task 
can be found in Table 5-8. Overall, complete data was available for 224 
participants (65.5%), partial data was available for 82 participants (24%) and 36 
participants did not complete any tasks (10.5%). Figure 5-2 shows the completion 
rates for each task in order of administration, including the learning phase of the 
Verbal Paired Associates task. The largest loss of participants is between the Digit 
Symbol Coding and the learning phase of the Verbal Paired Associates where 21 
participants discontinued. The second largest drop off point was between the 
Balloon Analogue Risk Task and Multiple Object Tracking where 15 participants 
discontinued. 
 
Table 5-8 Completion rates for the cognitive tasks 
Task 
Number of 
Participants 
Percentage of Missing 
Data 
Digit Symbol Coding 302 12 
Morphed Emotion Identification Task 271 21 
Verbal Paired Associates Task 265 23 
Backward Digit Span 257 25 
Hartshorne Visual Working Memory 248 28 
Matrix Reasoning Test 244 29 
Balloon Analogue Risk Task 244 29 
Multiple Object Tracking 229 33 
Vocabulary 234 32 
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Figure 5-2 Completion rates for each task in order of administration  
Verbal Paired Associates – Learn and Verbal Paired Associates – Test refer to the learning and test phases of the Verbal Paired Associates task respectively 
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Table 5-9 displays completion rates broken down according to diagnostic 
categories. The diagnostic groups did not differ on proportions of participants with 
complete, partial or no data (χ2(24)=26.04, p=0.36; Fisher’s exact test: p=0.49).  
 
Table 5-9 Completion rates by diagnostic group 
Diagnosis N 
Complete Data 
Available (%) 
Partial Data 
Available 
(%) 
No Data 
Available 
(%) 
Healthy controls 45 28 (62.2) 10 (22.2) 7 (15.6) 
Unipolar mood disorders1 100 67 (67) 24 (24) 9 (9) 
Bipolar spectrum disorders2 87 54 (62.1) 28 (32.2) 5 (5.7) 
Anxiety disorders3 20 13 (65) 4 (20) 3 (15) 
Post traumatic stress disorder 20 12 (60) 4 (20) 4 (20) 
Schizophrenia spectrum 
disorders4 
24 18 (75) 3 (12.5) 3 (12.5) 
Autism spectrum disorders5 10 6 (60) 4 (40) 0 (0) 
Personality disorders6 10 8 (80) 1 (10) 1 (10) 
Other psychiatric disorders7 6 6 (100) 0 (0) 0 (0) 
Attention deficit 
hyperactivity disorder 
7 4 (57.1) 2 (28.6) 1 (14.3) 
Eating disorders8 6 4 (66.7) 1 (16.7) 1 (16.7) 
Obsessive compulsive 
disorder 
6 4 (66.7) 1 (16.7) 1 (16.7) 
Other psychotic disorders9 1 0 (0) 0 (0) 1 (100) 
Total 342 224 (65.5) 82 (24.0) 36 (10.5) 
1Single episode or recurrent major depressive disorder and depressive disorder NOS; 2Bipolar disorder type I, 
type II, manic or hypomanic episode, cyclothymia and bipolar not otherwise specified (NOS); 3Panic disorder, 
agoraphobia, specific phobias, social phobias, generalised anxiety disorder, anxiety NOS; 4Schizophrenia and 
schizoaffective disorder; 5Autism, Asperger’s syndrome; 6Borderline personality disorder and other personality 
disorders; 7Participants were rated as having an “other psychiatric disorder” (N=3), “other mood disorder” 
(N=1), postnatal depression (N=1) and Alzheimer’s disease (N=1). More details on this category can be found 
in “Diagnostic categories” on page 209; 8Anorexia, bulimia, binge eating disorder and eating disorder NOS; 
9Delusional disorder, psychosis NOS, substance induced psychotic disorder   
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Participants were grouped into three categories based on the number of tasks they 
had completed: full data (9 tasks, N=224), partial data (1-8 tasks, N=82) or no data 
(0 tasks, N=36). The three groups did not differ on age (F(2,339)=0.93, p=0.4), 
HADS depression score (H(2)=1.86, p=0.4), HADS anxiety score (H(2)=0.72, 
p=0.7), highest educational attainment (H(2)=1.8, p=0.41) or WHODAS disability 
scores (H(2)=1.73, p=0.42). However, there was a significant effect of gender 
(χ2(2)=6.32, p=0.04), as fewer males and more females had full data than would be 
expected. 
Technical difficulties 
All participants who did not complete the full battery were contacted via email and 
asked if they had experienced technical difficulties. Eleven participants reported 
technical difficulties with completing the cognitive tasks. Four participants 
reported the same issue so eight technical issues were reported in total. The issues 
reported are shown in Table 5-10. Three of the eight technical issues were resolved 
at the time of writing. One of the issues reported was due to the participants 
responding using the mouse instead of the keyboard. Another issue was resolved by 
adjusting the cookie settings on the participant’s browser and another was resolved 
after the participant reloaded the tasks and tried using different keys on their 
keyboard. Three of the eleven participants were using touchscreen devices. Of the 
participants who reported technical difficulties, eight participants went on to 
complete all the tasks, two participants completed additional tasks and one 
participant did not complete any more tasks.  
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Table 5-10 Technical difficulties reported by participants 
Problem 
Reported 
Resolved or 
Ongoing? 
Number of 
Participants 
Touchscreen 
Device? 
Solution 
Participant was 
being redirected to 
the main 
“testmybrain.org” 
domain. 
Resolved 1 No The cookie settings 
on the participant’s 
browser needed to 
be turned on. 
Tasks were not 
responding to 
touchscreen 
presses on 
Samsung Galaxy 
phone. 
Ongoing 1 Yes Unable to obtain 
further information 
from participant. 
Digit Symbol 
Coding was not 
responding to 
mouse. 
Resolved 1 No Participants needed 
to use the keyboard 
rather than the 
mouse. 
Address bar on 
browser was 
partially 
obstructing the 
view of the tasks. 
Ongoing 1 Yes Developers unable 
to locate the issue 
and may have been 
a specific setting on 
the participant’s 
phone. 
Tasks were not 
responding to 
participant’s 
keyboard 
Resolved 1 No Participant was 
using the number 
pad so reloaded and 
used the other 
number keys, which 
worked.  
Touchscreen 
responses would 
not register on 
multiple object 
tracking. 
Ongoing 1 Yes  
Digit symbol 
coding was not 
responding to 
keyboard. 
Ongoing 4 No  
Verbal Paired 
Associates task 
would not load. 
Ongoing 1 No Unable to obtain 
further information 
from participant. 
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5.4.4 Analysis 4: Factor structure of the online battery 
Complete data was available on 292 participants, including 224 participants from 
the main study and 68 participants from the pilot and validation phases. Figure 5-3 
shows the correlations between all the online tasks. Scores on the tasks were 
correlated with one another. All but 4 of the 36 correlations were significant at the 
P<0.05 level and 29 of the correlations were significant at the Bonferroni-corrected 
p-value of 0.00139. The lowest correlations were observed between the vocabulary 
task and all other tasks (r=-0.05-0.24). Given these low correlations, the factor 
analysis was repeated without the vocabulary task based on the recommendation of 
Yong et al. [414].  
 
Figure 5-3 Correlations between online tasks  
Vocab - Vocabulary; BART - Balloon Analogue Risk Task; VPAL - Verbal Paired Associates Task; Backward 
DS - Backward Digit Span; Matrix – Matrix Reasoning Test; MOT – Multiple Object Tracking Test; Emotion 
ID – Morphed Emotion Identification Task; Digit Symbol – Digit Symbol Coding; Hartshorne – Hartshorne 
Visual Working Memory. *p<0.05; **p<0.01; ***Bonferroni-corrected p-value of 0.00139 (0.05/36 
comparisons).  
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When vocabulary was included, examination of the scree plot and parallel analysis 
indicated 2 factors with eigenvalues above 1. The factor loadings are shown in 
Table 5-11. All the measures except Vocabulary and Balloon Analogue Risk Task 
loaded onto the first factor. Only Vocabulary had a high loading on the second 
factor. The analysis was repeated excluding Vocabulary given the fact this task had 
low correlations with the other tasks (all r<0.25). Examination of the scree plot and 
parallel analysis indicated 1 factor with an eigenvalue above 1. However, the 
second factor had an eigenvalue of 0.95 so principal axis factoring was conducted 
specifying two factors. The factor loadings are shown in Table 5-11. The Multiple 
Object Tracking task, Digit Symbol Coding and the Hartshorne Visual Working 
Memory Test loaded onto the first factor. The Matrix Reasoning Test and Balloon 
Analogue Risk Task loaded onto the second factor. The results of the factor 
analysis were similar when imputed data was included (see Table 5-11). The 
correlations between vocabulary and the other tasks were higher in the dataset with 
imputed missing values (r ranged between 0.15 and 0.36). When vocabulary was 
excluded, examination of the scree plot and parallel analysis indicated 1 factor with 
an eigenvalue above 1.  
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Table 5-11 Factor loadings of the online tasks 
 With Vocabulary Without Vocabulary Imputed Data 
 Factor 1 Factor 2 Factor 1 Factor 2 Factor 1 Factor 2 
Multiple Object Tracking 0.72 0.04 0.69 0.07 0.73 0.03 
Vocabulary -0.03 0.74   -0.03 0.68 
Digit Symbol Coding 0.80 -0.10 0.70 0.10 0.81 -0.07 
Morphed Emotion Identification 0.60 0.00 0.39 0.25 0.60 0.03 
Hartshorne Visual Working 
Memory 
0.67 -0.15 0.75 -0.11 0.70 -0.16 
Matrix Reasoning Test 0.61 0.23 0.13 0.63 0.58 0.27 
Backward Digit Span 0.45 0.22 0.27 0.27 0.44 0.20 
Verbal Paired Associates 0.41 0.20 0.20 0.29 0.40 0.21 
Balloon Analogue Risk Task 0.25 0.30 -0.14 0.52 0.23 0.34 
Proportion of variance explained 0.77 0.23 0.65 0.35 0.78 0.22 
Loadings >0.4 are shown in bold. PCA: Principal Components Analysis. 
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Correlations between online tasks and ‘g’ 
In a final analysis, the correlations between each task and measures of ‘g’ derived 
from the online battery (excluding the relevant task) were examined. In the 
complete sample, eight out of nine tasks were correlated with ‘g’ at the Bonferroni-
corrected alpha level of 0.00556 (r ranged from 0.42 to 0.65). These tasks included 
Digit Symbol Coding (r=0.65, 95% CIs: 0.59-0.71), Verbal Paired Associates 
(r=0.42, 95% CIs: 0.31-0.52), Morphed Emotion Identification (r=0.53, 95% CIs: 
0.44-0.61), Backward Digit Span (r=0.46, 95% CIs: 0.37-0.55), Hartshorne Visual 
Working Memory (r=0.53, 95% CIs: 0.46-0.61), Matrix Reasoning Test (r=0.58, 
95% CIs: 0.50-0.66), Multiple Object Tracking (r=0.64, 95% CIs: 0.58-0.70) and 
the Balloon Analogue Risk Task (r=0.25, 95% CIs: 0.13-0.35). The results were 
equivalent when ‘g’ was derived using imputed data and MDS (see Table 5-12).
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Table 5-12 Correlations between each task and a measure of ‘g’ derived from the online battery 
Online Task 
PCA – Complete Data PCA – Including Imputed Values Multidimensional Scaling 
r 95% CIs p r 95% CIs p r 95% CIs p 
Digit Symbol Coding 0.65 0.59-0.71 8.7 x 10-37 0.67 0.60-0.73 3.6 x 10-42 0.66 0.60-0.72 2.9 x 10-41 
Verbal Paired 
Associates* 
0.42 0.31-0.52 5.2 x 10-14 0.43 0.33-0.52 1.1 x 10-15 0.42 0.33-0.52 5.2 x 10-15 
Morphed Emotion 
Identification 
0.53 0.44-0.61 2.7 x 10-22 0.54 0.46-0.61 1.3 x 10-25 0.54 0.45-0.62 7.6 x 10-26 
Backward Digit Span 0.46 0.37-0.55 1.5 x 10-16 0.47 0.39-0.54 1.2 x 10-18 0.47 0.38-0.54 1.6 x 10-18 
Hartshorne Visual 
Working Memory 
0.53 0.46-0.61 1.8 x 10-22 0.54 0.46-0.61 2.3 x 10-25 0.55 0.48-0.61 3.5 x 10-26 
Matrix Reasoning Test* 0.58 0.50-0.66 5.5 x 10-28 0.59 0.50-0.66 9.4 x 10-31 0.59 0.50-0.66 2.1 x 10-30 
Balloon Analogue Risk 
Task* 
0.25 0.13-0.35 1.7 x 10-5 0.24 0.12-0.34 2.2 x 10-5 0.24 0.14-0.33 2.5 x 10-5 
Multiple Object 
Tracking 
0.64 0.58-0.70 4.9 x 10-35 0.64 0.58-0.70 3.1 x 10-36 0.64 0.58-0.70 4.3 x 10-36 
Vocabulary* 0.14 0.02-0.26 0.02 0.15 0.03-0.26 0.009 0.15 0.03-0.26 0.007 
*Spearman’s rank correlation rho shown instead due to non-normal distribution for these tests. 
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5.5 Discussion 
In this chapter, participants from two studies within the MRC Centre for 
Neuropsychiatric Genetics and Genomics were invited to complete the online 
cognitive battery. The aims of this chapter were to evaluate whether online 
cognitive testing is a suitable method for mental health research and to examine the 
structure of the cognitive battery. Participants with a broad range of psychiatric 
disorders were invited to take part. The results of the four analyses indicated: 
1 Response rates were 2-23% across the diagnostic groups. The lowest 
response rates were observed for participants with schizophrenia, other 
psychotic disorders and post-traumatic stress disorder (PTSD). 
2 Comparisons between responders and non-responders indicated differences 
in diagnoses, lifetime occupations, educational attainment, method of 
recruitment into NCMH and age of onset. However, the results of logistic 
regression analysis indicated that only method of recruitment into NCMH 
predicted participation in the online study. 
3 Two-thirds of the participants completed all nine tasks in the battery. There 
were no differences between participants who completed all the tasks and 
those who did not, except that fewer males had full cognitive data.  
4 An exploratory analysis of the structure of the battery indicated that the 
majority of tasks were correlated with one another and the battery could be 
reduced to two factors. 
5.5.1 Recruitment rates and characteristics of the internet sample 
The online cognitive battery was an effective method for recruiting a large sample 
of participants within a short timeframe. During the three-month period of sending 
invitations (1st June to 30th September 2017), 325 individuals participated in the 
study. The response rate for participants from CoMPaSS was just 4%, which was 
lower than the response rate from NCMH. One reason for this may be that the 
CoMPaSS study has been recruiting participants for ten years (compared to five 
years of recruitment for NCMH) and therefore participants are more likely to have 
moved addresses and be difficult to contact. The response rate from participants 
with schizophrenia in the NCMH sample was 4.2%, which is comparable to the 
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response rate from participants in CoMPaSS. This suggests that participants with 
schizophrenia were less likely to participate.  
In NCMH, the response rate was 5% for letter invitations and 10% for email 
invitations. This is lower than the response rates that NCMH have recorded for 
previous follow-up questionnaires (30-33%). However, the protocol of the online 
study is more demanding than previous follow-up questionnaires and requires a 
substantial time commitment (one hour compared to a questionnaire that takes 20 
minutes to complete). In addition to this, previous follow-up with participants has 
been through postal questionnaires and so response rates for letter invitations were 
expected to be lower in this study due to the requirement of access to a computer 
and the internet.  
The response rates were between 2% and 23% across the diagnostic groups. The 
lowest response rates were for participants with schizophrenia, other psychotic 
disorders and PTSD. These results suggest online cognitive testing may be less 
suitable for recruitment of patients with schizophrenia and PTSD. However, the 
recruitment methods employed by NCMH were shown to have an effect on 
participation in the online study. Participants who took part in the online study 
were less likely to have originally been recruited into NCMH through secondary 
services and more likely to have been recruited through media campaigns or have 
been referred to NCMH from another study in the department. Participants 
recruited through the latter methods may be particularly motivated to take part in 
research. Most participants with schizophrenia and PTSD in the NCMH sample 
were originally recruited through secondary psychiatry services or services for 
veterans. Participants recruited from secondary services may have a more severe 
illness, which could affect their access to the internet and their ability to use a 
computer. There is evidence that patients with psychosis are less likely to have 
access to the internet [270].  
An examination of the demographic and clinical characteristics of the participants 
indicated that these participants were more highly educated and more likely to have 
worked in professional jobs during their lifetime than invited individuals who did 
not participate. Lack of money or knowledge of computers and internet have been 
shown to be barriers to using the internet for patients with psychiatric disorders 
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[270]. Participants with higher levels of education and professional occupations 
may be more likely to be able to afford internet access and have computing abilities. 
However, the results of the logistic regression analysis indicated that recruitment 
methods but not diagnosis, education or occupation predicted participation in the 
study. As noted above, recruitment methods may reflect the severity of a 
participant’s illness. Therefore, the differences in education and occupation 
between participants and non-participants may be explained by differences in 
illness severity, as patients with a chronic disorder are less likely to be employed or 
have a high level of education.  
The demographic and clinical characteristics of the healthy control group were 
analysed separately to ensure that differences between participants and non-
participants were not driven by the higher proportion of controls in the online study. 
This also allowed me to assess whether the controls were representative of those 
included in NCMH. Controls who participated in the online study were older than 
the non-participants. This may be explained by the fact that 22% of the control 
participants were retired at the time of the online assessment. Retired individuals 
may be more willing to allocate time to completing the online study. The 
participant group was also more educated than the non-participant group. These 
findings have important implications for the interpretation of any comparisons 
between cases and controls, as both age and education are associated with cognitive 
ability.  
It should be noted that the recruitment rates reported here are restricted to a given 
period (1st February to 30th September). Recruitment to the study is ongoing and 
some of the individuals in the non-participant group will go on to participate in the 
study. Each participant received one invitation to the study and therefore sending 
reminders may further enhance recruitment. The response rates of participants with 
certain diagnoses may also be increased through targeting the recruitment methods; 
for example, by using language in the emails and letters that targets specific 
diagnoses. The current invitations refer generally to mental illness, which may lead 
participants to think that the research may not be applicable to them.  
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5.5.2 Completion rates of the online cognitive battery 
Completion rates give an indication of the tolerability of the cognitive battery. Of 
the 342 participants that consented to take part in the study, 89% completed at least 
one task, which is comparable to the 87% reported by Lumsden et al. [410]. Most 
participants who consented to take part in the study completed all nine tasks in the 
cognitive battery (66%). This figure is comparable to the completion rates reported 
by the TED study for their online battery of eight tasks (65%), although the study 
assessed children [274]. This figure is lower than those reported for face-to-face 
cognitive studies of participants with psychiatric disorders [389, 411]. However, a 
lower completion rate was expected given that the participants are unsupervised 
because they would not have the encouragement from a research assistant to 
continue with the study, would not have assistance if they have questions or 
encounter problems and therefore they be more likely to leave the study early. 
There were three main drop-off points in the study: before the first task, after the 
first task and between the Balloon Analogue Risk Task and Multiple Object 
Tracking. Once a participant has completed the first task, they have a better 
understanding of what is involved in taking part in the study and may decide at that 
point that they do not wish to continue. It takes approximately 35-40 minutes to 
complete all tasks up to and including the Balloon Analogue Risk Task. Forty 
minutes may be the maximum amount of time that a proportion of the participants 
were willing or able to tolerate the tasks. Therefore, the third drop-off point may be 
the result of fatigue. Alternatively, aspects of certain tasks may discourage 
participants from continuing, although feedback from participants in the validation 
study did not indicate this (see Chapter 4). Another potential explanation for the 
loss of participants is technical issues. All participants who did not complete the 
tasks were contacted by email and asked if they had experienced any technical 
issues. Eleven participants reported issues with the website. Five participants 
reported problems with the first task, Digit Symbol Coding. This may explain why 
some participants did not complete any of the tasks. If a participant encountered a 
problem with the first task, then they may be discouraged from continuing with the 
study. One participant reported that the second task, Verbal Paired Associates, 
would not load and another reported a problem with inputting responses on the 
Multiple Object Tracking. If more participants had encountered these issues, then 
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this may explain the second and third drop-off points. However, it should be noted 
that the number of technical issues reported was small and technical issues are to 
be expected given the vast number of different devices and hardware, operating 
systems and internet browsers that the website needs to be compatible with. 
Despite the diverse range of devices used, the majority of participants completed 
all the tasks and eight of the eleven participants who reported technical difficulties 
went on to complete all the tasks. 
There were no differences in the clinical and demographic characteristics of 
participants who completed the full battery and those who did not, with the 
exception that fewer males had full data than would be expected. Completion rates 
were comparable across the diagnostic groups suggesting that participants with a 
variety of mental health diagnoses do not differ in their ability to tolerate the 
battery. Levels of disability were also similar between participants with full, partial 
or no cognitive data suggesting that more severe disability is not a barrier to 
completing the tasks once the participants has started. However, it is possible that 
participants with the most severe levels of disability do not participate in the study 
but data on disability in the non-participant group was not available so this could 
not be assessed. 
5.5.3 Factor structure of the online cognitive battery 
An exploratory factor analysis was conducted to examine the structure of the 
battery and identify separable domains. There was evidence that the tasks loaded 
onto two factors. The first factor included all the tasks except Vocabulary, which 
uniquely loaded onto the second factor. This first factor explained a high 
proportion of the variance (77%), which is consistent with previous studies 
showing that a large proportion of the variance in cognitive performance can be 
explained by a single factor [206, 412]. Vocabulary is a verbal task and was 
designed to assess crystallised intelligence, whilst the remaining tasks are 
predominantly nonverbal tasks designed to assess fluid intelligence. This may 
explain the low correlations between this task and all other online tasks. When 
Vocabulary was excluded, the tasks loaded onto two factors. The first factor 
explained 65% of the variance in cognitive scores. Multiple Object Tracking, Digit 
Symbol Coding and Hartshorne Visual Working Memory loaded onto the first 
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factor. There are similarities between these three tasks; in particular, all three tasks 
require attention and memory for abstract objects [195, 374, 376]. Visual scanning 
and tracking abilities are also required to complete these tasks [195, 374, 376]. 
Matrix Reasoning and Balloon Analogue Risk Task loaded onto the second factor. 
Both tasks assess executive processes, including reasoning and strategic problem 
solving [375, 424].  
The tasks in the online battery loaded predominantly onto a single factor, whereas 
studies have shown that tasks from the MCCB load onto three or seven factors 
[390-392]. Results from the validation study showed that each online task was 
correlated with multiple tasks from the MCCB, not just tasks measuring the same 
domain of cognition. Taken together, these results confirm the non-specificity of 
many of the tasks in the online battery and suggest that it may be more suitable as a 
general measure of cognitive function (similar to the BACS) rather than a 
comparable online version of the MCCB.  
Most of the tasks were at least moderately correlated with three measures of 
general cognitive function (r>0.4), with the exceptions of Balloon Analogue Risk 
Task (r=0.24-0.25 across three measures of ‘g’) and Vocabulary (r=0.14-0.15 
across three measures of ‘g’). This is consistent with research showing that 
cognitive tasks are related to a higher order factor of general cognitive ability (‘g’) 
[204, 205]. The finding that Balloon Analogue Risk Task is not correlated with ‘g’ 
mirrors the findings of Chapter 4, which showed a low correlation between this 
task and a measure of ‘g’ derived from the MATRICS Consensus Cognitive 
Battery. As noted in Chapter 4, Balloon Analogue Risk Task is a behavioural 
measure rather than a cognitive measure. This could explain the low correlations 
found between this task and measures of ‘g’, as well as low correlations between 
this task and other tasks in the online battery (r ranged between 0.13 and 0.31).  
Given that a high proportion of the variance in the online battery was explained by 
a single factor (‘g’), a shorter version of the battery may be suitable for assessing 
cognition whilst reducing the amount of missing data. The task with the highest 
correlations with measures of ‘g’ was Digit Symbol Coding (r=0.65-0.67). This 
relatively simple task has been shown to be a robust measure of cognitive function 
[195]. Its short administration time and previous studies indicating a relationship 
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between this measure and functional outcome [368, 369] suggest this measure 
would be a strong contender for inclusion in a brief version of the battery. The 
second highest correlations were observed for the Multiple Object Tracking 
(r=0.64). This task may be beneficial for keeping participants engaged as it 
measures active attention and was selected as the best task by a quarter of 
participants in Chapter 4. Therefore, it is another potential candidate for inclusion 
in a brief battery. Three other tasks had correlations greater than r=0.5 with 
measures of ‘g’: Matrix Reasoning Test (r=0.58-0.59), Morphed Emotion 
Identification (r=0.53-0.54) and Hartshorne Visual Working Memory (r=0.53-0.55). 
Future research should examine the relationship between each of these tasks and 
functional outcome. This will further inform which tasks would be most beneficial 
to include in a briefer version of the battery. However, it should be noted that the 
online battery in its current form has been validated against the MATRICS 
Consensus Cognitive Battery and the psychometric properties of a brief version of 
the battery would need to be evaluated.  
5.5.4 Generalizability of the results 
The results presented in this chapter highlight a number of important issues about 
the generalizability of findings from online cognitive testing in psychiatric samples. 
The response rate was lower from participants with schizophrenia, which indicates 
that online cognitive testing may not be suitable for this patient group. Future 
studies should examine the characteristics of their sample when recruiting 
participants with schizophrenia using online methods to determine whether the 
sample is representative of patients with schizophrenia, particularly given the 
findings here that the online sample was more highly educated and more likely to 
be professionals. These latter findings highlight further issues with the 
representativeness of the online sample and suggest that participants recruited 
using online cognitive testing may be less likely to be cognitively impaired. This 
could potentially lead to studies under-estimating the degree of cognitive 
impairment in patients with these disorders. The finding that differences in 
recruitment methods between the online and NCMH cohort can account for 
differences in diagnosis, education and occupation does not diminish the issue with 
recruitment bias in this sample. However, it suggests that sample 
representativeness may be improved through employing better recruitment 
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strategies, such as utilising online testing methods in clinical settings to recruit the 
most difficult to reach participants. This strategy would eliminate the need for all 
participants to have access to the internet and a computer but reintroduces some of 
the problems associated with traditional cognitive studies, such as travel and 
expenses. 
5.5.5 Concluding statements 
This study has demonstrated that it is possible to use online cognitive testing to 
gather a large sample of data for mental health research within a relatively short 
timeframe. A strength of the study is the availability of demographic and clinical 
data on individuals who did not participate. This allowed me to identify factors that 
may impact participation in an online cognitive study. Invitations were sent to 
participants with a range of diagnoses from NCMH, so it was possible to examine 
the response rates across diagnoses.  
Several limitations should be noted. Missing data was an issue for the factor 
analysis, as 24% of participants were missing data for at least one task. The 
analysis was repeated with imputed scores, but imputation assumes that data is 
missing at random and can affect the statistical properties of the data, such as mean 
and variance [425]. However, the results were similar when the factor analysis was 
conducted with complete data and with imputed scores. The online sample was 
compared to the NCMH sample but NCMH will also have ascertainment bias so 
these results do not indicate how representative the online sample is compared to 
the wider population of patients with psychiatric disorders. It should be noted that 
the NCMH has been recruiting participants since 2012 so data may be out of date 
for some participants. For example, participants may have gone on to obtain a 
higher qualification or have had a hospital admission since they participated in the 
NCMH study. It is also possible that invited individuals did not respond because 
they did not receive their invitation due to a change in contact details. Invitations 
were sent to over 3500 people, so it was not possible to contact each individual and 
confirm they had received their invitations. The NCMH study consists of a brief 
interview (30 minutes) so another interpretation of these results is that individuals 
who took part in the online study are simply more likely to take part in more in-
depth, longer studies. Even if this is the case, the results indicated that online 
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participants are largely representative of the original cohort, except for fewer 
participants with schizophrenia and PTSD. Therefore, online cognitive testing 
appears to be a suitable method for research of most psychiatric disorders. 
However, if participants with schizophrenia and PTSD are discouraged from taking 
part due to length of the study rather than the fact it is online, then recruitment rates 
within these groups may be higher with a brief cognitive battery. This should be 
explored in future research. A final limitation is that there were an insufficient 
number of participants from the CoMPaSS study (N=5) to compare the 
demographic and clinical characteristics of these participants to the original 
CoMPaSS cohort. This was due to a smaller response rate (4%) and the fact that 
recruitment from this study was in the initial stages at the time of writing. 
Recruitment from this study is ongoing and there will be sufficient numbers to 
examine the characteristics of this sample in the future.  
In conclusion, this chapter describes the recruitment of 342 participants to 
complete an online cognitive battery. There was evidence of differences in the 
diagnoses between those who participated and those who did not. Online cognitive 
testing may not be suitable for recruiting patients with schizophrenia and PTSD, 
although it is possible that more targeted recruitment strategies or a shortened 
version of the battery may encourage individuals with schizophrenia and PTSD to 
participate in the study. This should be examined in future research. Rates of 
participation amongst other diagnoses were higher suggesting that online cognitive 
testing is effective for recruiting large samples of participants with a range of 
psychiatric disorders, including bipolar disorders, unipolar depressive disorders, 
anxiety disorders, eating disorders and personality disorders. The battery was well 
tolerated with most participants completing all the tasks. There were no differences 
between participants who completed all the tasks and those who did not, except 
that fewer males had full cognitive data. An examination of the structure of the 
battery indicated a high proportion of the variance in cognitive performance across 
tasks was accounted for by the first factor. A brief version of the battery could 
improve participation rates further and may be particularly beneficial for males 
who were less likely to complete the full version of the battery. The most 
promising tasks for a shorter version of the battery included Digit Symbol Coding, 
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Multiple Object Tracking, Matrix Reasoning Test, Morphed Emotion Identification 
and Hartshorne Visual Working Memory. 
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Chapter 6: Examining Cognition across Psychiatric 
Disorders using an Online Cognitive Battery 
6.1 Introduction 
Psychiatric disorders are leading causes of disability worldwide with schizophrenia, 
bipolar disorder and major depressive disorder ranked in the top ten disabling 
conditions in young people [37, 38]. Current treatments have shown efficacy in 
alleviating affective and psychotic symptoms, but patients continue to exhibit 
impairment in social and occupational functioning. The presence of cognitive 
impairments has been established in patients with schizophrenia [191] and bipolar 
disorder [238]. These impairments have been shown to predict functional outcome 
[182, 183]. There is emerging evidence of cognitive impairments in patients with 
major depressive disorder, although effect sizes are smaller than those reported in 
meta-analyses of schizophrenia and bipolar disorder [426-429]. Like bipolar 
disorder and schizophrenia, these deficits persist during periods of remission [428, 
429] and are apparent in patients experiencing their first episode of depression 
[427]. Few studies have examined the relationship between cognitive deficits and 
functional outcomes in major depressive disorders but there is evidence that 
cognitive dysfunction is associated with poor occupational outcomes [430].  
To date, few studies have compared the nature and extent of cognitive impairments 
between major depressive disorder, bipolar disorder and schizophrenia or examined 
the impact of these impairments on functional outcomes across these three 
disorders. In a study of older adults (50 years or older) examining the effects of 
gender and diagnosis on cognition, males with bipolar disorder and females with 
depression performed better in memory tasks and had better overall cognitive 
function than males with schizoaffective disorder and females with schizophrenia 
[311]. Higher performance on cognitive tasks was associated with better social 
skills in the schizophrenia and depression groups but not in the bipolar disorder 
group. Another study found that participants with schizophrenia exhibited poorer 
performance on memory tasks than participants with depression [431]. There were 
no other differences between participants with schizophrenia, other psychotic 
disorders, bipolar disorder or depression, although all participants were currently 
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hospitalised. One study of participants with a first episode of schizophrenia, 
psychotic bipolar disorder or psychotic depression found similar cognitive profiles 
between the groups [432]. All diagnostic groups were impaired compared to 
controls. Participants with schizophrenia exhibited the poorest performance on 
cognitive tasks relative to controls. Performance in the bipolar disorder and 
depression groups was intermediate between healthy controls and schizophrenia. 
There were no differences between participants with bipolar disorder and 
depression. However, all participants had a lifetime history of psychosis, which has 
been associated with poorer cognitive function [241, 324, 433]. Similar findings 
were reported in a longitudinal study of adolescents and young adults (aged 12 to 
35 years) with recent-onset psychosis, bipolar disorder or depression [186]. 
Participants with psychosis were more cognitively impaired than participants with 
bipolar disorder and depression, whilst participants with bipolar disorder and 
depression did not differ on any cognitive measure. Participants were reassessed 
between 12 and 36 months after their initial assessment. Improved verbal memory 
and sustained attention were associated with greater reductions in disability. 
Cognitive function is impaired in some but not all patients with major depressive 
disorder, bipolar disorder and schizophrenia. For example, one study estimated that 
16-45% of those with schizophrenia, 42-64% of those with bipolar disorder and 42-
77% of those with major depressive disorder in their sample could be defined as 
cognitively normal [314]. Thus, there is individual variation within each diagnostic 
group. However, previous studies comparing cognitive function between these 
disorders have not included potential explanatory factors as covariates or explored 
the associations between clinical factors and cognition across disorders [186, 311, 
431, 432]. Clinical factors that have been shown to be associated with cognitive 
performance in previous studies are summarised in Table 6-1.  
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Table 6-1 Clinical variables associated with poorer cognitive performance 
Major Depressive 
Disorder 
Bipolar Disorder Schizophrenia 
History of psychosis [433] 
More severe depressive 
symptoms [426, 434] 
Late onset (after 50 years 
old) [429] 
 
History of psychosis [241] 
More severe depressive 
symptoms [258, 435] 
Earlier age of onset [436] 
Longer duration of illness 
[258, 436, 437] 
Higher number of episodes 
and hospitalisations [436] 
Antipsychotic medication 
after accounting for 
psychotic symptoms [258, 
346, 435, 437] 
Earlier age of onset [438] 
More severe negative 
symptoms [358, 439, 440] 
More severe depressive 
symptoms [363] 
 
In the current study, the associations between three clinical variables and cognitive 
function across disorders were examined: age of onset, depressive symptoms and 
anxiety symptoms. Current depressive symptoms and age of onset have been 
shown to be associated with cognitive function in all three disorders but these 
variables are not well studied in a cross-disorder sample. An earlier age of onset 
has been found to be associated with more severe cognitive impairments in studies 
of bipolar disorder [436] and schizophrenia [438]. Conversely, late onset (after 50 
years old) has been shown to be associated with lower cognitive performance in 
participants with depression [429]. More severe depressive symptoms have been 
found to be associated with more severe cognitive impairments in studies of major 
depressive disorder [426, 434] and bipolar disorder [258, 435]. There is conflicting 
evidence regarding the relationship between depressive symptoms and cognition in 
schizophrenia. Whilst some studies have shown an association between depressive 
symptoms and attention [363], psychomotor speed [363] and semantic encoding in 
memory, other studies have not found an association [440, 441]. 
The impact of anxiety symptoms on cognitive function has not been studied in 
participants with major depressive disorder, bipolar disorder and schizophrenia. 
Anxiety symptoms are common in patients with depression [442], bipolar disorder 
[443] and schizophrenia [444]. In studies of healthy older adults, increased anxiety 
has been shown to be associated with poorer cognitive function [445, 446]. 
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Cognitive impairments have been found in participants with generalised anxiety 
disorder [447-449], obsessive-compulsive disorder [450] and social phobia [450]. 
Thus, anxiety symptoms were included as the final cross-disorder clinical variable. 
6.2 Chapter aims and hypotheses 
In this chapter, cognitive function was examined in a cross-disorder sample 
recruited using an online cognitive assessment. The main diagnoses of interest 
were major depressive disorder, bipolar disorder and schizophrenia. However, 
cross-disorder analyses were also conducted including all participants with a 
psychiatric diagnosis. This chapter had three aims: 
1. To compare cognitive function between participants with major depressive 
disorder, bipolar disorder and schizophrenia. It was hypothesised that the 
schizophrenia group would exhibit greater cognitive impairments than the 
bipolar disorder and major depressive disorder groups. 
2. To examine the associations between clinical factors (current symptoms of 
depression and anxiety, and age of onset) and cognitive function both 
within and across disorders. It was hypothesised that more severe 
depressive symptoms, more severe anxiety symptoms and earlier age of 
onset would be associated with lower cognitive performance. 
3. To examine the associations between cognitive performance and functional 
outcome both within and across disorders. It was hypothesised that poorer 
cognitive performance would be associated with poorer functional outcome.  
6.3 Method 
6.3.1 Sample 
In order to maximise the sample numbers, the validity of combining the study 
samples from Chapters 4 and 5 was examined. There were few differences in 
cognitive performance between the two samples so these were combined for the 
analyses in this chapter (see Appendix M for comparisons). Full details of the 
recruitment for these studies have been described in Chapters 4 and 5. All 
participants gave informed consent by selecting a tick-box on the website. The 
study received ethical approval from the School of Medicine Research Ethics 
Committee at Cardiff University (SMREC reference number: 15/64).  
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Participants were recruited from the databases of two studies: Cognition in Mood, 
Psychosis and Schizophrenia Study (CoMPaSS) and the National Centre for 
Mental Health (NCMH). These studies have been described in detail elsewhere 
(see Chapters 3 and 4) but brief details of recruitment and diagnoses are provided 
here. Both studies include confirmation of consent from participants to be 
approached for other research within the centre. Inclusion criteria were aged 16 or 
above, able to understand written and spoken English and no uncorrected deficits in 
sight or hearing. There were no specific exclusion criteria given the practical 
difficulties involved in pre-screening participants for an online study but data was 
collected on current substance use, history of neurological conditions and whether 
participants had been admitted to hospital or had a change in their medication in 
the last three months. Overall, cognitive data was available for 381 participants 
including 62 healthy controls and 314 participants with a range of mental disorders. 
Further details of CoMPaSS, NCMH and recruitment of healthy controls are 
provided below.  
NCMH recruitment 
Cognitive data was available for 294 participants from NCMH, including 31 
participants who had been recruited as part of the validation study and 263 who had 
been recruited during the main study phase. In NCMH, diagnoses are determined 
through self-report using a brief clinical interview. Participants are asked the 
question, “Has a doctor or health professional ever told you that you have any of 
the following diagnoses?” Participants are given a list of diagnoses and asked to 
indicate all diagnoses that apply. They are then asked to indicate which of the 
diagnoses they have ticked they would consider to be their primary, secondary and 
tertiary diagnoses. Finally, they are asked, “If we were to speak to your clinical 
team or general practitioner, would they agree with that?” Their diagnosis is then 
confirmed with their clinical team where possible.  
CoMPaSS recruitment 
Cognitive data was available for 20 participants from CoMPaSS, including 15 
participants who had been recruited as part of the validation study and 5 who had 
been recruited during the main study phase. In CoMPaSS, consensus lifetime 
DSM-IV diagnoses were determined based on a clinical interview (Schedule for 
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Clinical Assessment in Neuropsychiatry, SCAN [331]) and review of available 
clinical records.  
Healthy controls 
There were 62 healthy controls with cognitive data, including 9 participants from 
the pilot study, 19 from the validation study and 34 participants recruited from 
NCMH during the main study phase. Initially, 39 participants were recruited as 
healthy controls from NCMH. However, 5 participants reported that they had been 
prescribed antidepressant medication since their participation in NCMH and so 
these participants were excluded from the study.  
Diagnoses 
The final sample included 62 healthy controls and 314 participants with a 
psychiatric disorder. The main diagnoses of interest in this study were major 
depressive disorder, bipolar disorder and schizophrenia (total N=227). There were 
106 participants with a diagnosis of major depressive disorder, including 96 with 
recurrent depressive episodes and 10 with a single episode. Participants with 
recurrent and single episodes of major depression were combined, as there was no 
significant difference in their overall cognitive performance (p=0.38). Of the 106 
participants with a self-reported diagnosis of major depressive disorder, 69 
participants were currently taking antidepressant medication and 93 participants 
had been prescribed antidepressant medication in the past. Of the remaining 14 
participants who had never been prescribed antidepressant medication, 2 had 
previously received a combination of mood stabilisers and psychotherapy, 1 had 
received cognitive behavioural therapy (CBT) and 7 had received a talking therapy 
other than CBT. 
The bipolar disorder group included 88 participants with bipolar disorder – type I 
(N=51) and bipolar disorder – type II (N=37). Participants with the subtypes of 
bipolar disorder were combined, as there was no significant difference in their 
overall cognitive performance (p=0.44). Of these 88 participants, 27 participants 
had also been interviewed with the Mini-International Neuropsychiatric Interview 
(MINI, [334]) as part of another study and their diagnosis of bipolar disorder was 
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confirmed. A further 2 participants had completed the SCAN interview as part of 
an in depth NCMH assessment and their diagnoses were confirmed. 
The schizophrenia group included 33 participants with schizophrenia (N=31) and 
schizoaffective disorder – depressive type (N=2). Participants with schizophrenia 
and schizoaffective disorder – depressive type were combined on the basis of 
previous findings indicating that cognitive performance between these groups is 
comparable (see Chapters 2 and 3). Of the 33 participants included in this group, 
17 participants had completed the SCAN interview and their diagnoses were 
confirmed according to DSM-IV criteria.  
The remaining participants (N=87) had a primary diagnosis of post traumatic stress 
disorder (N=16), generalised anxiety disorder (N=9), emotionally unstable 
personality disorder (N=9), Asperger’s syndrome (N=9), other bipolar affective 
disorder (N=7), other anxiety disorder (N=7), attention deficit hyperactivity 
disorder (N=6), obsessive compulsive disorder (N=5), anorexia (N=5), 
schizoaffective disorder – bipolar type (N=4), cyclothymia (N=2), social phobia 
(N=1), postnatal depression (N=1), autism (N=1), Alzheimer’s disease (N=1), other 
mood disorder (N=1) and three were rated as having an “other psychiatric disorder” 
(N=3).  
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6.3.2 Measures 
Cognitive assessment 
Full details of the online cognitive battery can be found in Chapter 4. The battery 
comprises of 9 tasks that each assess a separate domain of cognition. The domains 
are speed of processing, verbal learning, working memory, visual learning, 
reasoning and problem solving, attention, social cognition, strategic risk taking and 
premorbid IQ. The tasks are shown in order of administration in Table 5-2. 
Participants clicked on a study-specific website link to access the tasks. Each task 
loads in the participant’s internet browser and the data is stored locally until the 
task ends then the data is encrypted and uploaded to a secure server. The battery 
takes 45-60 minutes to complete.  
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Table 6-2 Descriptions of the tasks included in the online battery 
Domain Task Description Outcome Scoring 
Speed of 
Processing 
Digit Symbol 
Coding 
P uses the key to assign the 
correct numbers to a series 
of symbols. 
Number of correct responses 
in 90 seconds. 
Social 
Cognition 
Morphed 
Emotion 
Identification 
P decides whether a face 
looks angry, fearful, happy 
or disgusted. 
Number of correct responses 
out of 60 faces. 
Verbal 
Learning 
Verbal Paired 
Associates  
P must memorise word pairs 
and select the word that was 
shown with each target 
word. 
Number of correct responses 
out of 25 word pairs. 
Working 
Memory 
Backward 
Digit Span 
P recalls a sequence of 
numbers in reverse order.  
Maximum length of number 
sequence the participant was 
able to recall backwards.  
Visual 
Learning 
Hartshorne 
Visual 
Working 
Memory 
P decides whether an object 
is the same or different from 
the previous object in that 
location. 
Number of correct responses 
out of 42 trials. 
Reasoning 
and 
Problem 
Solving 
Matrix 
Reasoning 
Test 
P selects the image that best 
completes a pattern. 
Number of correct responses 
out of 35 patterns. 
Strategic 
Risk 
Taking 
Balloon 
Analogue Risk 
Task 
P collects as many points as 
possible by blowing up 
balloons but no points are 
given if the balloon pops. 
Number of points collected by 
inflating 30 balloons. Higher 
scores indicate more effective 
strategic risk-taking. 
Attention 
Multiple 
Object 
Tracking 
P follows multiple targets as 
they move amongst identical 
objects.  
Number of correct responses 
over 30 trials. Within a trial, 
each correctly identified target 
is 1 point.  
Premorbid 
IQ 
Vocabulary 
P select which word is 
closest in meaning to the 
target word. 
Number of correct responses 
out of 20 words. 
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Scoring and imputation 
The outcome measure for each task can be found in Table 5-2. For each task, z 
scores were derived using the mean and standard deviation of the healthy controls 
(N=62). Missing data was imputed using the method described in the manual of the 
MATRICS Consensus Cognitive Battery (MCCB) [338]. Full details of the 
imputation methods including formulas can be found in Appendix C. Imputed data 
was used solely to derive general cognitive performance scores (g). Imputed scores 
were not included in analyses of individual tasks given that the imputation 
algorithms rely on information from other tasks for that participant and so are not 
suitable for domain or task specific analyses. Data was imputed for participants that 
had completed at least 5 tasks of the battery, which is consistent with the approach 
used for MCCB data in Chapter 3, meaning that those with data for less than five 
tests were not included in the analysis calculating ‘g’. 
Three measures of general cognitive performance (‘g’) were derived using the 
approaches described in Chapter 5. Measures of ‘g’ were derived for participants 
who had completed at least 5 tasks (N=321). All the tasks from the battery were 
included. Principal component analysis (PCA) was conducted on complete data 
(N=292) and repeated in a dataset where missing scores had been imputed (N=321). 
The first component of the PCA was taken as a measure of ‘g’. Classical 
multidimensional scaling (MDS) was conducted on a Euclidean distance matrix to 
derive a third measure of ‘g’. MDS is an analogous approach to PCA but an 
advantage to this approach is that it can accommodate missing data [422, 423]. The 
‘g’ derived using MDS was highly correlated with the ‘g’ derived using complete 
data (r=0.997) and the ‘g’ derived including imputed data (r=0.987). Therefore, the 
results for analyses using ‘g’ derived using MDS are presented in this chapter. The 
results for analyses using ‘g’ derived by conducting PCA on imputed scores can be 
found in Appendix M. 
Clinical questionnaire 
Participants completed an online questionnaire prior to completing the cognitive 
battery. This questionnaire included questions about current diagnosis, medication, 
medical history, substance use, education, occupation, functional outcome and 
current mood. Current psychotic and negative symptoms were not assessed due to 
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the lack of reliable, valid self-report questionnaires. Current symptoms of 
depression and anxiety were assessed using the Hospital Anxiety and Depression 
Scale (HADS) [379]. Further details of the main variables included in these 
analyses are provided below. 
Depression and anxiety 
The HADS is a brief self-assessment scale, which was developed to identify cases 
of anxiety and depression among patients in hospital clinics [379]. The scale is 
separated into two subscales, depression and anxiety. The HADS consists of 14 
questions relating to non-physical symptoms of depression and anxiety. Each 
answer is scored on a scale of 0-3 with higher scores indicating greater severity of 
symptoms. Current depression and anxiety symptoms were recorded as total scores 
on the HADS depression and anxiety subscales respectively (maximum score for 
each subscale is 21).  
Age of onset 
Data on age of onset was taken from the parent studies, CoMPaSS and NCMH. In 
CoMPaSS, age of onset was defined as the age at which the participant’s symptoms 
of their diagnosed disorder caused impairment in their life. Impairment was defined 
as: 1) disruption in work or social life more or less completely, 2) fights or other 
violence, 3) job loss or unable to work, 4) police involvement, 5) family separation, 
6) hospital admission or 7) receiving specific treatment. This was rated according 
to participants’ responses to the SCAN interview and review of clinical records. In 
NCMH, participants were asked to report the age at which they first developed 
mental health problems and the age at which these problems caused impairment in 
their life. Age of first impairment was taken as the main measure of age of onset. 
There is greater uncertainty in reporting ages of onset less than 10 years old thus 
those who reported an age of onset of 1-9 years old were recorded as 10. 
Functional outcome 
The 12-item self-report version of the World Health Organisation Disability 
Assessment Schedule Version 2 (WHODAS 2.0) was included as a measure of 
functional outcome [415]. Participants completed the WHODAS 2.0 online prior to 
completing the cognitive assessment. The WHODAS 2.0 asks participants to rate 
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how much difficulty they have had in the last 30 days completing everyday tasks. It 
covers six domains of functioning: cognition (understanding and communicating), 
mobility, self-care, social interactions, life activities (domestic responsibilities, 
leisure and work) and participation in the community. Items were rated on a 
difficulty scale from none, mild, moderate, severe to extreme / cannot do and each 
item is allocated a score of 0-4 based on these respective ratings. The maximum 
score on the 12-item questionnaire is 48 and higher scores indicate poorer 
functional outcome. Participants were asked to record the number of days the 
difficulties were present in the last 30 days. They were also asked how many days 
they were either “totally unable” to carry out their activities or had to “cut back or 
reduce” their activities because of their illness. The primary outcome measure was 
total score on the 12 items (maximum score of 48). 
6.3.3 Statistical analysis 
Comparing cognition between diagnostic groups 
Statistical analyses to compare the groups were performed using R version 3.3.0. 
The groups included in these analyses were healthy controls (N=62), major 
depressive disorder (N=106), bipolar disorder (N=88) and schizophrenia (N=33). 
For each cognitive domain and across diagnostic groups, performance was 
compared using analysis of covariance (ANCOVA) with age and gender as 
covariates and followed up with Tukey’s HSD for pairwise comparisons. Pairwise 
comparisons were conducted between the following groups: 
1. Healthy controls and major depressive disorder 
2. Healthy controls and bipolar disorder 
3. Healthy controls and schizophrenia 
4. Major depressive disorder and bipolar disorder 
5. Major depressive disorder and schizophrenia 
6. Bipolar disorder and schizophrenia 
Bonferroni correction was used to adjust for multiple comparisons resulting in an 
alpha of 0.005 (0.05/10, 9 domains and ‘g’). The alpha was not corrected further 
for the number of pairwise comparisons, as Tukey’s HSD is already a conservative 
test that corrects for family-wise error rate. Hedges’ g effect sizes were calculated 
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by dividing mean group difference by the pooled standard deviation [344] (see 
Appendix A for formulas). Repeated measures analysis of variance was used to 
compare profiles of cognitive performance between groups. The within-subject 
factor was cognitive domain. This is consistent with the approach used in previous 
studies to compare cognitive profiles [266, 314]. 
The assumptions of ANCOVA include normal distribution of the residuals and 
homogeneity of variances across groups. Visual inspection of Q-Q plots revealed 
overall normal distributions. Homogeneity of variance was assessed with Levene’s 
test and by calculating the variance ratios (highest variance divided by lowest 
variance). The variances were homogeneous across the groups with no variance 
ratios exceeding a value of 2.  
Sensitivity analyses 
Sensitivity analyses were conducted excluding participants diagnosed with bipolar 
disorder – type II, as there is evidence that these individuals have better cognitive 
functioning than participants with bipolar disorder – type I [245, 345]. Sensitivity 
analyses were also conducted excluding participants with major depressive disorder 
who had only one episode of depression, as there is evidence that cognitive 
impairments worsen with recurrent episodes of depression [451]. 
Cross disorder clinical variables and cognitive performance 
The relationship between each predictor and cognitive performance was examined 
by conducting linear regressions analyses using R version 3.3.0. These analyses 
were conducted for cases only. In each analysis, the outcome measure was ‘g’ and 
age and gender were included as covariates. Three sets of analyses were conducted 
with one of the following as predictors: 1) HADS depression scores, 2) HADS 
anxiety scores or 3) age of onset. For the analyses of current mood, participants 
were only included if they completed the cognitive tasks on the same day as the 
mood questionnaires.  
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For each predictor, the linear regressions were conducted in the following groups: 
1. The whole sample including all participants with any psychiatric diagnosis 
2. A subset including all participants with a diagnosis of either major 
depressive disorder, bipolar disorder or schizophrenia 
3. Major depressive disorder only 
4. Bipolar disorder only 
5. Schizophrenia only 
Bonferroni correction was used to adjust for multiple comparisons resulting in an 
alpha of 0.0033 (0.05/15 analyses). 
Analyses of age of onset were also repeated in a subset of participants who only 
had one psychiatric diagnosis (N=89), as the onset of comorbid disorders may 
differ from the onset of a participant’s primary disorder. 
Two further sets of analyses were conducted to model the effects of diagnosis and 
mood symptoms on cognitive function. Either HADS depression or anxiety scores 
were included as covariates, along with age and gender, in an ANCOVA 
comparing cognitive performance between diagnostic groups (healthy controls, 
major depressive disorder, bipolar disorder and schizophrenia). HADS depression 
and anxiety were analysed separately, as scores on these scales were highly 
correlated (r=0.78) and thus violated the assumption of lack of collinearity between 
predictors. The ANCOVAs were followed up with Tukey’s HSD for pairwise 
comparisons. Bonferroni correction was used to adjust for multiple comparisons 
resulting in an alpha of 0.005 (0.05/10, 9 domains and composite score). The alpha 
was not corrected further for the number of pairwise comparisons, as Tukey’s HSD 
is already a conservative test that corrects for family-wise error rate. 
Inspections of Q-Q plots confirmed that the residuals for all analyses were 
normally distributed. Residuals and standardized residuals were plotted against 
fitted values to ensure homoscedasticity of the errors. Standardized residuals were 
plotted against leverage to identify potential outliers. Variance inflation factors 
were calculated to identify collinearity between the predictors.  
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Cognitive performance and functional outcome 
Linear regressions analyses were conducted using R version 3.3.0 to determine if 
measures of general cognitive performance (‘g’) and performance on each 
cognitive task were associated with functional outcome. These analyses were 
conducted with cases only, including all diagnoses and did not include participants 
from the pilot and validation study, as the WHODAS 2.0 was added to the website 
after these stages. Cognition scores were entered into linear regressions as 
predictors with total score on the WHODAS as the outcome and age and gender as 
covariates.  
Linear regressions with ‘g’ as the predictor and WHODAS scores as the outcome 
(with age and gender as covariates) were also conducted for the following groups: 
1. A subset including all participants with a diagnosis of either major 
depressive disorder, bipolar disorder or schizophrenia (N=133) 
2. A subset of participants with other disorders, excluding major depressive 
disorder, bipolar disorder and schizophrenia (N=67) 
3. Major depressive disorder only (N=67) 
4. Bipolar disorder only (N=53) 
5. Schizophrenia only (N=13) 
Bonferroni correction was used to adjust for multiple comparisons resulting in an 
alpha of 0.0033 (0.05/15 analyses). Inspections of Q-Q plots confirmed that the 
residuals for all analyses were normally distributed. Residuals and standardized 
residuals were plotted against fitted values to ensure homoscedasticity of the errors. 
Standardized residuals were plotted against leverage to identify potential outliers. 
Variance inflation factors were calculated to identify collinearity between the 
predictors.  
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6.4 Results 
6.4.1 Sample size and completeness of data 
Of the 381 participants in the sample, 293 participants had complete cognitive data. 
Data was available for the following number of participants on each task: Digit 
Symbol Coding (N=377), Morphed Emotion Identification (N=346), Verbal Paired 
Associates (N=338), Backward Digit Span (N=332), Hartshorne Visual Working 
Memory (N=321), Matrix Reasoning (N=318), Balloon Analogue Risk Task 
(N=317), Multiple Object Tracking (N=302) and Vocabulary (N=308). For 
participants with missing data, ‘g’ was calculated for participants who had 
completed at least five tasks (N=321). The number of available scores for each task 
for each diagnostic group (healthy controls, major depressive disorder, bipolar 
disorder and schizophrenia) can be found in Appendix L. 
6.4.2 Comparison of cognition between diagnostic groups 
Demographic and clinical characteristics 
The demographic and clinical characteristics of the full sample have been provided 
in Chapters 4 and 5. However, the demographic and clinical characteristics of the 
healthy control group and participants with major depressive disorder, bipolar 
disorder and schizophrenia are displayed in Table 6-3. There were no differences in 
age between the groups (F(3, 285)=1.06, p=0.37). Groups differed on the 
proportion of females (χ2(3)=11.47, p=0.01), with fewer females observed in the 
schizophrenia group; therefore gender was used as a covariate in all analyses. 
There were differences in highest educational attainment between the groups 
(Kruskal Wallis H(3)=36.22, p=6.7 x 10-8), as all diagnostic groups had lower 
educational attainment than the healthy control group. Participants with 
schizophrenia had lower educational attainment than participants with bipolar 
disorder. Amongst the cases, there were no differences between groups in current 
HADS depression (Kruskal Wallis H(2)=0.01, p=1), current HADS anxiety scores 
(Kruskal Wallis H(2)=0.63, p=0.73) or age of illness onset (Kruskal Wallis 
H(2)=2.95, p=0.23). The groups differed on the proportion of individuals who had 
ever been admitted to hospital (χ2(2)=81.5, p<2.2 x 10-16), as a higher proportion of 
the schizophrenia and bipolar disorder groups had been admitted to hospital and a 
lower proportion of the depression group had been admitted. Scores on the 
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functional outcome scale (WHODAS) did not differ between the groups (Kruskal 
Wallis H(2)=3.89, p=0.14).  
Representativeness of online sample 
The demographic and clinical characteristics of each diagnostic group were 
compared to participants with the same diagnosis from the original parent studies 
(NCMH or CoMPaSS) to examine whether the online participants were 
representative of the original cohorts. The online depressive disorder group did not 
differ from NCMH participants with major depressive disorder in age (t(1038)=-
0.75, p=0.45), sex (χ2(1)=0.09, p=0.76), education (Wilcoxon W=48022, p=0.43) 
or age of onset (Wilcoxon W=48606, p=0.45). The online bipolar disorder group 
did not differ from NCMH participants with bipolar disorder on age (t(123.1)=0.12, 
p=0.91), sex (χ2(1)=0.37, p=0.54) or age of onset (Wilcoxon W=30369, p=0.44). 
However, the cohorts differed on education, as the online participants with bipolar 
disorder were more highly educated than participants with bipolar disorder from 
NCMH (Wilcoxon W=23392, p=7.6 x 10-4). The online participants with 
schizophrenia were compared with participants with schizophrenia from the 
NCMH cohort and then those from the CoMPaSS cohort. The online schizophrenia 
group did not differ from NCMH participants with schizophrenia in age 
(t(355)=0.97, p=0.33), sex (χ2(1)=1.6 x 10-31, p=1), education (Wilcoxon W=4141, 
p=0.24) or age of onset (Wilcoxon W=4488, p=0.48). The online schizophrenia 
group did not differ from CoMPaSS participants with schizophrenia in sex 
(χ2(1)=0.06, p=0.8), age of onset (Wilcoxon W=11290, p=0.88) or education 
(Wilcoxon W=9634.5, p=0.21). However, the online schizophrenia group differed 
from the CoMPaSS participants in age (t(766)=-2.15, p=0.03), as the online 
participants were older.  
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Table 6-3 Demographic and clinical variables 
ICD-10 Diagnosis 
Healthy 
Controls 
Major 
Depressive 
Disorder 
Bipolar 
Disorder 
Schizophrenia  
Test 
Statistic 
P Value 
Pairwise 
Comparison 
N 62 106 88 33    
Age 48 (18.8) 47.1 (14.2) 50.7 (11.4) 47.9 (11.9) 1.06 0.37 NS 
Number of females (%) 43 (69.4) 70 (66) 62 (70.5) 13 (39.4) 11.47 0.01 
SZ < HC 
SZ < BD 
SZ < MDD 
Highest qualification     
36.22 6.7 x 10-8 
MDD < HC 
BD < HC 
SZ < HC 
SZ < BD 
None 0 3 0 2 
11+ 0 1 0 1 
CSE or equivalent 0 5 2 4 
GCSE or equivalent 1 17 17 5 
A-level or equivalent 10 35 25 10 
Degree 20 22 27 2 
Postgraduate degree 18 14 10 3 
Number of participants with ≥1 
admission (%) 
 13 (12.6) 49 (60.5) 29 (93.5) 81.5 <2.2 x 10-16 
MDD < SZ 
MDD < BD 
Age of Onset*  18 (14.5) 17 (12) 21 (7) 2.95 0.23 NS 
HADS depression score*  8 (6) 8 (8.5) 7 (8) 0.01 1.00 NS 
HADS anxiety score*  11 (7) 10 (9.25) 10 (9) 0.63 0.73 NS 
AMS score*  2 (4) 1 (4) 2 (3) 3.64 0.3 NS 
WHODAS score*  11.5 (14.75) 17 (20.25) 19 (19) 3.89 0.14 NS 
Figures represent means and standard deviations, except for proportions, ordinal scales and scores with non-normal distributions. *Median and interquartile range shown due to non-normal 
distribution. Test statistic is F (ANOVA) or H (Kruskal-Wallis Analysis of Variance) for continuous variables and Χ2 for proportions. Pairwise comparisons significant to p<.05. AMS, Altman 
Mania Scale; HADS, Hospital Anxiety and Depression Scale; WHODAS, World Health Organisation Disability Assessment Scale; NS, Not Significant. 
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Comparison of cognition between diagnostic groups 
There was a significant main effect of diagnosis for overall cognitive function ‘g’ 
(F(3, 239) = 10.71, p=1.3 x 10-6). Cognitive performance (‘g’) did not differ 
between participants with major depressive disorder and controls (Hedge’s g=0.25, 
p=0.47). Participants with bipolar disorder had impaired cognitive performance 
compared to controls, although this does not withstand correction for multiple 
testing (g=0.56, p=0.01). Participants with schizophrenia had impaired cognitive 
performance compared to controls (g=1.17, p<0.001). Participants with 
schizophrenia were more impaired than participants with major depressive disorder 
(g=0.93, p<0.001) and bipolar disorder (g=0.61, p=0.02), although the latter 
comparison did not withstand correction for multiple testing. Participants with 
bipolar disorder and major depressive disorder did not differ in their cognitive 
performance (g=0.31, p=0.2). Equivalent results were found when general 
cognitive function was derived using PCA on complete data and imputed data (see 
Appendix M).  
Comparison of cognitive profiles between diagnostic groups 
The main effects of diagnosis on each cognitive domain are displayed in Table 6-4. 
After correction for multiple testing, there was a significant main effect of 
diagnosis on speed of processing (F(3, 282)=7.01, p=1 x 10-4), social cognition 
(F(3, 257)=11.26, p=5.8 x 10-7) and reasoning and problem solving (F(3, 240)=4.88, 
p=0.003).  
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Table 6-4 Effect of diagnosis on each cognitive domain 
Domain Fdf p Partial η2 
Speed of Processing F3, 282=7.01 0.0001 0.07 
Verbal Learning F3, 251=2.11 0.1 0.02 
Social Cognition F3, 257=11.26 5.8 x 10-7 0.12 
Working Memory F3, 249=4.14 0.007 0.05 
Visual Learning F3, 241=3.18 0.02 0.04 
Reasoning & Problem Solving  F3, 240=4.88 0.003 0.06 
Strategic Risk Taking F3, 239=1.56 0.22 0.02 
Attention F3, 225=3.72 0.01 0.05 
Vocabulary F3, 230=4.16 0.007 0.05 
Partial η2 indicates the proportion of variance in cognitive scores that is associated with diagnosis. 
 
Effect sizes are displayed for each pairwise comparison in Figure 6-1. After 
correction for multiple testing, participants with schizophrenia were more impaired 
than controls on speed of processing (d=0.91, p<0.001), social cognition (d=1.23, 
p<0.001) and reasoning and problem solving (d=0.76, p=0.004). The schizophrenia 
group were more impaired than participants with major depressive disorder on 
speed of processing (d=0.67, p=0.0049) and social cognition (d=1.04, p<0.001). 
Finally, the schizophrenia group were more impaired than participants with bipolar 
disorder on the social cognition task (d=0.89, p<0.001). No other comparisons were 
significant after correction for multiple testing.  
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Figure 6-1 Pairwise comparisons  
Each 3x3 section displays the Cohen’s d effect sizes for the difference between two diagnostic groups for each 
domain of cognition. Positive effect sizes indicate that the group on the horizontal bottom row performed better 
than the group on the left-hand vertical column. Lighter shade p<0.05, darker shade p<0.005. 
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Figure 6-2 displays the mean z scores for each diagnostic group and the control 
group. Means for the control group are not exactly zero as the scores have been 
adjusted for age and gender (marginal means). Cognitive profiles were compared 
between diagnostic groups (excluding controls) using repeated measures analysis 
of variance, with cognitive domain included as the within-subject factor, to test 
whether between group differences were qualitative or merely quantitative. 
Mauchly’s test indicated that the assumption of sphericity had been violated 
(χ2(35)=82.49, p=1.1 x 10-5) therefore degrees of freedom were corrected using 
Huynh-Feldt estimates of sphericity. The diagnosis-by-domain interaction was not 
significant (F=1.43, df=15.54, 1243.52, p=0.12) indicating that patterns of 
cognitive ability did not differ by diagnostic group but rather differed quantitatively. 
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Figure 6-2 Cognitive profiles for participants with major depressive disorder, bipolar disorder and schizophrenia 
Error bars indicate ±1 standard error 
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Sensitivity analyses 
Bipolar disorder - type I only 
Given that there is some evidence to suggest patients with bipolar disorder – type II 
are less cognitively impaired than those with bipolar disorder – type I [245, 345], 
the analysis was repeated including only participants with bipolar disorder – type I 
(N=51). There were no significant differences between the bipolar disorder and 
schizophrenia groups on ‘g’ and vocabulary once participants with bipolar disorder 
– type II were excluded. Participants with bipolar disorder – type I were 
significantly more impaired than the healthy controls on attention. The remaining 
results did not differ from the main analysis (see Table 6-5). 
 
Table 6-5 Comparisons of cognitive performance when only bipolar disorder - type I was included 
Domain Effect of Diagnosis 
Pairwise 
Comparisons 
 Fdf p Partial η2  
General Cognitive 
Ability (‘g’) 
F3, 205=11.70 
4.2 x 10-
7 
0.15 
BD<HC1 
SZ<HC2 
SZ<MDD2 
Speed of Processing F3, 245=7.35 
9.8 x 10-
5 0.08 
BD<HC1 
SZ<HC2 
SZ<MDD1 
Verbal Learning F3, 216=2.79 0.04 0.04 NS 
Social Cognition F3, 222=11.33 
6.1 x 10-
7 0.13 
SZ<HC2 
SZ<MDD2 
SZ<BD2 
Working Memory F3, 215=3.65 0.01 0.05 SZ<MDD1 
Visual Learning F3, 207=3.94 0.009 0.05 
SZ<HC1 
SZ<MDD1 
Reasoning & Problem 
Solving  
F3, 207=5.48 0.001 0.07 
SZ<HC1 
SZ<MDD1 
BD<HC1 
Strategic Risk Taking F3, 206=1.48 0.22 0.02 NS 
Attention F3, 196=5.50 0.001 0.08 
BD<HC2 
SZ<HC1 
Vocabulary F3, 200=3.64 0.01 0.05 
SZ<HC1 
SZ<MDD1 
Partial η2 indicates the proportion of variance in cognitive scores that is associated with diagnosis. BD, Bipolar 
Disorder; HC, Healthy Controls; MDD, Major Depressive Disorder; SZ, Schizophrenia. 
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Major depressive disorder – recurrent only 
Given evidence that cognitive impairments worsen with recurrent episodes of 
depression [451], the analysis was repeated including only participants with 
recurrent episodes of depression (N=96). This did not change the results or post 
hoc comparisons (see Table 6-6). 
 
Table 6-6 Comparisons of cognitive performance when only participants with major depressive disorder 
- recurrent were included 
Domain Effect of Diagnosis 
Pairwise 
Comparisons 
 Fdf p Partial η2  
General Cognitive 
Ability (‘g’) 
F3, 232=10.84 
1.1 x 10-
6 
0.12 
BD<HC1 
SZ<HC2 
SZ<MDD2 
SZ<BD1 
Speed of Processing F3, 272=6.96 
1.6 x 10-
4 0.07 
BD<HC1 
SZ<HC2 
SZ<MDD1 
Verbal Learning F3, 244=2.06 0.11 0.02 NS 
Social Cognition F3, 250=11.51 
4.4 x 10-
7 0.12 
SZ<HC2 
SZ<MDD2 
SZ<BD2 
Working Memory F3, 242=4.35 0.005 0.05 
BD<MDD1 
SZ<MDD1 
Visual Learning F3, 234=3.10 0.03 0.04 SZ<MDD1 
Reasoning & Problem 
Solving  
F3, 233=4.87 0.003 0.06 
SZ<HC2 
SZ<MDD1 
BD<HC1 
Strategic Risk Taking F3, 232=1.36 0.26 0.02 NS 
Attention F3, 218=3.77 0.01 0.05 
BD<HC1 
SZ<HC1 
Vocabulary F3, 223=4.27 0.006 0.05 
SZ<HC1 
SZ<MDD1 
SZ<BD1 
Partial η2 indicates the proportion of variance in cognitive scores that is associated with diagnosis. BD, Bipolar 
Disorder; HC, Healthy Controls; MDD, Major Depressive Disorder; SZ, Schizophrenia. 
  
273 
 
6.4.3 Cross disorder clinical variables and cognitive performance 
Across diagnostic groups 
Figure 6-3 displays cognitive scores (‘g’) plotted against HADS depression scores 
across the whole sample and within the subgroups: major depressive disorder, 
bipolar disorder and schizophrenia. Figure 6-4 displays ‘g’ plotted against HADS 
anxiety scores across the whole sample and within the subgroups. Across the whole 
sample (cases only), higher HADS depression scores (B=-0.08, SE=0.02, p=2.1 x 
10-4) and higher HADS anxiety scores (B=-0.08, SE=0.02, p=4.7 x 10-5) at the time 
of cognitive testing were associated with lower cognitive performance (‘g’). Age of 
onset was not associated with cognitive performance (B=-0.009, SE=0.01, p=0.4). 
As a number of participants had two or more psychiatric diagnoses with different 
ages of onset, the analysis was repeated restricting the sample to participants with 
one diagnosis (N=89). As previously, age of onset was not associated with 
cognitive performance (B=-0.002, SE=0.02, p=0.92). The results were equivalent 
when the analyses were repeated with ‘g’ derived from imputed data using PCA 
(see Appendix M). 
The analyses were then repeated and restricted to the three main diagnoses of 
interest: major depressive disorder, bipolar disorder and schizophrenia. Across 
these three disorders, higher HADS depression scores (B=-0.08, SE=0.02, p=6.5 x 
10-4) and higher HADS anxiety scores (B=-0.08, SE=0.02, p=1.7 x 10-4) were 
associated with lower cognitive performance. Age of onset was not associated with 
cognitive performance (B=-0.001, SE=0.01, p=0.95). As previously, the analysis 
was restricted to participants with one diagnosis only (N=69) and there was no 
association between age of onset and cognitive performance (B=0.008, SE=0.02, 
p=0.72).  
Within diagnostic groups 
The associations between the clinical variables and cognitive performance within 
each diagnostic group are shown in Table 6-7. In the bipolar disorder group, higher 
HADS depression and anxiety scores were associated with lower cognitive 
performance (HADS Depression: B=-0.08, SE=0.04, p=0.04; HADS Anxiety: B=-
0.07, SE=0.04, p=0.046). Higher HADS depression and anxiety scores were also 
associated with lower cognitive performance in the major depressive disorder 
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group (HADS Depression: B=-0.07, SE=0.04, p=0.046; HADS Anxiety: B=-0.08, 
SE=0.04, p=0.03). In the schizophrenia group, higher scores on the HADS anxiety 
subscale were associated with lower cognitive performance (B=-0.10, SE=0.04, 
p=0.03). However, none of the results were significant after correction for multiple 
testing. 
 
Table 6-7 Associations between the clinical variables and cognitive performance 
 General Cognitive Function 
 N B SE p 
Bipolar Disorder     
HADS depression 71 -0.08 0.04 0.04 
HADS anxiety 71 -0.07 0.04 0.046 
Age of onset 69 0.001 0.02 0.95 
Major Depressive Disorder     
HADS depression 75 -0.07 0.04 0.046 
HADS anxiety 75 -0.08 0.04 0.03 
Age of onset 84 -0.01 0.02 0.61 
Schizophrenia     
HADS depression 28 -0.11 0.05 0.05 
HADS anxiety 28 -0.10 0.04 0.03 
Age of onset 32 0.02 0.03 0.49 
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Figure 6-3 HADS depression scores and cognitive performance ('g')  
From top left to bottom right: a) all diagnoses, b) major depressive disorder, c) bipolar disorder, d) 
schizophrenia. Line represents the regression line and the shaded region indicates 95% confidence intervals 
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Figure 6-4 HADS anxiety scores and cognitive performance ('g')  
From top left to bottom right: a) all diagnoses, b) major depressive disorder, c) bipolar disorder, d) 
schizophrenia. Line represents the regression line and the shaded region indicates 95% confidence intervals 
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Modelling the contributions of mood symptoms and diagnosis 
Current anxiety symptoms were associated with performance on speed of 
processing (F(1, 222)=18.44, p=2.6 x 10-5), verbal learning (F(1, 198)=16.57, 
p=6.8 x 10-5) and ‘g’ (F(1, 188)=15.31, p=1.3 x 10-4, see Table 6-8 for full results). 
The estimated proportion of variance in cognitive scores explained by current 
anxiety symptoms was 0.08. The effect of diagnosis on speed of processing (F(2, 
222)=5.96, p=0.003) and ‘g’ (F(2, 188)=11.30, p=2.3 x 10-5) remained significant 
after adjusting for anxiety symptoms. Current depressive symptoms were 
associated with speed of processing (F(1, 222)=19.81, p=1.4 x 10-5), attention (F(1, 
173)=8.02, p=0.005) and ‘g’ (F(1, 188)=13.20, p=3.6 x 10-4, see Table 6-9 for full 
results). The estimated proportion of variance in cognitive scores explained by 
current depressive symptoms ranged from 0.05 to 0.08. The effect of diagnosis on 
speed of processing (F(2, 222)=5.70, p=0.004) and ‘g’ (F(2, 188)=11.60, p=1.8 x 
10-5) remained significant after adjusting for depressive symptoms.  
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Table 6-8 The effects of diagnosis and HADS anxiety scores on cognitive performance 
Domain Effect of Diagnosis Effect of Current Anxiety Symptoms 
Pairwise 
Comparisons 
 Fdf p Partial η2 Fdf p Partial η2  
Speed of Processing F2, 222 = 5.96 0.003 0.05 F1, 222 = 18.44 2.6 x 10-5 0.08 SZ<MDD2 
Verbal Learning F2, 198 = 1.13 0.32 0.01 F1, 198 = 16.57 6.8 x 10-5 0.08 NS 
Social Cognition F2, 202 = 13.75 2.6 x 10-6 0.12 F1, 202 = 0.32 0.57 0.002 
SZ<BD2 
SZ<MDD2 
Working Memory F2, 196 = 6.05 0.003 0.06 F1, 196 = 2.69 0.1 0.01 
BD<MDD1 
SZ<MDD1 
Visual Learning F2, 189 = 4.16 0.02 0.04 F1, 189 = 3.85 0.05 0.02 SZ<MDD1 
Reasoning & Problem 
Solving  
F2, 187 = 4.30 0.01 0.04 F1, 187 = 5.18 0.02 0.03 SZ<MDD1 
Strategic Risk Taking F2, 187 = 2.32 0.1 0.02 F1, 187 = 2.39 0.12 0.01 NS 
Attention F2, 173 = 1.62 0.2 0.02 F1, 173 = 4.83 0.03 0.03 NS 
Vocabulary F2, 176 = 6.38 0.002 0.07 F1, 176 = 5.22 0.02 0.03 
SZ<BD2 
SZ<MDD1 
General Cognitive 
Function (‘g’) 
F2, 188 = 11.30 2.3 x 10-5 0.11 F1, 188 = 15.31 1.3 x 10-4 0.08 
SZ<MDD2 
SZ<BD1 
Partial η2 indicates the proportion of variance in cognitive scores that is associated with each variable. BD, bipolar disorder; HADS, Hospital Anxiety and Depression Scale; HC, healthy 
controls; MDD, major depressive disorder; SZ, schizophrenia; 1p<0.05; 2p<0.005 (Bonferroni-corrected)  
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Table 6-9 The effects of diagnosis and HADS depression scores on cognitive performance 
Domain Effect of Diagnosis Effect of Current Depressive Symptoms 
Pairwise 
Comparisons 
 Fdf p Partial η2 Fdf p Partial η2  
Speed of Processing F2, 222 = 5.70 0.004 0.05 F1, 222 = 19.81 1.4 x 10-5 0.08 SZ<MDD2 
Verbal Learning F2, 198 = 1.39 0.25 0.01 F1, 198 = 5.22 0.02 0.03 NS 
Social Cognition F2, 202 = 13.81 2.4 x 10-6 0.12 F1, 202 = 0.06 0.81 2.9 x 10-4 
SZ<BD2 
SZ<MDD2 
Working Memory F2, 196 = 5.96 0.003 0.06 F1, 196 = 1.34 0.25 0.01 
BD<MDD1 
SZ<MDD1 
Visual Learning F2, 189 = 4.23 0.02 0.04 F1, 189 = 3.27 0.07 0.02 SZ<MDD1 
Reasoning & Problem 
Solving  
F2, 187 = 4.40 0.01 0.05 F1, 187 = 4.61 0.03 0.02 SZ<MDD1 
Strategic Risk Taking F2, 187 = 2.37 0.10 0.03 F1, 187 = 0.57 0.45 0.003 NS 
Attention F2, 173 = 1.82 0.17 0.02 F1, 173 = 8.02 0.005 0.05 NS 
Vocabulary F2, 176 = 6.67 0.002 0.07 F1, 176 = 4.09 0.04 0.02 
SZ<BD2 
SZ<MDD2 
General Cognitive 
Function (‘g’) 
F2, 188 = 11.60 1.8 x 10-5 0.11 F1, 188 = 13.20 3.6 x 10-4 0.07 
SZ<MDD2 
SZ<BD2 
Partial η2 indicates the proportion of variance in cognitive scores that is associated with each variable. BD, bipolar disorder; HADS, Hospital Anxiety and Depression Scale; HC, healthy 
controls; MDD, major depressive disorder; SZ, schizophrenia; 1p<0.05; 2p<0.005 (Bonferroni-corrected) 
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6.4.4 Cognitive performance and functional outcome 
Across diagnostic groups 
Linear regression across the whole sample indicated that lower cognitive 
performance (‘g’) was associated with higher WHODAS scores, which indicates 
poorer functional outcome (B=-1.69, SE=0.45, p=2.2 x 10-4). The analyses were 
then repeated and restricted to the three main diagnoses of interest: major 
depressive disorder, bipolar disorder and schizophrenia. Across these three 
disorders, lower cognitive performance was associated with higher WHODAS 
scores (B=-1.36, SE=0.59, p=0.02) but this did not survive correction for multiple 
testing. In the subgroup of participants with other psychiatric disorders (excluding 
major depressive disorder, bipolar disorder and schizophrenia), lower cognitive 
performance was significantly associated with higher WHODAS scores (B=-2.08, 
SE=0.64, p=0.002).  
Relationships between cognitive tasks and functional outcome 
Four tasks were associated with functional outcome (see Table 6-10): Digit Symbol 
Coding, Backward Digit Span, Hartshorne Visual Working Memory Test and 
Balloon Analogue Risk Task. After correction for multiple testing, higher scores on 
three tasks were significantly associated with better functional outcome as 
measured by total WHODAS scores (Digit Symbol Coding: B=-0.35, SE=0.08, 
p=4.1 x 10-5; Backward Digit Span: B=-1.40, SE=0.44, p=0.002; Hartshorne 
Visual Working Memory Test: B=-0.53, SE=0.17, p=0.003).   
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Table 6-10 Associations between cognitive performance and functional outcome (WHODAS score) 
Task N B SE p 
Digit Symbol Coding 249 -3.39 0.81 4.1 x 10-5 
Verbal Paired Associates 219 -1.01 0.89 0.26 
Backward Digit Span 212 -2.60 0.82 0.002 
Hartshorne Visual Working Memory 
Test 
203 -2.49 0.82 0.003 
Morphed Emotion Identification 223 -1.48 0.93 0.11 
Matrix Reasoning Test 199 -1.34 0.80 0.09 
Balloon Analogue Risk Task 199 -1.51 0.66 0.02 
Multiple Object Tracking 185 -1.28 0.73 0.08 
Vocabulary 189 -0.90 1.02 0.38 
 
Within diagnostic groups 
In analyses of individual diagnostic groups, lower cognitive performance was 
associated with poorer functional outcome in the depression group only (B=-2.8, 
SE=0.74, p=3.7 x 10-4, see Table 6-11 for full results). Results were comparable 
when the analysis was repeated with ‘g’ derived from imputed data (see Appendix 
M). 
 
Table 6-11 Associations between ‘g’ and WHODAS score within diagnostic groups 
 N B SE p 
Across Three Groups 133 -1.36 0.59 0.02 
Bipolar Disorder 53 0.30 0.92 0.75 
Major Depressive Disorder 67 -2.80 0.74 3.7 x 10-4 
Schizophrenia 13 -3.12 1.72 0.1 
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6.5 Discussion 
This chapter had three main aims: 1) to examine the nature and extent of cognitive 
impairments in participants with major depressive disorder, bipolar disorder and 
schizophrenia; 2) to examine the associations between clinical features (current 
depressive symptoms, current anxiety symptoms and age of onset) and cognitive 
performance both within and across disorders; 3) to determine whether cognitive 
impairments predict functional outcome both within and across disorders. There 
were three main findings of this study: 
1. Cognitive impairments were present in participants with bipolar disorder 
and schizophrenia but participants with major depressive disorders did not 
exhibit impairments relative to controls. Differences between participants 
with bipolar disorder and healthy controls were not significant after 
correction for multiple testing.  
2. Greater depressive and anxiety symptoms were associated with poorer 
cognitive performance but there was no association between age of onset 
and cognition. 
3. Poorer cognitive performance was associated with poorer functional 
outcome across disorders.  
Each of these findings is discussed in detail in the following sections.  
6.5.1 Cognitive performance across disorders 
Comparisons of cognitive performance between groups indicated that participants 
with bipolar disorder and schizophrenia exhibited overall cognitive impairment, 
whilst participants with major depressive disorder did not. However, the difference 
in ‘g’ between participants with bipolar disorder and healthy controls did not 
survive correction for multiple testing. Cognitive profiles did not differ between 
diagnostic groups. There were significant effects of diagnosis on only three 
domains after correction for multiple testing: speed of processing, social cognition 
and reasoning and problem solving.  
The findings reported in this chapter replicate the findings of Chapter 3, which 
found similar cognitive profiles but greater cognitive impairment in the 
schizophrenia group than the bipolar group. However, the effect sizes reported in 
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this study are smaller than those reported in Chapter 3. Consequently, the 
difference in overall cognitive function between participants with bipolar disorder 
and healthy controls did not survive correction for multiple testing. The major 
depressive disorder group did not differ from the healthy control group. This is 
contrary to meta-analyses that have found small impairments in overall cognitive 
function, even in euthymic participants with major depressive disorder [426, 429]. 
In this study, major depressive disorder was broadly defined including both 
participants with single and recurrent episodes. The inclusion of participants with a 
single episode of depression may have obscured differences between the major 
depressive disorder group and healthy controls. However, only a small number of 
participants with a single episode were included (N=10), participants with single 
and recurrent episodes of depression did not differ in their cognitive performance 
and the results were equivalent when participants with single episodes of 
depression were excluded from analyses. This suggests the lack of impairments 
found in this study cannot be explained by the inclusion of a diverse group of 
participants with major depressive disorder.  
One explanation for the smaller effect sizes reported in this study may be due to the 
use of online cognitive testing. Participants in the online study were less likely to 
have been recruited through secondary psychiatry services (see Chapter 5). 
Therefore, participants with a more severe illness may be less likely to participate 
in an online study compared to the face-to-face interviews conducted in Chapter 3. 
The characteristics of the online sample were compared with the parent studies to 
examine whether the online sample was representative of the original cohorts. 
Online participants with bipolar disorder were more highly educated than 
participants with bipolar disorder from the NCMH cohort who did not participate. 
Online participants with schizophrenia did not significantly differ in education 
levels from participants with schizophrenia in the NCMH or CoMPaSS cohort. 
However, it should be noted that three participants in the online sample (9%) had 
post-graduate degrees compared to 2% of the CoMPaSS sample, which may be an 
indication that the online participants with schizophrenia are more highly educated 
than participants from CoMPaSS. This may explain why participants in this study 
exhibited smaller impairments and only analyses of three domains survived 
correction for multiple testing.  
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Participants did not differ in performance on two domains: verbal learning and 
strategic risk taking. The lack of significant differences in verbal learning between 
groups contradicts the findings of Chapter 3. In Chapter 3, verbal learning was 
assessed using the Hopkins Verbal Learning Test – Revised (HVLT-R) in a sample 
of participants with schizophrenia, schizoaffective disorder and bipolar disorder. 
The largest impairments across groups were exhibited on the HVLT-R. One 
plausible reason for the differences in results between these two studies is that the 
correlation between the Verbal Paired Associates task and HVLT-R was moderate 
(r=0.41, see Chapter 4). The two measures assess distinct aspects of verbal learning. 
The Verbal Paired Associates task assesses delayed associative learning (word 
pairs), whilst the HVLT-R assesses short-term free recall of a list [452]. It should 
also be noted that few participants obtained high scores on the Verbal Paired 
Associates task. For example, only 3% of participants obtained scores of 20 or 
above (out of 25) on this task. Therefore, another plausible explanation is a lack of 
variation in scores means the task is not sensitive enough to be able to detect 
differences between groups.  
To my knowledge, this study was the first to examine whether scores on the 
Balloon Analogue Risk Task (BART) differs between diagnostic groups. 
Performance on the BART did not differentiate between cases and controls. 
Although performance on the BART was associated with functional outcome, the 
coefficient was small (B=0.01) and did not survive correction for multiple testing. 
This calls into question the usefulness of this measure in psychiatric populations.  
Participants with schizophrenia exhibited impairments on the social cognition task 
(emotion identification), whilst participants with bipolar disorder and major 
depressive disorder did not. Previous studies have shown that participants with 
schizophrenia are more impaired on measures of emotion recognition than 
participants with mood disorders [370, 453]. Participants with bipolar disorder 
showed small, non-significant impairments in emotion identification. The effect 
size reported in this study (g=0.33) was comparable to that of a meta-analysis of 
studies comparing emotion identification between participants with bipolar 
disorder and healthy controls (d=0.35) [243]. Overall these findings are consistent 
with the findings of Chapter 3, which demonstrated that pronounced impairments 
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in social cognition are present in participants with schizophrenia and 
schizoaffective disorder but not bipolar disorder.  
6.5.2 Clinical predictors of cognitive function 
Current symptoms of depression and anxiety were associated with cognitive 
performance across disorders, although the effect of diagnosis remained significant 
when these variables were included as covariates. Pairwise differences between the 
groups did not change when anxiety or depression scores were included as 
covariates. Age of onset was not associated with cognitive performance either 
across or within diagnostic groups. 
Higher scores on the HADS depression subscale were associated with poorer 
performance on measures of processing speed, attention and overall cognitive 
function. That depressive symptoms are associated with performance on tasks 
assessing processing speed and attention is not surprising given that symptoms of 
depression include poor concentration and psychomotor retardation [8]. 
Associations between depression scores and cognition were found in the depression 
and bipolar disorder groups, which is consistent with previous studies [258, 426, 
434, 435]. There is conflicting evidence of the influence of depressive symptoms 
on cognitive impairment in schizophrenia. In the current study, the association 
between depression scores and cognitive performance was not significant in the 
schizophrenia group (p=0.05) so it was not possible to draw any firm conclusions 
in this group.  
Higher scores on the HADS anxiety subscale were also associated with poorer 
cognitive performance both within and across diagnostic groups. To my knowledge, 
this is the first study to examine the association between current anxiety symptoms 
and cognitive performance across disorders. Previous studies have found cognitive 
impairments in participants with a primary diagnosis of an anxiety disorder and in 
older adults with anxiety symptoms [445-450]. This study expands on these 
findings by showing that increased anxiety symptoms are associated with poorer 
cognitive performance in participants with major depressive disorder, bipolar 
disorder and schizophrenia. Anxiety symptoms were associated with speed of 
processing, verbal learning and overall cognitive function. There are several 
explanations for this finding. Anxiety symptoms may directly affect cognitive 
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performance. For example, participants who are experiencing symptoms of anxiety 
may have greater difficulty concentrating resulting in poorer performance. 
Alternatively, a high score on the HADS anxiety scale may be an indicator that the 
participant has a more severe course of illness or experiencing a relapse of their 
symptoms. Another possibility is that this result may be confounded by participants’ 
use of benzodiazepines, which may have a dulling effect on cognitive function 
[454]. Finally, the HADS depression and anxiety subscales were highly correlated 
in this study (r=0.78). Therefore, it was not possible to disentangle the effects of 
depression and anxiety in a single model, as this violated the assumption of no 
collinearity in regression analyses. 
Age of onset was not associated with cognitive performance within or across 
diagnostic groups. There is evidence that earlier age of onset is associated with 
poorer cognitive function in participants with bipolar disorder and schizophrenia. A 
study of participants with bipolar disorder demonstrated that both age of first 
symptom and age of first treatment are positively correlated with cognitive 
performance [436]. A meta-analysis compared cognitive performance between 
participants with youth-onset schizophrenia (19 years or younger), late-onset 
schizophrenia (40 years or older) and first-episode schizophrenia (20-39 years) 
[438]. The youth-onset group were more cognitively impaired than the first-episode 
and late-onset groups. The first-episode group were was impaired than the late-
onset group. In contrast, a meta-analysis of participants with major depressive 
disorder found poorer cognitive performance amongst participants with a late onset 
(defined as onset after 50 years) compared to participants with an earlier age of 
onset (18-50 years). These results suggest there may be a complex relationship 
between age of onset and cognitive performance across disorders. In the current 
study, age of onset was considered as a linear variable. An alternative approach 
would be to identify participants with an early onset and late onset and compare 
performance but there were an insufficient number of participants to do this. It 
should be noted that the majority of participants in this study were recruited from 
NCMH and so their age of onset was based on self-report and may not be as 
reliable as studies that have accessed clinical records. Age of onset was also higher 
(though not significantly different) in the schizophrenia group than the bipolar 
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disorder and major depressive groups, which may indicate participation bias. 
Therefore, caution is advised in the interpretation of this result.  
6.5.3 Cognitive performance and functional outcome 
In a cross-disorder analysis, poorer cognitive performance was associated with 
poorer functional outcome, as measured by the WHODAS. The WHODAS 
assesses six domains of functional outcomes, including cognition (understanding 
and communicating), mobility, self-care, social interactions, life activities 
(domestic responsibilities, leisure and work) and participation in the community. 
These results suggest that cognitive performance is an important indicator of 
overall functional outcome across a range of psychiatric diagnoses. This is 
consistent with an earlier prospective study that used the WHODAS to examine the 
association between cognitive performance and functional outcome in young 
participants with major depressive disorder, bipolar disorder and psychosis [186]. 
In the prospective study, improved verbal memory and sustained attention were 
associated with greater reductions in disability. The authors performed a cluster 
analysis and identified three cognitive subtypes associated with functional outcome. 
However, the clusters did not differ by diagnosis suggesting that cognitive 
improvement predicts functional outcome independent of diagnosis. This study 
expands on these findings by showing that cognitive performance is associated 
with functional outcome in a sample of adults with a broader range of psychiatric 
disorders.  
In contrast to the study by Lee et al. [186], measures of verbal memory and 
attention were not associated with scores on the WHODAS. In this study, 
performance on Digit Symbol Coding, Backward Digit Span and Hartshorne Visual 
Working Memory were associated with scores on the WHODAS. Scores on Digit 
Symbol Coding were most strongly associated with functional outcome and this is 
consistent with the findings of previous studies examining functional outcomes in 
schizophrenia [369, 455]. Previous studies have shown that impairments in 
working memory are associated with poor functional outcomes in participants with 
first episode psychosis [456] and major depressive disorder [457]. Both Digit 
Symbol Coding and Backward Digit Span have short administration times (under 
five minutes) so may be particularly suited for brief assessments of cognition in a 
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clinical setting. Future studies should investigate whether interventions that target 
impairments in processing speed and working memory are beneficial for improving 
functional outcomes in patients with psychiatric disorders. 
The analyses were repeated in three diagnostic groups: major depressive disorder, 
bipolar disorder and schizophrenia. Poorer cognitive performance was associated 
with poorer functional outcome in the major depressive disorder group only. In the 
schizophrenia group, the effect was in the expected direction but the sample size 
was small (N=13) and the analysis may have been inadequately powered to detect 
an association. In the bipolar disorder group, the regression coefficient was close to 
zero (B=0.3, 95% CI: -1.56-2.16) but the confidence intervals were wide, which 
suggests this analysis may also have been underpowered. It should be noted that 
functional outcomes did not differ between the three diagnostic groups, which may 
be indicate that a certain level of functioning is required to complete the online 
tasks and the online sample may be a higher functioning sample.   
The current study was cross-sectional so it was not possible to examine whether 
changes in cognitive function are associated with changes in functional outcome in 
cross-disorder samples. In addition, the WHODAS is a broad measure of functional 
outcome that assesses both occupational and social outcomes. Cognitive domains 
may differ in their associations with occupational and social outcomes. A seven-
year longitudinal study of participants with schizophrenia found that individual 
cognitive domains predicted different aspects of functional outcome [184]. Verbal 
memory was associated with recreational activities, whilst attention predicted 
occupational outcomes. Future research should examine whether the association 
with cognitive performance differs for occupational and social outcomes across 
psychiatric disorders. 
6.5.4 Generalizability of the results 
The issue of recruitment bias in the online sample has been discussed extensively 
in section 5.5.4. However, the findings of this chapter expand on the issues 
highlighted in Chapter 5. The effect sizes reported in this chapter are smaller than 
those reported in Chapter 3 and previous meta-analyses. This may be the result of 
recruitment bias. There was some evidence that the schizophrenia and bipolar 
disorder groups were more highly educated than participants with the same 
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disorders in the NCMH and CoMPaSS cohorts (for further discussion, see section 
6.5.1). Therefore, caution is advised in generalising the findings presented here to 
the population of people with these disorders.  
6.5.5 Concluding statements 
Several limitations of this study should be noted. Diagnosis was based on self-
report rather than a structured clinical interview. Participants’ diagnoses were 
confirmed with their clinical team where possible and they were asked to report 
diagnoses that they had been given by a health professional, which is consistent 
with the approach taken by other large studies with self-report measures of 
diagnosis, such as the UK Biobank [388]. In addition, most participants (N=244, 
76% of cases) were taking psychiatric medication at the time of assessment. The 
schizophrenia group was smaller than the bipolar and depression groups due to a 
lower response rate from participants with schizophrenia. It should be noted that 
recruitment to this study is ongoing and participants recruited through secondary 
services who completed structured clinical interviews are currently being invited to 
the study. Due to the study being online, clinical symptom measures were based on 
self-report rather than objective assessments. However, the HADS anxiety and 
depression scores have been demonstrated to have good validity when compared 
with observer ratings of mood symptoms [458]. It was not possible to consider 
negative or psychotic symptoms in these analyses due to the lack of reliable, valid 
self-report questionnaires. Participants were grouped according to their primary 
diagnosis in this study and co-morbid psychiatric diagnoses were not considered. 
This is particularly relevant for participants with major depressive disorder, as 
depression is highly comorbid with other psychiatric disorders and is more likely to 
occur after the onset of another psychiatric disorder [459, 460]. Whilst participants 
with comorbid diagnoses were not excluded, participants were only included in the 
depression group if their primary diagnosis was major depressive disorder, as 
opposed to having a diagnosis of another psychiatric disorder and a secondary 
diagnosis of depression.  
This study has several strengths. The sample is large and includes participants with 
a diverse range of psychiatric disorders. No single published study has compared 
cognition between adults with schizophrenia, bipolar disorder and depression, 
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examined factors associated with cognition and the relationship between cognition 
and functional outcome in a single cohort. The study included measures of current 
anxiety as well as current depression.  
In conclusion, I have recruited a large sample of participants with a range of 
psychiatric disorders using an online cognitive assessment. These findings should 
be considered preliminary as recruitment to this study is ongoing and the 
schizophrenia group was small. This study replicated the earlier findings of 
Chapter 3 showing similar cognitive profiles but more severe impairment in the 
schizophrenia group compared to those with bipolar disorder. This study was the 
first to demonstrate that current symptoms of depression and anxiety are associated 
with cognitive performance in a cross-disorder analysis. Poorer cognitive 
performance was associated with poorer functional outcome across disorders. Self-
reported functional outcome did not differ between diagnoses and was associated 
with cognitive performance even amongst participants with major depressive 
disorder, who did not differ from controls in their overall cognitive function. 
Overall, these results support a role for cognitive function in functional outcome 
that is independent of diagnostic boundaries.  
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Chapter 7: General Discussion 
7.1 Overview 
This thesis set out to characterise the nature and degree of cognitive impairment 
present in psychotic and affective disorders using large datasets and to develop an 
online cognitive battery for use in psychiatric research. Cognitive impairments are 
increasingly recognised as a core feature of psychotic and affective disorders and 
are a strong predictor of functional outcomes for patients [182, 183]. 
Understanding cognitive impairments across these disorders has implications for 
clinical practice and treatment, diagnostic classification of these disorders and to 
inform investigations of biology and genetics. Large cross-diagnostic datasets are 
needed to investigate the environmental and genetic factors that influence cognitive 
function. 
The first approach was to conduct a systematic review and meta-analysis 
comparing cognitive performance in schizoaffective disorder to schizophrenia and 
bipolar disorder. Individual studies that have examined cognitive performance in 
schizoaffective disorder have produced conflicting results. This work indicated that 
schizoaffective disorder was associated with poorer overall cognitive performance 
than bipolar disorder and better cognitive performance than schizophrenia. This 
suggested a gradient of increasing impairment from bipolar disorder to 
schizoaffective disorder to schizophrenia. There was initial evidence to suggest 
differential cognitive performance in the subtypes of schizoaffective disorder but 
few studies had separated the subtypes. The systematic review also confirmed 
earlier findings that a lifetime history of psychosis is associated with the presence 
of cognitive impairments. 
These findings were then built upon by examining cognition in a large and well-
characterised cross-diagnostic sample. Using ordinal regression modelling, it was 
demonstrated that there is a gradient of increasing cognitive impairment from 
bipolar disorder to schizoaffective bipolar to schizophrenia and schizoaffective 
depressive. Comparisons between the diagnoses confirmed that the subtypes of 
schizoaffective disorder show differential cognitive performance. Regression 
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analyses also showed that a dimensional measure of lifetime psychosis is linearly 
associated with cognition. Despite quantitative differences in cognitive impairment, 
the cognitive profiles of the disorders were similar, which could indicate common 
underlying neurobiology.  
An online cognitive battery was developed to gather data on a large cohort of 
participants for whom clinical and genetic data was already available. I developed 
the battery in collaboration with The Many Brains Project using their platform, 
“TestMyBrain.org”. Task selection was informed by the work of the Measurement 
and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) 
initiative. A pilot and validation study was then conducted. Sixty-five participants 
completed the new battery and the MATRICS Consensus Cognitive Battery on 
consecutive days. This study indicated that the online battery provided valid 
measurements of all the MATRICS domains except visual learning. The battery 
was well tolerated in the validation study with 58 out of 65 participants completing 
every task and the feedback was positive. 
The online battery was then rolled out to participants from two studies within the 
MRC Centre for Neuropsychiatric Genetics and Genomics: National Centre for 
Mental Health (NCMH) and Cognition in Mood, Psychosis and Schizophrenia 
Study (CoMPaSS). Participants from these studies have been previously 
administered a clinical interview and provided a blood sample so phenotype and 
genotype data were available. Recruitment for this study is ongoing but data was 
analysed from the first 342 participants who took part in the study. Participants 
were representative of the original cohort in terms of demographic characteristics 
although participants with schizophrenia and post-traumatic stress disorder were 
underrepresented in the online sample (see Chapter 5). Two-thirds of the sample 
completed all the online tasks. An exploratory factor analysis indicated two factors 
with the first factor explaining a high proportion of the variance in cognitive 
performance and the Vocabulary task (a measure of crystallised intelligence) 
uniquely loading onto the second factor. 
Finally, the data collected using the online cognitive battery was used to examine 
the nature and extent of cognitive impairments in participants with major 
depressive disorder, bipolar disorder and schizophrenia (Chapter 6). Findings from 
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this study mirrored those of Chapter 3, indicating that cognitive profiles are similar 
across disorders but participants with schizophrenia have more severe impairments 
than participants with bipolar disorder. Participants with major depressive disorder 
did not differ from healthy controls in their cognitive function. Regression analyses 
showed that concurrent symptoms of both depression and anxiety at the time of 
cognitive testing, are associated with cognitive performance across psychiatric 
disorders. An important concluding observation was that poorer cognitive 
performance was associated with poorer functional outcome across disorders.  
The findings of this thesis add to a growing literature showing the importance of 
examining cognitive function across psychiatric disorders. To date, it is the first 
study to develop and utilise an online cognitive assessment for psychiatric research. 
The key findings and potential implications of this work are discussed in the next 
section. 
7.2 Summary and context of findings 
The following summary is divided into two main sections based on the central aims 
of this thesis. The first section describes the main findings of the studies examining 
the nature and degree of cognitive impairment across disorders (Chapters 2, 3 and 
6). The second section describes the development of the online cognitive battery 
and the main findings from the validation and main recruitment phases of the study 
(Chapters 4 and 5). 
7.2.1 Cognition across major psychiatric disorders 
Cognition across the bipolar-schizophrenia diagnostic spectrum 
A central finding of this thesis is that there is a gradient of increasing cognitive 
impairment from bipolar disorder through schizoaffective disorder – bipolar type to 
schizoaffective disorder – depressive type and schizophrenia. This was supported 
by the findings of the meta-analysis and analysis of the CoMPaSS sample. 
Differences between the groups were smaller in magnitude in the meta-analysis. 
However, there was evidence of heterogeneity in the distribution of effect sizes for 
individual cognitive domains and few studies included data on the subtypes of 
schizoaffective disorder.  The CoMPaSS study included a large, well-characterised 
sample assessed with a recognised gold-standard battery of cognitive tasks. The 
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sample was sufficiently large enough to separate the subtypes of schizoaffective 
disorder. In the CoMPaSS study, the differences between groups were larger in 
magnitude. The cognitive impairments observed in the bipolar disorder group were 
on average 0.5-1.25 standard deviations below the control group, this increased to 
1-2 standard deviations in the schizoaffective disorder – bipolar type group and 1-
2.5 standard deviations in the schizoaffective disorder – depressive type and 
schizophrenia groups. The effect sizes reported in Chapter 3 are consistent with 
findings of meta-analyses of cognitive performance in bipolar disorder [237-240] 
and schizophrenia [191-193].  
The results of the meta-analysis and CoMPaSS studies expand on existing literature 
through three novel findings. Firstly, there was preliminary evidence in the meta-
analysis that cognitive impairments were similar in schizophrenia and 
schizoaffective disorder – depressive type but in contrast the bipolar type of 
schizoaffective disorder was associated with less severe impairments than 
schizophrenia. These initial findings were borne out in the analysis of the 
CoMPaSS sample. These results raise a potential limitation of previous studies that 
combined the subtypes of schizoaffective disorder for cognitive analysis, and 
which may have had the effect of obscuring differences between schizoaffective 
subtypes. Secondly, a gradient of increasing cognitive impairment from bipolar 
disorder to schizoaffective disorder – depressive type and schizophrenia was 
demonstrated in the CoMPaSS sample using ordinal regression modelling. Finally, 
the study showed that lifetime psychosis is linearly associated with severity of 
cognitive impairments. 
These results offer important insights for psychiatric nosology providing support 
for a dimensional model of psychotic and affective disorders. Diagnostic criteria 
such as DSM-5 and ICD-10 maintain Kraepelin’s dichotomy between 
schizophrenia and bipolar disorder, although ICD-11 will incorporate symptom 
specifiers (including cognition) that can be utilised across certain disorders [461]. 
The National Institute for Mental Health’s Research Domain Criteria (RDoC) 
encourages researchers to adopt a dimensional approach to measuring 
psychopathology (including cognition) rather than using existing categorical 
diagnoses [25, 28, 29]. The findings of Chapter 3 adds to a growing body of 
evidence showing overlap in the presentations of patients with schizophrenia and 
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bipolar disorder and demonstrates the value of examining psychopathology across 
disorders. Cognitive profiles were similar across the disorders and the groups 
differed chiefly on the severity of impairments (except for social cognition). This is 
consistent with dimensional models, including the model proposed by Owen et al. 
[24, 26, 27]. Owen and colleagues have proposed that intellectual disability, autism, 
schizophrenia, schizoaffective disorder and bipolar disorder occupy a gradient of 
neurodevelopmental impairment [24, 26, 27]. They argue that differences in 
cognitive impairment across the disorders are the result of quantitative rather than 
qualitative differences in neurobiological factors, such as polygenic risk, burden of 
copy number variants (CNVs) and neurobiological dysfunction. In support of this 
model, studies have identified overlapping polygenic risk between schizophrenia 
and bipolar disorder [73, 74]. Participants with schizophrenia show an increased 
burden of CNVs that are also associated with intellectual disability [65, 66] but 
such an increased burden is not found in studies of bipolar disorder [69-72]. There 
is evidence of reduced grey matter in similar regions of the brain across disorders 
(bipolar disorder, schizoaffective disorder and schizophrenia) [347, 348]. However, 
reductions in grey matter are less extensive in participants with bipolar disorder 
[347, 348]. These differences in genetic and neurobiological vulnerabilities may 
manifest in greater cognitive impairment for patients with schizophrenia. Genetic 
and neurobiological factors were not considered in this study but future studies 
should investigate whether these factors are associated with cognitive function in a 
cross-disorder sample. For example, the Bipolar-Schizophrenia Network on 
Intermediate Phenotypes (B-SNIP) study has measured grey matter volume, 
sensorimotor reactivity and cognitive performance in their sample of participants 
with bipolar disorder, schizoaffective disorder and schizophrenia [462]. They 
utilised cluster analysis in their cross-disorder sample and identified three 
subgroups. Group 1 was impaired on measures of cognition, sensorimotor 
reactivity and social functioning and had widespread grey matter reduction. Group 
2 had less severe impairments and regionally similar but smaller grey matter 
reductions compared to Group 1. Group 3 was cognitively normal with slight 
impairments in sensorimotor reactivity and modest localised reductions in grey 
matter. In both studies, diagnoses were represented across the groups but bipolar 
disorder was overrepresented in the cognitively normal group and schizophrenia 
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was overrepresented in the globally impaired group. Those with schizoaffective 
disorder were more evenly distributed across the clusters. 
The finding that all patient groups are impaired relative to the healthy controls has 
implications for the development of cognition-enhancing therapies. Pharmaceutical 
approaches to improve cognitive function in psychiatric disorders have targeted a 
wide range of neurotransmitter systems, including dopaminergic, noradrenergic, 
serotonergic and glutamatergic systems, although studies have reported limited 
efficacy [463]. Non-pharmaceutical approaches that have been examined include 
repetitive transcranial magnetic stimulation and cognitive remediation therapy 
[463]. Application of repetitive transcranial magnetic stimulation over the 
dorsolateral prefrontal cortex has been shown to have modest effects on cognitive 
function in participants with schizophrenia [464] and depression [465]. Cognitive 
remediation therapy has been shown to be beneficial to participants with 
schizophrenia in improving task-specific cognitive performance, although smaller 
effect sizes are reported when the outcome measure is overall functioning or 
negative symptoms [466-469]. Cognitive remediation therapy also requires a 
regular commitment of time and motivation, which may be a barrier for some 
patients [463]. If similar mechanisms are involved in the development of cognitive 
impairments across disorders, then any therapy developed to improve cognitive 
functioning may be beneficial for patients with a variety of psychiatric disorders 
[463].  
Examining cognition across disorders using an online cognitive battery 
The study in Chapter 6 develops approaches such as those reported in Chapter 3 by 
applying online cognitive assessment to examine cognitive impairment in a sample 
of participants with a diverse range of psychiatric disorders. Cognitive performance 
was compared between participants with major depressive disorder, bipolar 
disorder and schizophrenia. The associations between a set of clinical variables 
(current depressive symptoms, current anxiety symptoms and age of onset) and 
cognitive performance were examined both within and across disorders. The 
relationship between cognitive performance and functional outcome (as assessed 
by the World Health Organisation Disability Assessment Scale 2.0) was also 
examined within and across disorders. 
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The results of this chapter mirror the findings of Chapter 3 by demonstrating 
greater cognitive impairment in participants with schizophrenia than participants 
with bipolar disorder. Cognitive profiles did not differ between groups. However, 
this study expanded on these findings by including participants with major 
depressive disorder. Participants with major depressive disorder did not exhibit 
cognitive impairments relative to controls (Hedges’ g effect sizes ranged from -0.1 
to 0.31). These results contradict the findings of previous meta-analyses that have 
identified mild to moderate impairments in memory, attention and executive 
function and reported effect sizes ranging from 0.32 to 0.97 across domains [426, 
428, 429]. It was also noted that effect sizes for the bipolar disorder and 
schizophrenia groups were smaller in magnitude in this study compared to Chapter 
3. Performance in the bipolar disorder group was on average 0.1 to 0.5 standard 
deviations below the control group across the domains (compared to -0.5 to -1.25 
in Chapter 3). Performance in the schizophrenia group was on average 0.4 to 0.9 
standard deviations below the control group (compared to -1 to -2.5 in Chapter 3). 
This may be explained by the use of online assessments, which may have resulted 
in participation bias (discussed further in the following sections). In addition to this, 
the major depressive disorder group were mainly recruited into NCMH non-
systematically (primarily through media campaigns). Therefore, this group may not 
be as impaired as participants recruited through health services.   
Current symptoms of depression and anxiety were associated with cognitive 
performance in a cross-disorder analysis. Previous studies have shown that severity 
of depressive symptoms is associated with severity of cognitive impairments in 
participants with either major depressive disorder [426, 434] or bipolar disorder 
[258, 435]. To my knowledge, this is the first study to demonstrate that higher 
levels of anxiety are associated with greater cognitive impairment across disorders. 
This finding has important clinical implications. It suggests that patients 
experiencing increased depression or anxiety may exhibit poorer cognitive function, 
irrespective of their diagnosis. 
Another novel finding of this study was that poorer cognitive performance was 
associated with poorer functional outcome in a cross-disorder analysis. This 
expands on previous findings in schizophrenia [183], bipolar disorder [182] and 
major depressive disorder [430]. The result is consistent with a study of cognition 
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and functional outcome in young participants (aged 12-35 years) with recent-onset 
depression, bipolar disorder and psychosis [186]. Although the major depressive 
disorder group did not exhibit cognitive impairments on average, poorer cognitive 
performance was associated with poorer functional outcome in this group. This 
suggests that cognitive function is still clinically relevant in major depressive 
disorder. The association was also found when participants with a primary 
diagnosis of major depressive disorder, bipolar disorder or schizophrenia were 
excluded. However, it should be noted that the study was cross-sectional so it was 
not possible to establish the direction of causality. 
Social cognition 
Whilst deficits in neurocognitive domains were present across disorders, deficits in 
social cognition were associated with schizophrenia and schizoaffective disorder 
only. In Chapter 3, participants with bipolar disorder did not exhibit impairments 
on the Mayor-Salovey-Caruso Emotional Intelligence Test – Managing Emotions 
(MSCEIT-ME) subtest, whilst participants with schizophrenia and schizoaffective 
disorder were markedly impaired. Furthermore, current psychotic symptoms were 
associated with deficits in performance on the MSCEIT-ME but were not 
associated with any of the other domains. In Chapter 6, participants with 
schizophrenia exhibited impaired performance on the Morphed Emotion 
Identification task, whilst only small, non-significant impairments in performance 
were found in participants with bipolar disorder or major depressive disorder. 
These results are consistent with a recent meta-analysis that identified more severe 
deficits in facial emotion recognition and theory of mind in participants with 
schizophrenia than participants with bipolar disorder [265]. 
Participants with schizophrenia exhibit deficits in theory of mind, social perception, 
emotion perception and emotion processing [470]. The measures used in this thesis 
assess emotion processing (MSCEIT-ME) and facial emotion identification 
(Morphed Emotion Identification). The observation that social cognition was 
associated with positive symptoms may provide insights into the psychological 
modelling of psychotic symptoms. It has been proposed that social cognition may 
play a role in the development and maintenance of delusions [354]. Deficits in 
facial emotion recognition are apparent in participants at clinical high-risk for 
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schizophrenia and first-episode participants [471-473]. It has been proposed that an 
impaired ability to recognise emotions could predispose individuals to develop 
paranoid thoughts [474]. An alternative explanation could be that poor social 
functioning increases exposure to adverse environments that in turn increase risk 
for the development of psychosis [474]. One study did not find an association 
between deficits in emotion recognition and conversion to psychosis in at-risk 
individuals, although only 25 participants developed psychosis in the two-year 
follow-up period [472]. 
Other domains of social cognition were not considered in this thesis. For example, 
participants with schizophrenia exhibit pronounced deficits in theory of mind 
(ToM) [470]. These deficits are also present in ultra-high risk and first-episode 
participants [475]. Deficits in ToM have been shown to predict conversion to 
psychosis in participants at clinical high risk of psychosis [219]. ToM impairments 
are more severe in participants with schizophrenia than those observed in 
participants with bipolar disorder [265]. Future studies should examine whether 
other domains of social cognition follow the same pattern of findings, as those 
reported here for social processing and identification.  
7.2.2 Development of an online cognitive battery 
Cognitive data was collected using the MATRICS Consensus Cognitive Battery 
(MCCB) in Chapter 3. The MCCB is considered a gold standard assessment. 
However, administering the MCCB is labour intensive so gathering data on very 
large samples is logistically difficult and expensive. The battery requires a 
specially trained researcher to administer it [278]. All but one of the tasks are pen 
and paper tasks so presentation of the stimuli, scoring and recording the data is all 
done manually so there are potential experimenter effects [272]. The battery takes 
up to one and a half hours to administer so is time-consuming [277]. By contrast, 
an online battery is relatively inexpensive despite the initial setup costs, does not 
require specially trained administrators and data is scored and entered 
automatically [272]. At the time of writing, no online cognitive batteries had been 
shown to be suitable for collecting data from participants with psychiatric disorders. 
One of the main aims of the PhD was to develop an online cognitive battery that 
measured the MATRICS domains and pilot this battery in a cross-disorder sample. 
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The online battery assessed 9 domains of cognition: speed of processing, verbal 
learning, visual learning, reasoning and problem solving, working memory, 
attention, social cognition, strategic risk taking and premorbid IQ. Participants with 
schizophrenia, bipolar disorder or major depressive disorder were recruited to 
complete the MCCB and the online battery in a pilot and validation study (Chapter 
4). In Chapter 4, the convergent validity of the online tasks was evaluated. 
Convergent validity is measured by assessing the extent to which two tasks 
assumed to measure the same construct are correlated [476]. The results of these 
analyses indicated that seven out of eight online tasks were correlated with their 
MCCB equivalent, although scores on only four tasks had the highest correlations 
with their MCCB equivalents compared to other MCCB tasks. The online study 
was then rolled out to participants from two studies within the MRC Centre for 
Neuropsychiatric Genetics and Genomics at Cardiff University (Chapter 5). The 
data collected from these two chapters was used to examine cognitive impairments 
in a cross-disorder sample.  
Overall the results of the three chapters indicate that the online battery is a useful 
tool for gathering cognitive data in large cohorts and across disorders. The battery 
itself had five main strengths: 1) good convergent validity with the MCCB; 2) 
moderate to high correlations with general cognitive ability (‘g’) across tasks; 3) 
was associated with a measure of functional outcome; 4) discriminated between 
cases and controls; 5) can be run on touchscreen devices as well as computers. The 
properties of each task are summarised in Table 7-1. The main strength of using 
online recruitment was the large amount of cognitive data collected in a short time 
period at an inexpensive cost. The online sample was representative of the original 
cohort in terms of age, gender and clinical variables (age of onset and history of 
hospital admission) but there was evidence that online participants were more 
highly educated, less likely to be diagnosed with schizophrenia or post-traumatic 
stress disorder and less likely to have been recruited from secondary services.  
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Table 7-1 Summary of results from Chapters 4-6 
 
Correlates 
with MCCB 
equivalent? 
Correlates with 
measure of general 
cognitive ability (‘g’) 
derived from MCCB? 
Associated 
with 
functional 
outcome? 
Discriminates 
between cases 
and controls? 
Digit Symbol 
Coding 
Yes Yes Yes Yes 
Morphed 
Emotion 
Identification 
Yes1 Yes No Yes 
Verbal Paired 
Associates 
Yes Yes No Yes1 
Backward 
Digit Span 
Yes1 Yes Yes Yes1 
Hartshorne 
Visual 
Working 
Memory 
No Yes1 Yes Yes1 
Matrix 
Reasoning 
Yes Yes No Yes 
Multiple 
Object 
Tracking 
Yes1 Yes No Yes1 
Balloon 
Analogue Risk 
Task 
N/A2 No Yes1 No 
Vocabulary Yes Yes1 No Yes1 
1Not significant after correction for multiple testing; 2There is no equivalent to the Balloon Analogue Risk Task 
in the MCCB. N/A, not applicable. 
One shortcoming of the battery is the amount of missing data during later tasks. 
Excluding data collected during the pilot and validation, 66% of the sample had 
completed all tasks. In comparison, 89% of participants had full data on the MCCB 
in Chapter 3. This may be a consequence of unsupervised online testing, as studies 
utilising online cognitive assessments have reported similar completion rates [274, 
410]. However, other factors differed between the two studies and this may have 
affected completion rates. For example, participants were reimbursed for their time 
in CoMPaSS and whilst this was not conditional on completing the MCCB, 
participants may have assumed that they needed to complete the full battery. In the 
validation study, completion rates were comparable for the MCCB and the online 
battery suggesting that the use of unsupervised online testing does not fully explain 
the difference in completion rates between the two studies. 
302 
 
The effect sizes were smaller in Chapter 6 compared to those found using the 
MCCB, which may indicate that participants with more severe cognitive 
impairment are less likely to take part in the online study. In Chapter 5, the results 
indicated that online participants were less likely to have been recruited into 
NCMH through secondary services, which may suggest that they have a less severe 
illness. The duration of the battery (45-50 minutes) may discourage certain groups 
from participating and result in high drop-out rates for the later tasks. This could be 
resolved by reducing the number of tasks in the battery to create a brief assessment. 
The results of the factor analysis in Chapter 5 indicated high correlations between 
tasks and only two factors were extracted. Therefore, a condensed version of the 
battery may be a useful alternative for particularly impaired populations and is one 
area of further development. Tasks should be selected systematically based on 
specified criteria. Based on the results of Chapters 4-6 (see Table 7-1), Digit 
Symbol Coding and Backward Digit Span would be suitable candidates for 
inclusion in a brief battery, as the tasks are highly correlated with their MCCB 
equivalents and ‘g’, associated with functional outcome, discriminate cases and 
controls and have short administration times. In contrast, the Balloon Analogue 
Risk Task (BART) was found to have little value in research of psychiatric 
populations. Performance on the BART was shown to have a small association 
with functional outcome but did not discriminate between cases and controls.  
Another consideration in any online research is technical issues. Across the 
validation and main studies, 17 participants reported technical problems (4% of the 
total sample). Most participants went on to complete all online tasks. More work is 
needed to determine what impact technical issues have on performance. 
Researchers utilising online assessments need to anticipate the occurrence of 
technical issues in their study design and consider how to account for these in 
analyses of the data. In the current study, participants who reported technical issues 
were included in all analyses. However, if there is evidence that technical issues 
adversely impact performance on the remaining tasks then it may be better to 
exclude the participant’s scores on these tasks.  
One psychometric property of the battery that has not been assessed is test-retest 
reliability. The correlation between two tasks cannot exceed the square root of the 
product of the test-retest reliabilities of both tasks [272]. Therefore, the 
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interpretation of the correlations between the online battery and MCCB depend on 
the test-retest reliability of the tasks. This does not affect the magnitude or 
significance of the correlations that were found between the tasks, although it 
would be helpful for interpretation. Future research should evaluate the test-retest 
reliability of the battery.  
Existing cognitive batteries (including the MCCB) are predominantly under 
copyright and therefore expensive to administer. It is my intention to continue 
collaborating with The Many Brains Project to make the battery freely available to 
researchers and potentially healthcare providers, although this will require 
additional validation and impact studies. The findings so far indicate that the online 
battery is useful for collecting large samples of cognitive data from people with 
psychiatric disorders with some caveats. Access to the internet and a computer is 
essential for individuals who wish to take part and there is evidence of a digital 
divide between patients with psychiatric disorders and the general population [270, 
271]. However, the online battery can be run on touchscreen devices, such as tablet 
computers and smart phones, which is important given evidence that patients with 
psychiatric disorders are increasingly using these devices to access the internet 
[270]. Participation in an online study is also likely to be influenced by the person’s 
computing abilities and confidence in using the internet, although ability and 
confidence were not assessed in the current study. Based on the results of Chapter 5, 
there are a number of groups who are less likely to engage with an online cognitive 
assessment, including patients with schizophrenia, psychosis or PTSD and those 
with lower educational attainment. The most significant predictor of participation 
in the online study was recruitment method into NCMH, as participants originally 
recruited from secondary services were less likely to take part. This may indicate 
that online participants have a less severe illness but this was not formally assessed. 
However, providing additional support or motivation to participate may increase 
recruitment rates from these groups. The online battery can be used to measure 
general cognitive function and provides valid measurements of the majority of 
MATRICS domains. However, this online battery is not suitable for assessing free 
recall memory (particularly verbal memory) or reaction times.  
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7.3 Methodological considerations in cognitive research of psychiatric 
disorders 
7.3.1 Influence of demographic and clinical variables 
There are several demographic and clinical variables that may influence cognitive 
performance of participants with psychiatric disorders, including age, sex, current 
and lifetime symptoms and current and lifetime medication use. A strength of this 
PhD is the inclusion of covariates and the use of regression models to estimate the 
contributions of these factors to cognitive performance. In Chapter 3, the results of 
comparisons between groups were robust to the inclusion of age, sex, current 
psychotic symptoms, current negative symptoms, current dose of antipsychotic 
medication and duration of antipsychotic use as covariates. In Chapter 6, the results 
of comparisons were robust to the inclusion of age, sex, current depressive 
symptoms and current anxiety symptoms. The associations between symptoms and 
cognition were also examined in cross-disorder analyses. Overall, the results 
reported in this thesis indicate that factors associated with severity of cognitive 
impairments include: diagnosis, current and lifetime negative symptoms, lifetime 
history of psychosis, current dose of antipsychotic medication, duration of 
exposure to antipsychotic medication, current depressive symptoms and current 
anxiety symptoms. The relationship between diagnosis and cognitive impairments 
has been discussed in the previous section and the remaining factors are discussed 
in the remainder of this section. However, it should be noted that there are likely to 
be other unidentified confounding variables influencing the between-group 
comparisons.  
Negative symptoms explained a larger proportion of the variance in cognitive 
scores than diagnosis, although there was no association between negative 
symptoms and cognition when the analyses were restricted to participants with 
bipolar disorder and schizoaffective disorder – bipolar type (see Chapter 3). A 
review of 58 studies showed that negative and disorganised symptoms are 
associated with neurocognitive impairment, whilst positive symptoms were not 
[440]. Whether there is a causal relationship between negative symptoms and 
cognitive performance is unclear and three potential explanations for the 
association are described here. Firstly, poor cognitive performance may be the 
result of negative symptoms such as reduced motivation and interest. Secondly, 
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certain negative symptoms may be a manifestation of poor cognitive function. For 
example, anhedonia may be the result of reduced attention and memory that 
hinders patients’ ability to participate in and enjoy activities, whilst deficits in 
social cognition may make maintaining social relationships difficult. Thirdly, both 
cognitive impairments and negative symptoms may be manifestations of a single 
disease process. For example, dopamine hypoactivity in the prefrontal cortex has 
been associated with both negative symptoms and cognitive impairments [477]. 
Lifetime history of psychosis was associated with (decreased) cognitive function. 
Studies included in the systematic review reported milder or no cognitive 
impairments in participants with bipolar disorder and no history of psychosis [303, 
316, 319, 321], whilst participants with bipolar disorder and a history of psychosis 
exhibited deficits closer in magnitude to schizoaffective disorder [295, 308, 314, 
316]. In the CoMPaSS sample, greater frequency and severity of psychosis over the 
course of illness was associated with greater cognitive impairment across the 
diagnostic groups and within subgroups (see Chapter 3). A related finding was that 
participants who were taking higher doses of antipsychotic medication at the time 
of assessment or had longer duration of antipsychotic medication use showed more 
severe impairments. However, antipsychotic medication use did not fully account 
for the relationship between lifetime psychosis and cognitive performance. In 
addition, current psychosis was not associated with cognitive function, although it 
should be noted that the majority of participants were not acutely psychotic at the 
time of assessment so only chronic or residual psychotic symptoms were examined 
in this study. Other factors that might account for the relationship between more 
severe and frequent psychosis and greater cognitive impairments include younger 
age of onset, more frequent or prolonged hospitalisations or greater substance use. 
Alternatively, lifetime psychosis may be associated with cognitive function 
because both are markers of illness severity so participants with a more severe 
illness course exhibit greater cognitive impairment and more severe or frequent 
psychotic episodes.  
In Chapter 6, higher scores on scales assessing current depressive and anxiety 
symptoms were associated with lower cognitive performance. These effects were 
observed in a cross-disorder analysis but did not explain differences between 
participants with major depressive disorder, bipolar disorder and schizophrenia. 
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There are several possible explanations for this finding. More severe symptoms of 
depression or anxiety may affect cognitive performance directly by reducing the 
participant’s concentration or slowing psychomotor responses. An alternative 
explanation is that higher scores on the Hospital Anxiety and Depression Scale 
may indicate a more severe illness course or a relapse in the participant’s illness 
resulting in greater cognitive impairment. The results may be confounded by 
medication use, which was not explored in this study. Symptoms of depression and 
anxiety are highly correlated, so it was not possible to disentangle the contributions 
of these symptoms.  
Premorbid IQ was included as a covariate in a separate analysis to examine 
whether differences in IQ before onset of disorder could explain the differences 
between groups. However, caution is advised in the interpretation of these results. 
Cognitive deficits are present before the onset of schizophrenia and it has been 
argued that schizophrenia is a neurodevelopmental disorder [214, 215, 356]. As 
such, low premorbid IQ and schizophrenia are not independent. Covariates in 
analysis of covariance should be unrelated to the independent variable and 
controlling for premorbid IQ can result in over-correction for group differences 
[478]. The results of Chapter 3 suggested that cognitive decline is similar between 
participants with schizoaffective disorder and schizophrenia. Differences between 
schizoaffective disorder – bipolar type and bipolar disorder were larger after 
accounting for premorbid IQ suggesting that schizoaffective disorder – bipolar type 
is associated with greater cognitive decline than bipolar disorder. However, this 
was not empirically tested and should be investigated using a longitudinal design. 
One confounder that was not addressed in this thesis was substance use. The most 
commonly used substances were alcohol and tobacco. Current alcohol use was 
reported by 32% of participants in the CoMPaSS sample and 55% of the online 
sample. Whilst alcohol use causes acute cognitive impairments [479, 480], most 
participants in the samples (CoMPaSS: 95%; online: 87%) had not consumed 
alcohol for at least 12 hours and so this seems unlikely to have affected the results. 
The percentages of current smokers in each sample were 58% of the CoMPaSS 
sample and 19% of the online sample. However, smoking cigarettes has been 
associated with small improvements in cognitive performance in participants with 
schizophrenia suggesting that studies including participants who have recently 
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smoked may be more likely to underestimate the degree of impairment rather than 
overestimate it [481].  
The most commonly used illegal substance across the two samples was cannabis. 
Current cannabis use was reported by 6% of the CoMPaSS sample and 4% of the 
online sample. Cannabis use has been associated with acute impairments in 
memory [482], attention [483] and planning [483] in the general population. These 
impairments are transient with no differences found between non-users and 
cannabis-users who have abstained for at least 25 days [484]. A meta-analysis of 
cannabis use and cognitive function of participants with schizophrenia found 
superior performance in the user group compared to the non-user group [485]. The 
same authors found similar results amongst participants with first-episode 
psychosis. First-episode participants who used cannabis were impaired on 9 out of 
16 tasks, whilst participants who did not use cannabis were impaired on 15 tasks. 
The authors propose several explanations for these surprising results, including 
misdiagnosis of substance-induced psychosis as schizophrenia, that cannabis use 
may induce psychosis in individuals who are less “cognitively vulnerable” or may 
alleviate psychotic symptoms thus improving cognitive performance [485]. 
However, a more recent meta-analysis found that current cannabis users with 
schizophrenia exhibited worse performance on measures of premorbid IQ, current 
IQ and working memory [486]. Few participants across the samples reported 
current use of illicit substances other than cannabis (2% of CoMPaSS participants 
and 1% of online participants). In conclusion, it is unlikely that illicit substance use 
affected the results reported, as substance use was low both in the CoMPaSS and 
online samples. However, illicit substance use may be under-reported. 
Neither educational attainment nor socioeconomic status was included as a 
covariate in any analysis. Cognitive deficits are apparent before the onset of these 
disorders and onset is typically in late adolescence to early adulthood [214, 215, 
356]. A consequence of this can be a reduced number of years in education. 
Similarly, current socioeconomic status is also affected by diagnosis. Therefore, 
educational attainment and socioeconomic status can be a consequence of the 
pathology of the disorder rather than confounders. For this reason, controlling for 
these variables can eliminate the variance in cognitive performance between 
diagnostic groups.   
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7.3.2 Representativeness of samples included 
An important consideration in cognitive studies of participants with psychiatric 
disorders is recruiting representative samples. Participants should reflect the 
population of individuals with that disorder in the community. To encourage 
recruitment, tasks must be tolerable for participants and of reasonable duration and 
difficulty. Failure to recruit a representative sample can lead to an underestimation 
or overestimation of the extent of cognitive impairments in a patient group. The 
severity of cognitive impairments may be underestimated if participants with the 
most severe illness are unable or do not wish to participate. Conversely, the extent 
of impairments may be overestimated if the sample is underrepresented by 
participants with less severe illness courses. Individuals with a less severe illness 
course may be less likely to participate due to time constraints (such as work) or 
because they feel the study may be less relevant to them. They may also be harder 
to recruit if they have recovered and are no longer in contact with secondary 
services. The two studies described in this thesis used different recruitment 
methods and each has advantages and disadvantages. 
CoMPaSS is a large UK-based study, which recruits participants from the 
community via outpatient clinics, clozapine and depot clinics, early intervention 
psychosis services and using posters, leaflets, website and voluntary organisations. 
A wide range of recruitment methods is employed to ensure the sample is 
representative of the population, which is predominantly from south Wales but also 
north and west Wales, west England, and the cities of Leeds and Hull. Most 
participants are outpatients at the time of assessment. The study protocol takes two 
to three hours to complete and requires a face-to-face interview either at the 
participant’s home, local psychiatric clinic or at Cardiff University. This may be a 
barrier to participation for some individuals, particularly if they are more severely 
impaired or work full time. The main method of recruitment is through secondary 
services. As noted above, individuals who have shown good recovery may no 
longer be in contact with secondary services and therefore may be 
underrepresented in this study. The sample is also enriched for individuals with 
treatment-resistant schizophrenia due to recruitment from clozapine clinics. In 
contrast, the advantage of the online study is that individuals can take part at a time 
that best suits them. The study is also comparatively shorter taking approximately 
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one hour to complete. Results from Chapter 5 indicated that the study was largely 
representative of the original NCMH cohort but had lower response rates from 
participants with schizophrenia and post-traumatic stress disorder. A disadvantage 
of this study is that participants need computer skills and access to a computer and 
the Internet. Therefore, participants with more severe cognitive impairments may 
be underrepresented in this study.  
Another important consideration when recruiting participants with mood disorders 
and schizophrenia is phase of illness. Mood disorders typically have an episodic 
course, whilst schizophrenia is a chronic condition. It is debatable whether patients 
with mood disorders should be recruited when they are in a mood episode or 
remission. Studies that recruit stabilised patients (such as CoMPaSS) are likely to 
include participants with differing levels of symptoms. Participants with mood 
disorders are likely to be experiencing few or no symptoms, whilst participants 
with schizophrenia are more likely to have negative symptoms and residual 
psychotic symptoms. Participants with schizoaffective disorder may be 
experiencing mood, psychotic or negative symptoms, a combination of these or no 
symptoms. However, only recruiting participants who are symptom free would not 
be representative of the population of patients with these disorders and thus the 
results would be less generalizable. Other studies have recruited acutely unwell 
patients (for example, Amann et al. [295]) but this may overestimate the level of 
impairment and is less generalizable to patients in the community. 
7.3.3 Cognitive assessments 
The selection of suitable cognitive assessments is another important consideration 
in research. The tasks selected should be tolerable for participants and show good 
validity and reliability. The tolerability, validity and reliability of the MCCB (used 
in Chapter 3) is well-established [203]. One of the aims of this thesis was to 
develop an online alternative to the MCCB and establish its validity by comparing 
the two batteries. Seven out of eight online tasks were correlated with their MCCB 
equivalent (correlations ranged between 0.26 and 0.73). Two-thirds of participants 
completed all tasks and feedback from participants was positive suggesting the 
tasks are tolerable for most participants.  
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More generally, there are limitations that apply to the use of cognitive assessments, 
such as the ones utilised in this thesis [487]. Cognitive tasks were scored based on 
the speed or accuracy of performance and do not directly measure specific neural 
processes [212]. Performance on any cognitive task requires numerous neural 
processes to interact to achieve the goal. It is not possible to assess using these 
tasks how these individual processes interact, for example whether they run in 
serial or parallel. Analyses of cognitive data ignore the relationship between 
different components of cognition because they focus on measuring one specific 
domain, such as working memory. In addition, analysis of cognitive data assumes 
that each person tackles a cognitive task in the same way.  
All cognitive assessments require attention. Attention processes are influenced by 
numerous factors, including the nature and intensity of the stimuli and relevance of 
the stimuli to the individual’s goals. In the real world, a person’s attention can be 
drawn to aspects of the environment (stimulus-driven [488]) or driven by the 
person’s behaviour (goal-directed [489]) and in turn that person’s behaviour can 
change the stimuli around them. In cognitive assessments, the researcher rather 
than the participant manipulates the stimuli. Therefore, it has been argued that 
cognitive tasks lack ecological validity [487, 490]. 
Despite these limitations, performance on cognitive tasks predicts functional 
outcome in patients suggesting these tasks are functionally relevant and argues for 
their continued use in research of psychiatric disorders. In addition to this, 
cognitive performance is heritable [188] and studies have demonstrated polygenic 
overlap between cognitive performance and schizophrenia [491]. Stratifying 
participants by cognitive performance has also been shown to be useful in a study 
examining the burden of rare genetic variants in participants with schizophrenia 
[492].  
7.3.4 General or specific cognitive impairments 
Scores on pairs of cognitive tasks are moderately correlated. The fact that a portion 
of the variance in each task can be attributed to a general cognitive factor (known 
as ‘g’) was noted by Spearman [205]. Spearman described ‘g’ as the general 
intellectual function required for completing all cognitive tasks. This has remained 
a fundamental concept of cognitive psychology, although later theories of 
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intelligence posited a division between fluid and crystallised intelligence [493]. 
The implication of ‘g’ is that the deficits across cognitive domains seen in cases 
may be the result of a unitary deficit in general cognitive function. Approximately 
two-thirds of the difference in performance between participants with 
schizophrenia and healthy controls can be accounted for by ‘g’ [207, 208]. The 
results of Chapters 3 and 6 indicated that cognitive profiles across disorders were 
similar, which could indicate shared underlying neurobiology. An alternative 
explanation is that performance on the tasks depends on ‘g’. Thus, variation in the 
extent of impairments between cognitive domains may be related to some aspect of 
the individual tasks, such as difficulty.  
In Chapter 5, the factor structure of the online cognitive battery was examined and 
this provided further evidence that ‘g’ explains a large proportion of the variance in 
cognitive performance across domains. Performance on all the online tasks was at 
least moderately correlated (r ranged from 0.13 to 0.57). The first factor (‘g’) 
explained 77% of the variance in cognitive performance and all but two of the tasks 
loaded onto this first factor. This finding has several implications. If scores across 
the tasks are highly loaded on a single factor then this argues against using a large 
number of tasks to assess separate domains. Therefore, it may be more beneficial 
for studies to assess global cognition using a brief battery. This may reduce the 
amount of missing data and place less demand on participants, particularly amongst 
those with severe cognitive impairments. In addition to this, this suggests that 
unitary measures of ‘g’ can be combined from studies using different cognitive 
assessments, which is of particular importance in large genomic studies that 
aggregate genotype and phenotype data from multiple datasets [494]. A 
disadvantage of ‘g’ is it is a relatively non-specific measure and may not be useful 
for studies that seek to identify the specific underlying pathology that causes 
cognitive impairments. Tasks that assess specific cognitive mechanisms, such as 
those included in the Cognitive Neuroscience-Based Approaches to Measuring and 
Improving Treatment Effects on Cognition in Schizophrenia (CNTRICS) initiative 
[212], may be useful for identifying specific neurobiological mechanisms that 
contribute to the development of cognitive impairments.  
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7.4 Future work 
The discussion above has highlighted several potential questions for future research. 
Work is ongoing to invite participants from NCMH (over 10,000 individuals) and 
CoMPaSS (over 1,200 individuals) to complete the online battery, as well as 
expanding ethical approval to other studies within the department. To date (March 
2018), over 700 individuals have participated in the online cognition study. These 
participants have phenotype and genotype data available, which will enable us to 
examine a range of research questions. In Chapter 6, there were insufficient sample 
sizes of certain diagnoses to be able to examine cognitive function in participants 
with specific disorders and this could be explored in future analyses. There is 
currently limited phenotype data on the NCMH cohort but there is ongoing work to 
collect more in-depth data through questionnaires and structured clinical interviews. 
More extensive phenotype information could be used to examine whether the 
results of Chapter 3 can be extended to other disorders, such as major depressive 
disorder. These analyses could include examining whether there is a linear 
association between lifetime psychosis and cognition in depression and the impact 
of medications. There is also scope to examine whether genetic risk is associated 
with cognitive function.  
The neurobiological basis of cognitive impairments in psychiatric disorders is not 
well understood. One barrier is the lack of large samples with cognitive data. 
Current efforts to determine genetic risk factors for cognitive impairments rely on 
collating data from studies that use a diverse range of cognitive measures. One 
solution is for studies to use the same standardised battery, such as the MCCB. 
However, administration of the MCCB can be time-consuming and expensive, 
which is prohibitive to the collection of cognitive data in large samples. Whether 
the MCCB is sensitive to cognitive impairments in more diverse cross-disorder 
samples (not limited to schizophrenia and bipolar disorder) has not been 
established. Another solution is to take advantage of existing large databases of 
participants with genetic data and utilise online cognitive assessments. The findings 
of this thesis indicate it is possible to recruit large samples within a short time 
period and at a relatively low cost. As genetic studies rely on very large samples 
for statistical power, combining large datasets that have measured the same 
domains using comparable tasks is likely to be the best solution. There is a need for 
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consensus in the domains of cognition that should be assessed across disorders. 
This exists in schizophrenia research due to the work of the MATRICS initiative 
[201] and there have been efforts to achieve a similar consensus in bipolar disorder 
[242]. As the online sample grows, we will be able to examine whether the 
cognitive battery developed in this thesis is suitable for use in research of other 
psychiatric disorders. 
There are efforts to identify the specific cognitive processes affected in psychiatric 
disorders, such as the work of the Cognitive Neuroscience-Based Approaches to 
Measuring and Improving Treatment Effects on Cognition in Schizophrenia 
(CNTRICS) initiative [212]. The aim of the CNTRICS initiative was to use 
existing findings from cognitive neuroscience to select tasks for which the 
underlying neural systems involved are at least partly known. These tasks may be 
useful in identifying specific neural pathways involved in the aetiology of cognitive 
impairments.  
One of the main statistical approaches taken in Chapters 3 and 6 focused on 
identifying between-group differences. However, this approach does not account 
for the individual differences in cognitive performance within diagnostic groups. 
For example, one study estimated that 16-45% of those with schizophrenia and 42-
64% of those with bipolar disorder in their sample could be defined as cognitively 
normal [314]. This highlights the importance of cross-disorder analyses to identify 
associations between illness factors and cognitive performance, such as those 
undertaken in this thesis. There is increasing interest in using data-driven 
approaches to identify more homogeneous subgroups of participants. It is hoped 
that these neurocognitive subgroups may be more biologically and functionally 
relevant than current diagnostic classification and could be used in research of 
neurobiology and genetics, as well as in the development of cognition enhancing 
treatments or interventions [495]. Studies utilising cluster analysis across disorders 
(schizophrenia, schizoaffective disorder and bipolar disorder) have identified three 
to four clusters with differential patterns of impairment [462, 496]. Both studies 
included clusters of participants with normal cognitive function and diagnoses were 
represented across all clusters. This suggests that there is no clear boundary in 
cognitive performance between diagnoses. In addition, Clementz et al. [462] 
demonstrated that the clusters differed on measures of grey matter volume and 
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sensorimotor reactivity. The authors concluded that data-driven approaches could 
be used to identify neurobiologically distinct groups amongst patients with similar 
clinical phenotypes. Such approaches could be extended to the study of psychiatric 
genetics.  
7.5 Summary 
The main aims of this thesis were to examine cognitive impairment across the 
bipolar / schizophrenia diagnostic spectrum and develop a new online cognitive 
battery for use in large-scale studies of mental health disorders. The strengths of 
the methods utilised within this thesis have been discussed in previous chapters. 
However, the main strengths are briefly reiterated here. The main strengths of this 
thesis include: 1) the use of large datasets, including a large and well-characterised 
dataset of 927 participants in Chapter 3, 2) the use of cross-disorder datasets to 
examine the associations between clinical and cognitive factors that cross 
traditional diagnostic boundaries, 3) the inclusion of a range of demographic and 
clinical covariates in analyses, and 4) the development of a new cognitive battery 
based on the MATRICS domains. 
The work described in this thesis builds on existing scientific knowledge in several 
ways. Through meta-analytic approaches (Chapter 2) and utilising regression 
models in a large, well-characterised dataset (Chapter 3), it has been shown that 
there is a gradient of increasing cognitive impairment from bipolar disorder to 
schizoaffective disorder – bipolar type to schizophrenia and schizoaffective 
disorder – depressive type. It has also been demonstrated that participants with the 
subtypes of schizoaffective disorder differ in the extent of their cognitive 
impairments. These findings also indicated that lifetime severity and frequency of 
psychosis is linearly associated with cognitive function across disorders. These 
results offer important insights for psychiatric nosology and add to a growing body 
of literature that supports dimensional models of psychotic and affective disorders.  
In addition to analyses of existing data, I have developed a new online cognitive 
battery for use in research of psychiatric disorders. The battery assesses the 
domains outlined by the MATRICS initiative. To date, there have been no 
published studies that have examined whether online cognitive testing is suitable 
for collecting data from populations with psychiatric disorders. I have collected and 
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analysed cognitive data from a large number of participants with a wide range of 
psychiatric disorders, including but not limited to major depressive disorder, 
bipolar disorder, schizophrenia, anxiety disorders and post-traumatic stress disorder. 
This dataset presents new opportunities to examine the causes and impact of 
cognitive impairments across psychiatric disorders.  
Overall, these findings support the use of cognitive assessments to study 
psychiatric disorders. Cognitive function is an important indicator of functional 
outcome and therefore has relevance to clinical practice. Further, it is hoped that 
the use of cross-disorder samples will aid understanding of the aetiology of 
psychiatric disorders, particularly in molecular genetic studies that rely on large 
samples. This would facilitate the development of new treatments and improve 
functional outcomes for patients.  
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Appendix A: Hedges g Effect Sizes 
Hedges g effect sizes were calculated for each pair of comparisons using the 
formula described by Rosnow and Rosenthal [291] and Rosnow, Rosenthal and 
Rubin [292]. The formula for calculating Hedges g is: 
𝑑 =  
?̅?1 − ?̅?2
𝑆𝐷𝑝𝑜𝑜𝑙𝑒𝑑
 
?̅?1 = Mean of group 1 
?̅?2 = Mean of group 2 
𝑆𝐷𝑝𝑜𝑜𝑙𝑒𝑑 = Pooled standard deviation 
where the pooled standard deviation was weighted by each group’s sample size 
using the formula: 
𝑆𝐷𝑝𝑜𝑜𝑙𝑒𝑑 = √
(𝑛1 − 1)𝑆𝐷1
2 + (𝑛2 − 1)𝑆𝐷2
2
𝑛1 + 𝑛2
 
𝑛1 = Number of participants in group 1 
𝑛2 = Number of participants in group 2  
𝑆𝐷1
2 = Standard deviation of group 1 
𝑆𝐷2
2 = Standard deviation of group 2 
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Appendix B: Sensitivity analyses (Chapter 2) 
Two sets of sensitivity analyses were performed. Firstly, the meta-analysis 
comparing bipolar disorder and schizoaffective disorder was repeated excluding 
papers that included bipolar disorder - type II in their sample. Secondly, the 
analyses were repeated excluding two studies that had samples with a mean age 
between 58 and 65 years.  
Bipolar disorder – type I only 
Composite cognition effect sizes were calculated for six studies comparing 
schizoaffective disorder and bipolar disorder – type I. Participants with 
schizoaffective disorder performed worse than participants with bipolar disorder 
(g=-0.27, p<0.0001, see Figure B-1).  
 
Figure B-1 Forest plot of individual and pooled random effect estimates of mean differences between 
schizoaffective disorder and bipolar disorder - type I  
Positive effect sizes indicate better performance in the schizoaffective disorder group. 
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Older samples removed 
Composite cognition effect sizes were calculated for seven studies comparing 
schizoaffective disorder and bipolar disorder. The study by Mueser et al. [311] was 
excluded for this analysis, as the sample included older adults (50 years and older). 
Participants with schizoaffective disorder performed worse than participants with 
bipolar disorder (g=-0.28, p<0.0001, see Figure B-2).  
 
Figure B-2 Forest plot of individual and pooled random effect estimates of mean differences between 
schizoaffective disorder and bipolar disorder, excluding one study with an older sample  
Positive effect sizes indicate better performance in the schizoaffective disorder group. 
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Composite cognition effect sizes were calculated for 18 studies comparing 
schizoaffective disorder and schizophrenia. The studies by Mueser et al. [311] and 
Evans et al. [300] were excluded as both studies had older samples. Participants 
with schizoaffective disorder performed better than participants with schizophrenia 
based on composite cognition scores (g=0.20, p<0.0001, see Figure B-3).  
 
Figure B-3 Forest plot of individual and pooled random effect estimates of mean differences between 
schizophrenia and schizoaffective disorder  
Positive effect sizes indicate better performance in the schizoaffective disorder group. 
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Appendix C: MCCB Imputation Method 
Missing values were imputed using the formula described in the MCCB manual for 
all tests, with the exception of the CPT-IP, HVLT-R and BVMT-R. Imputed 
composite scores were only used when an individual had completed 5 or more of 
the domains. The imputed score (𝑌𝑑𝑖) is calculated using the mean Z score of that 
test for all cases (𝑌𝑑 +), the mean Z score of all completed tests for the individual 
(𝑌 + 𝑖) and the mean Z score of all tests for all individuals (𝑌 + +). The formula is: 
𝑌𝑑𝑖 = (𝑌𝑑 +) + (𝑌 + 𝑖) − (𝑌 + +) 
CPT-IP, HVLT-R and BVMT-R 
Missing scores were imputed differently on tests with three trials, as there was 
more information to enable the trial scores to be imputed in a way that would better 
reflect the participant’s performance on that particular test. To impute missing 
trials of the CPT-IP, the same formula was used but the mean z-scores were taken 
from CPT-IP trials only so did not include any other tests. Once the individual 
missing scores for the trials were imputed, the CPT-IP mean was calculated. If a 
participant was missing all of the trials then the mean score was imputed. To 
impute missing trials of the HVLT-R and BVMT-R, cases were selected with the 
same total score for the completed trials as the participant with the missing score. 
For example, if a participant’s scores on trials 1 and 2 were 3 and 5 respectively 
and they were missing trial 3, all cases with a total of 8 on trials 1 and 2 were 
selected. A mean z-score was calculated from the test totals of these selected cases. 
This mean z-score was used as the imputed total z-score for the participant with the 
missing score. This was then converted back into a raw total score and the missing 
value was filled in so that the total added up correctly. For example, if the 
participant described above had an imputed total score of 14 then their missing 
value on trial 3 would be 6. 
321 
 
Appendix D: Completeness of Data (Chapter 3) 
Complete data was available on all tasks for the healthy control group. The number 
of scores available for each domain is shown in Table D-1.  
 
Table D-1 Total number of scores available for each domain of the MCCB 
Domain 
Bipolar 
Disorder 
Schizoaffective 
Disorder – 
Bipolar Type 
Schizoaffective 
Disorder – 
Depressive 
Type 
Schizophrenia 
Complete 
Data for 
Cases 
Verbal 
Learning 
78 76 112 558 824 
Reasoning 
& 
Problem 
Solving 
78 76 112 558 824 
Visual 
Learning 
78 76 112 554 820 
Social 
Cognition 
75 75 110 544 804 
Attention / 
Vigilance 
77 72 102 518 769 
Speed of 
Processing 
78 76 112 558 824 
Working 
Memory 
78 76 112 558 824 
Composite 
Score 
78 76 112 557 823 
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Appendix E: Proportional Odds Assumption (Chapter 3) 
Schizoaffective disorder – depressive type and schizophrenia as one 
Ordinal regression analyses were conducted to test the hypothesis that cognition 
can be considered a dimensional phenotype showing increasing impairment from 
bipolar disorder to schizoaffective disorder – depressive type / schizophrenia. 
Participants were assigned scores from 0 to 2 based on their diagnosis (0 = 
schizoaffective disorder - depressive type / schizophrenia, 1 = schizoaffective 
disorder - bipolar type and 2 = bipolar disorder). Diagnosis was entered as the 
outcome variable with composite cognition scores as the predictor and age and sex 
as covariates. 
The assumption of proportional odds was confirmed using the test of parallel lines 
(𝜒2 = 4.97, df = 3, p = 0.174) and by examining the coefficients for binary 
regressions for each cut-off point in the scale (see Table E-1).  
Table E-1 Binary regressions for each threshold of the diagnostic scale 
 
B 
coefficients 
95% 
Confidence 
Intervals 
Odds ratios 
95% 
Confidence 
Intervals 
Lower categories 
vs. BD 
0.83 0.6 to 1.06 2.29 1.82 to 2.89 
SAD / SZ vs. 
higher categories 
0.65 0.49 to 0.82 1.92 1.63 to 2.27 
BD, Bipolar Disorder; SAD, Schizoaffective Disorder – Depressive Type; SZ, Schizophrenia. 
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All Groups 
In the second ordinal model, participants were assigned scores from 0 to 3 based on 
their diagnosis (0 = schizophrenia, 1 = schizoaffective disorder – depressive type, 2 
= schizoaffective disorder – bipolar type and 3 = bipolar disorder). The results of 
the parallel lines test indicated that the proportional odds assumption was violated 
in this model (𝜒2 = 27.61, df = 6, p = 1.1 x 10-4). This indicates that the logistic 
estimates are not equal across all levels of the dependent variable therefore the 
combined estimate for the model is not accurate. To investigate this further, I 
calculated the coefficients for binary regressions for each cut-off point in the scale. 
There are three cut-off points (thresholds) on this scale and therefore three binary 
regressions were conducted: 
1. Schizophrenia vs. all higher categories 
2. Schizophrenia and schizoaffective disorder – depressive type vs. 
schizoaffective disorder – bipolar type and bipolar disorder 
3. All lower categories vs. bipolar disorder 
The results of binary regressions examining each threshold of the diagnostic scale 
are shown in Table E-2. Overall, the coefficients were not equal across the analyses 
with the largest difference in coefficients between analysis 1 and analysis 3.  
 
Table E-2 Binary regression results for each threshold of the diagnostic scale 
 B coefficients 
95% Confidence 
Intervals 
Odds ratios 
95% 
Confidence 
Intervals 
1. SZ vs. higher 
categories 
0.38 0.26 to 0.51 1.46 1.3 to 1.67 
2. SAD and SZ vs. 
BD and SAB  
0.65 0.49 to 0.82 1.92 1.63 to 2.27 
3. Lower categories 
vs. BD 
0.83 0.6 to 1.06 2.29 1.82 to 2.89 
BD, Bipolar Disorder; SAB, Schizoaffective Disorder – Bipolar Type; SAD, Schizoaffective Disorder – 
Depressive Type; SZ, Schizophrenia. 
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Schizoaffective disorder as one 
The final ordinal model included schizoaffective disorder as a single category (0 = 
schizophrenia, 1 = schizoaffective disorder and 2 = bipolar disorder). The test of 
parallel lines was significant indicating that the proportional odds assumption had 
been violated in this model (𝜒2 = 20.03, df = 3, p = 1.7 x 10-4). The results of 
individual binary regressions for each cut-off point on the scale are shown in Table 
E-3. The coefficients for these models were not similar indicating that the 
coefficient in the ordinal regression model may not be accurate. 
 
Table E-3 Binary regression results for each cut-off point on the diagnostic scale 
 B 
Coefficient 
95% 
Confidence 
Intervals 
Odds ratios 95% 
Confidence 
Intervals 
Lower categories 
vs. BD 
0.83 0.6 to 1.06 2.29 1.82 to 2.89 
SZ vs. higher 
categories 
0.38 0.26 to 0.51 1.46 1.3 to 1.67 
BD, Bipolar Disorder; SZ, Schizophrenia. 
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Appendix F: Schizoaffective disorder as a single group 
Previous studies comparing cognitive function between diagnoses have combined 
the subtypes of schizoaffective disorder. Therefore, a further set of ANCOVAs was 
conducted that included schizoaffective disorder as a single group (combining the 
bipolar and depressive subtypes). This allowed me to evaluate whether 
amalgamation of the subtypes of schizoaffective disorder as a single group could 
be masking differences between the diagnoses. As previously, there was a main 
effect of diagnosis for all domains of cognition. Post hoc tests revealed 
significantly greater impairment in the schizoaffective group compared to the 
bipolar group on all measures, except attention (composite cognition: g=0.75, 
p<0.001, see Table F-1 for full results). The schizophrenia group was significantly 
more impaired than the schizoaffective group (composite cognition: g=0.29, 
p=0.005). 
Table F-1 Comparison of cognitive performance with schizoaffective disorder as a single group 
Domain 
Effect of Diagnosis Pairwise 
Comparisons 
Fdf p Partial η2 
Verbal Learning F3, 923=81.08  <2.2 x 10-16 0.21 
SA < BD2 
SZ < BD2 
Reasoning & 
Problem Solving 
F3, 923 =55.41 <2.2 x 10-16 0.15 
SA < BD2 
SZ < BD2 
Visual Learning F3, 923=68.42 <2.2 x 10-16 0.18 
SA < BD2 
SZ < BD2 
SZ < SA2 
Social Cognition F3, 903=33.37 <2.2 x 10-16 0.10 
SA < BD2 
SZ < BD2 
Attention / Vigilance F3, 868=45.24 <2.2 x 10-16 0.14 
SA < BD2 
SZ < BD2 
SZ < SA1 
Speed of Processing F3, 923=104.92 <2.2 x 10-16 0.26 
SA < BD2 
SZ < BD2 
SZ < SA1 
Working Memory F3, 923=66.03 <2.2 x 10-16 0.18 
SA < BD2 
SZ < BD2 
Composite Score F3, 922=120.71 <2.2 x 10-16 0.28 
SA < BD2 
SZ < BD2 
SZ < SA2 
All case-control comparisons were significant (p<.001), except for bipolar disorder on social cognition (no 
significant difference). Partial η2 indicates the proportion of variance in cognitive scores that is associated with 
diagnosis. BD, bipolar disorder; SA, schizoaffective disorder; SZ, schizophrenia; 1p<.05, 2p<.00625 
(Bonferroni-corrected) 
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Appendix G: Bristol Online Survey Questionnaire 
Participants who are sent a letter with a username and password see the login page 
below. Participants who are sent an email with their unique website link included 
do not see this page, as their details are entered automatically when they click on 
the link. Each page of the BOS questionnaire is displayed below. 
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Appendix H: TestMyBrain Online Cognitive Battery 
Website 
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Appendix I: Feedback Questionnaire (Chapter 4) 
COMPASS Web Pilot Questionnaire 
Participant ID: 
Part 1 - Questionnaire 
 Very Clear Clear Unclear Very Unclear 
Was the 
information 
provided at the 
start of the study 
clear? 
☐ ☐ ☐ ☐ 
How could we improve the information page? 
 Very 
Good 
Good Fair Poor Very Poor 
Overall, how would 
you rate the 
questionnaire: 
☐ ☐ ☐ ☐ ☐ 
Were there any parts of the questionnaire that you would change? 
Part 2 – Online Cognitive Tasks 
 Very Clear Clear Unclear Very Unclear 
Were the instructions 
for the tasks clear? ☐ ☐ ☐ ☐ 
Comments: 
 
 Yes No 
Did you experience any technical difficulties during the tasks? 
☐ ☐ 
If yes, please provide details:  
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Overall, how would you rate the online cognitive tasks on: 
 Very Good Good Fair Poor Very Poor 
Enjoyability ☐ ☐ ☐ ☐ ☐ 
Interest ☐ ☐ ☐ ☐ ☐ 
Duration ☐ ☐ ☐ ☐ ☐ 
Difficulty ☐ ☐ ☐ ☐ ☐ 
Comments: 
Were there any tasks that you particularly liked? Why? 
___________________________________________________________________ 
 
Were there any tasks that you particularly disliked? Why? 
___________________________________________________________________ 
 
How could we improve the study? 
___________________________________________________________________ 
 
 More 
likely 
Less 
likely 
Don’t 
know 
After having taken part in this study, are you more or less 
likely to take part in further online research studies? 
 
☐ ☐ ☐ 
 
Thank you. 
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Appendix J: Comparison of counter-balanced control 
groups (Chapter 4) 
In the validation study described in Chapter 4, the control group was 
counterbalanced such that ten participants completed the MCCB first and nine 
participants completed the online battery first. I compared scores on tasks between 
the two groups, adjusting for age and gender. There were no differences in 
performance between the groups, except that the group who completed the MCCB 
had better scores on the MSCEIT (see Table J-1).  
Table J-1 Comparisons of counter-balanced control groups 
 MCCB First Online First F p 
MCCB Task     
Digit Symbol Coding -0.16 (0.27) 0.18 (0.28) 0.72 0.41 
HVLT-R -0.16 (0.31) 0.17 (0.33) 0.51 0.49 
Letter Number 
Sequencing 
0.07 (0.35) -0.08 (0.37) 0.09 0.77 
BVMT-R 0.06 (0.33) -0.07 (0.35) 0.07 0.79 
MSCEIT: ME 0.48 (0.31) -0.53 (0.32) 4.9 0.04 
CPT-IP 0.06 (0.35) -0.07 (0.36) 0.07 0.8 
NAB Mazes -0.22 (0.28) 0.24 (0.30) 1.21 0.29 
NART 0.26 (0.34) -0.29 (0.36) 1.19 0.3 
Online Task     
Digit Symbol Coding -0.17 (0.33) 0.19 (0.35) 0.57 0.46 
VPA -0.09 (0.32) 0.1 (0.33) 0.16 0.7 
Morphed Emotion 
Identification 
-0.03 (0.27) 0.03 (0.28) 0.02 0.88 
Backward Digit Span 0.24 (0.34) -0.26 (0.36) 0.95 0.35 
Hartshorne Visual 
Working Memory 
-0.09 (0.34) 0.1 (0.36) 0.14 0.72 
Matrix Reasoning -0.3 (0.3) 0.33 (0.32) 2 0.18 
BART -0.2 (0.33) 0.22 (0.35) 0.73 0.41 
Multiple Object 
Tracking 
-0.13 (0.33) 0.14 (0.35) 0.3 0.59 
Vocabulary 0.15 (0.33) -0.15 (0.33) 0.41 0.53 
Mean and standard errors shown. BART, Balloon Analogue Risk Task; BVMT-R, Brief Visuospatial Memory 
Test – Revised; CPT-IP, Continuous Performance Test – Identical Pairs; HVLT-R, Hopkins Verbal Learning 
Test – Revised; MCCB, MATRICS Consensus Cognitive Battery; MSCEIT: ME, Mayer-Salovey-Caruso 
Emotional Intelligence Test: Managing Emotions; NAB, Neuropsychological Assessment Battery; NART, 
National Adult Reading Test; VPA, Verbal Paired Associates.  
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Appendix K: Recruitment letters 
Letters to CoMPaSS participants 
Division of Psychological Medicine and Clinical Neuroscience 
Hadyn Ellis Building 
Maindy Road 
Cardiff 
CF24 4HQ 
Dear [participant’s name], 
As you have previously helped us with our research at the Division of 
Psychological Medicine and Clinical Neuroscience, we are contacting you to let 
you know of an additional research opportunity that may be of interest to you.  
We are looking for volunteers to complete some online memory and problem 
solving tasks and brief questionnaires. This is important research, which will 
inform our ongoing work to improve outcomes for people with psychosis and 
mood disorders. You will need access to the internet to participate in this study. 
The total study time will be no more than 1 hour and you may take breaks 
whenever you wish.  
If you are interested in participating, would like further information or wish to 
contact us to let us know you do not wish to take part, please use one of the 
following options: 
1. You can visit the study website by typing this link into your web browser: 
https://cardiff.onlinesurveys.ac.uk/compass. Here you will find the study 
information sheet and consent form. To enter the study, please use the 
following information:  
Username: [ID number] 
Password: [password] 
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(Please note: Once you have started the study, do not close the page, as you will 
not be able to complete the study later. If you wish to take a break and come back, 
scroll to the bottom of the page and click “Finish later”.) 
2. You can contact the team for further information via phone 02920 688043 
or email compass@cardiff.ac.uk. 
3. You can return the reply slip included with this letter using the freepost 
envelope provided. 
 
Please note that if you do not have access to the internet but still wish to take part, 
it may be possible for the team to arrange internet access for you. It is your 
decision whether you take part in the research and you will be able to withdraw at 
any stage should you wish to do so. 
We like to keep our participants updated on new research and findings from our 
study through our newsletter. In order to do this, we need to regularly update your 
information to ensure the contact details we hold for you are up to date. We also 
plan to contact our participants via email, although this will not replace our postal 
newsletter. If your contact details have changed or you have not provided us with 
an email address, please update us with your details through the contact email or 
phone number above, or by returning the reply slip enclosed. We would be grateful 
if you could do this even if you do not wish to take part in the above study. If you 
would prefer us not to contact you by email, please let us know. 
Thank you once again for your ongoing co-operation. 
Yours sincerely, 
Amy Lynham, PhD student 
Dr James Walters, Clinical Reader, Honorary Consultant Psychiatrist 
Cognition in Mood, Psychosis and Schizophrenia Study (CoMPaSS) 
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Recruitment email to NCMH participants (cases) 
Dear [participant’s name], 
As you have previously helped us with our research at the National Centre for 
Mental Health (NCMH), we are contacting you to let you know of an additional 
research opportunity that may be of interest to you. 
We have developed an online way of conducting a number of learning and memory 
tasks, which will help us in our research on mental health. Examples may include 
memory and problem solving tasks. These are important questions because some 
people who have experienced mental health problems have difficulty with 
concentration and memory, which we know can impact on their day-to-day life. 
We are looking for volunteers to complete these tasks. The total study time will be 
no more than 1 hour and you may take breaks whenever you wish. 
If you are interested in participating or would like further information, you can visit 
the study website by clicking on the link below: 
[unique website link here] 
Once you have clicked on the link, do not close the page as you will not be able to 
complete the study later. If you wish to take a break and come back, scroll to the 
bottom of the page and click “Finish later”.  
It is your decision whether you take part in the research and you will be able to 
withdraw at any stage should you wish to do so.  
Kind regards 
Professor Ian Jones (NCMH Director) 
& The NCMH Team 
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Recruitment email to NCMH participants (controls) 
Dear [participant’s name], 
As you have previously helped us with our research at the National Centre for 
Mental Health (NCMH), we are contacting you to let you know of an additional 
research opportunity that may be of interest to you. 
We have developed an online way of conducting a number of learning and memory 
tasks, which will help us in our research on mental health. Examples may include 
memory and problem solving tasks. We are looking for volunteers who have not 
experienced significant mental health problems to complete these tasks. Your 
scores will be included as part of a comparison group, which will be compared to 
groups of participants with mental health problems. This will help us to determine 
if certain mental health disorders are associated with memory and concentration 
problems and to what extent. These are important questions because difficulties 
with memory and concentration can impact on a person’s day-to-day life. The total 
study time will be no more than 1 hour and you may take breaks whenever you 
wish.  
If you are interested in participating or would like further information, you can visit 
the study website by clicking on the link below: 
[website link here] 
Once you have clicked on the link, do not close the page as you will not be able to 
complete the study later. If you wish to take a break and come back, scroll to the 
bottom of the page and click “Finish later”.  
It is your decision whether you take part in the research and you will be able to 
withdraw at any stage should you wish to do so.  
Kind regards 
Professor Ian Jones (NCMH Director) 
& The NCMH Team 
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Recruitment letter to NCMH participants 
Division of Psychological Medicine and Clinical Neuroscience 
Hadyn Ellis Building 
Maindy Road 
Cardiff 
CF24 4HQ 
Dear [participant’s name], 
As you have previously helped us with our research at the National Centre for 
Mental Health (NCMH), we are contacting you to let you know of an additional 
research opportunity that may be of interest to you. 
We have developed an online (over the internet) way of conducting a number of 
learning and memory tasks, which will help us in our research on mental health. 
Examples may include memory and problem solving tasks. These are important 
questions because some people who have experienced mental health problems have 
difficulty with concentration and memory, which we know can impact on their day-
to-day life. We are looking for volunteers to complete these tasks and brief 
questionnaires. You will need access to the internet to participate in this study. The 
total study time will be no more than 1 hour and you may take breaks whenever 
you wish. 
If you are interested in participating, would like further information or wish to 
contact us to let us know you do not wish to take part, please use one of the 
following options: 
1. You can visit the study website by typing this link into your web browser: 
https://cardiff.onlinesurveys.ac.uk/compass. Here you will find the study 
information sheet and consent form. To enter the study, please use the 
following information:  
Username: [ID number] 
Password: [password] 
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(Please note: Once you have started the study, do not close the page, as you will 
not be able to complete the study later. If you wish to take a break and come back, 
scroll to the bottom of the page and click “Finish later”.) 
2. You can contact the team for further information via phone 02920 688043 
or email compass@cardiff.ac.uk. 
3. You can return the reply slip included with this letter using the freepost 
envelope provided. 
 
Please note that if you do not have access to the internet but still wish to take part, 
it may be possible for the team to arrange internet access for you. It is your 
decision whether you take part in the research and you will be able to withdraw at 
any stage should you wish to do so.  
Many thanks for your ongoing support. 
Professor Ian Jones 
Director, National Centre for Mental Health (NCMH) 
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Appendix L: Completeness of Data (Chapter 6) 
The number of scores available for each domain of the online battery is shown in 
Table L-1.  
 
Table L-1 Total number of scores available for each domain 
Domain 
Healthy 
Controls 
Bipolar 
Disorder 
Major 
Depressive 
Disorder 
Schizophrenia 
Complete 
Data 
Speed of 
Processing 
61 86 106 33 286 
Verbal 
Learning 
54 76 94 31 255 
Social 
Cognition 
56 78 94 33 261 
Working 
Memory 
54 75 91 33 253 
Visual 
Learning 
53 73 88 31 245 
Reasoning 
& Problem 
Solving  
54 72 86 32 244 
Strategic 
Risk Taking 
53 70 88 32 243 
Attention 53 63 82 31 229 
Vocabulary 55 65 83 31 234 
‘g’ 52 71 87 33 243 
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Appendix M: Additional analyses – Chapter 6 
Comparison of cognition between validation study and main study 
participants 
In order to maximise the sample numbers, I examined the validity of combining the 
study samples from Chapters 4 and 5. Within each diagnostic group, cognitive 
performance (‘g’) was compared between participants from the validation study 
and participants from the main study. There were no differences between the 
studies for healthy controls (t=0.35, p=0.73), participants with major depressive 
disorder (t=-0.06, p=0.96) and bipolar disorder (t=0.28, p=0.78). There was a 
significant difference between studies for participants with schizophrenia (t=2.34, 
p=0.03).  
Measures of ‘g’ 
Three measures of general cognitive performance (g) were derived using the 
approaches described in Chapter 5. Measures of ‘g’ were derived for participants 
who had completed at least 5 tasks (N=321). Principal component analysis (PCA) 
was conducted on complete data (N=292) and repeated in a dataset where missing 
scores had been imputed (N=321). The first component of the PCA was taken as a 
measure of ‘g’. Classical multidimensional scaling (MDS) was conducted on a 
Euclidean distance matrix to derive a third measure of ‘g’. MDS is an analogous 
approach to PCA but an advantage to this approach is that it can accommodate 
missing data. The ‘g’ derived using MDS was highly correlated with the ‘g’ 
derived using complete data (r=0.997) and the ‘g’ derived including imputed data 
(r=0.987). Therefore, the results for analyses using ‘g’ derived using MDS are 
presented in Chapter 6. The results for analyses using ‘g’ derived by conducting 
PCA on imputed scores and complete data are presented below.  
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Comparisons of cognitive function between diagnostic groups (Chapter 6) 
There was a significant main effect of diagnosis for overall cognitive function ‘g’ 
(complete data g: F(3, 216) = 8.97, p=1.3 x 10-5; imputed data g: F(3, 241) = 10.78, 
p=1.1 x 10-6). Pairwise comparisons are presented in Table M-1. 
Table M-1 Comparisons of g between diagnostic groups 
 Imputed data g Complete data g 
 Hedge’s g p Hedge’s g p 
HC vs. MDD 0.22 0.59 0.25 0.48 
HC vs. BD 0.49 0.03 0.43 0.1 
HC vs. SZ 1.18 <0.001 1.21 <0.001 
MDD vs. BD 0.28 0.3 0.19 0.69 
MDD vs. SZ 0.97 <0.001 0.97 <0.001 
BD vs. SZ 0.69 0.006 0.78 0.006 
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Cross disorder clinical variables and cognitive performance 
Across the whole sample (cases only), higher HADS depression scores and higher 
HADS anxiety scores were associated with lower cognitive performance (‘g’, see 
Table M-2). Age of onset was not associated with cognitive performance. The 
analyses were then repeated and restricted to the three main diagnoses of interest: 
major depressive disorder, bipolar disorder and schizophrenia. Across these three 
disorders, higher HADS depression scores and higher HADS anxiety scores were 
associated with lower cognitive performance. Age of onset was not associated with 
cognitive performance.  
 
Table M-2 Associations between clinical variables and ‘g’ derived using PCA 
 Whole Sample Three Diagnoses Only 
 B SE p B SE p 
Imputed data ‘g’       
HADS depression -0.04 0.01 1.6 x 10-4 -0.04 0.01 9.1 x 10-4 
HADS anxiety -0.05 0.01 2.2 x 10-5 -0.05 0.01 1.1 x 10-4 
Age of onset -0.004 0.01 0.43 0.001 0.01 0.89 
Complete data ‘g’       
HADS depression -0.03 0.01 0.003 -0.03 0.01 0.01 
HADS anxiety -0.04 0.01 1.2 x 10-4 -0.04 0.01 9.4 x 10-4 
Age of onset -0.006 0.01 0.28 0.001 0.01 0.89 
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The associations between the clinical variables and cognitive performance within 
each diagnostic group are shown in Table M-3. In the bipolar disorder group, 
higher HADS depression and anxiety scores were associated with lower cognitive 
performance in the imputed data set but not in the sample of participants with 
complete data only. Higher HADS anxiety scores were also associated with lower 
cognitive performance in the major depressive disorder group. In the schizophrenia 
group, higher scores on the HADS anxiety subscale were associated with lower 
cognitive performance. However, none of the results were significant after 
correction for multiple testing. 
 
Table M-3 Associations between clinical variables and ‘g’ within diagnostic groups 
 Imputed data ‘g’ Complete data ‘g’ 
 B SE p B SE p 
Bipolar Disorder       
HADS depression -0.04 0.02 0.049 -0.03 0.02 0.21 
HADS anxiety -0.04 0.02 0.04 -0.03 0.02 0.14 
Age of onset -0.0005 0.01 0.97 -0.002 0.01 0.85 
Major Depressive Disorder       
HADS depression -0.03 0.02 0.08 -0.04 0.02 0.04 
HADS anxiety -0.04 0.02 0.03 -0.06 0.02 0.005 
Age of onset -0.002 0.01 0.77 -0.004 0.01 0.63 
Schizophrenia       
HADS depression -0.05 0.03 0.08 -0.05 0.03 0.09 
HADS anxiety -0.05 0.02 0.04 -0.05 0.02 0.04 
Age of onset 0.02 0.02 0.41 0.03 0.02 0.19 
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Cognitive performance and functional outcome 
Linear regression across the whole sample indicated that lower cognitive 
performance was associated with more severe disability (complete data ‘g’: B=-
3.08, SE=0.91, p=8.7 x 10-4; imputed data ‘g’: B=-3.10, SE=0.84, p=3 x 10-4). The 
analyses were then repeated and restricted to the three main diagnoses of interest: 
major depressive disorder, bipolar disorder and schizophrenia. Across these three 
disorders, lower cognitive performance (as measured by ‘g’ derived from PCA of 
complete data) was associated with higher WHODAS scores but this did not 
survive correction for multiple testing (see Table M-4). In analyses of individual 
diagnostic groups, lower cognitive performance was associated with greater 
disability in the depression group only. 
 
Table M-4 Associations between cognitive performance (‘g’) and functional outcome within diagnostic 
groups 
 Imputed ‘g’ Complete data ‘g’ 
 B SE p B SE p 
Across Three Groups -2.17 1.11 0.05 -2.79 1.23 0.03 
Bipolar Disorder 0.90 1.73 0.52 0.18 2.15 0.93 
Major Depressive 
Disorder 
-4.97 1.40 7.5 x 10-4 -5.67 1.38 1.3 x 10-4 
Schizophrenia -4.79 3.41 0.19 -6.04 3.46 0.12 
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